id	sid	tid	token	lemma	pos
10_1101-2021_01_04_425177	1	1	The	the	DT
10_1101-2021_01_04_425177	1	2	engineered	engineer	VBN
10_1101-2021_01_04_425177	1	3	peptide	peptide	NN
10_1101-2021_01_04_425177	1	4	construct	construct	NN
10_1101-2021_01_04_425177	1	5	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	1	6	inhibits	inhibit	VBZ
10_1101-2021_01_04_425177	1	7	aggregation	aggregation	NN
10_1101-2021_01_04_425177	1	8	of	of	IN
10_1101-2021_01_04_425177	1	9	the	the	DT
10_1101-2021_01_04_425177	1	10	human	human	JJ
10_1101-2021_01_04_425177	1	11	prion	prion	NN
10_1101-2021_01_04_425177	1	12	protein	protein	NN
10_1101-2021_01_04_425177	1	13	(	(	-LRB-
10_1101-2021_01_04_425177	1	14	PrP	PrP	NNP
10_1101-2021_01_04_425177	1	15	)	)	-RRB-
10_1101-2021_01_04_425177	1	16	1	1	CD
10_1101-2021_01_04_425177	1	17	The	the	DT
10_1101-2021_01_04_425177	1	18	engineered	engineer	VBN
10_1101-2021_01_04_425177	1	19	peptide	peptide	NN
10_1101-2021_01_04_425177	1	20	construct	construct	NN
10_1101-2021_01_04_425177	1	21	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	1	22	inhibits	inhibit	VBZ
10_1101-2021_01_04_425177	1	23	aggregation	aggregation	NN
10_1101-2021_01_04_425177	1	24	of	of	IN
10_1101-2021_01_04_425177	1	25	the	the	DT
10_1101-2021_01_04_425177	1	26	human	human	JJ
10_1101-2021_01_04_425177	1	27	prion	prion	NN
10_1101-2021_01_04_425177	1	28	protein	protein	NN
10_1101-2021_01_04_425177	1	29	(	(	-LRB-
10_1101-2021_01_04_425177	1	30	PrP	PrP	NNP
10_1101-2021_01_04_425177	1	31	)	)	-RRB-
10_1101-2021_01_04_425177	1	32	Maciej	Maciej	NNP
10_1101-2021_01_04_425177	1	33	Gielnik	Gielnik	NNP
10_1101-2021_01_04_425177	1	34	1	1	CD
10_1101-2021_01_04_425177	1	35	,	,	,
10_1101-2021_01_04_425177	1	36	Lilia	Lilia	NNP
10_1101-2021_01_04_425177	1	37	Zhukova	Zhukova	NNP
10_1101-2021_01_04_425177	1	38	2	2	CD
10_1101-2021_01_04_425177	1	39	,	,	,
10_1101-2021_01_04_425177	1	40	Igor	Igor	NNP
10_1101-2021_01_04_425177	1	41	Zhukov	Zhukov	NNP
10_1101-2021_01_04_425177	1	42	2	2	CD
10_1101-2021_01_04_425177	1	43	,	,	,
10_1101-2021_01_04_425177	1	44	Astrid	Astrid	NNP
10_1101-2021_01_04_425177	1	45	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	1	46	3	3	CD
10_1101-2021_01_04_425177	1	47	,	,	,
10_1101-2021_01_04_425177	1	48	Maciej	Maciej	NNP
10_1101-2021_01_04_425177	1	49	Kozak	Kozak	NNP
10_1101-2021_01_04_425177	1	50	1,4	1,4	CD
10_1101-2021_01_04_425177	1	51	,	,	,
10_1101-2021_01_04_425177	1	52	Sebastian	Sebastian	NNP
10_1101-2021_01_04_425177	1	53	K.T.S.	K.T.S.	NNP
10_1101-2021_01_04_425177	2	1	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	2	2	3	3	CD
10_1101-2021_01_04_425177	2	3	,	,	,
10_1101-2021_01_04_425177	2	4	*	*	NFP
10_1101-2021_01_04_425177	2	5	1	1	CD
10_1101-2021_01_04_425177	2	6	Department	Department	NNP
10_1101-2021_01_04_425177	2	7	of	of	IN
10_1101-2021_01_04_425177	2	8	Macromolecular	Macromolecular	NNP
10_1101-2021_01_04_425177	2	9	Physics	Physics	NNP
10_1101-2021_01_04_425177	2	10	,	,	,
10_1101-2021_01_04_425177	2	11	Adam	Adam	NNP
10_1101-2021_01_04_425177	2	12	Mickiewicz	Mickiewicz	NNP
10_1101-2021_01_04_425177	2	13	University	University	NNP
10_1101-2021_01_04_425177	2	14	,	,	,
10_1101-2021_01_04_425177	2	15	Poznań	Poznań	NNP
10_1101-2021_01_04_425177	2	16	,	,	,
10_1101-2021_01_04_425177	2	17	Poland	Poland	NNP
10_1101-2021_01_04_425177	2	18	;	;	:
10_1101-2021_01_04_425177	2	19	maciejgielnik@amu.edu.pl	maciejgielnik@amu.edu.pl	NNP
10_1101-2021_01_04_425177	2	20	(	(	-LRB-
10_1101-2021_01_04_425177	2	21	M.G.	M.G.	NNP
10_1101-2021_01_04_425177	3	1	)	)	-RRB-
10_1101-2021_01_04_425177	3	2	;	;	:
10_1101-2021_01_04_425177	3	3	mkozak@amu.edu.pl	mkozak@amu.edu.pl	NNP
10_1101-2021_01_04_425177	3	4	(	(	-LRB-
10_1101-2021_01_04_425177	3	5	M.K.	M.K.	NNP
10_1101-2021_01_04_425177	3	6	)	)	-RRB-
10_1101-2021_01_04_425177	4	1	2	2	CD
10_1101-2021_01_04_425177	4	2	Institute	Institute	NNP
10_1101-2021_01_04_425177	4	3	of	of	IN
10_1101-2021_01_04_425177	4	4	Biochemistry	Biochemistry	NNP
10_1101-2021_01_04_425177	4	5	and	and	CC
10_1101-2021_01_04_425177	4	6	Biophysics	Biophysics	NNPS
10_1101-2021_01_04_425177	4	7	,	,	,
10_1101-2021_01_04_425177	4	8	Polish	Polish	NNP
10_1101-2021_01_04_425177	4	9	Academy	Academy	NNP
10_1101-2021_01_04_425177	4	10	of	of	IN
10_1101-2021_01_04_425177	4	11	Sciences	Sciences	NNPS
10_1101-2021_01_04_425177	4	12	,	,	,
10_1101-2021_01_04_425177	4	13	Warszawa	Warszawa	NNP
10_1101-2021_01_04_425177	4	14	,	,	,
10_1101-2021_01_04_425177	4	15	Poland	Poland	NNP
10_1101-2021_01_04_425177	4	16	;	;	:
10_1101-2021_01_04_425177	4	17	lilia@ibb.waw.pl	lilia@ibb.waw.pl	NNP
10_1101-2021_01_04_425177	4	18	(	(	-LRB-
10_1101-2021_01_04_425177	4	19	L.Z.	L.Z.	NNP
10_1101-2021_01_04_425177	5	1	)	)	-RRB-
10_1101-2021_01_04_425177	5	2	;	;	:
10_1101-2021_01_04_425177	5	3	igor@ibb.waw.pl	igor@ibb.waw.pl	NNP
10_1101-2021_01_04_425177	5	4	(	(	-LRB-
10_1101-2021_01_04_425177	5	5	I.Z.	I.Z.	NNP
10_1101-2021_01_04_425177	5	6	)	)	-RRB-
10_1101-2021_01_04_425177	6	1	3	3	CD
10_1101-2021_01_04_425177	6	2	Department	Department	NNP
10_1101-2021_01_04_425177	6	3	of	of	IN
10_1101-2021_01_04_425177	6	4	Biochemistry	Biochemistry	NNP
10_1101-2021_01_04_425177	6	5	and	and	CC
10_1101-2021_01_04_425177	6	6	Biophysics	Biophysics	NNPS
10_1101-2021_01_04_425177	6	7	,	,	,
10_1101-2021_01_04_425177	6	8	Arrhenius	Arrhenius	NNP
10_1101-2021_01_04_425177	6	9	Laboratories	Laboratories	NNP
10_1101-2021_01_04_425177	6	10	,	,	,
10_1101-2021_01_04_425177	6	11	Stockholm	Stockholm	NNP
10_1101-2021_01_04_425177	6	12	University	University	NNP
10_1101-2021_01_04_425177	6	13	,	,	,
10_1101-2021_01_04_425177	6	14	106	106	CD
10_1101-2021_01_04_425177	6	15	91	91	CD
10_1101-2021_01_04_425177	6	16	Stockholm	Stockholm	NNP
10_1101-2021_01_04_425177	6	17	,	,	,
10_1101-2021_01_04_425177	6	18	Sweden	Sweden	NNP
10_1101-2021_01_04_425177	6	19	;	;	:
10_1101-2021_01_04_425177	6	20	astrid@dbb.su.se	astrid@dbb.su.se	NN
10_1101-2021_01_04_425177	6	21	(	(	-LRB-
10_1101-2021_01_04_425177	6	22	A.G.	A.G.	NNP
10_1101-2021_01_04_425177	6	23	)	)	-RRB-
10_1101-2021_01_04_425177	6	24	;	;	:
10_1101-2021_01_04_425177	6	25	seb@dbb.su.se	seb@dbb.su.se	NNP
10_1101-2021_01_04_425177	6	26	(	(	-LRB-
10_1101-2021_01_04_425177	6	27	S.W.	S.W.	NNP
10_1101-2021_01_04_425177	6	28	)	)	-RRB-
10_1101-2021_01_04_425177	7	1	4	4	CD
10_1101-2021_01_04_425177	7	2	National	National	NNP
10_1101-2021_01_04_425177	7	3	Synchrotron	Synchrotron	NNP
10_1101-2021_01_04_425177	7	4	Radiation	Radiation	NNP
10_1101-2021_01_04_425177	7	5	Centre	Centre	NNP
10_1101-2021_01_04_425177	7	6	SOLARIS	SOLARIS	NNP
10_1101-2021_01_04_425177	7	7	,	,	,
10_1101-2021_01_04_425177	7	8	Jagiellonian	Jagiellonian	NNP
10_1101-2021_01_04_425177	7	9	University	University	NNP
10_1101-2021_01_04_425177	7	10	,	,	,
10_1101-2021_01_04_425177	7	11	Kraków	Kraków	NNP
10_1101-2021_01_04_425177	7	12	,	,	,
10_1101-2021_01_04_425177	7	13	Poland	Poland	NNP
10_1101-2021_01_04_425177	7	14	.	.	.
10_1101-2021_01_04_425177	8	1	*	*	NFP
10_1101-2021_01_04_425177	8	2	Correspondence	correspondence	NN
10_1101-2021_01_04_425177	8	3	:	:	:
10_1101-2021_01_04_425177	8	4	seb@dbb.su.se	seb@dbb.su.se	NN
10_1101-2021_01_04_425177	8	5	;	;	:
10_1101-2021_01_04_425177	8	6	Tel	Tel	NNP
10_1101-2021_01_04_425177	8	7	.	.	.
10_1101-2021_01_04_425177	9	1	:	:	:
10_1101-2021_01_04_425177	9	2	+46	+46	CD
10_1101-2021_01_04_425177	9	3	-	-	HYPH
10_1101-2021_01_04_425177	9	4	8	8	CD
10_1101-2021_01_04_425177	9	5	-	-	SYM
10_1101-2021_01_04_425177	9	6	16	16	CD
10_1101-2021_01_04_425177	9	7	24	24	CD
10_1101-2021_01_04_425177	9	8	44	44	CD
10_1101-2021_01_04_425177	9	9	Abstract	Abstract	NNP
10_1101-2021_01_04_425177	9	10	:	:	:
10_1101-2021_01_04_425177	9	11	In	in	IN
10_1101-2021_01_04_425177	9	12	prion	prion	NN
10_1101-2021_01_04_425177	9	13	diseases	disease	NNS
10_1101-2021_01_04_425177	9	14	,	,	,
10_1101-2021_01_04_425177	9	15	the	the	DT
10_1101-2021_01_04_425177	9	16	prion	prion	NN
10_1101-2021_01_04_425177	9	17	protein	protein	NN
10_1101-2021_01_04_425177	9	18	(	(	-LRB-
10_1101-2021_01_04_425177	9	19	PrP	PrP	NNP
10_1101-2021_01_04_425177	9	20	)	)	-RRB-
10_1101-2021_01_04_425177	9	21	becomes	become	VBZ
10_1101-2021_01_04_425177	9	22	misfolded	misfolded	JJ
10_1101-2021_01_04_425177	9	23	and	and	CC
10_1101-2021_01_04_425177	9	24	forms	form	NNS
10_1101-2021_01_04_425177	9	25	fibrillar	fibrillar	JJ
10_1101-2021_01_04_425177	9	26	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	9	27	,	,	,
10_1101-2021_01_04_425177	9	28	which	which	WDT
10_1101-2021_01_04_425177	9	29	are	be	VBP
10_1101-2021_01_04_425177	9	30	resistant	resistant	JJ
10_1101-2021_01_04_425177	9	31	to	to	TO
10_1101-2021_01_04_425177	9	32	proteinase	proteinase	VB
10_1101-2021_01_04_425177	9	33	degradation	degradation	NN
10_1101-2021_01_04_425177	9	34	and	and	CC
10_1101-2021_01_04_425177	9	35	become	become	VB
10_1101-2021_01_04_425177	9	36	responsible	responsible	JJ
10_1101-2021_01_04_425177	9	37	for	for	IN
10_1101-2021_01_04_425177	9	38	prion	prion	NN
10_1101-2021_01_04_425177	9	39	infectivity	infectivity	NN
10_1101-2021_01_04_425177	9	40	and	and	CC
10_1101-2021_01_04_425177	9	41	pathology	pathology	NN
10_1101-2021_01_04_425177	9	42	.	.	.
10_1101-2021_01_04_425177	10	1	So	so	RB
10_1101-2021_01_04_425177	10	2	far	far	RB
10_1101-2021_01_04_425177	10	3	,	,	,
10_1101-2021_01_04_425177	10	4	no	no	DT
10_1101-2021_01_04_425177	10	5	drug	drug	NN
10_1101-2021_01_04_425177	10	6	or	or	CC
10_1101-2021_01_04_425177	10	7	treatment	treatment	NN
10_1101-2021_01_04_425177	10	8	procedures	procedure	NNS
10_1101-2021_01_04_425177	10	9	have	have	VBP
10_1101-2021_01_04_425177	10	10	been	be	VBN
10_1101-2021_01_04_425177	10	11	approved	approve	VBN
10_1101-2021_01_04_425177	10	12	for	for	IN
10_1101-2021_01_04_425177	10	13	prion	prion	NN
10_1101-2021_01_04_425177	10	14	disease	disease	NN
10_1101-2021_01_04_425177	10	15	treatment	treatment	NN
10_1101-2021_01_04_425177	10	16	.	.	.
10_1101-2021_01_04_425177	11	1	We	-PRON-	PRP
10_1101-2021_01_04_425177	11	2	have	have	VBP
10_1101-2021_01_04_425177	11	3	previously	previously	RB
10_1101-2021_01_04_425177	11	4	shown	show	VBN
10_1101-2021_01_04_425177	11	5	that	that	IN
10_1101-2021_01_04_425177	11	6	engineered	engineer	VBN
10_1101-2021_01_04_425177	11	7	cell	cell	NN
10_1101-2021_01_04_425177	11	8	-	-	HYPH
10_1101-2021_01_04_425177	11	9	penetrating	penetrate	VBG
10_1101-2021_01_04_425177	11	10	peptide	peptide	NN
10_1101-2021_01_04_425177	11	11	constructs	construct	NNS
10_1101-2021_01_04_425177	11	12	can	can	MD
10_1101-2021_01_04_425177	11	13	reduce	reduce	VB
10_1101-2021_01_04_425177	11	14	the	the	DT
10_1101-2021_01_04_425177	11	15	amount	amount	NN
10_1101-2021_01_04_425177	11	16	of	of	IN
10_1101-2021_01_04_425177	11	17	prion	prion	NN
10_1101-2021_01_04_425177	11	18	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	11	19	in	in	IN
10_1101-2021_01_04_425177	11	20	infected	infected	JJ
10_1101-2021_01_04_425177	11	21	cells	cell	NNS
10_1101-2021_01_04_425177	11	22	.	.	.
10_1101-2021_01_04_425177	12	1	The	the	DT
10_1101-2021_01_04_425177	12	2	molecular	molecular	JJ
10_1101-2021_01_04_425177	12	3	mechanisms	mechanism	NNS
10_1101-2021_01_04_425177	12	4	underlying	underlie	VBG
10_1101-2021_01_04_425177	12	5	this	this	DT
10_1101-2021_01_04_425177	12	6	effect	effect	NN
10_1101-2021_01_04_425177	12	7	are	be	VBP
10_1101-2021_01_04_425177	12	8	however	however	RB
10_1101-2021_01_04_425177	12	9	unknown	unknown	JJ
10_1101-2021_01_04_425177	12	10	.	.	.
10_1101-2021_01_04_425177	13	1	Here	here	RB
10_1101-2021_01_04_425177	13	2	,	,	,
10_1101-2021_01_04_425177	13	3	we	-PRON-	PRP
10_1101-2021_01_04_425177	13	4	use	use	VBP
10_1101-2021_01_04_425177	13	5	atomic	atomic	JJ
10_1101-2021_01_04_425177	13	6	force	force	NN
10_1101-2021_01_04_425177	13	7	microscopy	microscopy	JJ
10_1101-2021_01_04_425177	13	8	(	(	-LRB-
10_1101-2021_01_04_425177	13	9	AFM	AFM	NNP
10_1101-2021_01_04_425177	13	10	)	)	-RRB-
10_1101-2021_01_04_425177	13	11	imaging	image	VBG
10_1101-2021_01_04_425177	13	12	to	to	TO
10_1101-2021_01_04_425177	13	13	show	show	VB
10_1101-2021_01_04_425177	13	14	that	that	IN
10_1101-2021_01_04_425177	13	15	the	the	DT
10_1101-2021_01_04_425177	13	16	aggregation	aggregation	NN
10_1101-2021_01_04_425177	13	17	of	of	IN
10_1101-2021_01_04_425177	13	18	the	the	DT
10_1101-2021_01_04_425177	13	19	human	human	JJ
10_1101-2021_01_04_425177	13	20	PrP	PrP	NNP
10_1101-2021_01_04_425177	13	21	protein	protein	NN
10_1101-2021_01_04_425177	13	22	can	can	MD
10_1101-2021_01_04_425177	13	23	be	be	VB
10_1101-2021_01_04_425177	13	24	inhibited	inhibit	VBN
10_1101-2021_01_04_425177	13	25	by	by	IN
10_1101-2021_01_04_425177	13	26	equimolar	equimolar	JJ
10_1101-2021_01_04_425177	13	27	amounts	amount	NNS
10_1101-2021_01_04_425177	13	28	of	of	IN
10_1101-2021_01_04_425177	13	29	the	the	DT
10_1101-2021_01_04_425177	13	30	25	25	CD
10_1101-2021_01_04_425177	13	31	residues	residue	NNS
10_1101-2021_01_04_425177	13	32	long	long	RB
10_1101-2021_01_04_425177	13	33	engineered	engineer	VBN
10_1101-2021_01_04_425177	13	34	peptide	peptide	NN
10_1101-2021_01_04_425177	13	35	construct	construct	NN
10_1101-2021_01_04_425177	13	36	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	13	37	.	.	.
10_1101-2021_01_04_425177	14	1	Keywords	keyword	NNS
10_1101-2021_01_04_425177	14	2	:	:	:
10_1101-2021_01_04_425177	14	3	Creutzfeldt	Creutzfeldt	NNP
10_1101-2021_01_04_425177	14	4	-	-	HYPH
10_1101-2021_01_04_425177	14	5	Jakob	Jakob	NNP
10_1101-2021_01_04_425177	14	6	disease	disease	NN
10_1101-2021_01_04_425177	14	7	;	;	:
10_1101-2021_01_04_425177	14	8	AFM	AFM	NNP
10_1101-2021_01_04_425177	14	9	imaging	imaging	NN
10_1101-2021_01_04_425177	14	10	;	;	:
10_1101-2021_01_04_425177	14	11	amyloid	amyloid	NN
10_1101-2021_01_04_425177	14	12	;	;	:
10_1101-2021_01_04_425177	14	13	drug	drug	NN
10_1101-2021_01_04_425177	14	14	design	design	NN
10_1101-2021_01_04_425177	14	15	;	;	:
10_1101-2021_01_04_425177	14	16	drug	drug	NN
10_1101-2021_01_04_425177	14	17	transport	transport	NN
10_1101-2021_01_04_425177	14	18	;	;	:
10_1101-2021_01_04_425177	14	19	protein	protein	NN
10_1101-2021_01_04_425177	14	20	-	-	HYPH
10_1101-2021_01_04_425177	14	21	peptide	peptide	NN
10_1101-2021_01_04_425177	14	22	binding	binding	NN
10_1101-2021_01_04_425177	14	23	.CC	.CC	:
10_1101-2021_01_04_425177	14	24	-	-	HYPH
10_1101-2021_01_04_425177	14	25	BY	by	IN
10_1101-2021_01_04_425177	14	26	-	-	HYPH
10_1101-2021_01_04_425177	14	27	NC	NC	NNP
10_1101-2021_01_04_425177	14	28	-	-	HYPH
10_1101-2021_01_04_425177	14	29	ND	ND	NNP
10_1101-2021_01_04_425177	14	30	4.0	4.0	CD
10_1101-2021_01_04_425177	14	31	International	international	JJ
10_1101-2021_01_04_425177	14	32	licensemade	licensemade	NN
10_1101-2021_01_04_425177	14	33	available	available	JJ
10_1101-2021_01_04_425177	14	34	under	under	IN
10_1101-2021_01_04_425177	14	35	a	a	DT
10_1101-2021_01_04_425177	14	36	(	(	-LRB-
10_1101-2021_01_04_425177	14	37	which	which	WDT
10_1101-2021_01_04_425177	14	38	was	be	VBD
10_1101-2021_01_04_425177	14	39	not	not	RB
10_1101-2021_01_04_425177	14	40	certified	certify	VBN
10_1101-2021_01_04_425177	14	41	by	by	IN
10_1101-2021_01_04_425177	14	42	peer	peer	NN
10_1101-2021_01_04_425177	14	43	review	review	NN
10_1101-2021_01_04_425177	14	44	)	)	-RRB-
10_1101-2021_01_04_425177	14	45	is	be	VBZ
10_1101-2021_01_04_425177	14	46	the	the	DT
10_1101-2021_01_04_425177	14	47	author	author	NN
10_1101-2021_01_04_425177	14	48	/	/	SYM
10_1101-2021_01_04_425177	14	49	funder	funder	NN
10_1101-2021_01_04_425177	14	50	,	,	,
10_1101-2021_01_04_425177	14	51	who	who	WP
10_1101-2021_01_04_425177	14	52	has	have	VBZ
10_1101-2021_01_04_425177	14	53	granted	grant	VBN
10_1101-2021_01_04_425177	14	54	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	14	55	a	a	DT
10_1101-2021_01_04_425177	14	56	license	license	NN
10_1101-2021_01_04_425177	14	57	to	to	TO
10_1101-2021_01_04_425177	14	58	display	display	VB
10_1101-2021_01_04_425177	14	59	the	the	DT
10_1101-2021_01_04_425177	14	60	preprint	preprint	NN
10_1101-2021_01_04_425177	14	61	in	in	IN
10_1101-2021_01_04_425177	14	62	perpetuity	perpetuity	NN
10_1101-2021_01_04_425177	14	63	.	.	.
10_1101-2021_01_04_425177	15	1	It	-PRON-	PRP
10_1101-2021_01_04_425177	15	2	is	be	VBZ
10_1101-2021_01_04_425177	15	3	The	the	DT
10_1101-2021_01_04_425177	15	4	copyright	copyright	NN
10_1101-2021_01_04_425177	15	5	holder	holder	NN
10_1101-2021_01_04_425177	15	6	for	for	IN
10_1101-2021_01_04_425177	15	7	this	this	DT
10_1101-2021_01_04_425177	15	8	preprintthis	preprintthis	NN
10_1101-2021_01_04_425177	15	9	version	version	NN
10_1101-2021_01_04_425177	15	10	posted	post	VBD
10_1101-2021_01_04_425177	15	11	January	January	NNP
10_1101-2021_01_04_425177	15	12	4	4	CD
10_1101-2021_01_04_425177	15	13	,	,	,
10_1101-2021_01_04_425177	15	14	2021	2021	CD
10_1101-2021_01_04_425177	15	15	.	.	.
10_1101-2021_01_04_425177	15	16	;	;	:
10_1101-2021_01_04_425177	15	17	https://doi.org/10.1101/2021.01.04.425177doi	https://doi.org/10.1101/2021.01.04.425177doi	ADD
10_1101-2021_01_04_425177	15	18	:	:	:
10_1101-2021_01_04_425177	15	19	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	15	20	preprint	preprint	NN
10_1101-2021_01_04_425177	15	21	https://doi.org/10.1101/2021.01.04.425177	https://doi.org/10.1101/2021.01.04.425177	VBZ
10_1101-2021_01_04_425177	15	22	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2021_01_04_425177	15	23	2	2	CD
10_1101-2021_01_04_425177	15	24	1	1	CD
10_1101-2021_01_04_425177	15	25	.	.	.
10_1101-2021_01_04_425177	16	1	Introduction	introduction	NN
10_1101-2021_01_04_425177	16	2	Prion	prion	NN
10_1101-2021_01_04_425177	16	3	and	and	CC
10_1101-2021_01_04_425177	16	4	amyloid	amyloid	NN
10_1101-2021_01_04_425177	16	5	diseases	disease	NNS
10_1101-2021_01_04_425177	16	6	are	be	VBP
10_1101-2021_01_04_425177	16	7	both	both	DT
10_1101-2021_01_04_425177	16	8	characterized	characterize	VBN
10_1101-2021_01_04_425177	16	9	by	by	IN
10_1101-2021_01_04_425177	16	10	aggregation	aggregation	NN
10_1101-2021_01_04_425177	16	11	of	of	IN
10_1101-2021_01_04_425177	16	12	misfolded	misfolde	VBN
10_1101-2021_01_04_425177	16	13	proteins	protein	NNS
10_1101-2021_01_04_425177	16	14	or	or	CC
10_1101-2021_01_04_425177	16	15	peptides	peptide	NNS
10_1101-2021_01_04_425177	16	16	(	(	-LRB-
10_1101-2021_01_04_425177	16	17	Jaunmuktane	Jaunmuktane	NNP
10_1101-2021_01_04_425177	16	18	and	and	CC
10_1101-2021_01_04_425177	16	19	Brandner	Brandner	NNP
10_1101-2021_01_04_425177	16	20	,	,	,
10_1101-2021_01_04_425177	16	21	2019	2019	CD
10_1101-2021_01_04_425177	16	22	;	;	:
10_1101-2021_01_04_425177	16	23	Miller	Miller	NNP
10_1101-2021_01_04_425177	16	24	,	,	,
10_1101-2021_01_04_425177	16	25	2009	2009	CD
10_1101-2021_01_04_425177	16	26	;	;	:
10_1101-2021_01_04_425177	16	27	Sengupta	Sengupta	NNP
10_1101-2021_01_04_425177	16	28	and	and	CC
10_1101-2021_01_04_425177	16	29	Udgaonkar	Udgaonkar	NNP
10_1101-2021_01_04_425177	16	30	,	,	,
10_1101-2021_01_04_425177	16	31	2018	2018	CD
10_1101-2021_01_04_425177	16	32	;	;	:
10_1101-2021_01_04_425177	16	33	Verma	Verma	NNP
10_1101-2021_01_04_425177	16	34	et	et	FW
10_1101-2021_01_04_425177	16	35	al	al	NNP
10_1101-2021_01_04_425177	16	36	.	.	NNP
10_1101-2021_01_04_425177	16	37	,	,	,
10_1101-2021_01_04_425177	16	38	2015	2015	CD
10_1101-2021_01_04_425177	16	39	)	)	-RRB-
10_1101-2021_01_04_425177	16	40	,	,	,
10_1101-2021_01_04_425177	16	41	such	such	JJ
10_1101-2021_01_04_425177	16	42	as	as	IN
10_1101-2021_01_04_425177	16	43	the	the	DT
10_1101-2021_01_04_425177	16	44	prion	prion	NN
10_1101-2021_01_04_425177	16	45	(	(	-LRB-
10_1101-2021_01_04_425177	16	46	PrP	PrP	NNP
10_1101-2021_01_04_425177	16	47	)	)	-RRB-
10_1101-2021_01_04_425177	16	48	protein	protein	NN
10_1101-2021_01_04_425177	16	49	(	(	-LRB-
10_1101-2021_01_04_425177	16	50	Creutzfeldt-	Creutzfeldt-	NNP
10_1101-2021_01_04_425177	16	51	Jakob	Jakob	NNP
10_1101-2021_01_04_425177	16	52	disease	disease	NN
10_1101-2021_01_04_425177	16	53	)	)	-RRB-
10_1101-2021_01_04_425177	16	54	,	,	,
10_1101-2021_01_04_425177	16	55	α	α	NNP
10_1101-2021_01_04_425177	16	56	-	-	HYPH
10_1101-2021_01_04_425177	16	57	synuclein	synuclein	NNP
10_1101-2021_01_04_425177	16	58	(	(	-LRB-
10_1101-2021_01_04_425177	16	59	Parkinson	Parkinson	NNP
10_1101-2021_01_04_425177	16	60	’s	’s	POS
10_1101-2021_01_04_425177	16	61	disease	disease	NN
10_1101-2021_01_04_425177	16	62	)	)	-RRB-
10_1101-2021_01_04_425177	16	63	,	,	,
10_1101-2021_01_04_425177	16	64	and	and	CC
10_1101-2021_01_04_425177	16	65	amyloid	amyloid	NN
10_1101-2021_01_04_425177	16	66	-	-	HYPH
10_1101-2021_01_04_425177	16	67	β	β	NNP
10_1101-2021_01_04_425177	16	68	(	(	-LRB-
10_1101-2021_01_04_425177	16	69	Aβ	Aβ	NNP
10_1101-2021_01_04_425177	16	70	)	)	-RRB-
10_1101-2021_01_04_425177	16	71	and	and	CC
10_1101-2021_01_04_425177	16	72	tau	tau	NNP
10_1101-2021_01_04_425177	16	73	(	(	-LRB-
10_1101-2021_01_04_425177	16	74	Alzheimer	Alzheimer	NNP
10_1101-2021_01_04_425177	16	75	’s	’s	POS
10_1101-2021_01_04_425177	16	76	disease	disease	NN
10_1101-2021_01_04_425177	16	77	)	)	-RRB-
10_1101-2021_01_04_425177	16	78	.	.	.
10_1101-2021_01_04_425177	17	1	Many	many	JJ
10_1101-2021_01_04_425177	17	2	of	of	IN
10_1101-2021_01_04_425177	17	3	these	these	DT
10_1101-2021_01_04_425177	17	4	proteins	protein	NNS
10_1101-2021_01_04_425177	17	5	and	and	CC
10_1101-2021_01_04_425177	17	6	peptides	peptide	NNS
10_1101-2021_01_04_425177	17	7	may	may	MD
10_1101-2021_01_04_425177	17	8	co	co	VB
10_1101-2021_01_04_425177	17	9	-	-	VB
10_1101-2021_01_04_425177	17	10	aggregate	aggregate	VB
10_1101-2021_01_04_425177	17	11	or	or	CC
10_1101-2021_01_04_425177	17	12	at	at	IN
10_1101-2021_01_04_425177	17	13	least	least	JJS
10_1101-2021_01_04_425177	17	14	influence	influence	VB
10_1101-2021_01_04_425177	17	15	each	each	DT
10_1101-2021_01_04_425177	17	16	other	other	JJ
10_1101-2021_01_04_425177	17	17	’s	’s	POS
10_1101-2021_01_04_425177	17	18	aggregation	aggregation	NN
10_1101-2021_01_04_425177	17	19	(	(	-LRB-
10_1101-2021_01_04_425177	17	20	Luo	Luo	NNP
10_1101-2021_01_04_425177	17	21	et	et	NNP
10_1101-2021_01_04_425177	17	22	al	al	NNP
10_1101-2021_01_04_425177	17	23	.	.	NNP
10_1101-2021_01_04_425177	17	24	,	,	,
10_1101-2021_01_04_425177	17	25	2016	2016	CD
10_1101-2021_01_04_425177	17	26	,	,	,
10_1101-2021_01_04_425177	17	27	2017	2017	CD
10_1101-2021_01_04_425177	17	28	;	;	:
10_1101-2021_01_04_425177	17	29	Ren	Ren	NNP
10_1101-2021_01_04_425177	17	30	et	et	NNP
10_1101-2021_01_04_425177	17	31	al	al	NNP
10_1101-2021_01_04_425177	17	32	.	.	NNP
10_1101-2021_01_04_425177	17	33	,	,	,
10_1101-2021_01_04_425177	17	34	2019	2019	CD
10_1101-2021_01_04_425177	17	35	;	;	:
10_1101-2021_01_04_425177	17	36	Wallin	Wallin	NNP
10_1101-2021_01_04_425177	17	37	et	et	NNP
10_1101-2021_01_04_425177	17	38	al	al	NNP
10_1101-2021_01_04_425177	17	39	.	.	NNP
10_1101-2021_01_04_425177	17	40	,	,	,
10_1101-2021_01_04_425177	17	41	2018	2018	CD
10_1101-2021_01_04_425177	17	42	)	)	-RRB-
10_1101-2021_01_04_425177	17	43	.	.	.
10_1101-2021_01_04_425177	18	1	Factors	factor	NNS
10_1101-2021_01_04_425177	18	2	that	that	WDT
10_1101-2021_01_04_425177	18	3	modulate	modulate	VBP
10_1101-2021_01_04_425177	18	4	the	the	DT
10_1101-2021_01_04_425177	18	5	aggregation	aggregation	NN
10_1101-2021_01_04_425177	18	6	of	of	IN
10_1101-2021_01_04_425177	18	7	one	one	CD
10_1101-2021_01_04_425177	18	8	of	of	IN
10_1101-2021_01_04_425177	18	9	these	these	DT
10_1101-2021_01_04_425177	18	10	proteins	protein	NNS
10_1101-2021_01_04_425177	18	11	,	,	,
10_1101-2021_01_04_425177	18	12	such	such	JJ
10_1101-2021_01_04_425177	18	13	as	as	IN
10_1101-2021_01_04_425177	18	14	small	small	JJ
10_1101-2021_01_04_425177	18	15	molecules	molecule	NNS
10_1101-2021_01_04_425177	18	16	,	,	,
10_1101-2021_01_04_425177	18	17	potential	potential	JJ
10_1101-2021_01_04_425177	18	18	drug	drug	NN
10_1101-2021_01_04_425177	18	19	compounds	compound	NNS
10_1101-2021_01_04_425177	18	20	,	,	,
10_1101-2021_01_04_425177	18	21	lipids	lipid	NNS
10_1101-2021_01_04_425177	18	22	,	,	,
10_1101-2021_01_04_425177	18	23	and	and	CC
10_1101-2021_01_04_425177	18	24	metal	metal	NN
10_1101-2021_01_04_425177	18	25	ions	ion	NNS
10_1101-2021_01_04_425177	18	26	,	,	,
10_1101-2021_01_04_425177	18	27	can	can	MD
10_1101-2021_01_04_425177	18	28	often	often	RB
10_1101-2021_01_04_425177	18	29	modulate	modulate	VB
10_1101-2021_01_04_425177	18	30	also	also	RB
10_1101-2021_01_04_425177	18	31	the	the	DT
10_1101-2021_01_04_425177	18	32	aggregation	aggregation	NN
10_1101-2021_01_04_425177	18	33	processes	process	NNS
10_1101-2021_01_04_425177	18	34	of	of	IN
10_1101-2021_01_04_425177	18	35	other	other	JJ
10_1101-2021_01_04_425177	18	36	proteins	protein	NNS
10_1101-2021_01_04_425177	18	37	in	in	IN
10_1101-2021_01_04_425177	18	38	this	this	DT
10_1101-2021_01_04_425177	18	39	family	family	NN
10_1101-2021_01_04_425177	18	40	(	(	-LRB-
10_1101-2021_01_04_425177	18	41	Ambadi	Ambadi	NNP
10_1101-2021_01_04_425177	18	42	Thody	Thody	NNP
10_1101-2021_01_04_425177	18	43	et	et	FW
10_1101-2021_01_04_425177	18	44	al	al	NNP
10_1101-2021_01_04_425177	18	45	.	.	NNP
10_1101-2021_01_04_425177	18	46	,	,	,
10_1101-2021_01_04_425177	18	47	2018	2018	CD
10_1101-2021_01_04_425177	18	48	;	;	:
10_1101-2021_01_04_425177	18	49	Chemerovski	Chemerovski	NNP
10_1101-2021_01_04_425177	18	50	-	-	HYPH
10_1101-2021_01_04_425177	18	51	Glikman	Glikman	NNP
10_1101-2021_01_04_425177	18	52	et	et	NNP
10_1101-2021_01_04_425177	18	53	al	al	NNP
10_1101-2021_01_04_425177	18	54	.	.	NNP
10_1101-2021_01_04_425177	18	55	,	,	,
10_1101-2021_01_04_425177	18	56	2016	2016	CD
10_1101-2021_01_04_425177	18	57	;	;	:
10_1101-2021_01_04_425177	18	58	Gielnik	Gielnik	NNP
10_1101-2021_01_04_425177	18	59	et	et	FW
10_1101-2021_01_04_425177	18	60	al	al	NNP
10_1101-2021_01_04_425177	18	61	.	.	NNP
10_1101-2021_01_04_425177	18	62	,	,	,
10_1101-2021_01_04_425177	18	63	2019	2019	CD
10_1101-2021_01_04_425177	18	64	;	;	:
10_1101-2021_01_04_425177	18	65	Owen	Owen	NNP
10_1101-2021_01_04_425177	18	66	et	et	NNP
10_1101-2021_01_04_425177	18	67	al	al	NNP
10_1101-2021_01_04_425177	18	68	.	.	NNP
10_1101-2021_01_04_425177	18	69	,	,	,
10_1101-2021_01_04_425177	18	70	2019	2019	CD
10_1101-2021_01_04_425177	18	71	;	;	:
10_1101-2021_01_04_425177	18	72	Richman	Richman	NNP
10_1101-2021_01_04_425177	18	73	et	et	FW
10_1101-2021_01_04_425177	18	74	al	al	NNP
10_1101-2021_01_04_425177	18	75	.	.	NNP
10_1101-2021_01_04_425177	18	76	,	,	,
10_1101-2021_01_04_425177	18	77	2013	2013	CD
10_1101-2021_01_04_425177	18	78	;	;	:
10_1101-2021_01_04_425177	18	79	Robinson	Robinson	NNP
10_1101-2021_01_04_425177	18	80	and	and	CC
10_1101-2021_01_04_425177	18	81	Pinheiro	Pinheiro	NNP
10_1101-2021_01_04_425177	18	82	,	,	,
10_1101-2021_01_04_425177	18	83	2010	2010	CD
10_1101-2021_01_04_425177	18	84	;	;	:
10_1101-2021_01_04_425177	18	85	Wallin	Wallin	NNP
10_1101-2021_01_04_425177	18	86	et	et	NNP
10_1101-2021_01_04_425177	18	87	al	al	NNP
10_1101-2021_01_04_425177	18	88	.	.	NNP
10_1101-2021_01_04_425177	18	89	,	,	,
10_1101-2021_01_04_425177	18	90	2017	2017	CD
10_1101-2021_01_04_425177	18	91	;	;	:
10_1101-2021_01_04_425177	18	92	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	18	93	et	et	FW
10_1101-2021_01_04_425177	18	94	al	al	NNP
10_1101-2021_01_04_425177	18	95	.	.	NNP
10_1101-2021_01_04_425177	18	96	,	,	,
10_1101-2021_01_04_425177	18	97	2013	2013	CD
10_1101-2021_01_04_425177	18	98	;	;	:
10_1101-2021_01_04_425177	18	99	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	18	100	et	et	FW
10_1101-2021_01_04_425177	18	101	al	al	NNP
10_1101-2021_01_04_425177	18	102	.	.	NNP
10_1101-2021_01_04_425177	18	103	,	,	,
10_1101-2021_01_04_425177	18	104	2019	2019	CD
10_1101-2021_01_04_425177	18	105	;	;	:
10_1101-2021_01_04_425177	18	106	Österlund	Österlund	NNP
10_1101-2021_01_04_425177	18	107	et	et	NNP
10_1101-2021_01_04_425177	18	108	al	al	NNP
10_1101-2021_01_04_425177	18	109	.	.	NNP
10_1101-2021_01_04_425177	18	110	,	,	,
10_1101-2021_01_04_425177	18	111	2018	2018	CD
10_1101-2021_01_04_425177	18	112	)	)	-RRB-
10_1101-2021_01_04_425177	18	113	.	.	.
10_1101-2021_01_04_425177	19	1	This	this	DT
10_1101-2021_01_04_425177	19	2	suggests	suggest	VBZ
10_1101-2021_01_04_425177	19	3	that	that	IN
10_1101-2021_01_04_425177	19	4	the	the	DT
10_1101-2021_01_04_425177	19	5	underlying	underlie	VBG
10_1101-2021_01_04_425177	19	6	mechanisms	mechanism	NNS
10_1101-2021_01_04_425177	19	7	may	may	MD
10_1101-2021_01_04_425177	19	8	be	be	VB
10_1101-2021_01_04_425177	19	9	the	the	DT
10_1101-2021_01_04_425177	19	10	same	same	JJ
10_1101-2021_01_04_425177	19	11	in	in	IN
10_1101-2021_01_04_425177	19	12	prion	prion	NN
10_1101-2021_01_04_425177	19	13	and	and	CC
10_1101-2021_01_04_425177	19	14	amyloid	amyloid	NN
10_1101-2021_01_04_425177	19	15	diseases	disease	NNS
10_1101-2021_01_04_425177	19	16	(	(	-LRB-
10_1101-2021_01_04_425177	19	17	Jaunmuktane	Jaunmuktane	NNP
10_1101-2021_01_04_425177	19	18	and	and	CC
10_1101-2021_01_04_425177	19	19	Brandner	Brandner	NNP
10_1101-2021_01_04_425177	19	20	,	,	,
10_1101-2021_01_04_425177	19	21	2019	2019	CD
10_1101-2021_01_04_425177	19	22	;	;	:
10_1101-2021_01_04_425177	19	23	Jucker	Jucker	NNP
10_1101-2021_01_04_425177	19	24	and	and	CC
10_1101-2021_01_04_425177	19	25	Walker	Walker	NNP
10_1101-2021_01_04_425177	19	26	,	,	,
10_1101-2021_01_04_425177	19	27	2018	2018	CD
10_1101-2021_01_04_425177	19	28	;	;	:
10_1101-2021_01_04_425177	19	29	Miller	Miller	NNP
10_1101-2021_01_04_425177	19	30	,	,	,
10_1101-2021_01_04_425177	19	31	2009	2009	CD
10_1101-2021_01_04_425177	19	32	)	)	-RRB-
10_1101-2021_01_04_425177	19	33	.	.	.
10_1101-2021_01_04_425177	20	1	Prion	prion	NN
10_1101-2021_01_04_425177	20	2	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	20	3	are	be	VBP
10_1101-2021_01_04_425177	20	4	however	however	RB
10_1101-2021_01_04_425177	20	5	particularly	particularly	RB
10_1101-2021_01_04_425177	20	6	infectious	infectious	JJ
10_1101-2021_01_04_425177	20	7	,	,	,
10_1101-2021_01_04_425177	20	8	as	as	IN
10_1101-2021_01_04_425177	20	9	they	-PRON-	PRP
10_1101-2021_01_04_425177	20	10	spread	spread	VBD
10_1101-2021_01_04_425177	20	11	between	between	IN
10_1101-2021_01_04_425177	20	12	cells	cell	NNS
10_1101-2021_01_04_425177	20	13	(	(	-LRB-
10_1101-2021_01_04_425177	20	14	Jaunmuktane	Jaunmuktane	NNP
10_1101-2021_01_04_425177	20	15	and	and	CC
10_1101-2021_01_04_425177	20	16	Brandner	Brandner	NNP
10_1101-2021_01_04_425177	20	17	,	,	,
10_1101-2021_01_04_425177	20	18	2019	2019	CD
10_1101-2021_01_04_425177	20	19	;	;	:
10_1101-2021_01_04_425177	20	20	Jucker	Jucker	NNP
10_1101-2021_01_04_425177	20	21	and	and	CC
10_1101-2021_01_04_425177	20	22	Walker	Walker	NNP
10_1101-2021_01_04_425177	20	23	,	,	,
10_1101-2021_01_04_425177	20	24	2018	2018	CD
10_1101-2021_01_04_425177	20	25	)	)	-RRB-
10_1101-2021_01_04_425177	20	26	,	,	,
10_1101-2021_01_04_425177	20	27	and	and	CC
10_1101-2021_01_04_425177	20	28	are	be	VBP
10_1101-2021_01_04_425177	20	29	not	not	RB
10_1101-2021_01_04_425177	20	30	degraded	degrade	VBN
10_1101-2021_01_04_425177	20	31	by	by	IN
10_1101-2021_01_04_425177	20	32	cellular	cellular	JJ
10_1101-2021_01_04_425177	20	33	processes	process	NNS
10_1101-2021_01_04_425177	20	34	such	such	JJ
10_1101-2021_01_04_425177	20	35	as	as	IN
10_1101-2021_01_04_425177	20	36	proteinase	proteinase	NN
10_1101-2021_01_04_425177	20	37	digestion	digestion	NN
10_1101-2021_01_04_425177	20	38	(	(	-LRB-
10_1101-2021_01_04_425177	20	39	Jaunmuktane	Jaunmuktane	NNP
10_1101-2021_01_04_425177	20	40	and	and	CC
10_1101-2021_01_04_425177	20	41	Brandner	Brandner	NNP
10_1101-2021_01_04_425177	20	42	,	,	,
10_1101-2021_01_04_425177	20	43	2019	2019	CD
10_1101-2021_01_04_425177	20	44	;	;	:
10_1101-2021_01_04_425177	20	45	Löfgren	Löfgren	NNP
10_1101-2021_01_04_425177	20	46	et	et	NNP
10_1101-2021_01_04_425177	20	47	al	al	NNP
10_1101-2021_01_04_425177	20	48	.	.	NNP
10_1101-2021_01_04_425177	20	49	,	,	,
10_1101-2021_01_04_425177	20	50	2008	2008	CD
10_1101-2021_01_04_425177	20	51	;	;	:
10_1101-2021_01_04_425177	20	52	Söderberg	Söderberg	NNP
10_1101-2021_01_04_425177	20	53	et	et	NNP
10_1101-2021_01_04_425177	20	54	al	al	NNP
10_1101-2021_01_04_425177	20	55	.	.	NNP
10_1101-2021_01_04_425177	20	56	,	,	,
10_1101-2021_01_04_425177	20	57	2014	2014	CD
10_1101-2021_01_04_425177	20	58	)	)	-RRB-
10_1101-2021_01_04_425177	20	59	.	.	.
10_1101-2021_01_04_425177	21	1	The	the	DT
10_1101-2021_01_04_425177	21	2	toxic	toxic	JJ
10_1101-2021_01_04_425177	21	3	species	specie	NNS
10_1101-2021_01_04_425177	21	4	in	in	IN
10_1101-2021_01_04_425177	21	5	amyloid	amyloid	NN
10_1101-2021_01_04_425177	21	6	and	and	CC
10_1101-2021_01_04_425177	21	7	prion	prion	NN
10_1101-2021_01_04_425177	21	8	diseases	disease	NNS
10_1101-2021_01_04_425177	21	9	are	be	VBP
10_1101-2021_01_04_425177	21	10	generally	generally	RB
10_1101-2021_01_04_425177	21	11	considered	consider	VBN
10_1101-2021_01_04_425177	21	12	to	to	TO
10_1101-2021_01_04_425177	21	13	be	be	VB
10_1101-2021_01_04_425177	21	14	small	small	JJ
10_1101-2021_01_04_425177	21	15	toxic	toxic	JJ
10_1101-2021_01_04_425177	21	16	oligomeric	oligomeric	JJ
10_1101-2021_01_04_425177	21	17	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	21	18	(	(	-LRB-
10_1101-2021_01_04_425177	21	19	Sengupta	Sengupta	NNP
10_1101-2021_01_04_425177	21	20	and	and	CC
10_1101-2021_01_04_425177	21	21	Udgaonkar	Udgaonkar	NNP
10_1101-2021_01_04_425177	21	22	,	,	,
10_1101-2021_01_04_425177	21	23	2018	2018	CD
10_1101-2021_01_04_425177	21	24	;	;	:
10_1101-2021_01_04_425177	21	25	Verma	Verma	NNP
10_1101-2021_01_04_425177	21	26	et	et	FW
10_1101-2021_01_04_425177	21	27	al	al	NNP
10_1101-2021_01_04_425177	21	28	.	.	NNP
10_1101-2021_01_04_425177	21	29	,	,	,
10_1101-2021_01_04_425177	21	30	2015	2015	CD
10_1101-2021_01_04_425177	21	31	)	)	-RRB-
10_1101-2021_01_04_425177	21	32	,	,	,
10_1101-2021_01_04_425177	21	33	but	but	CC
10_1101-2021_01_04_425177	21	34	so	so	RB
10_1101-2021_01_04_425177	21	35	far	far	RB
10_1101-2021_01_04_425177	21	36	no	no	DT
10_1101-2021_01_04_425177	21	37	drugs	drug	NNS
10_1101-2021_01_04_425177	21	38	or	or	CC
10_1101-2021_01_04_425177	21	39	treatments	treatment	NNS
10_1101-2021_01_04_425177	21	40	that	that	WDT
10_1101-2021_01_04_425177	21	41	target	target	VBP
10_1101-2021_01_04_425177	21	42	such	such	JJ
10_1101-2021_01_04_425177	21	43	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	21	44	have	have	VBP
10_1101-2021_01_04_425177	21	45	been	be	VBN
10_1101-2021_01_04_425177	21	46	approved	approve	VBN
10_1101-2021_01_04_425177	21	47	against	against	IN
10_1101-2021_01_04_425177	21	48	prion	prion	NN
10_1101-2021_01_04_425177	21	49	diseases	disease	NNS
10_1101-2021_01_04_425177	21	50	(	(	-LRB-
10_1101-2021_01_04_425177	21	51	Hyeon	Hyeon	NNP
10_1101-2021_01_04_425177	21	52	et	et	NNP
10_1101-2021_01_04_425177	21	53	al	al	NNP
10_1101-2021_01_04_425177	21	54	.	.	NNP
10_1101-2021_01_04_425177	21	55	,	,	,
10_1101-2021_01_04_425177	21	56	2020	2020	CD
10_1101-2021_01_04_425177	21	57	;	;	:
10_1101-2021_01_04_425177	21	58	Lee	Lee	NNP
10_1101-2021_01_04_425177	21	59	et	et	FW
10_1101-2021_01_04_425177	21	60	al	al	NNP
10_1101-2021_01_04_425177	21	61	.	.	NNP
10_1101-2021_01_04_425177	21	62	,	,	,
10_1101-2021_01_04_425177	21	63	2019	2019	CD
10_1101-2021_01_04_425177	21	64	;	;	:
10_1101-2021_01_04_425177	21	65	Mashima	Mashima	NNP
10_1101-2021_01_04_425177	21	66	et	et	NNP
10_1101-2021_01_04_425177	21	67	al	al	NNP
10_1101-2021_01_04_425177	21	68	.	.	NNP
10_1101-2021_01_04_425177	21	69	,	,	,
10_1101-2021_01_04_425177	21	70	2020	2020	CD
10_1101-2021_01_04_425177	21	71	)	)	-RRB-
10_1101-2021_01_04_425177	21	72	.	.	.
10_1101-2021_01_04_425177	22	1	Potential	potential	JJ
10_1101-2021_01_04_425177	22	2	drug	drug	NN
10_1101-2021_01_04_425177	22	3	molecules	molecule	NNS
10_1101-2021_01_04_425177	22	4	may	may	MD
10_1101-2021_01_04_425177	22	5	interfere	interfere	VB
10_1101-2021_01_04_425177	22	6	with	with	IN
10_1101-2021_01_04_425177	22	7	oligomer	oligomer	JJ
10_1101-2021_01_04_425177	22	8	formation	formation	NN
10_1101-2021_01_04_425177	22	9	in	in	IN
10_1101-2021_01_04_425177	22	10	various	various	JJ
10_1101-2021_01_04_425177	22	11	ways	way	NNS
10_1101-2021_01_04_425177	22	12	:	:	:
10_1101-2021_01_04_425177	22	13	by	by	IN
10_1101-2021_01_04_425177	22	14	reducing	reduce	VBG
10_1101-2021_01_04_425177	22	15	production	production	NN
10_1101-2021_01_04_425177	22	16	of	of	IN
10_1101-2021_01_04_425177	22	17	the	the	DT
10_1101-2021_01_04_425177	22	18	protein	protein	NN
10_1101-2021_01_04_425177	22	19	,	,	,
10_1101-2021_01_04_425177	22	20	by	by	IN
10_1101-2021_01_04_425177	22	21	inhibiting	inhibit	VBG
10_1101-2021_01_04_425177	22	22	its	-PRON-	PRP$
10_1101-2021_01_04_425177	22	23	aggregation	aggregation	NN
10_1101-2021_01_04_425177	22	24	,	,	,
10_1101-2021_01_04_425177	22	25	by	by	IN
10_1101-2021_01_04_425177	22	26	diverting	divert	VBG
10_1101-2021_01_04_425177	22	27	the	the	DT
10_1101-2021_01_04_425177	22	28	aggregation	aggregation	NN
10_1101-2021_01_04_425177	22	29	pathway(s	pathway(s	NNP
10_1101-2021_01_04_425177	22	30	)	)	-RRB-
10_1101-2021_01_04_425177	22	31	towards	towards	IN
10_1101-2021_01_04_425177	22	32	non	non	JJ
10_1101-2021_01_04_425177	22	33	-	-	JJ
10_1101-2021_01_04_425177	22	34	toxic	toxic	JJ
10_1101-2021_01_04_425177	22	35	forms	form	NNS
10_1101-2021_01_04_425177	22	36	,	,	,
10_1101-2021_01_04_425177	22	37	or	or	CC
10_1101-2021_01_04_425177	22	38	by	by	IN
10_1101-2021_01_04_425177	22	39	reducing	reduce	VBG
10_1101-2021_01_04_425177	22	40	the	the	DT
10_1101-2021_01_04_425177	22	41	lifetime	lifetime	NN
10_1101-2021_01_04_425177	22	42	of	of	IN
10_1101-2021_01_04_425177	22	43	the	the	DT
10_1101-2021_01_04_425177	22	44	toxic	toxic	JJ
10_1101-2021_01_04_425177	22	45	forms	form	NNS
10_1101-2021_01_04_425177	22	46	,	,	,
10_1101-2021_01_04_425177	22	47	for	for	IN
10_1101-2021_01_04_425177	22	48	example	example	NN
10_1101-2021_01_04_425177	22	49	by	by	IN
10_1101-2021_01_04_425177	22	50	promoting	promote	VBG
10_1101-2021_01_04_425177	22	51	rapid	rapid	JJ
10_1101-2021_01_04_425177	22	52	aggregation	aggregation	NN
10_1101-2021_01_04_425177	22	53	into	into	IN
10_1101-2021_01_04_425177	22	54	larger	large	JJR
10_1101-2021_01_04_425177	22	55	non	non	JJ
10_1101-2021_01_04_425177	22	56	-	-	JJ
10_1101-2021_01_04_425177	22	57	toxic	toxic	JJ
10_1101-2021_01_04_425177	22	58	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	22	59	.	.	.
10_1101-2021_01_04_425177	23	1	We	-PRON-	PRP
10_1101-2021_01_04_425177	23	2	have	have	VBP
10_1101-2021_01_04_425177	23	3	previously	previously	RB
10_1101-2021_01_04_425177	23	4	demonstrated	demonstrate	VBN
10_1101-2021_01_04_425177	23	5	anti	anti	JJ
10_1101-2021_01_04_425177	23	6	-	-	JJ
10_1101-2021_01_04_425177	23	7	prion	prion	JJ
10_1101-2021_01_04_425177	23	8	properties	property	NNS
10_1101-2021_01_04_425177	23	9	in	in	IN
10_1101-2021_01_04_425177	23	10	short	short	JJ
10_1101-2021_01_04_425177	23	11	peptide	peptide	NN
10_1101-2021_01_04_425177	23	12	constructs	construct	NNS
10_1101-2021_01_04_425177	23	13	(	(	-LRB-
10_1101-2021_01_04_425177	23	14	up	up	IN
10_1101-2021_01_04_425177	23	15	to	to	TO
10_1101-2021_01_04_425177	23	16	30	30	CD
10_1101-2021_01_04_425177	23	17	residues	residue	NNS
10_1101-2021_01_04_425177	23	18	)	)	-RRB-
10_1101-2021_01_04_425177	23	19	with	with	IN
10_1101-2021_01_04_425177	23	20	sequences	sequence	NNS
10_1101-2021_01_04_425177	23	21	derived	derive	VBN
10_1101-2021_01_04_425177	23	22	from	from	IN
10_1101-2021_01_04_425177	23	23	the	the	DT
10_1101-2021_01_04_425177	23	24	unprocessed	unprocessed	JJ
10_1101-2021_01_04_425177	23	25	N	N	NNP
10_1101-2021_01_04_425177	23	26	-	-	HYPH
10_1101-2021_01_04_425177	23	27	termini	termini	NN
10_1101-2021_01_04_425177	23	28	of	of	IN
10_1101-2021_01_04_425177	23	29	mouse	mouse	NN
10_1101-2021_01_04_425177	23	30	and	and	CC
10_1101-2021_01_04_425177	23	31	.CC	.CC	:
10_1101-2021_01_04_425177	23	32	-	-	:
10_1101-2021_01_04_425177	23	33	BY	by	IN
10_1101-2021_01_04_425177	23	34	-	-	HYPH
10_1101-2021_01_04_425177	23	35	NC	NC	NNP
10_1101-2021_01_04_425177	23	36	-	-	HYPH
10_1101-2021_01_04_425177	23	37	ND	ND	NNP
10_1101-2021_01_04_425177	23	38	4.0	4.0	CD
10_1101-2021_01_04_425177	23	39	International	international	JJ
10_1101-2021_01_04_425177	23	40	licensemade	licensemade	NN
10_1101-2021_01_04_425177	23	41	available	available	JJ
10_1101-2021_01_04_425177	23	42	under	under	IN
10_1101-2021_01_04_425177	23	43	a	a	DT
10_1101-2021_01_04_425177	23	44	(	(	-LRB-
10_1101-2021_01_04_425177	23	45	which	which	WDT
10_1101-2021_01_04_425177	23	46	was	be	VBD
10_1101-2021_01_04_425177	23	47	not	not	RB
10_1101-2021_01_04_425177	23	48	certified	certify	VBN
10_1101-2021_01_04_425177	23	49	by	by	IN
10_1101-2021_01_04_425177	23	50	peer	peer	NN
10_1101-2021_01_04_425177	23	51	review	review	NN
10_1101-2021_01_04_425177	23	52	)	)	-RRB-
10_1101-2021_01_04_425177	23	53	is	be	VBZ
10_1101-2021_01_04_425177	23	54	the	the	DT
10_1101-2021_01_04_425177	23	55	author	author	NN
10_1101-2021_01_04_425177	23	56	/	/	SYM
10_1101-2021_01_04_425177	23	57	funder	funder	NN
10_1101-2021_01_04_425177	23	58	,	,	,
10_1101-2021_01_04_425177	23	59	who	who	WP
10_1101-2021_01_04_425177	23	60	has	have	VBZ
10_1101-2021_01_04_425177	23	61	granted	grant	VBN
10_1101-2021_01_04_425177	23	62	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	23	63	a	a	DT
10_1101-2021_01_04_425177	23	64	license	license	NN
10_1101-2021_01_04_425177	23	65	to	to	TO
10_1101-2021_01_04_425177	23	66	display	display	VB
10_1101-2021_01_04_425177	23	67	the	the	DT
10_1101-2021_01_04_425177	23	68	preprint	preprint	NN
10_1101-2021_01_04_425177	23	69	in	in	IN
10_1101-2021_01_04_425177	23	70	perpetuity	perpetuity	NN
10_1101-2021_01_04_425177	23	71	.	.	.
10_1101-2021_01_04_425177	24	1	It	-PRON-	PRP
10_1101-2021_01_04_425177	24	2	is	be	VBZ
10_1101-2021_01_04_425177	24	3	The	the	DT
10_1101-2021_01_04_425177	24	4	copyright	copyright	NN
10_1101-2021_01_04_425177	24	5	holder	holder	NN
10_1101-2021_01_04_425177	24	6	for	for	IN
10_1101-2021_01_04_425177	24	7	this	this	DT
10_1101-2021_01_04_425177	24	8	preprintthis	preprintthis	NN
10_1101-2021_01_04_425177	24	9	version	version	NN
10_1101-2021_01_04_425177	24	10	posted	post	VBD
10_1101-2021_01_04_425177	24	11	January	January	NNP
10_1101-2021_01_04_425177	24	12	4	4	CD
10_1101-2021_01_04_425177	24	13	,	,	,
10_1101-2021_01_04_425177	24	14	2021	2021	CD
10_1101-2021_01_04_425177	24	15	.	.	.
10_1101-2021_01_04_425177	24	16	;	;	:
10_1101-2021_01_04_425177	24	17	https://doi.org/10.1101/2021.01.04.425177doi	https://doi.org/10.1101/2021.01.04.425177doi	ADD
10_1101-2021_01_04_425177	24	18	:	:	:
10_1101-2021_01_04_425177	24	19	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	24	20	preprint	preprint	NN
10_1101-2021_01_04_425177	24	21	https://doi.org/10.1101/2021.01.04.425177	https://doi.org/10.1101/2021.01.04.425177	VBZ
10_1101-2021_01_04_425177	24	22	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2021_01_04_425177	24	23	3	3	CD
10_1101-2021_01_04_425177	24	24	bovine	bovine	NN
10_1101-2021_01_04_425177	24	25	prion	prion	NN
10_1101-2021_01_04_425177	24	26	proteins	protein	NNS
10_1101-2021_01_04_425177	24	27	:	:	:
10_1101-2021_01_04_425177	24	28	such	such	JJ
10_1101-2021_01_04_425177	24	29	PrP	prp	NN
10_1101-2021_01_04_425177	24	30	-	-	HYPH
10_1101-2021_01_04_425177	24	31	derived	derive	VBN
10_1101-2021_01_04_425177	24	32	peptides	peptide	NNS
10_1101-2021_01_04_425177	24	33	induced	induce	VBD
10_1101-2021_01_04_425177	24	34	lower	low	JJR
10_1101-2021_01_04_425177	24	35	amounts	amount	NNS
10_1101-2021_01_04_425177	24	36	of	of	IN
10_1101-2021_01_04_425177	24	37	prion	prion	NN
10_1101-2021_01_04_425177	24	38	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	24	39	resistant	resistant	JJ
10_1101-2021_01_04_425177	24	40	to	to	TO
10_1101-2021_01_04_425177	24	41	proteinase	proteinase	VB
10_1101-2021_01_04_425177	24	42	K	K	NNP
10_1101-2021_01_04_425177	24	43	in	in	IN
10_1101-2021_01_04_425177	24	44	prion	prion	NN
10_1101-2021_01_04_425177	24	45	-	-	HYPH
10_1101-2021_01_04_425177	24	46	infected	infect	VBN
10_1101-2021_01_04_425177	24	47	cells	cell	NNS
10_1101-2021_01_04_425177	24	48	(	(	-LRB-
10_1101-2021_01_04_425177	24	49	Löfgren	Löfgren	NNP
10_1101-2021_01_04_425177	24	50	et	et	NNP
10_1101-2021_01_04_425177	24	51	al	al	NNP
10_1101-2021_01_04_425177	24	52	.	.	NNP
10_1101-2021_01_04_425177	24	53	,	,	,
10_1101-2021_01_04_425177	24	54	2008	2008	CD
10_1101-2021_01_04_425177	24	55	;	;	:
10_1101-2021_01_04_425177	24	56	Söderberg	Söderberg	NNP
10_1101-2021_01_04_425177	24	57	et	et	NNP
10_1101-2021_01_04_425177	24	58	al	al	NNP
10_1101-2021_01_04_425177	24	59	.	.	NNP
10_1101-2021_01_04_425177	24	60	,	,	,
10_1101-2021_01_04_425177	24	61	2014	2014	CD
10_1101-2021_01_04_425177	24	62	)	)	-RRB-
10_1101-2021_01_04_425177	24	63	.	.	.
10_1101-2021_01_04_425177	25	1	The	the	DT
10_1101-2021_01_04_425177	25	2	PrP	prp	NN
10_1101-2021_01_04_425177	25	3	-	-	HYPH
10_1101-2021_01_04_425177	25	4	derived	derive	VBN
10_1101-2021_01_04_425177	25	5	peptides	peptide	NNS
10_1101-2021_01_04_425177	25	6	consisted	consist	VBD
10_1101-2021_01_04_425177	25	7	of	of	IN
10_1101-2021_01_04_425177	25	8	an	an	DT
10_1101-2021_01_04_425177	25	9	N	N	NNP
10_1101-2021_01_04_425177	25	10	-	-	HYPH
10_1101-2021_01_04_425177	25	11	terminal	terminal	NN
10_1101-2021_01_04_425177	25	12	signal	signal	NN
10_1101-2021_01_04_425177	25	13	peptide	peptide	NN
10_1101-2021_01_04_425177	25	14	segment	segment	NN
10_1101-2021_01_04_425177	25	15	(	(	-LRB-
10_1101-2021_01_04_425177	25	16	different	different	JJ
10_1101-2021_01_04_425177	25	17	for	for	IN
10_1101-2021_01_04_425177	25	18	mouse	mouse	NN
10_1101-2021_01_04_425177	25	19	and	and	CC
10_1101-2021_01_04_425177	25	20	bovine	bovine	NNP
10_1101-2021_01_04_425177	25	21	PrP	PrP	NNP
10_1101-2021_01_04_425177	25	22	)	)	-RRB-
10_1101-2021_01_04_425177	25	23	,	,	,
10_1101-2021_01_04_425177	25	24	together	together	RB
10_1101-2021_01_04_425177	25	25	with	with	IN
10_1101-2021_01_04_425177	25	26	a	a	DT
10_1101-2021_01_04_425177	25	27	conserved	conserve	VBN
10_1101-2021_01_04_425177	25	28	positively	positively	RB
10_1101-2021_01_04_425177	25	29	charged	charge	VBN
10_1101-2021_01_04_425177	25	30	and	and	CC
10_1101-2021_01_04_425177	25	31	hydrophobic	hydrophobic	JJ
10_1101-2021_01_04_425177	25	32	hexapeptide	hexapeptide	NN
10_1101-2021_01_04_425177	25	33	(	(	-LRB-
10_1101-2021_01_04_425177	25	34	KKRPKP	KKRPKP	NNP
10_1101-2021_01_04_425177	25	35	)	)	-RRB-
10_1101-2021_01_04_425177	25	36	corresponding	correspond	VBG
10_1101-2021_01_04_425177	25	37	to	to	IN
10_1101-2021_01_04_425177	25	38	the	the	DT
10_1101-2021_01_04_425177	25	39	first	first	JJ
10_1101-2021_01_04_425177	25	40	six	six	CD
10_1101-2021_01_04_425177	25	41	residues	residue	NNS
10_1101-2021_01_04_425177	25	42	of	of	IN
10_1101-2021_01_04_425177	25	43	the	the	DT
10_1101-2021_01_04_425177	25	44	processed	process	VBN
10_1101-2021_01_04_425177	25	45	PrP	PrP	NNP
10_1101-2021_01_04_425177	25	46	protein	protein	NN
10_1101-2021_01_04_425177	25	47	.	.	.
10_1101-2021_01_04_425177	26	1	Our	-PRON-	PRP$
10_1101-2021_01_04_425177	26	2	earlier	early	JJR
10_1101-2021_01_04_425177	26	3	studies	study	NNS
10_1101-2021_01_04_425177	26	4	had	have	VBD
10_1101-2021_01_04_425177	26	5	shown	show	VBN
10_1101-2021_01_04_425177	26	6	that	that	IN
10_1101-2021_01_04_425177	26	7	peptides	peptide	NNS
10_1101-2021_01_04_425177	26	8	with	with	IN
10_1101-2021_01_04_425177	26	9	such	such	JJ
10_1101-2021_01_04_425177	26	10	sequences	sequence	NNS
10_1101-2021_01_04_425177	26	11	were	be	VBD
10_1101-2021_01_04_425177	26	12	able	able	JJ
10_1101-2021_01_04_425177	26	13	to	to	TO
10_1101-2021_01_04_425177	26	14	interact	interact	VB
10_1101-2021_01_04_425177	26	15	with	with	IN
10_1101-2021_01_04_425177	26	16	and	and	CC
10_1101-2021_01_04_425177	26	17	penetrate	penetrate	VB
10_1101-2021_01_04_425177	26	18	cell	cell	NN
10_1101-2021_01_04_425177	26	19	membranes	membrane	NNS
10_1101-2021_01_04_425177	26	20	(	(	-LRB-
10_1101-2021_01_04_425177	26	21	Lundberg	Lundberg	NNP
10_1101-2021_01_04_425177	26	22	et	et	FW
10_1101-2021_01_04_425177	26	23	al	al	NNP
10_1101-2021_01_04_425177	26	24	.	.	NNP
10_1101-2021_01_04_425177	26	25	,	,	,
10_1101-2021_01_04_425177	26	26	2002	2002	CD
10_1101-2021_01_04_425177	26	27	;	;	:
10_1101-2021_01_04_425177	26	28	Magzoub	Magzoub	NNP
10_1101-2021_01_04_425177	26	29	et	et	NNP
10_1101-2021_01_04_425177	26	30	al	al	NNP
10_1101-2021_01_04_425177	26	31	.	.	NNP
10_1101-2021_01_04_425177	26	32	,	,	,
10_1101-2021_01_04_425177	26	33	2005	2005	CD
10_1101-2021_01_04_425177	26	34	;	;	:
10_1101-2021_01_04_425177	26	35	Magzoub	Magzoub	NNP
10_1101-2021_01_04_425177	26	36	et	et	NNP
10_1101-2021_01_04_425177	26	37	al	al	NNP
10_1101-2021_01_04_425177	26	38	.	.	NNP
10_1101-2021_01_04_425177	26	39	,	,	,
10_1101-2021_01_04_425177	26	40	2006	2006	CD
10_1101-2021_01_04_425177	26	41	;	;	:
10_1101-2021_01_04_425177	26	42	Oglecka	Oglecka	NNP
10_1101-2021_01_04_425177	26	43	et	et	NNP
10_1101-2021_01_04_425177	26	44	al	al	NNP
10_1101-2021_01_04_425177	26	45	.	.	NNP
10_1101-2021_01_04_425177	26	46	,	,	,
10_1101-2021_01_04_425177	26	47	2008	2008	CD
10_1101-2021_01_04_425177	26	48	)	)	-RRB-
10_1101-2021_01_04_425177	26	49	.	.	.
10_1101-2021_01_04_425177	27	1	The	the	DT
10_1101-2021_01_04_425177	27	2	anti-	anti-	NN
10_1101-2021_01_04_425177	27	3	prion	prion	NN
10_1101-2021_01_04_425177	27	4	effects	effect	NNS
10_1101-2021_01_04_425177	27	5	of	of	IN
10_1101-2021_01_04_425177	27	6	the	the	DT
10_1101-2021_01_04_425177	27	7	PrP	prp	NN
10_1101-2021_01_04_425177	27	8	-	-	HYPH
10_1101-2021_01_04_425177	27	9	derived	derive	VBN
10_1101-2021_01_04_425177	27	10	peptides	peptide	NNS
10_1101-2021_01_04_425177	27	11	were	be	VBD
10_1101-2021_01_04_425177	27	12	lost	lose	VBN
10_1101-2021_01_04_425177	27	13	when	when	WRB
10_1101-2021_01_04_425177	27	14	the	the	DT
10_1101-2021_01_04_425177	27	15	KKRPKP	KKRPKP	NNP
10_1101-2021_01_04_425177	27	16	hexapeptide	hexapeptide	NN
10_1101-2021_01_04_425177	27	17	was	be	VBD
10_1101-2021_01_04_425177	27	18	coupled	couple	VBN
10_1101-2021_01_04_425177	27	19	to	to	IN
10_1101-2021_01_04_425177	27	20	various	various	JJ
10_1101-2021_01_04_425177	27	21	peptides	peptide	NNS
10_1101-2021_01_04_425177	27	22	with	with	IN
10_1101-2021_01_04_425177	27	23	cell	cell	NN
10_1101-2021_01_04_425177	27	24	-	-	HYPH
10_1101-2021_01_04_425177	27	25	penetrating	penetrating	NN
10_1101-2021_01_04_425177	27	26	properties	property	NNS
10_1101-2021_01_04_425177	27	27	(	(	-LRB-
10_1101-2021_01_04_425177	27	28	Söderberg	Söderberg	NNP
10_1101-2021_01_04_425177	27	29	et	et	NNP
10_1101-2021_01_04_425177	27	30	al	al	NNP
10_1101-2021_01_04_425177	27	31	.	.	NNP
10_1101-2021_01_04_425177	27	32	,	,	,
10_1101-2021_01_04_425177	27	33	2014	2014	CD
10_1101-2021_01_04_425177	27	34	)	)	-RRB-
10_1101-2021_01_04_425177	27	35	.	.	.
10_1101-2021_01_04_425177	28	1	The	the	DT
10_1101-2021_01_04_425177	28	2	anti	anti	JJ
10_1101-2021_01_04_425177	28	3	-	-	JJ
10_1101-2021_01_04_425177	28	4	prion	prion	JJ
10_1101-2021_01_04_425177	28	5	effects	effect	NNS
10_1101-2021_01_04_425177	28	6	were	be	VBD
10_1101-2021_01_04_425177	28	7	however	however	RB
10_1101-2021_01_04_425177	28	8	retained	retain	VBN
10_1101-2021_01_04_425177	28	9	when	when	WRB
10_1101-2021_01_04_425177	28	10	KKRPKP	KKRPKP	NNP
10_1101-2021_01_04_425177	28	11	was	be	VBD
10_1101-2021_01_04_425177	28	12	coupled	couple	VBN
10_1101-2021_01_04_425177	28	13	to	to	IN
10_1101-2021_01_04_425177	28	14	the	the	DT
10_1101-2021_01_04_425177	28	15	signal	signal	JJ
10_1101-2021_01_04_425177	28	16	sequence	sequence	NN
10_1101-2021_01_04_425177	28	17	of	of	IN
10_1101-2021_01_04_425177	28	18	the	the	DT
10_1101-2021_01_04_425177	28	19	Neural	neural	JJ
10_1101-2021_01_04_425177	28	20	cell	cell	NN
10_1101-2021_01_04_425177	28	21	adhesion	adhesion	NN
10_1101-2021_01_04_425177	28	22	molecule-1	molecule-1	NNP
10_1101-2021_01_04_425177	28	23	(	(	-LRB-
10_1101-2021_01_04_425177	28	24	i.e.	i.e.	FW
10_1101-2021_01_04_425177	28	25	,	,	,
10_1101-2021_01_04_425177	28	26	NCAM11	NCAM11	NNP
10_1101-2021_01_04_425177	28	27	-	-	HYPH
10_1101-2021_01_04_425177	28	28	19	19	CD
10_1101-2021_01_04_425177	28	29	)	)	-RRB-
10_1101-2021_01_04_425177	28	30	(	(	-LRB-
10_1101-2021_01_04_425177	28	31	Söderberg	Söderberg	NNP
10_1101-2021_01_04_425177	28	32	et	et	NNP
10_1101-2021_01_04_425177	28	33	al	al	NNP
10_1101-2021_01_04_425177	28	34	.	.	NNP
10_1101-2021_01_04_425177	28	35	,	,	,
10_1101-2021_01_04_425177	28	36	2014	2014	CD
10_1101-2021_01_04_425177	28	37	)	)	-RRB-
10_1101-2021_01_04_425177	28	38	.	.	.
10_1101-2021_01_04_425177	29	1	The	the	DT
10_1101-2021_01_04_425177	29	2	mouse	mouse	NN
10_1101-2021_01_04_425177	29	3	PrP1	prp1	NN
10_1101-2021_01_04_425177	29	4	-	-	HYPH
10_1101-2021_01_04_425177	29	5	28	28	CD
10_1101-2021_01_04_425177	29	6	segment	segment	NN
10_1101-2021_01_04_425177	29	7	and	and	CC
10_1101-2021_01_04_425177	29	8	the	the	DT
10_1101-2021_01_04_425177	29	9	NCAM11	NCAM11	NNP
10_1101-2021_01_04_425177	29	10	-	-	HYPH
10_1101-2021_01_04_425177	29	11	19-KKRPKP	19-KKRPKP	NNP
10_1101-2021_01_04_425177	29	12	construct	construct	NN
10_1101-2021_01_04_425177	29	13	are	be	VBP
10_1101-2021_01_04_425177	29	14	both	both	DT
10_1101-2021_01_04_425177	29	15	amyloidogenic	amyloidogenic	JJ
10_1101-2021_01_04_425177	29	16	in	in	IN
10_1101-2021_01_04_425177	29	17	themselves	-PRON-	PRP
10_1101-2021_01_04_425177	29	18	,	,	,
10_1101-2021_01_04_425177	29	19	as	as	IN
10_1101-2021_01_04_425177	29	20	they	-PRON-	PRP
10_1101-2021_01_04_425177	29	21	form	form	VBP
10_1101-2021_01_04_425177	29	22	amyloid	amyloid	NN
10_1101-2021_01_04_425177	29	23	fibrils	fibril	NNS
10_1101-2021_01_04_425177	29	24	by	by	IN
10_1101-2021_01_04_425177	29	25	self	self	NN
10_1101-2021_01_04_425177	29	26	-	-	HYPH
10_1101-2021_01_04_425177	29	27	aggregation	aggregation	NN
10_1101-2021_01_04_425177	29	28	(	(	-LRB-
10_1101-2021_01_04_425177	29	29	Mukundan	Mukundan	NNP
10_1101-2021_01_04_425177	29	30	et	et	FW
10_1101-2021_01_04_425177	29	31	al	al	NNP
10_1101-2021_01_04_425177	29	32	.	.	NNP
10_1101-2021_01_04_425177	29	33	,	,	,
10_1101-2021_01_04_425177	29	34	2017	2017	CD
10_1101-2021_01_04_425177	29	35	;	;	:
10_1101-2021_01_04_425177	29	36	Pansieri	Pansieri	NNP
10_1101-2021_01_04_425177	29	37	et	et	FW
10_1101-2021_01_04_425177	29	38	al	al	NNP
10_1101-2021_01_04_425177	29	39	.	.	NNP
10_1101-2021_01_04_425177	29	40	,	,	,
10_1101-2021_01_04_425177	29	41	2019	2019	CD
10_1101-2021_01_04_425177	29	42	)	)	-RRB-
10_1101-2021_01_04_425177	29	43	.	.	.
10_1101-2021_01_04_425177	30	1	The	the	DT
10_1101-2021_01_04_425177	30	2	NCAM11	NCAM11	NNP
10_1101-2021_01_04_425177	30	3	-	-	HYPH
10_1101-2021_01_04_425177	30	4	19-KKRPKP	19-KKRPKP	NNP
10_1101-2021_01_04_425177	30	5	construct	construct	NN
10_1101-2021_01_04_425177	30	6	was	be	VBD
10_1101-2021_01_04_425177	30	7	recently	recently	RB
10_1101-2021_01_04_425177	30	8	shown	show	VBN
10_1101-2021_01_04_425177	30	9	to	to	TO
10_1101-2021_01_04_425177	30	10	inhibit	inhibit	VB
10_1101-2021_01_04_425177	30	11	aggregation	aggregation	NN
10_1101-2021_01_04_425177	30	12	of	of	IN
10_1101-2021_01_04_425177	30	13	the	the	DT
10_1101-2021_01_04_425177	30	14	amyloid	amyloid	NN
10_1101-2021_01_04_425177	30	15	-	-	HYPH
10_1101-2021_01_04_425177	30	16	β	β	NN
10_1101-2021_01_04_425177	30	17	peptide	peptide	NN
10_1101-2021_01_04_425177	30	18	involved	involve	VBN
10_1101-2021_01_04_425177	30	19	in	in	IN
10_1101-2021_01_04_425177	30	20	Alzheimer	Alzheimer	NNP
10_1101-2021_01_04_425177	30	21	’s	’s	POS
10_1101-2021_01_04_425177	30	22	disease	disease	NN
10_1101-2021_01_04_425177	30	23	(	(	-LRB-
10_1101-2021_01_04_425177	30	24	Henning	Henning	NNP
10_1101-2021_01_04_425177	30	25	-	-	HYPH
10_1101-2021_01_04_425177	30	26	Knechtel	Knechtel	NNP
10_1101-2021_01_04_425177	30	27	et	et	FW
10_1101-2021_01_04_425177	30	28	al	al	NNP
10_1101-2021_01_04_425177	30	29	.	.	NNP
10_1101-2021_01_04_425177	30	30	,	,	,
10_1101-2021_01_04_425177	30	31	2020	2020	CD
10_1101-2021_01_04_425177	30	32	)	)	-RRB-
10_1101-2021_01_04_425177	30	33	,	,	,
10_1101-2021_01_04_425177	30	34	and	and	CC
10_1101-2021_01_04_425177	30	35	to	to	TO
10_1101-2021_01_04_425177	30	36	promote	promote	VB
10_1101-2021_01_04_425177	30	37	in	in	IN
10_1101-2021_01_04_425177	30	38	vitro	vitro	FW
10_1101-2021_01_04_425177	30	39	aggregation	aggregation	NN
10_1101-2021_01_04_425177	30	40	of	of	IN
10_1101-2021_01_04_425177	30	41	the	the	DT
10_1101-2021_01_04_425177	30	42	amyloid	amyloid	NN
10_1101-2021_01_04_425177	30	43	protein	protein	NN
10_1101-2021_01_04_425177	30	44	S100A9	S100A9	NNP
10_1101-2021_01_04_425177	30	45	(	(	-LRB-
10_1101-2021_01_04_425177	30	46	Pansieri	Pansieri	NNP
10_1101-2021_01_04_425177	30	47	et	et	FW
10_1101-2021_01_04_425177	30	48	al	al	NNP
10_1101-2021_01_04_425177	30	49	.	.	NNP
10_1101-2021_01_04_425177	30	50	,	,	,
10_1101-2021_01_04_425177	30	51	2019	2019	CD
10_1101-2021_01_04_425177	30	52	)	)	-RRB-
10_1101-2021_01_04_425177	30	53	,	,	,
10_1101-2021_01_04_425177	30	54	which	which	WDT
10_1101-2021_01_04_425177	30	55	is	be	VBZ
10_1101-2021_01_04_425177	30	56	involved	involve	VBN
10_1101-2021_01_04_425177	30	57	in	in	IN
10_1101-2021_01_04_425177	30	58	amyloid	amyloid	NN
10_1101-2021_01_04_425177	30	59	-	-	HYPH
10_1101-2021_01_04_425177	30	60	related	relate	VBN
10_1101-2021_01_04_425177	30	61	and	and	CC
10_1101-2021_01_04_425177	30	62	other	other	JJ
10_1101-2021_01_04_425177	30	63	inflammatory	inflammatory	JJ
10_1101-2021_01_04_425177	30	64	processes	process	NNS
10_1101-2021_01_04_425177	30	65	(	(	-LRB-
10_1101-2021_01_04_425177	30	66	Horvath	Horvath	NNP
10_1101-2021_01_04_425177	30	67	et	et	NNP
10_1101-2021_01_04_425177	30	68	al	al	NNP
10_1101-2021_01_04_425177	30	69	.	.	NNP
10_1101-2021_01_04_425177	30	70	,	,	,
10_1101-2021_01_04_425177	30	71	2018	2018	CD
10_1101-2021_01_04_425177	30	72	;	;	:
10_1101-2021_01_04_425177	30	73	Wang	Wang	NNP
10_1101-2021_01_04_425177	30	74	et	et	NNP
10_1101-2021_01_04_425177	30	75	al	al	NNP
10_1101-2021_01_04_425177	30	76	.	.	NNP
10_1101-2021_01_04_425177	30	77	,	,	,
10_1101-2021_01_04_425177	30	78	2019	2019	CD
10_1101-2021_01_04_425177	30	79	;	;	:
10_1101-2021_01_04_425177	30	80	Wang	Wang	NNP
10_1101-2021_01_04_425177	30	81	et	et	NNP
10_1101-2021_01_04_425177	30	82	al	al	NNP
10_1101-2021_01_04_425177	30	83	.	.	NNP
10_1101-2021_01_04_425177	30	84	,	,	,
10_1101-2021_01_04_425177	30	85	2014	2014	CD
10_1101-2021_01_04_425177	30	86	)	)	-RRB-
10_1101-2021_01_04_425177	30	87	.	.	.
10_1101-2021_01_04_425177	31	1	Almost	almost	RB
10_1101-2021_01_04_425177	31	2	identical	identical	JJ
10_1101-2021_01_04_425177	31	3	results	result	NNS
10_1101-2021_01_04_425177	31	4	were	be	VBD
10_1101-2021_01_04_425177	31	5	obtained	obtain	VBN
10_1101-2021_01_04_425177	31	6	for	for	IN
10_1101-2021_01_04_425177	31	7	a	a	DT
10_1101-2021_01_04_425177	31	8	similar	similar	JJ
10_1101-2021_01_04_425177	31	9	amyloidogenic	amyloidogenic	JJ
10_1101-2021_01_04_425177	31	10	25	25	CD
10_1101-2021_01_04_425177	31	11	residue	residue	NN
10_1101-2021_01_04_425177	31	12	-	-	HYPH
10_1101-2021_01_04_425177	31	13	construct	construct	NN
10_1101-2021_01_04_425177	31	14	,	,	,
10_1101-2021_01_04_425177	31	15	i.e.	i.e.	FW
10_1101-2021_01_04_425177	32	1	NCAM11	NCAM11	NNP
10_1101-2021_01_04_425177	32	2	-	-	HYPH
10_1101-2021_01_04_425177	32	3	19-KKLVFF	19-KKLVFF	NNP
10_1101-2021_01_04_425177	32	4	(	(	-LRB-
10_1101-2021_01_04_425177	32	5	from	from	IN
10_1101-2021_01_04_425177	32	6	here	here	RB
10_1101-2021_01_04_425177	32	7	onwards	onwards	RB
10_1101-2021_01_04_425177	32	8	:	:	:
10_1101-2021_01_04_425177	32	9	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	32	10	)	)	-RRB-
10_1101-2021_01_04_425177	32	11	(	(	-LRB-
10_1101-2021_01_04_425177	32	12	Pansieri	Pansieri	NNP
10_1101-2021_01_04_425177	32	13	et	et	FW
10_1101-2021_01_04_425177	32	14	al	al	NNP
10_1101-2021_01_04_425177	32	15	.	.	NNP
10_1101-2021_01_04_425177	32	16	,	,	,
10_1101-2021_01_04_425177	32	17	2019	2019	CD
10_1101-2021_01_04_425177	32	18	)	)	-RRB-
10_1101-2021_01_04_425177	32	19	.	.	.
10_1101-2021_01_04_425177	33	1	The	the	DT
10_1101-2021_01_04_425177	33	2	KLVFF	KLVFF	NNP
10_1101-2021_01_04_425177	33	3	sequence	sequence	NN
10_1101-2021_01_04_425177	33	4	originates	originate	VBZ
10_1101-2021_01_04_425177	33	5	from	from	IN
10_1101-2021_01_04_425177	33	6	the	the	DT
10_1101-2021_01_04_425177	33	7	hydrophobic	hydrophobic	JJ
10_1101-2021_01_04_425177	33	8	core	core	NN
10_1101-2021_01_04_425177	33	9	(	(	-LRB-
10_1101-2021_01_04_425177	33	10	residues	residues	NNP
10_1101-2021_01_04_425177	33	11	16	16	CD
10_1101-2021_01_04_425177	33	12	-	-	SYM
10_1101-2021_01_04_425177	33	13	20	20	CD
10_1101-2021_01_04_425177	33	14	)	)	-RRB-
10_1101-2021_01_04_425177	33	15	of	of	IN
10_1101-2021_01_04_425177	33	16	the	the	DT
10_1101-2021_01_04_425177	33	17	Aβ	Aβ	NNP
10_1101-2021_01_04_425177	33	18	peptide	peptide	NN
10_1101-2021_01_04_425177	33	19	:	:	:
10_1101-2021_01_04_425177	33	20	this	this	DT
10_1101-2021_01_04_425177	33	21	pentapeptide	pentapeptide	NN
10_1101-2021_01_04_425177	33	22	is	be	VBZ
10_1101-2021_01_04_425177	33	23	known	know	VBN
10_1101-2021_01_04_425177	33	24	to	to	TO
10_1101-2021_01_04_425177	33	25	inhibit	inhibit	VB
10_1101-2021_01_04_425177	33	26	aggregation	aggregation	NN
10_1101-2021_01_04_425177	33	27	of	of	IN
10_1101-2021_01_04_425177	33	28	the	the	DT
10_1101-2021_01_04_425177	33	29	full	full	JJ
10_1101-2021_01_04_425177	33	30	-	-	HYPH
10_1101-2021_01_04_425177	33	31	length	length	NN
10_1101-2021_01_04_425177	33	32	Aβ	Aβ	NNP
10_1101-2021_01_04_425177	33	33	peptide	peptide	NN
10_1101-2021_01_04_425177	33	34	(	(	-LRB-
10_1101-2021_01_04_425177	33	35	Tjernberg	Tjernberg	NNP
10_1101-2021_01_04_425177	33	36	et	et	NNP
10_1101-2021_01_04_425177	33	37	al	al	NNP
10_1101-2021_01_04_425177	33	38	.	.	NNP
10_1101-2021_01_04_425177	33	39	,	,	,
10_1101-2021_01_04_425177	33	40	1996	1996	CD
10_1101-2021_01_04_425177	33	41	)	)	-RRB-
10_1101-2021_01_04_425177	33	42	.	.	.
10_1101-2021_01_04_425177	34	1	In	in	IN
10_1101-2021_01_04_425177	34	2	the	the	DT
10_1101-2021_01_04_425177	34	3	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	34	4	construct	construct	NN
10_1101-2021_01_04_425177	34	5	,	,	,
10_1101-2021_01_04_425177	34	6	an	an	DT
10_1101-2021_01_04_425177	34	7	additional	additional	JJ
10_1101-2021_01_04_425177	34	8	lysine	lysine	NN
10_1101-2021_01_04_425177	34	9	residue	residue	NN
10_1101-2021_01_04_425177	34	10	was	be	VBD
10_1101-2021_01_04_425177	34	11	added	add	VBN
10_1101-2021_01_04_425177	34	12	to	to	IN
10_1101-2021_01_04_425177	34	13	the	the	DT
10_1101-2021_01_04_425177	34	14	KLVFF	KLVFF	NNP
10_1101-2021_01_04_425177	34	15	sequence	sequence	NN
10_1101-2021_01_04_425177	34	16	for	for	IN
10_1101-2021_01_04_425177	34	17	increased	increase	VBN
10_1101-2021_01_04_425177	34	18	solubility	solubility	NN
10_1101-2021_01_04_425177	34	19	(	(	-LRB-
10_1101-2021_01_04_425177	34	20	Pansieri	Pansieri	NNP
10_1101-2021_01_04_425177	34	21	et	et	FW
10_1101-2021_01_04_425177	34	22	al	al	NNP
10_1101-2021_01_04_425177	34	23	.	.	NNP
10_1101-2021_01_04_425177	34	24	,	,	,
10_1101-2021_01_04_425177	34	25	2019	2019	CD
10_1101-2021_01_04_425177	34	26	)	)	-RRB-
10_1101-2021_01_04_425177	34	27	.	.	.
10_1101-2021_01_04_425177	35	1	The	the	DT
10_1101-2021_01_04_425177	35	2	molecular	molecular	JJ
10_1101-2021_01_04_425177	35	3	properties	property	NNS
10_1101-2021_01_04_425177	35	4	of	of	IN
10_1101-2021_01_04_425177	35	5	the	the	DT
10_1101-2021_01_04_425177	35	6	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	35	7	sequence	sequence	NN
10_1101-2021_01_04_425177	35	8	and	and	CC
10_1101-2021_01_04_425177	35	9	its	-PRON-	PRP$
10_1101-2021_01_04_425177	35	10	segments	segment	NNS
10_1101-2021_01_04_425177	35	11	are	be	VBP
10_1101-2021_01_04_425177	35	12	shown	show	VBN
10_1101-2021_01_04_425177	35	13	in	in	IN
10_1101-2021_01_04_425177	35	14	Table	table	NN
10_1101-2021_01_04_425177	35	15	1	1	CD
10_1101-2021_01_04_425177	35	16	,	,	,
10_1101-2021_01_04_425177	35	17	including	include	VBG
10_1101-2021_01_04_425177	35	18	.CC	.CC	:
10_1101-2021_01_04_425177	35	19	-	-	HYPH
10_1101-2021_01_04_425177	35	20	BY	by	IN
10_1101-2021_01_04_425177	35	21	-	-	HYPH
10_1101-2021_01_04_425177	35	22	NC	NC	NNP
10_1101-2021_01_04_425177	35	23	-	-	HYPH
10_1101-2021_01_04_425177	35	24	ND	ND	NNP
10_1101-2021_01_04_425177	35	25	4.0	4.0	CD
10_1101-2021_01_04_425177	35	26	International	international	JJ
10_1101-2021_01_04_425177	35	27	licensemade	licensemade	NN
10_1101-2021_01_04_425177	35	28	available	available	JJ
10_1101-2021_01_04_425177	35	29	under	under	IN
10_1101-2021_01_04_425177	35	30	a	a	DT
10_1101-2021_01_04_425177	35	31	(	(	-LRB-
10_1101-2021_01_04_425177	35	32	which	which	WDT
10_1101-2021_01_04_425177	35	33	was	be	VBD
10_1101-2021_01_04_425177	35	34	not	not	RB
10_1101-2021_01_04_425177	35	35	certified	certify	VBN
10_1101-2021_01_04_425177	35	36	by	by	IN
10_1101-2021_01_04_425177	35	37	peer	peer	NN
10_1101-2021_01_04_425177	35	38	review	review	NN
10_1101-2021_01_04_425177	35	39	)	)	-RRB-
10_1101-2021_01_04_425177	35	40	is	be	VBZ
10_1101-2021_01_04_425177	35	41	the	the	DT
10_1101-2021_01_04_425177	35	42	author	author	NN
10_1101-2021_01_04_425177	35	43	/	/	SYM
10_1101-2021_01_04_425177	35	44	funder	funder	NN
10_1101-2021_01_04_425177	35	45	,	,	,
10_1101-2021_01_04_425177	35	46	who	who	WP
10_1101-2021_01_04_425177	35	47	has	have	VBZ
10_1101-2021_01_04_425177	35	48	granted	grant	VBN
10_1101-2021_01_04_425177	35	49	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	35	50	a	a	DT
10_1101-2021_01_04_425177	35	51	license	license	NN
10_1101-2021_01_04_425177	35	52	to	to	TO
10_1101-2021_01_04_425177	35	53	display	display	VB
10_1101-2021_01_04_425177	35	54	the	the	DT
10_1101-2021_01_04_425177	35	55	preprint	preprint	NN
10_1101-2021_01_04_425177	35	56	in	in	IN
10_1101-2021_01_04_425177	35	57	perpetuity	perpetuity	NN
10_1101-2021_01_04_425177	35	58	.	.	.
10_1101-2021_01_04_425177	36	1	It	-PRON-	PRP
10_1101-2021_01_04_425177	36	2	is	be	VBZ
10_1101-2021_01_04_425177	36	3	The	the	DT
10_1101-2021_01_04_425177	36	4	copyright	copyright	NN
10_1101-2021_01_04_425177	36	5	holder	holder	NN
10_1101-2021_01_04_425177	36	6	for	for	IN
10_1101-2021_01_04_425177	36	7	this	this	DT
10_1101-2021_01_04_425177	36	8	preprintthis	preprintthis	NN
10_1101-2021_01_04_425177	36	9	version	version	NN
10_1101-2021_01_04_425177	36	10	posted	post	VBD
10_1101-2021_01_04_425177	36	11	January	January	NNP
10_1101-2021_01_04_425177	36	12	4	4	CD
10_1101-2021_01_04_425177	36	13	,	,	,
10_1101-2021_01_04_425177	36	14	2021	2021	CD
10_1101-2021_01_04_425177	36	15	.	.	.
10_1101-2021_01_04_425177	36	16	;	;	:
10_1101-2021_01_04_425177	36	17	https://doi.org/10.1101/2021.01.04.425177doi	https://doi.org/10.1101/2021.01.04.425177doi	ADD
10_1101-2021_01_04_425177	36	18	:	:	:
10_1101-2021_01_04_425177	36	19	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	36	20	preprint	preprint	NN
10_1101-2021_01_04_425177	36	21	https://doi.org/10.1101/2021.01.04.425177	https://doi.org/10.1101/2021.01.04.425177	VBZ
10_1101-2021_01_04_425177	36	22	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2021_01_04_425177	36	23	4	4	CD
10_1101-2021_01_04_425177	36	24	hydrophobicity	hydrophobicity	NN
10_1101-2021_01_04_425177	36	25	values	value	NNS
10_1101-2021_01_04_425177	36	26	calculated	calculate	VBN
10_1101-2021_01_04_425177	36	27	according	accord	VBG
10_1101-2021_01_04_425177	36	28	to	to	IN
10_1101-2021_01_04_425177	36	29	the	the	DT
10_1101-2021_01_04_425177	36	30	Wimley	Wimley	NNP
10_1101-2021_01_04_425177	36	31	-	-	HYPH
10_1101-2021_01_04_425177	36	32	White	White	NNP
10_1101-2021_01_04_425177	36	33	whole	whole	JJ
10_1101-2021_01_04_425177	36	34	residue	residue	JJ
10_1101-2021_01_04_425177	36	35	hydrophobicity	hydrophobicity	NN
10_1101-2021_01_04_425177	36	36	scale	scale	NN
10_1101-2021_01_04_425177	36	37	(	(	-LRB-
10_1101-2021_01_04_425177	36	38	Wang	Wang	NNP
10_1101-2021_01_04_425177	36	39	et	et	NNP
10_1101-2021_01_04_425177	36	40	al	al	NNP
10_1101-2021_01_04_425177	36	41	.	.	NNP
10_1101-2021_01_04_425177	36	42	,	,	,
10_1101-2021_01_04_425177	36	43	2016	2016	CD
10_1101-2021_01_04_425177	36	44	;	;	:
10_1101-2021_01_04_425177	36	45	Wimley	Wimley	NNP
10_1101-2021_01_04_425177	36	46	and	and	CC
10_1101-2021_01_04_425177	36	47	White	White	NNP
10_1101-2021_01_04_425177	36	48	,	,	,
10_1101-2021_01_04_425177	36	49	1996	1996	CD
10_1101-2021_01_04_425177	36	50	)	)	-RRB-
10_1101-2021_01_04_425177	36	51	.	.	.
10_1101-2021_01_04_425177	37	1	As	as	IN
10_1101-2021_01_04_425177	37	2	the	the	DT
10_1101-2021_01_04_425177	37	3	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	37	4	construct	construct	VBP
10_1101-2021_01_04_425177	37	5	inhibits	inhibit	NNS
10_1101-2021_01_04_425177	37	6	fibrillation	fibrillation	NN
10_1101-2021_01_04_425177	37	7	of	of	IN
10_1101-2021_01_04_425177	37	8	the	the	DT
10_1101-2021_01_04_425177	37	9	Aβ	Aβ	NNP
10_1101-2021_01_04_425177	37	10	peptide	peptide	NN
10_1101-2021_01_04_425177	37	11	(	(	-LRB-
10_1101-2021_01_04_425177	37	12	Henning-	Henning-	NNP
10_1101-2021_01_04_425177	37	13	Knechtel	Knechtel	NNP
10_1101-2021_01_04_425177	37	14	et	et	FW
10_1101-2021_01_04_425177	37	15	al	al	NNP
10_1101-2021_01_04_425177	37	16	.	.	NNP
10_1101-2021_01_04_425177	37	17	,	,	,
10_1101-2021_01_04_425177	37	18	2020	2020	CD
10_1101-2021_01_04_425177	37	19	)	)	-RRB-
10_1101-2021_01_04_425177	37	20	,	,	,
10_1101-2021_01_04_425177	37	21	but	but	CC
10_1101-2021_01_04_425177	37	22	promotes	promote	VBZ
10_1101-2021_01_04_425177	37	23	(	(	-LRB-
10_1101-2021_01_04_425177	37	24	co-)aggregation	co-)aggregation	NN
10_1101-2021_01_04_425177	37	25	of	of	IN
10_1101-2021_01_04_425177	37	26	the	the	DT
10_1101-2021_01_04_425177	37	27	S100A9	s100a9	JJ
10_1101-2021_01_04_425177	37	28	protein	protein	NN
10_1101-2021_01_04_425177	37	29	(	(	-LRB-
10_1101-2021_01_04_425177	37	30	Pansieri	Pansieri	NNP
10_1101-2021_01_04_425177	37	31	et	et	FW
10_1101-2021_01_04_425177	37	32	al	al	NNP
10_1101-2021_01_04_425177	37	33	.	.	NNP
10_1101-2021_01_04_425177	37	34	,	,	,
10_1101-2021_01_04_425177	37	35	2019	2019	CD
10_1101-2021_01_04_425177	37	36	)	)	-RRB-
10_1101-2021_01_04_425177	37	37	,	,	,
10_1101-2021_01_04_425177	37	38	it	-PRON-	PRP
10_1101-2021_01_04_425177	37	39	is	be	VBZ
10_1101-2021_01_04_425177	37	40	unclear	unclear	JJ
10_1101-2021_01_04_425177	37	41	how	how	WRB
10_1101-2021_01_04_425177	37	42	the	the	DT
10_1101-2021_01_04_425177	37	43	construct	construct	NN
10_1101-2021_01_04_425177	37	44	may	may	MD
10_1101-2021_01_04_425177	37	45	affect	affect	VB
10_1101-2021_01_04_425177	37	46	the	the	DT
10_1101-2021_01_04_425177	37	47	aggregation	aggregation	NN
10_1101-2021_01_04_425177	37	48	of	of	IN
10_1101-2021_01_04_425177	37	49	the	the	DT
10_1101-2021_01_04_425177	37	50	PrP	PrP	NNP
10_1101-2021_01_04_425177	37	51	protein	protein	NN
10_1101-2021_01_04_425177	37	52	(	(	-LRB-
10_1101-2021_01_04_425177	37	53	if	if	IN
10_1101-2021_01_04_425177	37	54	at	at	RB
10_1101-2021_01_04_425177	37	55	all	all	RB
10_1101-2021_01_04_425177	37	56	)	)	-RRB-
10_1101-2021_01_04_425177	37	57	.	.	.
10_1101-2021_01_04_425177	38	1	Here	here	RB
10_1101-2021_01_04_425177	38	2	,	,	,
10_1101-2021_01_04_425177	38	3	we	-PRON-	PRP
10_1101-2021_01_04_425177	38	4	use	use	VBP
10_1101-2021_01_04_425177	38	5	Atomic	Atomic	NNP
10_1101-2021_01_04_425177	38	6	Force	Force	NNP
10_1101-2021_01_04_425177	38	7	Microscopy	Microscopy	NNP
10_1101-2021_01_04_425177	38	8	(	(	-LRB-
10_1101-2021_01_04_425177	38	9	AFM	AFM	NNP
10_1101-2021_01_04_425177	38	10	)	)	-RRB-
10_1101-2021_01_04_425177	38	11	imaging	image	VBG
10_1101-2021_01_04_425177	38	12	to	to	TO
10_1101-2021_01_04_425177	38	13	investigate	investigate	VB
10_1101-2021_01_04_425177	38	14	if	if	IN
10_1101-2021_01_04_425177	38	15	there	there	EX
10_1101-2021_01_04_425177	38	16	is	be	VBZ
10_1101-2021_01_04_425177	38	17	a	a	DT
10_1101-2021_01_04_425177	38	18	direct	direct	JJ
10_1101-2021_01_04_425177	38	19	effect	effect	NN
10_1101-2021_01_04_425177	38	20	of	of	IN
10_1101-2021_01_04_425177	38	21	the	the	DT
10_1101-2021_01_04_425177	38	22	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	38	23	construct	construct	VB
10_1101-2021_01_04_425177	38	24	on	on	IN
10_1101-2021_01_04_425177	38	25	the	the	DT
10_1101-2021_01_04_425177	38	26	in	in	FW
10_1101-2021_01_04_425177	38	27	vitro	vitro	FW
10_1101-2021_01_04_425177	38	28	aggregation	aggregation	NN
10_1101-2021_01_04_425177	38	29	of	of	IN
10_1101-2021_01_04_425177	38	30	the	the	DT
10_1101-2021_01_04_425177	38	31	human	human	JJ
10_1101-2021_01_04_425177	38	32	PrP	PrP	NNP
10_1101-2021_01_04_425177	38	33	protein	protein	NN
10_1101-2021_01_04_425177	38	34	.	.	.
10_1101-2021_01_04_425177	39	1	Answering	answer	VBG
10_1101-2021_01_04_425177	39	2	this	this	DT
10_1101-2021_01_04_425177	39	3	question	question	NN
10_1101-2021_01_04_425177	39	4	might	may	MD
10_1101-2021_01_04_425177	39	5	help	help	VB
10_1101-2021_01_04_425177	39	6	clarify	clarify	VB
10_1101-2021_01_04_425177	39	7	the	the	DT
10_1101-2021_01_04_425177	39	8	mechanisms	mechanism	NNS
10_1101-2021_01_04_425177	39	9	underlying	underlie	VBG
10_1101-2021_01_04_425177	39	10	the	the	DT
10_1101-2021_01_04_425177	39	11	previously	previously	RB
10_1101-2021_01_04_425177	39	12	observed	observe	VBN
10_1101-2021_01_04_425177	39	13	beneficial	beneficial	JJ
10_1101-2021_01_04_425177	39	14	effects	effect	NNS
10_1101-2021_01_04_425177	39	15	of	of	IN
10_1101-2021_01_04_425177	39	16	such	such	JJ
10_1101-2021_01_04_425177	39	17	peptide	peptide	JJ
10_1101-2021_01_04_425177	39	18	constructs	construct	NNS
10_1101-2021_01_04_425177	39	19	on	on	IN
10_1101-2021_01_04_425177	39	20	PrP	PrP	NNP
10_1101-2021_01_04_425177	39	21	infectivity	infectivity	NN
10_1101-2021_01_04_425177	39	22	(	(	-LRB-
10_1101-2021_01_04_425177	39	23	Löfgren	Löfgren	NNP
10_1101-2021_01_04_425177	39	24	et	et	NNP
10_1101-2021_01_04_425177	39	25	al	al	NNP
10_1101-2021_01_04_425177	39	26	.	.	NNP
10_1101-2021_01_04_425177	39	27	,	,	,
10_1101-2021_01_04_425177	39	28	2008	2008	CD
10_1101-2021_01_04_425177	39	29	;	;	:
10_1101-2021_01_04_425177	39	30	Söderberg	Söderberg	NNP
10_1101-2021_01_04_425177	39	31	et	et	NNP
10_1101-2021_01_04_425177	39	32	al	al	NNP
10_1101-2021_01_04_425177	39	33	.	.	NNP
10_1101-2021_01_04_425177	39	34	,	,	,
10_1101-2021_01_04_425177	39	35	2014	2014	CD
10_1101-2021_01_04_425177	39	36	)	)	-RRB-
10_1101-2021_01_04_425177	39	37	.	.	.
10_1101-2021_01_04_425177	40	1	Table	table	NN
10_1101-2021_01_04_425177	40	2	1	1	CD
10_1101-2021_01_04_425177	40	3	.	.	.
10_1101-2021_01_04_425177	41	1	Primary	primary	JJ
10_1101-2021_01_04_425177	41	2	sequences	sequence	NNS
10_1101-2021_01_04_425177	41	3	and	and	CC
10_1101-2021_01_04_425177	41	4	molecular	molecular	JJ
10_1101-2021_01_04_425177	41	5	properties	property	NNS
10_1101-2021_01_04_425177	41	6	of	of	IN
10_1101-2021_01_04_425177	41	7	the	the	DT
10_1101-2021_01_04_425177	41	8	human	human	JJ
10_1101-2021_01_04_425177	41	9	PrP	PrP	NNP
10_1101-2021_01_04_425177	41	10	protein	protein	NN
10_1101-2021_01_04_425177	41	11	,	,	,
10_1101-2021_01_04_425177	41	12	the	the	DT
10_1101-2021_01_04_425177	41	13	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	41	14	peptide	peptide	NN
10_1101-2021_01_04_425177	41	15	construct	construct	NN
10_1101-2021_01_04_425177	41	16	,	,	,
10_1101-2021_01_04_425177	41	17	and	and	CC
10_1101-2021_01_04_425177	41	18	its	-PRON-	PRP$
10_1101-2021_01_04_425177	41	19	parts	part	NNS
10_1101-2021_01_04_425177	41	20	.	.	.
10_1101-2021_01_04_425177	42	1	Protein	Protein	NNP
10_1101-2021_01_04_425177	42	2	Sequence	Sequence	NNP
10_1101-2021_01_04_425177	42	3	Isoelectric	Isoelectric	NNP
10_1101-2021_01_04_425177	42	4	point	point	NN
10_1101-2021_01_04_425177	42	5	(	(	-LRB-
10_1101-2021_01_04_425177	42	6	pI	pI	NNP
10_1101-2021_01_04_425177	42	7	)	)	-RRB-
10_1101-2021_01_04_425177	42	8	Molecular	molecular	JJ
10_1101-2021_01_04_425177	42	9	weight	weight	NN
10_1101-2021_01_04_425177	42	10	[	[	-LRB-
10_1101-2021_01_04_425177	42	11	g	g	NN
10_1101-2021_01_04_425177	42	12	mol-1	mol-1	UH
10_1101-2021_01_04_425177	42	13	]	]	-RRB-
10_1101-2021_01_04_425177	42	14	Net	net	JJ
10_1101-2021_01_04_425177	42	15	charge	charge	NN
10_1101-2021_01_04_425177	42	16	at	at	IN
10_1101-2021_01_04_425177	42	17	pH	pH	NNP
10_1101-2021_01_04_425177	42	18	7	7	CD
10_1101-2021_01_04_425177	42	19	Theoretical	theoretical	JJ
10_1101-2021_01_04_425177	42	20	hydrophobicity	hydrophobicity	NN
10_1101-2021_01_04_425177	42	21	[	[	-LRB-
10_1101-2021_01_04_425177	42	22	kcal	kcal	JJ
10_1101-2021_01_04_425177	42	23	mol-1	mol-1	NNP
10_1101-2021_01_04_425177	42	24	]	]	-RRB-
10_1101-2021_01_04_425177	42	25	huPrP23	huprp23	NN
10_1101-2021_01_04_425177	42	26	-	-	HYPH
10_1101-2021_01_04_425177	42	27	231	231	CD
10_1101-2021_01_04_425177	42	28	UniProt	UniProt	NNP
10_1101-2021_01_04_425177	42	29	ID	ID	NNP
10_1101-2021_01_04_425177	42	30	:	:	:
10_1101-2021_01_04_425177	42	31	P04156	P04156	NNP
10_1101-2021_01_04_425177	42	32	(	(	-LRB-
10_1101-2021_01_04_425177	42	33	209	209	CD
10_1101-2021_01_04_425177	42	34	aa	aa	NNP
10_1101-2021_01_04_425177	42	35	)	)	-RRB-
10_1101-2021_01_04_425177	42	36	9.39	9.39	CD
10_1101-2021_01_04_425177	42	37	22747	22747	CD
10_1101-2021_01_04_425177	42	38	+7	+7	CD
10_1101-2021_01_04_425177	42	39	-	-	HYPH
10_1101-2021_01_04_425177	42	40	NCAM11	ncam11	NN
10_1101-2021_01_04_425177	42	41	-	-	HYPH
10_1101-2021_01_04_425177	42	42	19-K-	19-K-	VBN
10_1101-2021_01_04_425177	42	43	Aβ16	Aβ16	NNP
10_1101-2021_01_04_425177	42	44	-	-	:
10_1101-2021_01_04_425177	42	45	20	20	CD
10_1101-2021_01_04_425177	42	46	(	(	-LRB-
10_1101-2021_01_04_425177	42	47	NCAM1-	NCAM1-	NNP
10_1101-2021_01_04_425177	42	48	Aβ	Aβ	NNP
10_1101-2021_01_04_425177	42	49	)	)	-RRB-
10_1101-2021_01_04_425177	42	50	NH2-MLRTKDLIWTL	NH2-MLRTKDLIWTL	NNP
10_1101-2021_01_04_425177	42	51	FFLGTAVSKKLVFF-	FFLGTAVSKKLVFF-	VBD
10_1101-2021_01_04_425177	42	52	NH2	NH2	NNP
10_1101-2021_01_04_425177	42	53	11.67	11.67	CD
10_1101-2021_01_04_425177	42	54	2974.7	2974.7	CD
10_1101-2021_01_04_425177	42	55	+4	+4	CD
10_1101-2021_01_04_425177	42	56	-3.83	-3.83	CD
10_1101-2021_01_04_425177	42	57	NCAM11	NCAM11	NNP
10_1101-2021_01_04_425177	42	58	-	-	HYPH
10_1101-2021_01_04_425177	42	59	19	19	CD
10_1101-2021_01_04_425177	42	60	(	(	-LRB-
10_1101-2021_01_04_425177	42	61	NCAM1	ncam1	NN
10_1101-2021_01_04_425177	42	62	)	)	-RRB-
10_1101-2021_01_04_425177	42	63	NH2-MLRTKDLIWTL	NH2-MLRTKDLIWTL	NNP
10_1101-2021_01_04_425177	42	64	FFLGTAVS	FFLGTAVS	NNP
10_1101-2021_01_04_425177	42	65	-	-	HYPH
10_1101-2021_01_04_425177	42	66	NH2	NH2	NNP
10_1101-2021_01_04_425177	42	67	11.39	11.39	CD
10_1101-2021_01_04_425177	42	68	2211.7	2211.7	CD
10_1101-2021_01_04_425177	42	69	+2	+2	SYM
10_1101-2021_01_04_425177	42	70	-3.06	-3.06	CD
10_1101-2021_01_04_425177	42	71	KKLVFF	KKLVFF	NNP
10_1101-2021_01_04_425177	42	72	NH2-KKLVFF	NH2-KKLVFF	NNP
10_1101-2021_01_04_425177	42	73	-	-	HYPH
10_1101-2021_01_04_425177	42	74	COOH	COOH	NNP
10_1101-2021_01_04_425177	42	75	10.69	10.69	CD
10_1101-2021_01_04_425177	42	76	781	781	CD
10_1101-2021_01_04_425177	42	77	+2	+2	JJ
10_1101-2021_01_04_425177	42	78	-0.77	-0.77	CD
10_1101-2021_01_04_425177	42	79	.CC	.CC	NFP
10_1101-2021_01_04_425177	42	80	-	-	HYPH
10_1101-2021_01_04_425177	42	81	BY	by	IN
10_1101-2021_01_04_425177	42	82	-	-	HYPH
10_1101-2021_01_04_425177	42	83	NC	NC	NNP
10_1101-2021_01_04_425177	42	84	-	-	HYPH
10_1101-2021_01_04_425177	42	85	ND	ND	NNP
10_1101-2021_01_04_425177	42	86	4.0	4.0	CD
10_1101-2021_01_04_425177	42	87	International	international	JJ
10_1101-2021_01_04_425177	42	88	licensemade	licensemade	NN
10_1101-2021_01_04_425177	42	89	available	available	JJ
10_1101-2021_01_04_425177	42	90	under	under	IN
10_1101-2021_01_04_425177	42	91	a	a	DT
10_1101-2021_01_04_425177	42	92	(	(	-LRB-
10_1101-2021_01_04_425177	42	93	which	which	WDT
10_1101-2021_01_04_425177	42	94	was	be	VBD
10_1101-2021_01_04_425177	42	95	not	not	RB
10_1101-2021_01_04_425177	42	96	certified	certify	VBN
10_1101-2021_01_04_425177	42	97	by	by	IN
10_1101-2021_01_04_425177	42	98	peer	peer	NN
10_1101-2021_01_04_425177	42	99	review	review	NN
10_1101-2021_01_04_425177	42	100	)	)	-RRB-
10_1101-2021_01_04_425177	42	101	is	be	VBZ
10_1101-2021_01_04_425177	42	102	the	the	DT
10_1101-2021_01_04_425177	42	103	author	author	NN
10_1101-2021_01_04_425177	42	104	/	/	SYM
10_1101-2021_01_04_425177	42	105	funder	funder	NN
10_1101-2021_01_04_425177	42	106	,	,	,
10_1101-2021_01_04_425177	42	107	who	who	WP
10_1101-2021_01_04_425177	42	108	has	have	VBZ
10_1101-2021_01_04_425177	42	109	granted	grant	VBN
10_1101-2021_01_04_425177	42	110	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	42	111	a	a	DT
10_1101-2021_01_04_425177	42	112	license	license	NN
10_1101-2021_01_04_425177	42	113	to	to	TO
10_1101-2021_01_04_425177	42	114	display	display	VB
10_1101-2021_01_04_425177	42	115	the	the	DT
10_1101-2021_01_04_425177	42	116	preprint	preprint	NN
10_1101-2021_01_04_425177	42	117	in	in	IN
10_1101-2021_01_04_425177	42	118	perpetuity	perpetuity	NN
10_1101-2021_01_04_425177	42	119	.	.	.
10_1101-2021_01_04_425177	43	1	It	-PRON-	PRP
10_1101-2021_01_04_425177	43	2	is	be	VBZ
10_1101-2021_01_04_425177	43	3	The	the	DT
10_1101-2021_01_04_425177	43	4	copyright	copyright	NN
10_1101-2021_01_04_425177	43	5	holder	holder	NN
10_1101-2021_01_04_425177	43	6	for	for	IN
10_1101-2021_01_04_425177	43	7	this	this	DT
10_1101-2021_01_04_425177	43	8	preprintthis	preprintthis	NN
10_1101-2021_01_04_425177	43	9	version	version	NN
10_1101-2021_01_04_425177	43	10	posted	post	VBD
10_1101-2021_01_04_425177	43	11	January	January	NNP
10_1101-2021_01_04_425177	43	12	4	4	CD
10_1101-2021_01_04_425177	43	13	,	,	,
10_1101-2021_01_04_425177	43	14	2021	2021	CD
10_1101-2021_01_04_425177	43	15	.	.	.
10_1101-2021_01_04_425177	43	16	;	;	:
10_1101-2021_01_04_425177	43	17	https://doi.org/10.1101/2021.01.04.425177doi	https://doi.org/10.1101/2021.01.04.425177doi	ADD
10_1101-2021_01_04_425177	43	18	:	:	:
10_1101-2021_01_04_425177	43	19	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	43	20	preprint	preprint	NN
10_1101-2021_01_04_425177	43	21	https://doi.org/10.1101/2021.01.04.425177	https://doi.org/10.1101/2021.01.04.425177	NNP
10_1101-2021_01_04_425177	43	22	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2021_01_04_425177	43	23	5	5	CD
10_1101-2021_01_04_425177	43	24	2	2	CD
10_1101-2021_01_04_425177	43	25	.	.	.
10_1101-2021_01_04_425177	44	1	Materials	material	NNS
10_1101-2021_01_04_425177	44	2	and	and	CC
10_1101-2021_01_04_425177	44	3	Methods	method	NNS
10_1101-2021_01_04_425177	44	4	2.1	2.1	CD
10_1101-2021_01_04_425177	44	5	Sample	Sample	NNP
10_1101-2021_01_04_425177	44	6	preparation	preparation	NN
10_1101-2021_01_04_425177	44	7	Human	human	JJ
10_1101-2021_01_04_425177	44	8	recombinant	recombinant	JJ
10_1101-2021_01_04_425177	44	9	prion	prion	NN
10_1101-2021_01_04_425177	44	10	protein	protein	NN
10_1101-2021_01_04_425177	44	11	(	(	-LRB-
10_1101-2021_01_04_425177	44	12	huPrP	huPrP	NNP
10_1101-2021_01_04_425177	44	13	)	)	-RRB-
10_1101-2021_01_04_425177	44	14	was	be	VBD
10_1101-2021_01_04_425177	44	15	prepared	prepare	VBN
10_1101-2021_01_04_425177	44	16	according	accord	VBG
10_1101-2021_01_04_425177	44	17	to	to	IN
10_1101-2021_01_04_425177	44	18	a	a	DT
10_1101-2021_01_04_425177	44	19	previously	previously	RB
10_1101-2021_01_04_425177	44	20	published	publish	VBN
10_1101-2021_01_04_425177	44	21	protocol	protocol	NN
10_1101-2021_01_04_425177	44	22	(	(	-LRB-
10_1101-2021_01_04_425177	44	23	Morillas	Morillas	NNP
10_1101-2021_01_04_425177	44	24	et	et	NNP
10_1101-2021_01_04_425177	44	25	al	al	NNP
10_1101-2021_01_04_425177	44	26	.	.	NNP
10_1101-2021_01_04_425177	44	27	,	,	,
10_1101-2021_01_04_425177	44	28	1999	1999	CD
10_1101-2021_01_04_425177	44	29	;	;	:
10_1101-2021_01_04_425177	44	30	Zahn	Zahn	NNP
10_1101-2021_01_04_425177	44	31	et	et	NNP
10_1101-2021_01_04_425177	44	32	al	al	NNP
10_1101-2021_01_04_425177	44	33	.	.	NNP
10_1101-2021_01_04_425177	44	34	,	,	,
10_1101-2021_01_04_425177	44	35	1997	1997	CD
10_1101-2021_01_04_425177	44	36	)	)	-RRB-
10_1101-2021_01_04_425177	44	37	,	,	,
10_1101-2021_01_04_425177	44	38	albeit	albeit	IN
10_1101-2021_01_04_425177	44	39	with	with	IN
10_1101-2021_01_04_425177	44	40	some	some	DT
10_1101-2021_01_04_425177	44	41	modifications	modification	NNS
10_1101-2021_01_04_425177	44	42	.	.	.
10_1101-2021_01_04_425177	45	1	The	the	DT
10_1101-2021_01_04_425177	45	2	plasmid	plasmid	NN
10_1101-2021_01_04_425177	45	3	contained	contain	VBD
10_1101-2021_01_04_425177	45	4	the	the	DT
10_1101-2021_01_04_425177	45	5	full	full	JJ
10_1101-2021_01_04_425177	45	6	-	-	HYPH
10_1101-2021_01_04_425177	45	7	length	length	NN
10_1101-2021_01_04_425177	45	8	(	(	-LRB-
10_1101-2021_01_04_425177	45	9	23	23	CD
10_1101-2021_01_04_425177	45	10	-	-	HYPH
10_1101-2021_01_04_425177	45	11	231)huPrP	231)huprp	CD
10_1101-2021_01_04_425177	45	12	protein	protein	NN
10_1101-2021_01_04_425177	45	13	in	in	IN
10_1101-2021_01_04_425177	45	14	fusion	fusion	NN
10_1101-2021_01_04_425177	45	15	with	with	IN
10_1101-2021_01_04_425177	45	16	an	an	DT
10_1101-2021_01_04_425177	45	17	N	n	NN
10_1101-2021_01_04_425177	45	18	-	-	HYPH
10_1101-2021_01_04_425177	45	19	terminal	terminal	NN
10_1101-2021_01_04_425177	45	20	HisTag	HisTag	NNP
10_1101-2021_01_04_425177	45	21	,	,	,
10_1101-2021_01_04_425177	45	22	and	and	CC
10_1101-2021_01_04_425177	45	23	the	the	DT
10_1101-2021_01_04_425177	45	24	thrombin	thrombin	NN
10_1101-2021_01_04_425177	45	25	cleavage	cleavage	NN
10_1101-2021_01_04_425177	45	26	site	site	NN
10_1101-2021_01_04_425177	45	27	was	be	VBD
10_1101-2021_01_04_425177	45	28	cloned	clone	VBN
10_1101-2021_01_04_425177	45	29	into	into	IN
10_1101-2021_01_04_425177	45	30	the	the	DT
10_1101-2021_01_04_425177	45	31	pRSETB	prsetb	NN
10_1101-2021_01_04_425177	45	32	vector	vector	NN
10_1101-2021_01_04_425177	45	33	(	(	-LRB-
10_1101-2021_01_04_425177	45	34	Invitrogen	Invitrogen	NNP
10_1101-2021_01_04_425177	45	35	,	,	,
10_1101-2021_01_04_425177	45	36	USA	USA	NNP
10_1101-2021_01_04_425177	45	37	)	)	-RRB-
10_1101-2021_01_04_425177	45	38	.	.	.
10_1101-2021_01_04_425177	46	1	The	the	DT
10_1101-2021_01_04_425177	46	2	construct	construct	NN
10_1101-2021_01_04_425177	46	3	was	be	VBD
10_1101-2021_01_04_425177	46	4	expressed	express	VBN
10_1101-2021_01_04_425177	46	5	in	in	IN
10_1101-2021_01_04_425177	46	6	E.	E.	NNP
10_1101-2021_01_04_425177	46	7	Coli	Coli	NNP
10_1101-2021_01_04_425177	46	8	(	(	-LRB-
10_1101-2021_01_04_425177	46	9	BL21-	BL21-	``
10_1101-2021_01_04_425177	46	10	DE3	DE3	NNP
10_1101-2021_01_04_425177	46	11	)	)	-RRB-
10_1101-2021_01_04_425177	46	12	grown	grow	VBN
10_1101-2021_01_04_425177	46	13	in	in	IN
10_1101-2021_01_04_425177	46	14	LB	LB	NNP
10_1101-2021_01_04_425177	46	15	growth	growth	NN
10_1101-2021_01_04_425177	46	16	medium	medium	NN
10_1101-2021_01_04_425177	46	17	with	with	IN
10_1101-2021_01_04_425177	46	18	100	100	CD
10_1101-2021_01_04_425177	46	19	µg	µg	NNS
10_1101-2021_01_04_425177	46	20	/	/	SYM
10_1101-2021_01_04_425177	46	21	mL	mL	NNP
10_1101-2021_01_04_425177	46	22	ampicillin	ampicillin	NNP
10_1101-2021_01_04_425177	46	23	.	.	.
10_1101-2021_01_04_425177	47	1	Expression	expression	NN
10_1101-2021_01_04_425177	47	2	was	be	VBD
10_1101-2021_01_04_425177	47	3	induced	induce	VBN
10_1101-2021_01_04_425177	47	4	by	by	IN
10_1101-2021_01_04_425177	47	5	isopropyl	isopropyl	JJ
10_1101-2021_01_04_425177	47	6	β	β	NNP
10_1101-2021_01_04_425177	47	7	-	-	HYPH
10_1101-2021_01_04_425177	47	8	D	D	NNP
10_1101-2021_01_04_425177	47	9	-	-	HYPH
10_1101-2021_01_04_425177	47	10	galactopyranoside	galactopyranoside	NN
10_1101-2021_01_04_425177	47	11	(	(	-LRB-
10_1101-2021_01_04_425177	47	12	IPTG	iptg	NN
10_1101-2021_01_04_425177	47	13	)	)	-RRB-
10_1101-2021_01_04_425177	47	14	at	at	IN
10_1101-2021_01_04_425177	47	15	OD600	od600	NN
10_1101-2021_01_04_425177	47	16	=	=	SYM
10_1101-2021_01_04_425177	47	17	0.8	0.8	CD
10_1101-2021_01_04_425177	47	18	.	.	.
10_1101-2021_01_04_425177	48	1	Sonication	sonication	NN
10_1101-2021_01_04_425177	48	2	of	of	IN
10_1101-2021_01_04_425177	48	3	the	the	DT
10_1101-2021_01_04_425177	48	4	lysates	lysate	NNS
10_1101-2021_01_04_425177	48	5	was	be	VBD
10_1101-2021_01_04_425177	48	6	performed	perform	VBN
10_1101-2021_01_04_425177	48	7	in	in	IN
10_1101-2021_01_04_425177	48	8	a	a	DT
10_1101-2021_01_04_425177	48	9	buffer	buffer	NN
10_1101-2021_01_04_425177	48	10	containing	contain	VBG
10_1101-2021_01_04_425177	48	11	100	100	CD
10_1101-2021_01_04_425177	48	12	mM	mm	NN
10_1101-2021_01_04_425177	48	13	Tris	Tris	NNP
10_1101-2021_01_04_425177	48	14	at	at	IN
10_1101-2021_01_04_425177	48	15	pH	pH	NNP
10_1101-2021_01_04_425177	48	16	8	8	CD
10_1101-2021_01_04_425177	48	17	,	,	,
10_1101-2021_01_04_425177	48	18	10	10	CD
10_1101-2021_01_04_425177	48	19	mM	mm	NN
10_1101-2021_01_04_425177	48	20	K2HPO4	k2hpo4	NN
10_1101-2021_01_04_425177	48	21	,	,	,
10_1101-2021_01_04_425177	48	22	10	10	CD
10_1101-2021_01_04_425177	48	23	mM	mm	NN
10_1101-2021_01_04_425177	48	24	glutathione	glutathione	NN
10_1101-2021_01_04_425177	48	25	(	(	-LRB-
10_1101-2021_01_04_425177	48	26	GSH	GSH	NNP
10_1101-2021_01_04_425177	48	27	)	)	-RRB-
10_1101-2021_01_04_425177	48	28	,	,	,
10_1101-2021_01_04_425177	48	29	6	6	CD
10_1101-2021_01_04_425177	48	30	M	m	NN
10_1101-2021_01_04_425177	48	31	GuHCl	GuHCl	NNS
10_1101-2021_01_04_425177	48	32	,	,	,
10_1101-2021_01_04_425177	48	33	and	and	CC
10_1101-2021_01_04_425177	48	34	0.5	0.5	CD
10_1101-2021_01_04_425177	48	35	mM	mm	NN
10_1101-2021_01_04_425177	48	36	phenylmethane	phenylmethane	NN
10_1101-2021_01_04_425177	48	37	sulfonyl	sulfonyl	NN
10_1101-2021_01_04_425177	48	38	fluoride	fluoride	NN
10_1101-2021_01_04_425177	48	39	(	(	-LRB-
10_1101-2021_01_04_425177	48	40	PMSF	PMSF	NNP
10_1101-2021_01_04_425177	48	41	)	)	-RRB-
10_1101-2021_01_04_425177	48	42	.	.	.
10_1101-2021_01_04_425177	49	1	The	the	DT
10_1101-2021_01_04_425177	49	2	solution	solution	NN
10_1101-2021_01_04_425177	49	3	was	be	VBD
10_1101-2021_01_04_425177	49	4	centrifuged	centrifuge	VBN
10_1101-2021_01_04_425177	49	5	and	and	CC
10_1101-2021_01_04_425177	49	6	the	the	DT
10_1101-2021_01_04_425177	49	7	supernatant	supernatant	JJ
10_1101-2021_01_04_425177	49	8	loaded	load	VBN
10_1101-2021_01_04_425177	49	9	to	to	IN
10_1101-2021_01_04_425177	49	10	Ni	Ni	NNP
10_1101-2021_01_04_425177	49	11	-	-	HYPH
10_1101-2021_01_04_425177	49	12	NTA	NTA	NNP
10_1101-2021_01_04_425177	49	13	resin	resin	NN
10_1101-2021_01_04_425177	49	14	(	(	-LRB-
10_1101-2021_01_04_425177	49	15	GE	GE	NNP
10_1101-2021_01_04_425177	49	16	Healthcare	Healthcare	NNP
10_1101-2021_01_04_425177	49	17	)	)	-RRB-
10_1101-2021_01_04_425177	49	18	and	and	CC
10_1101-2021_01_04_425177	49	19	eluted	elute	VBN
10_1101-2021_01_04_425177	49	20	with	with	IN
10_1101-2021_01_04_425177	49	21	buffer	buffer	NN
10_1101-2021_01_04_425177	49	22	E	e	NN
10_1101-2021_01_04_425177	49	23	(	(	-LRB-
10_1101-2021_01_04_425177	49	24	100	100	CD
10_1101-2021_01_04_425177	49	25	mM	mm	NN
10_1101-2021_01_04_425177	49	26	Tris	Tris	NNP
10_1101-2021_01_04_425177	49	27	at	at	IN
10_1101-2021_01_04_425177	49	28	pH	pH	NNP
10_1101-2021_01_04_425177	49	29	5.8	5.8	CD
10_1101-2021_01_04_425177	49	30	,	,	,
10_1101-2021_01_04_425177	49	31	10	10	CD
10_1101-2021_01_04_425177	49	32	mM	mm	NN
10_1101-2021_01_04_425177	49	33	K2HPO4	k2hpo4	NN
10_1101-2021_01_04_425177	49	34	,	,	,
10_1101-2021_01_04_425177	49	35	and	and	CC
10_1101-2021_01_04_425177	49	36	500	500	CD
10_1101-2021_01_04_425177	49	37	mM	mM	NNP
10_1101-2021_01_04_425177	49	38	imidazole	imidazole	NN
10_1101-2021_01_04_425177	49	39	)	)	-RRB-
10_1101-2021_01_04_425177	49	40	.	.	.
10_1101-2021_01_04_425177	50	1	After	after	IN
10_1101-2021_01_04_425177	50	2	washing	wash	VBG
10_1101-2021_01_04_425177	50	3	the	the	DT
10_1101-2021_01_04_425177	50	4	resin	resin	NN
10_1101-2021_01_04_425177	50	5	,	,	,
10_1101-2021_01_04_425177	50	6	the	the	DT
10_1101-2021_01_04_425177	50	7	protein	protein	NN
10_1101-2021_01_04_425177	50	8	was	be	VBD
10_1101-2021_01_04_425177	50	9	purified	purify	VBN
10_1101-2021_01_04_425177	50	10	with	with	IN
10_1101-2021_01_04_425177	50	11	two-	two-	NN
10_1101-2021_01_04_425177	50	12	step	step	NN
10_1101-2021_01_04_425177	50	13	dialysis	dialysis	NN
10_1101-2021_01_04_425177	50	14	,	,	,
10_1101-2021_01_04_425177	50	15	initially	initially	RB
10_1101-2021_01_04_425177	50	16	against	against	IN
10_1101-2021_01_04_425177	50	17	10	10	CD
10_1101-2021_01_04_425177	50	18	mM	mM	NNP
10_1101-2021_01_04_425177	50	19	phosphate	phosphate	NN
10_1101-2021_01_04_425177	50	20	buffer	buffer	NN
10_1101-2021_01_04_425177	50	21	with	with	IN
10_1101-2021_01_04_425177	50	22	0.1	0.1	CD
10_1101-2021_01_04_425177	50	23	mM	mm	NN
10_1101-2021_01_04_425177	50	24	PMSF	pmsf	NN
10_1101-2021_01_04_425177	50	25	at	at	IN
10_1101-2021_01_04_425177	50	26	pH	pH	NNP
10_1101-2021_01_04_425177	50	27	5.8	5.8	CD
10_1101-2021_01_04_425177	50	28	,	,	,
10_1101-2021_01_04_425177	50	29	and	and	CC
10_1101-2021_01_04_425177	50	30	then	then	RB
10_1101-2021_01_04_425177	50	31	against	against	IN
10_1101-2021_01_04_425177	50	32	Milli	Milli	NNP
10_1101-2021_01_04_425177	50	33	-	-	HYPH
10_1101-2021_01_04_425177	50	34	Q	Q	NNP
10_1101-2021_01_04_425177	50	35	H2O	h2o	NN
10_1101-2021_01_04_425177	50	36	with	with	IN
10_1101-2021_01_04_425177	50	37	0.1	0.1	CD
10_1101-2021_01_04_425177	50	38	mM	mm	NN
10_1101-2021_01_04_425177	50	39	PMSF	pmsf	JJ
10_1101-2021_01_04_425177	50	40	.	.	.
10_1101-2021_01_04_425177	51	1	After	after	IN
10_1101-2021_01_04_425177	51	2	thrombin	thrombin	NN
10_1101-2021_01_04_425177	51	3	cleavage	cleavage	NN
10_1101-2021_01_04_425177	51	4	,	,	,
10_1101-2021_01_04_425177	51	5	the	the	DT
10_1101-2021_01_04_425177	51	6	pure	pure	JJ
10_1101-2021_01_04_425177	51	7	huPrP	huprp	NN
10_1101-2021_01_04_425177	51	8	protein	protein	NN
10_1101-2021_01_04_425177	51	9	(	(	-LRB-
10_1101-2021_01_04_425177	51	10	i.e.	i.e.	FW
10_1101-2021_01_04_425177	51	11	,	,	,
10_1101-2021_01_04_425177	51	12	with	with	IN
10_1101-2021_01_04_425177	51	13	the	the	DT
10_1101-2021_01_04_425177	51	14	HisTag	HisTag	NNP
10_1101-2021_01_04_425177	51	15	removed	remove	VBN
10_1101-2021_01_04_425177	51	16	)	)	-RRB-
10_1101-2021_01_04_425177	51	17	was	be	VBD
10_1101-2021_01_04_425177	51	18	concentrated	concentrate	VBN
10_1101-2021_01_04_425177	51	19	using	use	VBG
10_1101-2021_01_04_425177	51	20	an	an	DT
10_1101-2021_01_04_425177	51	21	Amicon	Amicon	NNP
10_1101-2021_01_04_425177	51	22	Ultra	Ultra	NNP
10_1101-2021_01_04_425177	51	23	0.5	0.5	CD
10_1101-2021_01_04_425177	51	24	ml	ml	NN
10_1101-2021_01_04_425177	51	25	centrifugal	centrifugal	JJ
10_1101-2021_01_04_425177	51	26	filter	filter	NN
10_1101-2021_01_04_425177	51	27	(	(	-LRB-
10_1101-2021_01_04_425177	51	28	Merck	Merck	NNP
10_1101-2021_01_04_425177	51	29	&	&	CC
10_1101-2021_01_04_425177	51	30	Co.	Co.	NNP
10_1101-2021_01_04_425177	51	31	,	,	,
10_1101-2021_01_04_425177	51	32	USA	USA	NNP
10_1101-2021_01_04_425177	51	33	)	)	-RRB-
10_1101-2021_01_04_425177	51	34	with	with	IN
10_1101-2021_01_04_425177	51	35	an	an	DT
10_1101-2021_01_04_425177	51	36	NMWL	NMWL	NNP
10_1101-2021_01_04_425177	51	37	cutoff	cutoff	NN
10_1101-2021_01_04_425177	51	38	of	of	IN
10_1101-2021_01_04_425177	51	39	3	3	CD
10_1101-2021_01_04_425177	51	40	kDa	kDa	NNS
10_1101-2021_01_04_425177	51	41	.	.	.
10_1101-2021_01_04_425177	52	1	The	the	DT
10_1101-2021_01_04_425177	52	2	final	final	JJ
10_1101-2021_01_04_425177	52	3	protein	protein	NN
10_1101-2021_01_04_425177	52	4	concentration	concentration	NN
10_1101-2021_01_04_425177	52	5	was	be	VBD
10_1101-2021_01_04_425177	52	6	determined	determine	VBN
10_1101-2021_01_04_425177	52	7	by	by	IN
10_1101-2021_01_04_425177	52	8	spectrophotometry	spectrophotometry	NNP
10_1101-2021_01_04_425177	52	9	using	use	VBG
10_1101-2021_01_04_425177	52	10	an	an	DT
10_1101-2021_01_04_425177	52	11	extinction	extinction	NN
10_1101-2021_01_04_425177	52	12	coefficient	coefficient	NN
10_1101-2021_01_04_425177	52	13	of	of	IN
10_1101-2021_01_04_425177	52	14	ε280	ε280	NNP
10_1101-2021_01_04_425177	52	15	=	=	NFP
10_1101-2021_01_04_425177	52	16	57995	57995	CD
10_1101-2021_01_04_425177	52	17	M	m	NN
10_1101-2021_01_04_425177	52	18	-1cm-1	-1cm-1	:
10_1101-2021_01_04_425177	52	19	(	(	-LRB-
10_1101-2021_01_04_425177	52	20	Gasteiger	Gasteiger	NNP
10_1101-2021_01_04_425177	52	21	et	et	FW
10_1101-2021_01_04_425177	52	22	al	al	NNP
10_1101-2021_01_04_425177	52	23	.	.	NNP
10_1101-2021_01_04_425177	52	24	,	,	,
10_1101-2021_01_04_425177	52	25	2005	2005	CD
10_1101-2021_01_04_425177	52	26	)	)	-RRB-
10_1101-2021_01_04_425177	52	27	.	.	.
10_1101-2021_01_04_425177	53	1	The	the	DT
10_1101-2021_01_04_425177	53	2	quality	quality	NN
10_1101-2021_01_04_425177	53	3	of	of	IN
10_1101-2021_01_04_425177	53	4	the	the	DT
10_1101-2021_01_04_425177	53	5	final	final	JJ
10_1101-2021_01_04_425177	53	6	protein	protein	NN
10_1101-2021_01_04_425177	53	7	was	be	VBD
10_1101-2021_01_04_425177	53	8	controlled	control	VBN
10_1101-2021_01_04_425177	53	9	by	by	IN
10_1101-2021_01_04_425177	53	10	mass	mass	NNP
10_1101-2021_01_04_425177	53	11	spectrometry	spectrometry	NNP
10_1101-2021_01_04_425177	53	12	(	(	-LRB-
10_1101-2021_01_04_425177	53	13	molecular	molecular	NNP
10_1101-2021_01_04_425177	53	14	mass	mass	NN
10_1101-2021_01_04_425177	53	15	22747	22747	CD
10_1101-2021_01_04_425177	53	16	Da	Da	NNP
10_1101-2021_01_04_425177	53	17	-	-	HYPH
10_1101-2021_01_04_425177	53	18	Table	Table	NNP
10_1101-2021_01_04_425177	53	19	1	1	CD
10_1101-2021_01_04_425177	53	20	)	)	-RRB-
10_1101-2021_01_04_425177	53	21	.	.	.
10_1101-2021_01_04_425177	54	1	The	the	DT
10_1101-2021_01_04_425177	54	2	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	54	3	peptide	peptide	NN
10_1101-2021_01_04_425177	54	4	(	(	-LRB-
10_1101-2021_01_04_425177	54	5	Table	table	NN
10_1101-2021_01_04_425177	54	6	1	1	CD
10_1101-2021_01_04_425177	54	7	)	)	-RRB-
10_1101-2021_01_04_425177	54	8	was	be	VBD
10_1101-2021_01_04_425177	54	9	purchased	purchase	VBN
10_1101-2021_01_04_425177	54	10	as	as	IN
10_1101-2021_01_04_425177	54	11	a	a	DT
10_1101-2021_01_04_425177	54	12	custom	custom	NN
10_1101-2021_01_04_425177	54	13	order	order	NN
10_1101-2021_01_04_425177	54	14	from	from	IN
10_1101-2021_01_04_425177	54	15	the	the	DT
10_1101-2021_01_04_425177	54	16	PolyPeptide	PolyPeptide	NNP
10_1101-2021_01_04_425177	54	17	Group	Group	NNP
10_1101-2021_01_04_425177	54	18	(	(	-LRB-
10_1101-2021_01_04_425177	54	19	France	France	NNP
10_1101-2021_01_04_425177	54	20	)	)	-RRB-
10_1101-2021_01_04_425177	54	21	in	in	IN
10_1101-2021_01_04_425177	54	22	lyophilized	lyophilize	VBN
10_1101-2021_01_04_425177	54	23	form	form	NN
10_1101-2021_01_04_425177	54	24	.	.	.
10_1101-2021_01_04_425177	55	1	The	the	DT
10_1101-2021_01_04_425177	55	2	peptide	peptide	NN
10_1101-2021_01_04_425177	55	3	was	be	VBD
10_1101-2021_01_04_425177	55	4	dissolved	dissolve	VBN
10_1101-2021_01_04_425177	55	5	in	in	IN
10_1101-2021_01_04_425177	55	6	Milli	Milli	NNP
10_1101-2021_01_04_425177	55	7	-	-	HYPH
10_1101-2021_01_04_425177	55	8	Q	Q	NNP
10_1101-2021_01_04_425177	55	9	water	water	NN
10_1101-2021_01_04_425177	55	10	,	,	,
10_1101-2021_01_04_425177	55	11	and	and	CC
10_1101-2021_01_04_425177	55	12	its	-PRON-	PRP$
10_1101-2021_01_04_425177	55	13	concentration	concentration	NN
10_1101-2021_01_04_425177	55	14	was	be	VBD
10_1101-2021_01_04_425177	55	15	determined	determine	VBN
10_1101-2021_01_04_425177	55	16	via	via	IN
10_1101-2021_01_04_425177	55	17	triplicate	triplicate	NN
10_1101-2021_01_04_425177	55	18	UV	uv	NN
10_1101-2021_01_04_425177	55	19	absorption	absorption	NN
10_1101-2021_01_04_425177	55	20	measurements	measurement	NNS
10_1101-2021_01_04_425177	55	21	at	at	IN
10_1101-2021_01_04_425177	55	22	280	280	CD
10_1101-2021_01_04_425177	55	23	nm	nm	UH
10_1101-2021_01_04_425177	55	24	,	,	,
10_1101-2021_01_04_425177	55	25	using	use	VBG
10_1101-2021_01_04_425177	55	26	a	a	DT
10_1101-2021_01_04_425177	55	27	DS-11	DS-11	NNP
10_1101-2021_01_04_425177	55	28	spectrophotometer	spectrophotometer	NN
10_1101-2021_01_04_425177	55	29	(	(	-LRB-
10_1101-2021_01_04_425177	55	30	DeNovix	DeNovix	NNP
10_1101-2021_01_04_425177	55	31	,	,	,
10_1101-2021_01_04_425177	55	32	USA	USA	NNP
10_1101-2021_01_04_425177	55	33	)	)	-RRB-
10_1101-2021_01_04_425177	55	34	and	and	CC
10_1101-2021_01_04_425177	55	35	an	an	DT
10_1101-2021_01_04_425177	55	36	extinction	extinction	NN
10_1101-2021_01_04_425177	55	37	coefficient	coefficient	NN
10_1101-2021_01_04_425177	55	38	of	of	IN
10_1101-2021_01_04_425177	55	39	ε280	ε280	NNP
10_1101-2021_01_04_425177	55	40	=	=	NN
10_1101-2021_01_04_425177	55	41	5500	5500	CD
10_1101-2021_01_04_425177	55	42	M	m	NN
10_1101-2021_01_04_425177	55	43	-1cm-1	-1cm-1	:
10_1101-2021_01_04_425177	55	44	(	(	-LRB-
10_1101-2021_01_04_425177	55	45	Gasteiger	Gasteiger	NNP
10_1101-2021_01_04_425177	55	46	et	et	FW
10_1101-2021_01_04_425177	55	47	al	al	NNP
10_1101-2021_01_04_425177	55	48	.	.	NNP
10_1101-2021_01_04_425177	55	49	,	,	,
10_1101-2021_01_04_425177	55	50	2005	2005	CD
10_1101-2021_01_04_425177	55	51	)	)	-RRB-
10_1101-2021_01_04_425177	55	52	.	.	.
10_1101-2021_01_04_425177	56	1	.CC	.CC	NFP
10_1101-2021_01_04_425177	56	2	-	-	:
10_1101-2021_01_04_425177	56	3	BY	by	IN
10_1101-2021_01_04_425177	56	4	-	-	HYPH
10_1101-2021_01_04_425177	56	5	NC	NC	NNP
10_1101-2021_01_04_425177	56	6	-	-	HYPH
10_1101-2021_01_04_425177	56	7	ND	ND	NNP
10_1101-2021_01_04_425177	56	8	4.0	4.0	CD
10_1101-2021_01_04_425177	56	9	International	international	JJ
10_1101-2021_01_04_425177	56	10	licensemade	licensemade	NN
10_1101-2021_01_04_425177	56	11	available	available	JJ
10_1101-2021_01_04_425177	56	12	under	under	IN
10_1101-2021_01_04_425177	56	13	a	a	DT
10_1101-2021_01_04_425177	56	14	(	(	-LRB-
10_1101-2021_01_04_425177	56	15	which	which	WDT
10_1101-2021_01_04_425177	56	16	was	be	VBD
10_1101-2021_01_04_425177	56	17	not	not	RB
10_1101-2021_01_04_425177	56	18	certified	certify	VBN
10_1101-2021_01_04_425177	56	19	by	by	IN
10_1101-2021_01_04_425177	56	20	peer	peer	NN
10_1101-2021_01_04_425177	56	21	review	review	NN
10_1101-2021_01_04_425177	56	22	)	)	-RRB-
10_1101-2021_01_04_425177	56	23	is	be	VBZ
10_1101-2021_01_04_425177	56	24	the	the	DT
10_1101-2021_01_04_425177	56	25	author	author	NN
10_1101-2021_01_04_425177	56	26	/	/	SYM
10_1101-2021_01_04_425177	56	27	funder	funder	NN
10_1101-2021_01_04_425177	56	28	,	,	,
10_1101-2021_01_04_425177	56	29	who	who	WP
10_1101-2021_01_04_425177	56	30	has	have	VBZ
10_1101-2021_01_04_425177	56	31	granted	grant	VBN
10_1101-2021_01_04_425177	56	32	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	56	33	a	a	DT
10_1101-2021_01_04_425177	56	34	license	license	NN
10_1101-2021_01_04_425177	56	35	to	to	TO
10_1101-2021_01_04_425177	56	36	display	display	VB
10_1101-2021_01_04_425177	56	37	the	the	DT
10_1101-2021_01_04_425177	56	38	preprint	preprint	NN
10_1101-2021_01_04_425177	56	39	in	in	IN
10_1101-2021_01_04_425177	56	40	perpetuity	perpetuity	NN
10_1101-2021_01_04_425177	56	41	.	.	.
10_1101-2021_01_04_425177	57	1	It	-PRON-	PRP
10_1101-2021_01_04_425177	57	2	is	be	VBZ
10_1101-2021_01_04_425177	57	3	The	the	DT
10_1101-2021_01_04_425177	57	4	copyright	copyright	NN
10_1101-2021_01_04_425177	57	5	holder	holder	NN
10_1101-2021_01_04_425177	57	6	for	for	IN
10_1101-2021_01_04_425177	57	7	this	this	DT
10_1101-2021_01_04_425177	57	8	preprintthis	preprintthis	NN
10_1101-2021_01_04_425177	57	9	version	version	NN
10_1101-2021_01_04_425177	57	10	posted	post	VBD
10_1101-2021_01_04_425177	57	11	January	January	NNP
10_1101-2021_01_04_425177	57	12	4	4	CD
10_1101-2021_01_04_425177	57	13	,	,	,
10_1101-2021_01_04_425177	57	14	2021	2021	CD
10_1101-2021_01_04_425177	57	15	.	.	.
10_1101-2021_01_04_425177	57	16	;	;	:
10_1101-2021_01_04_425177	57	17	https://doi.org/10.1101/2021.01.04.425177doi	https://doi.org/10.1101/2021.01.04.425177doi	ADD
10_1101-2021_01_04_425177	57	18	:	:	:
10_1101-2021_01_04_425177	57	19	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	57	20	preprint	preprint	NN
10_1101-2021_01_04_425177	57	21	https://doi.org/10.1101/2021.01.04.425177	https://doi.org/10.1101/2021.01.04.425177	VBZ
10_1101-2021_01_04_425177	57	22	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2021_01_04_425177	57	23	6	6	CD
10_1101-2021_01_04_425177	57	24	2.2	2.2	CD
10_1101-2021_01_04_425177	57	25	Sample	sample	NN
10_1101-2021_01_04_425177	57	26	incubation	incubation	NN
10_1101-2021_01_04_425177	57	27	The	the	DT
10_1101-2021_01_04_425177	57	28	initial	initial	JJ
10_1101-2021_01_04_425177	57	29	buffer	buffer	NN
10_1101-2021_01_04_425177	57	30	in	in	IN
10_1101-2021_01_04_425177	57	31	the	the	DT
10_1101-2021_01_04_425177	57	32	huPrP	huprp	NN
10_1101-2021_01_04_425177	57	33	solution	solution	NN
10_1101-2021_01_04_425177	57	34	was	be	VBD
10_1101-2021_01_04_425177	57	35	exchanged	exchange	VBN
10_1101-2021_01_04_425177	57	36	to	to	TO
10_1101-2021_01_04_425177	57	37	ultrapure	ultrapure	VB
10_1101-2021_01_04_425177	57	38	water	water	NN
10_1101-2021_01_04_425177	57	39	by	by	IN
10_1101-2021_01_04_425177	57	40	triplicate	triplicate	NN
10_1101-2021_01_04_425177	57	41	diafiltration	diafiltration	NN
10_1101-2021_01_04_425177	57	42	using	use	VBG
10_1101-2021_01_04_425177	57	43	an	an	DT
10_1101-2021_01_04_425177	57	44	Amicon	Amicon	NNP
10_1101-2021_01_04_425177	57	45	Ultra	Ultra	NNP
10_1101-2021_01_04_425177	57	46	0.5	0.5	CD
10_1101-2021_01_04_425177	57	47	ml	ml	NN
10_1101-2021_01_04_425177	57	48	centrifugal	centrifugal	JJ
10_1101-2021_01_04_425177	57	49	filter	filter	NN
10_1101-2021_01_04_425177	57	50	(	(	-LRB-
10_1101-2021_01_04_425177	57	51	Merck	Merck	NNP
10_1101-2021_01_04_425177	57	52	&	&	CC
10_1101-2021_01_04_425177	57	53	Co.	Co.	NNP
10_1101-2021_01_04_425177	57	54	,	,	,
10_1101-2021_01_04_425177	57	55	USA	USA	NNP
10_1101-2021_01_04_425177	57	56	)	)	-RRB-
10_1101-2021_01_04_425177	57	57	with	with	IN
10_1101-2021_01_04_425177	57	58	an	an	DT
10_1101-2021_01_04_425177	57	59	NMWL	NMWL	NNP
10_1101-2021_01_04_425177	57	60	cutoff	cutoff	NN
10_1101-2021_01_04_425177	57	61	of	of	IN
10_1101-2021_01_04_425177	57	62	3	3	CD
10_1101-2021_01_04_425177	57	63	kDa	kDa	NNS
10_1101-2021_01_04_425177	57	64	.	.	.
10_1101-2021_01_04_425177	58	1	Samples	sample	NNS
10_1101-2021_01_04_425177	58	2	of	of	IN
10_1101-2021_01_04_425177	58	3	0.5	0.5	CD
10_1101-2021_01_04_425177	58	4	µM	µM	NNP
10_1101-2021_01_04_425177	58	5	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	58	6	,	,	,
10_1101-2021_01_04_425177	58	7	2.5	2.5	CD
10_1101-2021_01_04_425177	58	8	µM	µM	NNP
10_1101-2021_01_04_425177	58	9	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	58	10	,	,	,
10_1101-2021_01_04_425177	58	11	0.5	0.5	CD
10_1101-2021_01_04_425177	58	12	µM	µM	NNP
10_1101-2021_01_04_425177	58	13	huPrP	huprp	NN
10_1101-2021_01_04_425177	58	14	,	,	,
10_1101-2021_01_04_425177	58	15	and	and	CC
10_1101-2021_01_04_425177	58	16	0.5	0.5	CD
10_1101-2021_01_04_425177	58	17	µM	µM	NNP
10_1101-2021_01_04_425177	58	18	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	58	19	+	+	NNP
10_1101-2021_01_04_425177	58	20	0.5	0.5	CD
10_1101-2021_01_04_425177	58	21	µM	µM	NNP
10_1101-2021_01_04_425177	58	22	huPrP	huPrP	NNS
10_1101-2021_01_04_425177	58	23	were	be	VBD
10_1101-2021_01_04_425177	58	24	then	then	RB
10_1101-2021_01_04_425177	58	25	prepared	prepare	VBN
10_1101-2021_01_04_425177	58	26	in	in	IN
10_1101-2021_01_04_425177	58	27	10	10	CD
10_1101-2021_01_04_425177	58	28	mM	mm	NN
10_1101-2021_01_04_425177	58	29	sodium	sodium	NN
10_1101-2021_01_04_425177	58	30	phosphate	phosphate	NN
10_1101-2021_01_04_425177	58	31	buffer	buffer	NN
10_1101-2021_01_04_425177	58	32	,	,	,
10_1101-2021_01_04_425177	58	33	pH	pH	NNP
10_1101-2021_01_04_425177	58	34	7.5	7.5	CD
10_1101-2021_01_04_425177	58	35	,	,	,
10_1101-2021_01_04_425177	58	36	with	with	IN
10_1101-2021_01_04_425177	58	37	100	100	CD
10_1101-2021_01_04_425177	58	38	mM	mm	NN
10_1101-2021_01_04_425177	58	39	NaCl	NaCl	NNP
10_1101-2021_01_04_425177	58	40	and	and	CC
10_1101-2021_01_04_425177	58	41	2	2	CD
10_1101-2021_01_04_425177	58	42	M	M	NNP
10_1101-2021_01_04_425177	58	43	urea	urea	NNP
10_1101-2021_01_04_425177	58	44	.	.	.
10_1101-2021_01_04_425177	59	1	The	the	DT
10_1101-2021_01_04_425177	59	2	urea	urea	NN
10_1101-2021_01_04_425177	59	3	was	be	VBD
10_1101-2021_01_04_425177	59	4	added	add	VBN
10_1101-2021_01_04_425177	59	5	as	as	IN
10_1101-2021_01_04_425177	59	6	it	-PRON-	PRP
10_1101-2021_01_04_425177	59	7	has	have	VBZ
10_1101-2021_01_04_425177	59	8	previously	previously	RB
10_1101-2021_01_04_425177	59	9	been	be	VBN
10_1101-2021_01_04_425177	59	10	shown	show	VBN
10_1101-2021_01_04_425177	59	11	to	to	TO
10_1101-2021_01_04_425177	59	12	promote	promote	VB
10_1101-2021_01_04_425177	59	13	unfolding	unfolding	NN
10_1101-2021_01_04_425177	59	14	of	of	IN
10_1101-2021_01_04_425177	59	15	the	the	DT
10_1101-2021_01_04_425177	59	16	native	native	JJ
10_1101-2021_01_04_425177	59	17	PrP	PrP	NNP
10_1101-2021_01_04_425177	59	18	structure	structure	NN
10_1101-2021_01_04_425177	59	19	,	,	,
10_1101-2021_01_04_425177	59	20	which	which	WDT
10_1101-2021_01_04_425177	59	21	is	be	VBZ
10_1101-2021_01_04_425177	59	22	the	the	DT
10_1101-2021_01_04_425177	59	23	first	first	JJ
10_1101-2021_01_04_425177	59	24	step	step	NN
10_1101-2021_01_04_425177	59	25	towards	towards	IN
10_1101-2021_01_04_425177	59	26	aggregation	aggregation	NN
10_1101-2021_01_04_425177	59	27	(	(	-LRB-
10_1101-2021_01_04_425177	59	28	Julien	Julien	NNP
10_1101-2021_01_04_425177	59	29	et	et	NNP
10_1101-2021_01_04_425177	59	30	al	al	NNP
10_1101-2021_01_04_425177	59	31	.	.	NNP
10_1101-2021_01_04_425177	59	32	,	,	,
10_1101-2021_01_04_425177	59	33	2009	2009	CD
10_1101-2021_01_04_425177	59	34	;	;	:
10_1101-2021_01_04_425177	59	35	Swietnicki	Swietnicki	NNP
10_1101-2021_01_04_425177	59	36	et	et	FW
10_1101-2021_01_04_425177	59	37	al	al	NNP
10_1101-2021_01_04_425177	59	38	.	.	NNP
10_1101-2021_01_04_425177	59	39	,	,	,
10_1101-2021_01_04_425177	59	40	2000	2000	CD
10_1101-2021_01_04_425177	59	41	)	)	-RRB-
10_1101-2021_01_04_425177	59	42	.	.	.
10_1101-2021_01_04_425177	60	1	The	the	DT
10_1101-2021_01_04_425177	60	2	samples	sample	NNS
10_1101-2021_01_04_425177	60	3	were	be	VBD
10_1101-2021_01_04_425177	60	4	incubated	incubate	VBN
10_1101-2021_01_04_425177	60	5	for	for	IN
10_1101-2021_01_04_425177	60	6	72	72	CD
10_1101-2021_01_04_425177	60	7	hours	hour	NNS
10_1101-2021_01_04_425177	60	8	at	at	IN
10_1101-2021_01_04_425177	60	9	50	50	CD
10_1101-2021_01_04_425177	60	10	℃	℃	NN
10_1101-2021_01_04_425177	60	11	with	with	IN
10_1101-2021_01_04_425177	60	12	magnetic	magnetic	JJ
10_1101-2021_01_04_425177	60	13	stirring	stirring	NN
10_1101-2021_01_04_425177	60	14	at	at	IN
10_1101-2021_01_04_425177	60	15	400	400	CD
10_1101-2021_01_04_425177	60	16	rpm	rpm	NN
10_1101-2021_01_04_425177	60	17	.	.	.
10_1101-2021_01_04_425177	61	1	Subsamples	subsample	NNS
10_1101-2021_01_04_425177	61	2	were	be	VBD
10_1101-2021_01_04_425177	61	3	taken	take	VBN
10_1101-2021_01_04_425177	61	4	out	out	RP
10_1101-2021_01_04_425177	61	5	for	for	IN
10_1101-2021_01_04_425177	61	6	AFM	AFM	NNP
10_1101-2021_01_04_425177	61	7	imaging	imaging	NN
10_1101-2021_01_04_425177	61	8	(	(	-LRB-
10_1101-2021_01_04_425177	61	9	below	below	RB
10_1101-2021_01_04_425177	61	10	)	)	-RRB-
10_1101-2021_01_04_425177	61	11	after	after	IN
10_1101-2021_01_04_425177	61	12	8	8	CD
10_1101-2021_01_04_425177	61	13	and	and	CC
10_1101-2021_01_04_425177	61	14	72	72	CD
10_1101-2021_01_04_425177	61	15	hours	hour	NNS
10_1101-2021_01_04_425177	61	16	,	,	,
10_1101-2021_01_04_425177	61	17	respectively	respectively	RB
10_1101-2021_01_04_425177	61	18	.	.	.
10_1101-2021_01_04_425177	62	1	2.3	2.3	CD
10_1101-2021_01_04_425177	62	2	Atomic	atomic	JJ
10_1101-2021_01_04_425177	62	3	force	force	NN
10_1101-2021_01_04_425177	62	4	microscopy	microscopy	JJ
10_1101-2021_01_04_425177	62	5	(	(	-LRB-
10_1101-2021_01_04_425177	62	6	AFM	AFM	NNP
10_1101-2021_01_04_425177	62	7	)	)	-RRB-
10_1101-2021_01_04_425177	62	8	imaging	image	VBG
10_1101-2021_01_04_425177	62	9	Incubated	incubate	VBN
10_1101-2021_01_04_425177	62	10	samples	sample	NNS
10_1101-2021_01_04_425177	62	11	(	(	-LRB-
10_1101-2021_01_04_425177	62	12	5	5	CD
10_1101-2021_01_04_425177	62	13	μl	μl	NN
10_1101-2021_01_04_425177	62	14	)	)	-RRB-
10_1101-2021_01_04_425177	62	15	were	be	VBD
10_1101-2021_01_04_425177	62	16	transferred	transfer	VBN
10_1101-2021_01_04_425177	62	17	to	to	TO
10_1101-2021_01_04_425177	62	18	freshly	freshly	RB
10_1101-2021_01_04_425177	62	19	cleaved	cleave	VBN
10_1101-2021_01_04_425177	62	20	mica	mica	NNP
10_1101-2021_01_04_425177	62	21	plates	plate	NNS
10_1101-2021_01_04_425177	62	22	and	and	CC
10_1101-2021_01_04_425177	62	23	left	leave	VBD
10_1101-2021_01_04_425177	62	24	to	to	TO
10_1101-2021_01_04_425177	62	25	absorb	absorb	VB
10_1101-2021_01_04_425177	62	26	for	for	IN
10_1101-2021_01_04_425177	62	27	1	1	CD
10_1101-2021_01_04_425177	62	28	min	min	NN
10_1101-2021_01_04_425177	62	29	,	,	,
10_1101-2021_01_04_425177	62	30	rinsed	rinse	VBN
10_1101-2021_01_04_425177	62	31	three	three	CD
10_1101-2021_01_04_425177	62	32	times	time	NNS
10_1101-2021_01_04_425177	62	33	with	with	IN
10_1101-2021_01_04_425177	62	34	300	300	CD
10_1101-2021_01_04_425177	62	35	μl	μl	NN
10_1101-2021_01_04_425177	62	36	of	of	IN
10_1101-2021_01_04_425177	62	37	pure	pure	JJ
10_1101-2021_01_04_425177	62	38	water	water	NN
10_1101-2021_01_04_425177	62	39	,	,	,
10_1101-2021_01_04_425177	62	40	and	and	CC
10_1101-2021_01_04_425177	62	41	then	then	RB
10_1101-2021_01_04_425177	62	42	dried	dry	VBN
10_1101-2021_01_04_425177	62	43	under	under	IN
10_1101-2021_01_04_425177	62	44	a	a	DT
10_1101-2021_01_04_425177	62	45	gentle	gentle	JJ
10_1101-2021_01_04_425177	62	46	flow	flow	NN
10_1101-2021_01_04_425177	62	47	of	of	IN
10_1101-2021_01_04_425177	62	48	nitrogen	nitrogen	NN
10_1101-2021_01_04_425177	62	49	.	.	.
10_1101-2021_01_04_425177	63	1	AFM	AFM	NNP
10_1101-2021_01_04_425177	63	2	imaging	imaging	NNP
10_1101-2021_01_04_425177	63	3	was	be	VBD
10_1101-2021_01_04_425177	63	4	performed	perform	VBN
10_1101-2021_01_04_425177	63	5	on	on	IN
10_1101-2021_01_04_425177	63	6	a	a	DT
10_1101-2021_01_04_425177	63	7	JPK	JPK	NNP
10_1101-2021_01_04_425177	63	8	Nanowizard	Nanowizard	NNP
10_1101-2021_01_04_425177	63	9	4	4	CD
10_1101-2021_01_04_425177	63	10	(	(	-LRB-
10_1101-2021_01_04_425177	63	11	Bruker	Bruker	NNP
10_1101-2021_01_04_425177	63	12	,	,	,
10_1101-2021_01_04_425177	63	13	Germany	Germany	NNP
10_1101-2021_01_04_425177	63	14	)	)	-RRB-
10_1101-2021_01_04_425177	63	15	AFM	AFM	NNP
10_1101-2021_01_04_425177	63	16	unit	unit	NN
10_1101-2021_01_04_425177	63	17	using	use	VBG
10_1101-2021_01_04_425177	63	18	Tap150Al	Tap150Al	NNP
10_1101-2021_01_04_425177	63	19	-	-	HYPH
10_1101-2021_01_04_425177	63	20	G	g	NN
10_1101-2021_01_04_425177	63	21	cantilevers	cantilever	NNS
10_1101-2021_01_04_425177	63	22	(	(	-LRB-
10_1101-2021_01_04_425177	63	23	Ted	Ted	NNP
10_1101-2021_01_04_425177	63	24	Pella	Pella	NNP
10_1101-2021_01_04_425177	63	25	Inc.	Inc.	NNP
10_1101-2021_01_04_425177	63	26	,	,	,
10_1101-2021_01_04_425177	63	27	USA	USA	NNP
10_1101-2021_01_04_425177	63	28	)	)	-RRB-
10_1101-2021_01_04_425177	63	29	in	in	IN
10_1101-2021_01_04_425177	63	30	air	air	NN
10_1101-2021_01_04_425177	63	31	intermittent	intermittent	JJ
10_1101-2021_01_04_425177	63	32	contact	contact	NN
10_1101-2021_01_04_425177	63	33	mode	mode	NN
10_1101-2021_01_04_425177	63	34	.	.	.
10_1101-2021_01_04_425177	64	1	The	the	DT
10_1101-2021_01_04_425177	64	2	scan	scan	JJ
10_1101-2021_01_04_425177	64	3	rate	rate	NN
10_1101-2021_01_04_425177	64	4	was	be	VBD
10_1101-2021_01_04_425177	64	5	0.3	0.3	CD
10_1101-2021_01_04_425177	64	6	-	-	SYM
10_1101-2021_01_04_425177	64	7	0.7	0.7	CD
10_1101-2021_01_04_425177	64	8	Hz	Hz	NNP
10_1101-2021_01_04_425177	64	9	,	,	,
10_1101-2021_01_04_425177	64	10	the	the	DT
10_1101-2021_01_04_425177	64	11	scan	scan	JJ
10_1101-2021_01_04_425177	64	12	area	area	NN
10_1101-2021_01_04_425177	64	13	size	size	NN
10_1101-2021_01_04_425177	64	14	was	be	VBD
10_1101-2021_01_04_425177	64	15	5	5	CD
10_1101-2021_01_04_425177	64	16	μm	μm	NNS
10_1101-2021_01_04_425177	64	17	x	x	SYM
10_1101-2021_01_04_425177	64	18	5	5	CD
10_1101-2021_01_04_425177	64	19	μm	μm	NNS
10_1101-2021_01_04_425177	64	20	or	or	CC
10_1101-2021_01_04_425177	64	21	10	10	CD
10_1101-2021_01_04_425177	64	22	μm	μm	NNS
10_1101-2021_01_04_425177	64	23	x	x	SYM
10_1101-2021_01_04_425177	64	24	10	10	CD
10_1101-2021_01_04_425177	64	25	μm	μm	NNS
10_1101-2021_01_04_425177	64	26	,	,	,
10_1101-2021_01_04_425177	64	27	with	with	IN
10_1101-2021_01_04_425177	64	28	512	512	CD
10_1101-2021_01_04_425177	64	29	x	x	SYM
10_1101-2021_01_04_425177	64	30	512	512	CD
10_1101-2021_01_04_425177	64	31	or	or	CC
10_1101-2021_01_04_425177	64	32	1024	1024	CD
10_1101-2021_01_04_425177	64	33	x	x	SYM
10_1101-2021_01_04_425177	64	34	1024	1024	CD
10_1101-2021_01_04_425177	64	35	pixel	pixel	NNP
10_1101-2021_01_04_425177	64	36	resolution	resolution	NN
10_1101-2021_01_04_425177	64	37	respectively	respectively	RB
10_1101-2021_01_04_425177	64	38	.	.	.
10_1101-2021_01_04_425177	65	1	The	the	DT
10_1101-2021_01_04_425177	65	2	AFM	afm	NN
10_1101-2021_01_04_425177	65	3	images	image	NNS
10_1101-2021_01_04_425177	65	4	were	be	VBD
10_1101-2021_01_04_425177	65	5	analyzed	analyze	VBN
10_1101-2021_01_04_425177	65	6	using	use	VBG
10_1101-2021_01_04_425177	65	7	the	the	DT
10_1101-2021_01_04_425177	65	8	Gwyddion	Gwyddion	NNP
10_1101-2021_01_04_425177	65	9	2.54	2.54	CD
10_1101-2021_01_04_425177	65	10	software	software	NN
10_1101-2021_01_04_425177	65	11	(	(	-LRB-
10_1101-2021_01_04_425177	65	12	Necas	Necas	NNP
10_1101-2021_01_04_425177	65	13	and	and	CC
10_1101-2021_01_04_425177	65	14	Klapetek	Klapetek	NNP
10_1101-2021_01_04_425177	65	15	,	,	,
10_1101-2021_01_04_425177	65	16	2012	2012	CD
10_1101-2021_01_04_425177	65	17	)	)	-RRB-
10_1101-2021_01_04_425177	65	18	.	.	.
10_1101-2021_01_04_425177	66	1	3	3	LS
10_1101-2021_01_04_425177	66	2	.	.	.
10_1101-2021_01_04_425177	67	1	Results	result	NNS
10_1101-2021_01_04_425177	67	2	and	and	CC
10_1101-2021_01_04_425177	67	3	Discussion	Discussion	NNP
10_1101-2021_01_04_425177	67	4	AFM	AFM	NNP
10_1101-2021_01_04_425177	67	5	images	image	NNS
10_1101-2021_01_04_425177	67	6	of	of	IN
10_1101-2021_01_04_425177	67	7	the	the	DT
10_1101-2021_01_04_425177	67	8	aggregation	aggregation	NN
10_1101-2021_01_04_425177	67	9	products	product	NNS
10_1101-2021_01_04_425177	67	10	present	present	JJ
10_1101-2021_01_04_425177	67	11	in	in	IN
10_1101-2021_01_04_425177	67	12	the	the	DT
10_1101-2021_01_04_425177	67	13	samples	sample	NNS
10_1101-2021_01_04_425177	67	14	after	after	IN
10_1101-2021_01_04_425177	67	15	8	8	CD
10_1101-2021_01_04_425177	67	16	hours	hour	NNS
10_1101-2021_01_04_425177	67	17	of	of	IN
10_1101-2021_01_04_425177	67	18	incubation	incubation	NN
10_1101-2021_01_04_425177	67	19	are	be	VBP
10_1101-2021_01_04_425177	67	20	shown	show	VBN
10_1101-2021_01_04_425177	67	21	in	in	IN
10_1101-2021_01_04_425177	67	22	Figs	Figs	NNP
10_1101-2021_01_04_425177	67	23	.	.	.
10_1101-2021_01_04_425177	68	1	1A	1a	LS
10_1101-2021_01_04_425177	68	2	-	-	HYPH
10_1101-2021_01_04_425177	68	3	D.	D.	NNP
10_1101-2021_01_04_425177	69	1	The	the	DT
10_1101-2021_01_04_425177	69	2	sample	sample	NN
10_1101-2021_01_04_425177	69	3	of	of	IN
10_1101-2021_01_04_425177	69	4	0.5	0.5	CD
10_1101-2021_01_04_425177	69	5	µM	µM	NNP
10_1101-2021_01_04_425177	69	6	huPrP	huPrP	NNP
10_1101-2021_01_04_425177	69	7	readily	readily	RB
10_1101-2021_01_04_425177	69	8	self-	self-	VBD
10_1101-2021_01_04_425177	69	9	aggregated	aggregate	VBN
10_1101-2021_01_04_425177	69	10	into	into	IN
10_1101-2021_01_04_425177	69	11	long	long	JJ
10_1101-2021_01_04_425177	69	12	fibrils	fibril	NNS
10_1101-2021_01_04_425177	69	13	(	(	-LRB-
10_1101-2021_01_04_425177	69	14	Fig	fig	NN
10_1101-2021_01_04_425177	69	15	.	.	.
10_1101-2021_01_04_425177	70	1	1A	1a	LS
10_1101-2021_01_04_425177	70	2	)	)	-RRB-
10_1101-2021_01_04_425177	70	3	that	that	WDT
10_1101-2021_01_04_425177	70	4	are	be	VBP
10_1101-2021_01_04_425177	70	5	approximately	approximately	RB
10_1101-2021_01_04_425177	70	6	3	3	CD
10_1101-2021_01_04_425177	70	7	-	-	SYM
10_1101-2021_01_04_425177	70	8	4	4	CD
10_1101-2021_01_04_425177	70	9	nm	nm	NN
10_1101-2021_01_04_425177	70	10	thick	thick	JJ
10_1101-2021_01_04_425177	70	11	(	(	-LRB-
10_1101-2021_01_04_425177	70	12	judged	judge	VBN
10_1101-2021_01_04_425177	70	13	by	by	IN
10_1101-2021_01_04_425177	70	14	their	-PRON-	PRP$
10_1101-2021_01_04_425177	70	15	measured	measure	VBN
10_1101-2021_01_04_425177	70	16	height	height	NN
10_1101-2021_01_04_425177	70	17	,	,	,
10_1101-2021_01_04_425177	70	18	as	as	IN
10_1101-2021_01_04_425177	70	19	width	width	NN
10_1101-2021_01_04_425177	70	20	is	be	VBZ
10_1101-2021_01_04_425177	70	21	not	not	RB
10_1101-2021_01_04_425177	70	22	accurately	accurately	RB
10_1101-2021_01_04_425177	70	23	represented	represent	VBN
10_1101-2021_01_04_425177	70	24	in	in	IN
10_1101-2021_01_04_425177	70	25	AFM	AFM	NNP
10_1101-2021_01_04_425177	70	26	images	image	NNS
10_1101-2021_01_04_425177	70	27	)	)	-RRB-
10_1101-2021_01_04_425177	70	28	.	.	.
10_1101-2021_01_04_425177	71	1	This	this	DT
10_1101-2021_01_04_425177	71	2	is	be	VBZ
10_1101-2021_01_04_425177	71	3	somewhat	somewhat	RB
10_1101-2021_01_04_425177	71	4	thinner	thin	JJR
10_1101-2021_01_04_425177	71	5	but	but	CC
10_1101-2021_01_04_425177	71	6	still	still	RB
10_1101-2021_01_04_425177	71	7	in	in	IN
10_1101-2021_01_04_425177	71	8	line	line	NN
10_1101-2021_01_04_425177	71	9	with	with	IN
10_1101-2021_01_04_425177	71	10	the	the	DT
10_1101-2021_01_04_425177	71	11	results	result	NNS
10_1101-2021_01_04_425177	71	12	of	of	IN
10_1101-2021_01_04_425177	71	13	previous	previous	JJ
10_1101-2021_01_04_425177	71	14	studies	study	NNS
10_1101-2021_01_04_425177	71	15	on	on	IN
10_1101-2021_01_04_425177	71	16	PrP	PrP	NNP
10_1101-2021_01_04_425177	71	17	fibrils	fibril	NNS
10_1101-2021_01_04_425177	71	18	(	(	-LRB-
10_1101-2021_01_04_425177	71	19	Terry	Terry	NNP
10_1101-2021_01_04_425177	71	20	and	and	CC
10_1101-2021_01_04_425177	71	21	Wadsworth	Wadsworth	NNP
10_1101-2021_01_04_425177	71	22	,	,	,
10_1101-2021_01_04_425177	71	23	2019	2019	CD
10_1101-2021_01_04_425177	71	24	;	;	:
10_1101-2021_01_04_425177	71	25	Vazquez	Vazquez	NNP
10_1101-2021_01_04_425177	71	26	-	-	HYPH
10_1101-2021_01_04_425177	71	27	Fernandez	Fernandez	NNP
10_1101-2021_01_04_425177	71	28	et	et	FW
10_1101-2021_01_04_425177	71	29	al	al	NNP
10_1101-2021_01_04_425177	71	30	.	.	NNP
10_1101-2021_01_04_425177	71	31	,	,	,
10_1101-2021_01_04_425177	71	32	2017	2017	CD
10_1101-2021_01_04_425177	71	33	;	;	:
10_1101-2021_01_04_425177	71	34	Yamaguchi	Yamaguchi	NNP
10_1101-2021_01_04_425177	71	35	and	and	CC
10_1101-2021_01_04_425177	71	36	Kuwata	Kuwata	NNP
10_1101-2021_01_04_425177	71	37	,	,	,
10_1101-2021_01_04_425177	71	38	2018	2018	CD
10_1101-2021_01_04_425177	71	39	)	)	-RRB-
10_1101-2021_01_04_425177	71	40	.	.	.
10_1101-2021_01_04_425177	72	1	A	a	DT
10_1101-2021_01_04_425177	72	2	few	few	JJ
10_1101-2021_01_04_425177	72	3	very	very	RB
10_1101-2021_01_04_425177	72	4	large	large	JJ
10_1101-2021_01_04_425177	72	5	aggregate	aggregate	JJ
10_1101-2021_01_04_425177	72	6	clumps	clump	NNS
10_1101-2021_01_04_425177	72	7	,	,	,
10_1101-2021_01_04_425177	72	8	over	over	IN
10_1101-2021_01_04_425177	72	9	10	10	CD
10_1101-2021_01_04_425177	72	10	nm	nm	IN
10_1101-2021_01_04_425177	72	11	high	high	JJ
10_1101-2021_01_04_425177	72	12	,	,	,
10_1101-2021_01_04_425177	72	13	can	can	MD
10_1101-2021_01_04_425177	72	14	also	also	RB
10_1101-2021_01_04_425177	72	15	be	be	VB
10_1101-2021_01_04_425177	72	16	seen	see	VBN
10_1101-2021_01_04_425177	72	17	(	(	-LRB-
10_1101-2021_01_04_425177	72	18	Fig	fig	NN
10_1101-2021_01_04_425177	72	19	.	.	.
10_1101-2021_01_04_425177	73	1	1A	1a	LS
10_1101-2021_01_04_425177	73	2	)	)	-RRB-
10_1101-2021_01_04_425177	73	3	.	.	.
10_1101-2021_01_04_425177	74	1	For	for	IN
10_1101-2021_01_04_425177	74	2	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	74	3	,	,	,
10_1101-2021_01_04_425177	74	4	the	the	DT
10_1101-2021_01_04_425177	74	5	0.5	0.5	CD
10_1101-2021_01_04_425177	74	6	µM	µM	NNP
10_1101-2021_01_04_425177	74	7	sample	sample	NN
10_1101-2021_01_04_425177	74	8	shows	show	VBZ
10_1101-2021_01_04_425177	74	9	small	small	JJ
10_1101-2021_01_04_425177	74	10	aggregate	aggregate	NN
10_1101-2021_01_04_425177	74	11	clumps	clump	NNS
10_1101-2021_01_04_425177	74	12	(	(	-LRB-
10_1101-2021_01_04_425177	74	13	Fig	fig	NN
10_1101-2021_01_04_425177	74	14	.CC	.CC	:
10_1101-2021_01_04_425177	74	15	-	-	:
10_1101-2021_01_04_425177	74	16	BY	by	IN
10_1101-2021_01_04_425177	74	17	-	-	HYPH
10_1101-2021_01_04_425177	74	18	NC	NC	NNP
10_1101-2021_01_04_425177	74	19	-	-	HYPH
10_1101-2021_01_04_425177	74	20	ND	ND	NNP
10_1101-2021_01_04_425177	74	21	4.0	4.0	CD
10_1101-2021_01_04_425177	74	22	International	international	JJ
10_1101-2021_01_04_425177	74	23	licensemade	licensemade	NN
10_1101-2021_01_04_425177	74	24	available	available	JJ
10_1101-2021_01_04_425177	74	25	under	under	IN
10_1101-2021_01_04_425177	74	26	a	a	DT
10_1101-2021_01_04_425177	74	27	(	(	-LRB-
10_1101-2021_01_04_425177	74	28	which	which	WDT
10_1101-2021_01_04_425177	74	29	was	be	VBD
10_1101-2021_01_04_425177	74	30	not	not	RB
10_1101-2021_01_04_425177	74	31	certified	certify	VBN
10_1101-2021_01_04_425177	74	32	by	by	IN
10_1101-2021_01_04_425177	74	33	peer	peer	NN
10_1101-2021_01_04_425177	74	34	review	review	NN
10_1101-2021_01_04_425177	74	35	)	)	-RRB-
10_1101-2021_01_04_425177	74	36	is	be	VBZ
10_1101-2021_01_04_425177	74	37	the	the	DT
10_1101-2021_01_04_425177	74	38	author	author	NN
10_1101-2021_01_04_425177	74	39	/	/	SYM
10_1101-2021_01_04_425177	74	40	funder	funder	NN
10_1101-2021_01_04_425177	74	41	,	,	,
10_1101-2021_01_04_425177	74	42	who	who	WP
10_1101-2021_01_04_425177	74	43	has	have	VBZ
10_1101-2021_01_04_425177	74	44	granted	grant	VBN
10_1101-2021_01_04_425177	74	45	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	74	46	a	a	DT
10_1101-2021_01_04_425177	74	47	license	license	NN
10_1101-2021_01_04_425177	74	48	to	to	TO
10_1101-2021_01_04_425177	74	49	display	display	VB
10_1101-2021_01_04_425177	74	50	the	the	DT
10_1101-2021_01_04_425177	74	51	preprint	preprint	NN
10_1101-2021_01_04_425177	74	52	in	in	IN
10_1101-2021_01_04_425177	74	53	perpetuity	perpetuity	NN
10_1101-2021_01_04_425177	74	54	.	.	.
10_1101-2021_01_04_425177	75	1	It	-PRON-	PRP
10_1101-2021_01_04_425177	75	2	is	be	VBZ
10_1101-2021_01_04_425177	75	3	The	the	DT
10_1101-2021_01_04_425177	75	4	copyright	copyright	NN
10_1101-2021_01_04_425177	75	5	holder	holder	NN
10_1101-2021_01_04_425177	75	6	for	for	IN
10_1101-2021_01_04_425177	75	7	this	this	DT
10_1101-2021_01_04_425177	75	8	preprintthis	preprintthis	NN
10_1101-2021_01_04_425177	75	9	version	version	NN
10_1101-2021_01_04_425177	75	10	posted	post	VBD
10_1101-2021_01_04_425177	75	11	January	January	NNP
10_1101-2021_01_04_425177	75	12	4	4	CD
10_1101-2021_01_04_425177	75	13	,	,	,
10_1101-2021_01_04_425177	75	14	2021	2021	CD
10_1101-2021_01_04_425177	75	15	.	.	.
10_1101-2021_01_04_425177	75	16	;	;	:
10_1101-2021_01_04_425177	75	17	https://doi.org/10.1101/2021.01.04.425177doi	https://doi.org/10.1101/2021.01.04.425177doi	ADD
10_1101-2021_01_04_425177	75	18	:	:	:
10_1101-2021_01_04_425177	75	19	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	75	20	preprint	preprint	NN
10_1101-2021_01_04_425177	75	21	https://doi.org/10.1101/2021.01.04.425177	https://doi.org/10.1101/2021.01.04.425177	NNP
10_1101-2021_01_04_425177	75	22	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NNP
10_1101-2021_01_04_425177	75	23	7	7	CD
10_1101-2021_01_04_425177	75	24	1B	1b	NN
10_1101-2021_01_04_425177	75	25	)	)	-RRB-
10_1101-2021_01_04_425177	75	26	.	.	.
10_1101-2021_01_04_425177	76	1	Some	some	DT
10_1101-2021_01_04_425177	76	2	of	of	IN
10_1101-2021_01_04_425177	76	3	them	-PRON-	PRP
10_1101-2021_01_04_425177	76	4	are	be	VBP
10_1101-2021_01_04_425177	76	5	relatively	relatively	RB
10_1101-2021_01_04_425177	76	6	large	large	JJ
10_1101-2021_01_04_425177	76	7	,	,	,
10_1101-2021_01_04_425177	76	8	with	with	IN
10_1101-2021_01_04_425177	76	9	heights	height	NNS
10_1101-2021_01_04_425177	76	10	over	over	IN
10_1101-2021_01_04_425177	76	11	6	6	CD
10_1101-2021_01_04_425177	76	12	nm	nm	CD
10_1101-2021_01_04_425177	76	13	,	,	,
10_1101-2021_01_04_425177	76	14	and	and	CC
10_1101-2021_01_04_425177	76	15	may	may	MD
10_1101-2021_01_04_425177	76	16	or	or	CC
10_1101-2021_01_04_425177	76	17	may	may	MD
10_1101-2021_01_04_425177	76	18	not	not	RB
10_1101-2021_01_04_425177	76	19	be	be	VB
10_1101-2021_01_04_425177	76	20	early	early	JJ
10_1101-2021_01_04_425177	76	21	stages	stage	NNS
10_1101-2021_01_04_425177	76	22	of	of	IN
10_1101-2021_01_04_425177	76	23	fibrillar	fibrillar	JJ
10_1101-2021_01_04_425177	76	24	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	76	25	(	(	-LRB-
10_1101-2021_01_04_425177	76	26	Luo	Luo	NNP
10_1101-2021_01_04_425177	76	27	et	et	NNP
10_1101-2021_01_04_425177	76	28	al	al	NNP
10_1101-2021_01_04_425177	76	29	.	.	NNP
10_1101-2021_01_04_425177	76	30	,	,	,
10_1101-2021_01_04_425177	76	31	2014	2014	CD
10_1101-2021_01_04_425177	76	32	)	)	-RRB-
10_1101-2021_01_04_425177	76	33	.	.	.
10_1101-2021_01_04_425177	77	1	The	the	DT
10_1101-2021_01_04_425177	77	2	2.5	2.5	CD
10_1101-2021_01_04_425177	77	3	µM	µM	NNP
10_1101-2021_01_04_425177	77	4	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	77	5	sample	sample	NN
10_1101-2021_01_04_425177	77	6	shows	show	VBZ
10_1101-2021_01_04_425177	77	7	numerous	numerous	JJ
10_1101-2021_01_04_425177	77	8	mature	mature	JJ
10_1101-2021_01_04_425177	77	9	fibrils	fibril	NNS
10_1101-2021_01_04_425177	77	10	,	,	,
10_1101-2021_01_04_425177	77	11	about	about	RB
10_1101-2021_01_04_425177	77	12	2	2	CD
10_1101-2021_01_04_425177	77	13	–	–	SYM
10_1101-2021_01_04_425177	77	14	3	3	CD
10_1101-2021_01_04_425177	77	15	nm	nm	CC
10_1101-2021_01_04_425177	77	16	high	high	JJ
10_1101-2021_01_04_425177	77	17	,	,	,
10_1101-2021_01_04_425177	77	18	together	together	RB
10_1101-2021_01_04_425177	77	19	with	with	IN
10_1101-2021_01_04_425177	77	20	aggregate	aggregate	JJ
10_1101-2021_01_04_425177	77	21	clumps	clump	NNS
10_1101-2021_01_04_425177	77	22	(	(	-LRB-
10_1101-2021_01_04_425177	77	23	Fig	fig	NN
10_1101-2021_01_04_425177	77	24	.	.	.
10_1101-2021_01_04_425177	78	1	1C	1C	NNP
10_1101-2021_01_04_425177	78	2	)	)	-RRB-
10_1101-2021_01_04_425177	78	3	.	.	.
10_1101-2021_01_04_425177	79	1	The	the	DT
10_1101-2021_01_04_425177	79	2	more	more	RBR
10_1101-2021_01_04_425177	79	3	abundant	abundant	JJ
10_1101-2021_01_04_425177	79	4	amount	amount	NN
10_1101-2021_01_04_425177	79	5	of	of	IN
10_1101-2021_01_04_425177	79	6	fibrils	fibril	NNS
10_1101-2021_01_04_425177	79	7	for	for	IN
10_1101-2021_01_04_425177	79	8	2.5	2.5	CD
10_1101-2021_01_04_425177	79	9	µM	µM	NNP
10_1101-2021_01_04_425177	79	10	of	of	IN
10_1101-2021_01_04_425177	79	11	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	79	12	confirms	confirm	VBZ
10_1101-2021_01_04_425177	79	13	earlier	early	JJR
10_1101-2021_01_04_425177	79	14	results	result	NNS
10_1101-2021_01_04_425177	79	15	showing	show	VBG
10_1101-2021_01_04_425177	79	16	that	that	IN
10_1101-2021_01_04_425177	79	17	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	79	18	self	self	NN
10_1101-2021_01_04_425177	79	19	-	-	HYPH
10_1101-2021_01_04_425177	79	20	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	79	21	faster	fast	RBR
10_1101-2021_01_04_425177	79	22	at	at	IN
10_1101-2021_01_04_425177	79	23	higher	high	JJR
10_1101-2021_01_04_425177	79	24	concentrations	concentration	NNS
10_1101-2021_01_04_425177	79	25	(	(	-LRB-
10_1101-2021_01_04_425177	79	26	Pansieri	Pansieri	NNP
10_1101-2021_01_04_425177	79	27	et	et	FW
10_1101-2021_01_04_425177	79	28	al	al	NNP
10_1101-2021_01_04_425177	79	29	.	.	NNP
10_1101-2021_01_04_425177	79	30	,	,	,
10_1101-2021_01_04_425177	79	31	2019	2019	CD
10_1101-2021_01_04_425177	79	32	)	)	-RRB-
10_1101-2021_01_04_425177	79	33	.	.	.
10_1101-2021_01_04_425177	80	1	Figure	figure	NN
10_1101-2021_01_04_425177	80	2	1	1	CD
10_1101-2021_01_04_425177	80	3	.	.	.
10_1101-2021_01_04_425177	81	1	AFM	afm	NN
10_1101-2021_01_04_425177	81	2	images	image	NNS
10_1101-2021_01_04_425177	81	3	of	of	IN
10_1101-2021_01_04_425177	81	4	:	:	:
10_1101-2021_01_04_425177	81	5	(	(	-LRB-
10_1101-2021_01_04_425177	81	6	A	a	NN
10_1101-2021_01_04_425177	81	7	)	)	-RRB-
10_1101-2021_01_04_425177	81	8	0.5	0.5	CD
10_1101-2021_01_04_425177	81	9	µM	µm	NN
10_1101-2021_01_04_425177	81	10	huPrP	huprp	NN
10_1101-2021_01_04_425177	81	11	protein	protein	NN
10_1101-2021_01_04_425177	81	12	;	;	.
10_1101-2021_01_04_425177	81	13	(	(	-LRB-
10_1101-2021_01_04_425177	81	14	B	b	NN
10_1101-2021_01_04_425177	81	15	)	)	-RRB-
10_1101-2021_01_04_425177	81	16	0.5	0.5	CD
10_1101-2021_01_04_425177	81	17	µM	µM	NNP
10_1101-2021_01_04_425177	81	18	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	81	19	peptide	peptide	NN
10_1101-2021_01_04_425177	81	20	;	;	,
10_1101-2021_01_04_425177	81	21	(	(	-LRB-
10_1101-2021_01_04_425177	81	22	C	c	NN
10_1101-2021_01_04_425177	81	23	)	)	-RRB-
10_1101-2021_01_04_425177	81	24	2.5	2.5	CD
10_1101-2021_01_04_425177	81	25	µM	µM	NNP
10_1101-2021_01_04_425177	81	26	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	81	27	peptide	peptide	NN
10_1101-2021_01_04_425177	81	28	;	;	,
10_1101-2021_01_04_425177	81	29	and	and	CC
10_1101-2021_01_04_425177	81	30	(	(	-LRB-
10_1101-2021_01_04_425177	81	31	D	d	NN
10_1101-2021_01_04_425177	81	32	)	)	-RRB-
10_1101-2021_01_04_425177	81	33	0.5	0.5	CD
10_1101-2021_01_04_425177	81	34	µM	µm	NN
10_1101-2021_01_04_425177	81	35	huPrP	huprp	NN
10_1101-2021_01_04_425177	81	36	protein	protein	NN
10_1101-2021_01_04_425177	81	37	+	+	SYM
10_1101-2021_01_04_425177	81	38	0.5	0.5	CD
10_1101-2021_01_04_425177	81	39	µM	µM	NNP
10_1101-2021_01_04_425177	81	40	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	81	41	peptide	peptide	NN
10_1101-2021_01_04_425177	81	42	.	.	.
10_1101-2021_01_04_425177	82	1	All	all	DT
10_1101-2021_01_04_425177	82	2	samples	sample	NNS
10_1101-2021_01_04_425177	82	3	in	in	IN
10_1101-2021_01_04_425177	82	4	A	a	NN
10_1101-2021_01_04_425177	82	5	-	-	HYPH
10_1101-2021_01_04_425177	82	6	D	D	NNP
10_1101-2021_01_04_425177	82	7	were	be	VBD
10_1101-2021_01_04_425177	82	8	incubated	incubate	VBN
10_1101-2021_01_04_425177	82	9	for	for	IN
10_1101-2021_01_04_425177	82	10	8	8	CD
10_1101-2021_01_04_425177	82	11	hours	hour	NNS
10_1101-2021_01_04_425177	82	12	.	.	.
10_1101-2021_01_04_425177	83	1	(	(	-LRB-
10_1101-2021_01_04_425177	83	2	E	e	NN
10_1101-2021_01_04_425177	83	3	)	)	-RRB-
10_1101-2021_01_04_425177	83	4	0.5	0.5	CD
10_1101-2021_01_04_425177	83	5	µM	µm	NN
10_1101-2021_01_04_425177	83	6	huPrP	huprp	NN
10_1101-2021_01_04_425177	83	7	protein	protein	NN
10_1101-2021_01_04_425177	83	8	+	+	SYM
10_1101-2021_01_04_425177	83	9	0.5	0.5	CD
10_1101-2021_01_04_425177	83	10	µM	µM	NNP
10_1101-2021_01_04_425177	83	11	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	83	12	peptide	peptide	NN
10_1101-2021_01_04_425177	83	13	,	,	,
10_1101-2021_01_04_425177	83	14	incubated	incubate	VBD
10_1101-2021_01_04_425177	83	15	for	for	IN
10_1101-2021_01_04_425177	83	16	72	72	CD
10_1101-2021_01_04_425177	83	17	hours	hour	NNS
10_1101-2021_01_04_425177	83	18	.	.	.
10_1101-2021_01_04_425177	84	1	All	all	DT
10_1101-2021_01_04_425177	84	2	studied	study	VBN
10_1101-2021_01_04_425177	84	3	samples	sample	NNS
10_1101-2021_01_04_425177	84	4	were	be	VBD
10_1101-2021_01_04_425177	84	5	incubated	incubate	VBN
10_1101-2021_01_04_425177	84	6	at	at	IN
10_1101-2021_01_04_425177	84	7	50	50	CD
10_1101-2021_01_04_425177	84	8	℃	℃	NNP
10_1101-2021_01_04_425177	84	9	in	in	IN
10_1101-2021_01_04_425177	84	10	10	10	CD
10_1101-2021_01_04_425177	84	11	mM	mm	NN
10_1101-2021_01_04_425177	84	12	sodium	sodium	NN
10_1101-2021_01_04_425177	84	13	phosphate	phosphate	NN
10_1101-2021_01_04_425177	84	14	buffer	buffer	NN
10_1101-2021_01_04_425177	84	15	,	,	,
10_1101-2021_01_04_425177	84	16	pH	pH	NNP
10_1101-2021_01_04_425177	84	17	7.5	7.5	CD
10_1101-2021_01_04_425177	84	18	,	,	,
10_1101-2021_01_04_425177	84	19	with	with	IN
10_1101-2021_01_04_425177	84	20	100	100	CD
10_1101-2021_01_04_425177	84	21	mM	mm	NN
10_1101-2021_01_04_425177	84	22	NaCl	NaCl	NNP
10_1101-2021_01_04_425177	84	23	and	and	CC
10_1101-2021_01_04_425177	84	24	2	2	CD
10_1101-2021_01_04_425177	84	25	M	M	NNP
10_1101-2021_01_04_425177	84	26	urea	urea	NN
10_1101-2021_01_04_425177	84	27	,	,	,
10_1101-2021_01_04_425177	84	28	and	and	CC
10_1101-2021_01_04_425177	84	29	with	with	IN
10_1101-2021_01_04_425177	84	30	magnetic	magnetic	JJ
10_1101-2021_01_04_425177	84	31	stirring	stirring	NN
10_1101-2021_01_04_425177	84	32	at	at	IN
10_1101-2021_01_04_425177	84	33	400	400	CD
10_1101-2021_01_04_425177	84	34	rpm	rpm	NN
10_1101-2021_01_04_425177	84	35	.	.	.
10_1101-2021_01_04_425177	85	1	The	the	DT
10_1101-2021_01_04_425177	85	2	white	white	JJ
10_1101-2021_01_04_425177	85	3	scale	scale	NN
10_1101-2021_01_04_425177	85	4	bars	bar	NNS
10_1101-2021_01_04_425177	85	5	are	be	VBP
10_1101-2021_01_04_425177	85	6	500	500	CD
10_1101-2021_01_04_425177	85	7	nm	nm	NN
10_1101-2021_01_04_425177	85	8	.	.	.
10_1101-2021_01_04_425177	86	1	.CC	.CC	NFP
10_1101-2021_01_04_425177	86	2	-	-	:
10_1101-2021_01_04_425177	86	3	BY	by	IN
10_1101-2021_01_04_425177	86	4	-	-	HYPH
10_1101-2021_01_04_425177	86	5	NC	NC	NNP
10_1101-2021_01_04_425177	86	6	-	-	HYPH
10_1101-2021_01_04_425177	86	7	ND	ND	NNP
10_1101-2021_01_04_425177	86	8	4.0	4.0	CD
10_1101-2021_01_04_425177	86	9	International	international	JJ
10_1101-2021_01_04_425177	86	10	licensemade	licensemade	NN
10_1101-2021_01_04_425177	86	11	available	available	JJ
10_1101-2021_01_04_425177	86	12	under	under	IN
10_1101-2021_01_04_425177	86	13	a	a	DT
10_1101-2021_01_04_425177	86	14	(	(	-LRB-
10_1101-2021_01_04_425177	86	15	which	which	WDT
10_1101-2021_01_04_425177	86	16	was	be	VBD
10_1101-2021_01_04_425177	86	17	not	not	RB
10_1101-2021_01_04_425177	86	18	certified	certify	VBN
10_1101-2021_01_04_425177	86	19	by	by	IN
10_1101-2021_01_04_425177	86	20	peer	peer	NN
10_1101-2021_01_04_425177	86	21	review	review	NN
10_1101-2021_01_04_425177	86	22	)	)	-RRB-
10_1101-2021_01_04_425177	86	23	is	be	VBZ
10_1101-2021_01_04_425177	86	24	the	the	DT
10_1101-2021_01_04_425177	86	25	author	author	NN
10_1101-2021_01_04_425177	86	26	/	/	SYM
10_1101-2021_01_04_425177	86	27	funder	funder	NN
10_1101-2021_01_04_425177	86	28	,	,	,
10_1101-2021_01_04_425177	86	29	who	who	WP
10_1101-2021_01_04_425177	86	30	has	have	VBZ
10_1101-2021_01_04_425177	86	31	granted	grant	VBN
10_1101-2021_01_04_425177	86	32	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	86	33	a	a	DT
10_1101-2021_01_04_425177	86	34	license	license	NN
10_1101-2021_01_04_425177	86	35	to	to	TO
10_1101-2021_01_04_425177	86	36	display	display	VB
10_1101-2021_01_04_425177	86	37	the	the	DT
10_1101-2021_01_04_425177	86	38	preprint	preprint	NN
10_1101-2021_01_04_425177	86	39	in	in	IN
10_1101-2021_01_04_425177	86	40	perpetuity	perpetuity	NN
10_1101-2021_01_04_425177	86	41	.	.	.
10_1101-2021_01_04_425177	87	1	It	-PRON-	PRP
10_1101-2021_01_04_425177	87	2	is	be	VBZ
10_1101-2021_01_04_425177	87	3	The	the	DT
10_1101-2021_01_04_425177	87	4	copyright	copyright	NN
10_1101-2021_01_04_425177	87	5	holder	holder	NN
10_1101-2021_01_04_425177	87	6	for	for	IN
10_1101-2021_01_04_425177	87	7	this	this	DT
10_1101-2021_01_04_425177	87	8	preprintthis	preprintthis	NN
10_1101-2021_01_04_425177	87	9	version	version	NN
10_1101-2021_01_04_425177	87	10	posted	post	VBD
10_1101-2021_01_04_425177	87	11	January	January	NNP
10_1101-2021_01_04_425177	87	12	4	4	CD
10_1101-2021_01_04_425177	87	13	,	,	,
10_1101-2021_01_04_425177	87	14	2021	2021	CD
10_1101-2021_01_04_425177	87	15	.	.	.
10_1101-2021_01_04_425177	87	16	;	;	:
10_1101-2021_01_04_425177	87	17	https://doi.org/10.1101/2021.01.04.425177doi	https://doi.org/10.1101/2021.01.04.425177doi	ADD
10_1101-2021_01_04_425177	87	18	:	:	:
10_1101-2021_01_04_425177	87	19	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	87	20	preprint	preprint	NN
10_1101-2021_01_04_425177	87	21	https://doi.org/10.1101/2021.01.04.425177	https://doi.org/10.1101/2021.01.04.425177	NNP
10_1101-2021_01_04_425177	87	22	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	NN
10_1101-2021_01_04_425177	87	23	8	8	CD
10_1101-2021_01_04_425177	87	24	Interestingly	interestingly	RB
10_1101-2021_01_04_425177	87	25	,	,	,
10_1101-2021_01_04_425177	87	26	the	the	DT
10_1101-2021_01_04_425177	87	27	sample	sample	NN
10_1101-2021_01_04_425177	87	28	containing	contain	VBG
10_1101-2021_01_04_425177	87	29	both	both	CC
10_1101-2021_01_04_425177	87	30	0.5	0.5	CD
10_1101-2021_01_04_425177	87	31	µM	µM	NNP
10_1101-2021_01_04_425177	87	32	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	87	33	and	and	CC
10_1101-2021_01_04_425177	87	34	0.5	0.5	CD
10_1101-2021_01_04_425177	87	35	µM	µM	NNP
10_1101-2021_01_04_425177	87	36	huPrP	huprp	NN
10_1101-2021_01_04_425177	87	37	displays	display	VBZ
10_1101-2021_01_04_425177	87	38	no	no	DT
10_1101-2021_01_04_425177	87	39	fibrils	fibril	NNS
10_1101-2021_01_04_425177	87	40	,	,	,
10_1101-2021_01_04_425177	87	41	but	but	CC
10_1101-2021_01_04_425177	87	42	only	only	RB
10_1101-2021_01_04_425177	87	43	numerous	numerous	JJ
10_1101-2021_01_04_425177	87	44	small	small	JJ
10_1101-2021_01_04_425177	87	45	aggregate	aggregate	NN
10_1101-2021_01_04_425177	87	46	clumps	clump	NNS
10_1101-2021_01_04_425177	87	47	,	,	,
10_1101-2021_01_04_425177	87	48	about	about	RB
10_1101-2021_01_04_425177	87	49	2	2	CD
10_1101-2021_01_04_425177	87	50	nm	nm	CC
10_1101-2021_01_04_425177	87	51	high	high	JJ
10_1101-2021_01_04_425177	87	52	(	(	-LRB-
10_1101-2021_01_04_425177	87	53	Fig	fig	NN
10_1101-2021_01_04_425177	87	54	.	.	.
10_1101-2021_01_04_425177	88	1	1D	1D	NNP
10_1101-2021_01_04_425177	88	2	)	)	-RRB-
10_1101-2021_01_04_425177	88	3	.	.	.
10_1101-2021_01_04_425177	89	1	Even	even	RB
10_1101-2021_01_04_425177	89	2	after	after	IN
10_1101-2021_01_04_425177	89	3	72	72	CD
10_1101-2021_01_04_425177	89	4	hours	hour	NNS
10_1101-2021_01_04_425177	89	5	no	no	DT
10_1101-2021_01_04_425177	89	6	fibrils	fibril	NNS
10_1101-2021_01_04_425177	89	7	can	can	MD
10_1101-2021_01_04_425177	89	8	be	be	VB
10_1101-2021_01_04_425177	89	9	seen	see	VBN
10_1101-2021_01_04_425177	89	10	,	,	,
10_1101-2021_01_04_425177	89	11	but	but	CC
10_1101-2021_01_04_425177	89	12	the	the	DT
10_1101-2021_01_04_425177	89	13	aggregate	aggregate	JJ
10_1101-2021_01_04_425177	89	14	clumps	clump	NNS
10_1101-2021_01_04_425177	89	15	are	be	VBP
10_1101-2021_01_04_425177	89	16	then	then	RB
10_1101-2021_01_04_425177	89	17	fewer	few	JJR
10_1101-2021_01_04_425177	89	18	and	and	CC
10_1101-2021_01_04_425177	89	19	larger	large	JJR
10_1101-2021_01_04_425177	89	20	,	,	,
10_1101-2021_01_04_425177	89	21	around	around	RB
10_1101-2021_01_04_425177	89	22	3	3	CD
10_1101-2021_01_04_425177	89	23	–	–	SYM
10_1101-2021_01_04_425177	89	24	4	4	CD
10_1101-2021_01_04_425177	89	25	nm	nm	CC
10_1101-2021_01_04_425177	89	26	high	high	JJ
10_1101-2021_01_04_425177	89	27	(	(	-LRB-
10_1101-2021_01_04_425177	89	28	Fig	fig	NN
10_1101-2021_01_04_425177	89	29	1E	1E	NNP
10_1101-2021_01_04_425177	89	30	)	)	-RRB-
10_1101-2021_01_04_425177	89	31	.	.	.
10_1101-2021_01_04_425177	90	1	As	as	IN
10_1101-2021_01_04_425177	90	2	it	-PRON-	PRP
10_1101-2021_01_04_425177	90	3	can	can	MD
10_1101-2021_01_04_425177	90	4	not	not	RB
10_1101-2021_01_04_425177	90	5	be	be	VB
10_1101-2021_01_04_425177	90	6	ruled	rule	VBN
10_1101-2021_01_04_425177	90	7	out	out	RP
10_1101-2021_01_04_425177	90	8	that	that	IN
10_1101-2021_01_04_425177	90	9	these	these	DT
10_1101-2021_01_04_425177	90	10	small	small	JJ
10_1101-2021_01_04_425177	90	11	aggregate	aggregate	NN
10_1101-2021_01_04_425177	90	12	clumps	clump	NNS
10_1101-2021_01_04_425177	90	13	will	will	MD
10_1101-2021_01_04_425177	90	14	eventually	eventually	RB
10_1101-2021_01_04_425177	90	15	form	form	VB
10_1101-2021_01_04_425177	90	16	fibrils	fibril	NNS
10_1101-2021_01_04_425177	90	17	,	,	,
10_1101-2021_01_04_425177	90	18	it	-PRON-	PRP
10_1101-2021_01_04_425177	90	19	is	be	VBZ
10_1101-2021_01_04_425177	90	20	not	not	RB
10_1101-2021_01_04_425177	90	21	possible	possible	JJ
10_1101-2021_01_04_425177	90	22	to	to	TO
10_1101-2021_01_04_425177	90	23	tell	tell	VB
10_1101-2021_01_04_425177	90	24	if	if	IN
10_1101-2021_01_04_425177	90	25	fibrillation	fibrillation	NN
10_1101-2021_01_04_425177	90	26	is	be	VBZ
10_1101-2021_01_04_425177	90	27	completely	completely	RB
10_1101-2021_01_04_425177	90	28	inhibited	inhibit	VBN
10_1101-2021_01_04_425177	90	29	,	,	,
10_1101-2021_01_04_425177	90	30	or	or	CC
10_1101-2021_01_04_425177	90	31	if	if	IN
10_1101-2021_01_04_425177	90	32	the	the	DT
10_1101-2021_01_04_425177	90	33	fibrillation	fibrillation	NN
10_1101-2021_01_04_425177	90	34	rate	rate	NN
10_1101-2021_01_04_425177	90	35	merely	merely	RB
10_1101-2021_01_04_425177	90	36	is	be	VBZ
10_1101-2021_01_04_425177	90	37	significantly	significantly	RB
10_1101-2021_01_04_425177	90	38	reduced	reduce	VBN
10_1101-2021_01_04_425177	90	39	.	.	.
10_1101-2021_01_04_425177	91	1	Nonetheless	nonetheless	RB
10_1101-2021_01_04_425177	91	2	,	,	,
10_1101-2021_01_04_425177	91	3	the	the	DT
10_1101-2021_01_04_425177	91	4	absence	absence	NN
10_1101-2021_01_04_425177	91	5	of	of	IN
10_1101-2021_01_04_425177	91	6	fibrillar	fibrillar	JJ
10_1101-2021_01_04_425177	91	7	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	91	8	of	of	IN
10_1101-2021_01_04_425177	91	9	huPrP	huprp	NN
10_1101-2021_01_04_425177	91	10	in	in	IN
10_1101-2021_01_04_425177	91	11	the	the	DT
10_1101-2021_01_04_425177	91	12	presence	presence	NN
10_1101-2021_01_04_425177	91	13	of	of	IN
10_1101-2021_01_04_425177	91	14	equimolar	equimolar	JJ
10_1101-2021_01_04_425177	91	15	concentrations	concentration	NNS
10_1101-2021_01_04_425177	91	16	of	of	IN
10_1101-2021_01_04_425177	91	17	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	91	18	clearly	clearly	RB
10_1101-2021_01_04_425177	91	19	shows	show	VBZ
10_1101-2021_01_04_425177	91	20	that	that	IN
10_1101-2021_01_04_425177	91	21	the	the	DT
10_1101-2021_01_04_425177	91	22	peptide	peptide	NN
10_1101-2021_01_04_425177	91	23	construct	construct	VBP
10_1101-2021_01_04_425177	91	24	directly	directly	RB
10_1101-2021_01_04_425177	91	25	interacts	interact	VBZ
10_1101-2021_01_04_425177	91	26	with	with	IN
10_1101-2021_01_04_425177	91	27	the	the	DT
10_1101-2021_01_04_425177	91	28	huPrP	huprp	JJ
10_1101-2021_01_04_425177	91	29	protein	protein	NN
10_1101-2021_01_04_425177	91	30	and	and	CC
10_1101-2021_01_04_425177	91	31	interferes	interfere	VBZ
10_1101-2021_01_04_425177	91	32	with	with	IN
10_1101-2021_01_04_425177	91	33	its	-PRON-	PRP$
10_1101-2021_01_04_425177	91	34	aggregation	aggregation	NN
10_1101-2021_01_04_425177	91	35	.	.	.
10_1101-2021_01_04_425177	92	1	As	as	IN
10_1101-2021_01_04_425177	92	2	both	both	DT
10_1101-2021_01_04_425177	92	3	molecules	molecule	NNS
10_1101-2021_01_04_425177	92	4	are	be	VBP
10_1101-2021_01_04_425177	92	5	positively	positively	RB
10_1101-2021_01_04_425177	92	6	charged	charge	VBN
10_1101-2021_01_04_425177	92	7	(	(	-LRB-
10_1101-2021_01_04_425177	92	8	Table	table	NN
10_1101-2021_01_04_425177	92	9	1	1	CD
10_1101-2021_01_04_425177	92	10	)	)	-RRB-
10_1101-2021_01_04_425177	92	11	,	,	,
10_1101-2021_01_04_425177	92	12	it	-PRON-	PRP
10_1101-2021_01_04_425177	92	13	stands	stand	VBZ
10_1101-2021_01_04_425177	92	14	to	to	TO
10_1101-2021_01_04_425177	92	15	reason	reason	NN
10_1101-2021_01_04_425177	92	16	that	that	IN
10_1101-2021_01_04_425177	92	17	they	-PRON-	PRP
10_1101-2021_01_04_425177	92	18	interact	interact	VBP
10_1101-2021_01_04_425177	92	19	mainly	mainly	RB
10_1101-2021_01_04_425177	92	20	via	via	IN
10_1101-2021_01_04_425177	92	21	hydrophobic	hydrophobic	JJ
10_1101-2021_01_04_425177	92	22	forces	force	NNS
10_1101-2021_01_04_425177	92	23	.	.	.
10_1101-2021_01_04_425177	93	1	The	the	DT
10_1101-2021_01_04_425177	93	2	aggregation	aggregation	NN
10_1101-2021_01_04_425177	93	3	-	-	HYPH
10_1101-2021_01_04_425177	93	4	inhibiting	inhibit	VBG
10_1101-2021_01_04_425177	93	5	effect	effect	NN
10_1101-2021_01_04_425177	93	6	of	of	IN
10_1101-2021_01_04_425177	93	7	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	93	8	(	(	-LRB-
10_1101-2021_01_04_425177	93	9	Fig	fig	NN
10_1101-2021_01_04_425177	93	10	.	.	.
10_1101-2021_01_04_425177	94	1	1	1	LS
10_1101-2021_01_04_425177	94	2	)	)	-RRB-
10_1101-2021_01_04_425177	94	3	appears	appear	VBZ
10_1101-2021_01_04_425177	94	4	to	to	TO
10_1101-2021_01_04_425177	94	5	provide	provide	VB
10_1101-2021_01_04_425177	94	6	an	an	DT
10_1101-2021_01_04_425177	94	7	explanation	explanation	NN
10_1101-2021_01_04_425177	94	8	,	,	,
10_1101-2021_01_04_425177	94	9	at	at	IN
10_1101-2021_01_04_425177	94	10	a	a	DT
10_1101-2021_01_04_425177	94	11	molecular	molecular	JJ
10_1101-2021_01_04_425177	94	12	level	level	NN
10_1101-2021_01_04_425177	94	13	,	,	,
10_1101-2021_01_04_425177	94	14	to	to	IN
10_1101-2021_01_04_425177	94	15	our	-PRON-	PRP$
10_1101-2021_01_04_425177	94	16	earlier	early	JJR
10_1101-2021_01_04_425177	94	17	observations	observation	NNS
10_1101-2021_01_04_425177	94	18	that	that	IN
10_1101-2021_01_04_425177	94	19	such	such	JJ
10_1101-2021_01_04_425177	94	20	peptide	peptide	NN
10_1101-2021_01_04_425177	94	21	constructs	construct	NNS
10_1101-2021_01_04_425177	94	22	significantly	significantly	RB
10_1101-2021_01_04_425177	94	23	reduce	reduce	VBP
10_1101-2021_01_04_425177	94	24	the	the	DT
10_1101-2021_01_04_425177	94	25	levels	level	NNS
10_1101-2021_01_04_425177	94	26	of	of	IN
10_1101-2021_01_04_425177	94	27	prion	prion	NN
10_1101-2021_01_04_425177	94	28	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	94	29	in	in	IN
10_1101-2021_01_04_425177	94	30	prion	prion	NN
10_1101-2021_01_04_425177	94	31	-	-	HYPH
10_1101-2021_01_04_425177	94	32	infected	infect	VBN
10_1101-2021_01_04_425177	94	33	cells	cell	NNS
10_1101-2021_01_04_425177	94	34	(	(	-LRB-
10_1101-2021_01_04_425177	94	35	Löfgren	Löfgren	NNP
10_1101-2021_01_04_425177	94	36	et	et	NNP
10_1101-2021_01_04_425177	94	37	al	al	NNP
10_1101-2021_01_04_425177	94	38	.	.	NNP
10_1101-2021_01_04_425177	94	39	,	,	,
10_1101-2021_01_04_425177	94	40	2008	2008	CD
10_1101-2021_01_04_425177	94	41	;	;	:
10_1101-2021_01_04_425177	94	42	Söderberg	Söderberg	NNP
10_1101-2021_01_04_425177	94	43	et	et	NNP
10_1101-2021_01_04_425177	94	44	al	al	NNP
10_1101-2021_01_04_425177	94	45	.	.	NNP
10_1101-2021_01_04_425177	94	46	,	,	,
10_1101-2021_01_04_425177	94	47	2014	2014	CD
10_1101-2021_01_04_425177	94	48	)	)	-RRB-
10_1101-2021_01_04_425177	94	49	.	.	.
10_1101-2021_01_04_425177	95	1	As	as	IN
10_1101-2021_01_04_425177	95	2	both	both	DT
10_1101-2021_01_04_425177	95	3	the	the	DT
10_1101-2021_01_04_425177	95	4	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	95	5	peptide	peptide	NN
10_1101-2021_01_04_425177	95	6	and	and	CC
10_1101-2021_01_04_425177	95	7	the	the	DT
10_1101-2021_01_04_425177	95	8	huPrP	huprp	NN
10_1101-2021_01_04_425177	95	9	protein	protein	NN
10_1101-2021_01_04_425177	95	10	can	can	MD
10_1101-2021_01_04_425177	95	11	form	form	VB
10_1101-2021_01_04_425177	95	12	amyloid	amyloid	NN
10_1101-2021_01_04_425177	95	13	fibrils	fibril	NNS
10_1101-2021_01_04_425177	95	14	by	by	IN
10_1101-2021_01_04_425177	95	15	themselves	-PRON-	PRP
10_1101-2021_01_04_425177	95	16	(	(	-LRB-
10_1101-2021_01_04_425177	95	17	Figs	fig	NNS
10_1101-2021_01_04_425177	95	18	.	.	.
10_1101-2021_01_04_425177	96	1	1A	1A	NNP
10_1101-2021_01_04_425177	96	2	and	and	CC
10_1101-2021_01_04_425177	96	3	1C	1C	NNP
10_1101-2021_01_04_425177	96	4	)	)	-RRB-
10_1101-2021_01_04_425177	96	5	,	,	,
10_1101-2021_01_04_425177	96	6	the	the	DT
10_1101-2021_01_04_425177	96	7	two	two	CD
10_1101-2021_01_04_425177	96	8	molecules	molecule	NNS
10_1101-2021_01_04_425177	96	9	may	may	MD
10_1101-2021_01_04_425177	96	10	interact	interact	VB
10_1101-2021_01_04_425177	96	11	via	via	IN
10_1101-2021_01_04_425177	96	12	cross	cross	NN
10_1101-2021_01_04_425177	96	13	-	-	NN
10_1101-2021_01_04_425177	96	14	aggregation	aggregation	NN
10_1101-2021_01_04_425177	96	15	,	,	,
10_1101-2021_01_04_425177	96	16	to	to	TO
10_1101-2021_01_04_425177	96	17	form	form	VB
10_1101-2021_01_04_425177	96	18	smaller	small	JJR
10_1101-2021_01_04_425177	96	19	non	non	JJ
10_1101-2021_01_04_425177	96	20	-	-	JJ
10_1101-2021_01_04_425177	96	21	fibrillar	fibrillar	JJ
10_1101-2021_01_04_425177	96	22	co-	co-	JJ
10_1101-2021_01_04_425177	96	23	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	96	24	(	(	-LRB-
10_1101-2021_01_04_425177	96	25	Fig	fig	NN
10_1101-2021_01_04_425177	96	26	.	.	.
10_1101-2021_01_04_425177	97	1	1E	1E	NNP
10_1101-2021_01_04_425177	97	2	)	)	-RRB-
10_1101-2021_01_04_425177	97	3	that	that	WDT
10_1101-2021_01_04_425177	97	4	could	could	MD
10_1101-2021_01_04_425177	97	5	be	be	VB
10_1101-2021_01_04_425177	97	6	less	less	RBR
10_1101-2021_01_04_425177	97	7	toxic	toxic	JJ
10_1101-2021_01_04_425177	97	8	than	than	IN
10_1101-2021_01_04_425177	97	9	pure	pure	JJ
10_1101-2021_01_04_425177	97	10	huPrP	huprp	NN
10_1101-2021_01_04_425177	97	11	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	97	12	(	(	-LRB-
10_1101-2021_01_04_425177	97	13	Luo	Luo	NNP
10_1101-2021_01_04_425177	97	14	et	et	NNP
10_1101-2021_01_04_425177	97	15	al	al	NNP
10_1101-2021_01_04_425177	97	16	.	.	NNP
10_1101-2021_01_04_425177	97	17	,	,	,
10_1101-2021_01_04_425177	97	18	2016	2016	CD
10_1101-2021_01_04_425177	97	19	,	,	,
10_1101-2021_01_04_425177	97	20	2017	2017	CD
10_1101-2021_01_04_425177	97	21	)	)	-RRB-
10_1101-2021_01_04_425177	97	22	.	.	.
10_1101-2021_01_04_425177	98	1	If	if	IN
10_1101-2021_01_04_425177	98	2	so	so	RB
10_1101-2021_01_04_425177	98	3	,	,	,
10_1101-2021_01_04_425177	98	4	the	the	DT
10_1101-2021_01_04_425177	98	5	huPrP	huprp	NN
10_1101-2021_01_04_425177	98	6	/	/	SYM
10_1101-2021_01_04_425177	98	7	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	98	8	interactions	interaction	NNS
10_1101-2021_01_04_425177	98	9	would	would	MD
10_1101-2021_01_04_425177	98	10	be	be	VB
10_1101-2021_01_04_425177	98	11	similar	similar	JJ
10_1101-2021_01_04_425177	98	12	to	to	IN
10_1101-2021_01_04_425177	98	13	the	the	DT
10_1101-2021_01_04_425177	98	14	interactions	interaction	NNS
10_1101-2021_01_04_425177	98	15	between	between	IN
10_1101-2021_01_04_425177	98	16	Aβ	Aβ	NNP
10_1101-2021_01_04_425177	98	17	and	and	CC
10_1101-2021_01_04_425177	98	18	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	98	19	(	(	-LRB-
10_1101-2021_01_04_425177	98	20	Henning	Henning	NNP
10_1101-2021_01_04_425177	98	21	-	-	HYPH
10_1101-2021_01_04_425177	98	22	Knechtel	Knechtel	NNP
10_1101-2021_01_04_425177	98	23	et	et	FW
10_1101-2021_01_04_425177	98	24	al	al	NNP
10_1101-2021_01_04_425177	98	25	.	.	NNP
10_1101-2021_01_04_425177	98	26	,	,	,
10_1101-2021_01_04_425177	98	27	2020	2020	CD
10_1101-2021_01_04_425177	98	28	)	)	-RRB-
10_1101-2021_01_04_425177	98	29	.	.	.
10_1101-2021_01_04_425177	99	1	In	in	IN
10_1101-2021_01_04_425177	99	2	any	any	DT
10_1101-2021_01_04_425177	99	3	case	case	NN
10_1101-2021_01_04_425177	99	4	,	,	,
10_1101-2021_01_04_425177	99	5	the	the	DT
10_1101-2021_01_04_425177	99	6	huPrP	huprp	NN
10_1101-2021_01_04_425177	99	7	/	/	SYM
10_1101-2021_01_04_425177	99	8	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	99	9	interactions	interaction	NNS
10_1101-2021_01_04_425177	99	10	are	be	VBP
10_1101-2021_01_04_425177	99	11	very	very	RB
10_1101-2021_01_04_425177	99	12	different	different	JJ
10_1101-2021_01_04_425177	99	13	from	from	IN
10_1101-2021_01_04_425177	99	14	the	the	DT
10_1101-2021_01_04_425177	99	15	interactions	interaction	NNS
10_1101-2021_01_04_425177	99	16	between	between	IN
10_1101-2021_01_04_425177	99	17	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	99	18	and	and	CC
10_1101-2021_01_04_425177	99	19	S100A9	s100a9	VB
10_1101-2021_01_04_425177	99	20	protein	protein	NN
10_1101-2021_01_04_425177	99	21	,	,	,
10_1101-2021_01_04_425177	99	22	where	where	WRB
10_1101-2021_01_04_425177	99	23	amyloid	amyloid	NNP
10_1101-2021_01_04_425177	99	24	aggregation	aggregation	NN
10_1101-2021_01_04_425177	99	25	is	be	VBZ
10_1101-2021_01_04_425177	99	26	promoted	promote	VBN
10_1101-2021_01_04_425177	99	27	(	(	-LRB-
10_1101-2021_01_04_425177	99	28	Pansieri	Pansieri	NNP
10_1101-2021_01_04_425177	99	29	et	et	FW
10_1101-2021_01_04_425177	99	30	al	al	NNP
10_1101-2021_01_04_425177	99	31	.	.	NNP
10_1101-2021_01_04_425177	99	32	,	,	,
10_1101-2021_01_04_425177	99	33	2019	2019	CD
10_1101-2021_01_04_425177	99	34	)	)	-RRB-
10_1101-2021_01_04_425177	99	35	.	.	.
10_1101-2021_01_04_425177	100	1	Because	because	IN
10_1101-2021_01_04_425177	100	2	the	the	DT
10_1101-2021_01_04_425177	100	3	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	100	4	construct	construct	NN
10_1101-2021_01_04_425177	100	5	has	have	VBZ
10_1101-2021_01_04_425177	100	6	different	different	JJ
10_1101-2021_01_04_425177	100	7	effects	effect	NNS
10_1101-2021_01_04_425177	100	8	on	on	IN
10_1101-2021_01_04_425177	100	9	different	different	JJ
10_1101-2021_01_04_425177	100	10	aggregating	aggregate	VBG
10_1101-2021_01_04_425177	100	11	proteins	protein	NNS
10_1101-2021_01_04_425177	100	12	,	,	,
10_1101-2021_01_04_425177	100	13	it	-PRON-	PRP
10_1101-2021_01_04_425177	100	14	would	would	MD
10_1101-2021_01_04_425177	100	15	be	be	VB
10_1101-2021_01_04_425177	100	16	interesting	interesting	JJ
10_1101-2021_01_04_425177	100	17	to	to	TO
10_1101-2021_01_04_425177	100	18	study	study	VB
10_1101-2021_01_04_425177	100	19	how	how	WRB
10_1101-2021_01_04_425177	100	20	this	this	DT
10_1101-2021_01_04_425177	100	21	construct	construct	NN
10_1101-2021_01_04_425177	100	22	might	may	MD
10_1101-2021_01_04_425177	100	23	affect	affect	VB
10_1101-2021_01_04_425177	100	24	the	the	DT
10_1101-2021_01_04_425177	100	25	aggregation	aggregation	NN
10_1101-2021_01_04_425177	100	26	of	of	IN
10_1101-2021_01_04_425177	100	27	other	other	JJ
10_1101-2021_01_04_425177	100	28	disease	disease	NN
10_1101-2021_01_04_425177	100	29	-	-	HYPH
10_1101-2021_01_04_425177	100	30	related	relate	VBN
10_1101-2021_01_04_425177	100	31	prion	prion	NN
10_1101-2021_01_04_425177	100	32	proteins	protein	NNS
10_1101-2021_01_04_425177	100	33	,	,	,
10_1101-2021_01_04_425177	100	34	such	such	JJ
10_1101-2021_01_04_425177	100	35	as	as	IN
10_1101-2021_01_04_425177	100	36	those	those	DT
10_1101-2021_01_04_425177	100	37	involved	involve	VBN
10_1101-2021_01_04_425177	100	38	in	in	IN
10_1101-2021_01_04_425177	100	39	animal	animal	NN
10_1101-2021_01_04_425177	100	40	diseases	disease	NNS
10_1101-2021_01_04_425177	100	41	like	like	IN
10_1101-2021_01_04_425177	100	42	bovine	bovine	JJ
10_1101-2021_01_04_425177	100	43	spongiform	spongiform	NN
10_1101-2021_01_04_425177	100	44	encephalopathy	encephalopathy	NNP
10_1101-2021_01_04_425177	100	45	(	(	-LRB-
10_1101-2021_01_04_425177	100	46	BSE	BSE	NNP
10_1101-2021_01_04_425177	100	47	)	)	-RRB-
10_1101-2021_01_04_425177	100	48	,	,	,
10_1101-2021_01_04_425177	100	49	chronic	chronic	JJ
10_1101-2021_01_04_425177	100	50	wasting	waste	VBG
10_1101-2021_01_04_425177	100	51	disease	disease	NN
10_1101-2021_01_04_425177	100	52	in	in	IN
10_1101-2021_01_04_425177	100	53	cervids	cervid	NNS
10_1101-2021_01_04_425177	100	54	,	,	,
10_1101-2021_01_04_425177	100	55	and	and	CC
10_1101-2021_01_04_425177	100	56	sheep	sheep	NN
10_1101-2021_01_04_425177	100	57	scrapie	scrapie	NN
10_1101-2021_01_04_425177	100	58	(	(	-LRB-
10_1101-2021_01_04_425177	100	59	Vazquez	Vazquez	NNP
10_1101-2021_01_04_425177	100	60	-	-	HYPH
10_1101-2021_01_04_425177	100	61	Fernandez	Fernandez	NNP
10_1101-2021_01_04_425177	100	62	et	et	FW
10_1101-2021_01_04_425177	100	63	al	al	NNP
10_1101-2021_01_04_425177	100	64	.	.	NNP
10_1101-2021_01_04_425177	100	65	,	,	,
10_1101-2021_01_04_425177	100	66	2017	2017	CD
10_1101-2021_01_04_425177	100	67	)	)	-RRB-
10_1101-2021_01_04_425177	100	68	.	.	.
10_1101-2021_01_04_425177	101	1	.CC	.CC	NFP
10_1101-2021_01_04_425177	101	2	-	-	:
10_1101-2021_01_04_425177	101	3	BY	by	IN
10_1101-2021_01_04_425177	101	4	-	-	HYPH
10_1101-2021_01_04_425177	101	5	NC	NC	NNP
10_1101-2021_01_04_425177	101	6	-	-	HYPH
10_1101-2021_01_04_425177	101	7	ND	ND	NNP
10_1101-2021_01_04_425177	101	8	4.0	4.0	CD
10_1101-2021_01_04_425177	101	9	International	international	JJ
10_1101-2021_01_04_425177	101	10	licensemade	licensemade	NN
10_1101-2021_01_04_425177	101	11	available	available	JJ
10_1101-2021_01_04_425177	101	12	under	under	IN
10_1101-2021_01_04_425177	101	13	a	a	DT
10_1101-2021_01_04_425177	101	14	(	(	-LRB-
10_1101-2021_01_04_425177	101	15	which	which	WDT
10_1101-2021_01_04_425177	101	16	was	be	VBD
10_1101-2021_01_04_425177	101	17	not	not	RB
10_1101-2021_01_04_425177	101	18	certified	certify	VBN
10_1101-2021_01_04_425177	101	19	by	by	IN
10_1101-2021_01_04_425177	101	20	peer	peer	NN
10_1101-2021_01_04_425177	101	21	review	review	NN
10_1101-2021_01_04_425177	101	22	)	)	-RRB-
10_1101-2021_01_04_425177	101	23	is	be	VBZ
10_1101-2021_01_04_425177	101	24	the	the	DT
10_1101-2021_01_04_425177	101	25	author	author	NN
10_1101-2021_01_04_425177	101	26	/	/	SYM
10_1101-2021_01_04_425177	101	27	funder	funder	NN
10_1101-2021_01_04_425177	101	28	,	,	,
10_1101-2021_01_04_425177	101	29	who	who	WP
10_1101-2021_01_04_425177	101	30	has	have	VBZ
10_1101-2021_01_04_425177	101	31	granted	grant	VBN
10_1101-2021_01_04_425177	101	32	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	101	33	a	a	DT
10_1101-2021_01_04_425177	101	34	license	license	NN
10_1101-2021_01_04_425177	101	35	to	to	TO
10_1101-2021_01_04_425177	101	36	display	display	VB
10_1101-2021_01_04_425177	101	37	the	the	DT
10_1101-2021_01_04_425177	101	38	preprint	preprint	NN
10_1101-2021_01_04_425177	101	39	in	in	IN
10_1101-2021_01_04_425177	101	40	perpetuity	perpetuity	NN
10_1101-2021_01_04_425177	101	41	.	.	.
10_1101-2021_01_04_425177	102	1	It	-PRON-	PRP
10_1101-2021_01_04_425177	102	2	is	be	VBZ
10_1101-2021_01_04_425177	102	3	The	the	DT
10_1101-2021_01_04_425177	102	4	copyright	copyright	NN
10_1101-2021_01_04_425177	102	5	holder	holder	NN
10_1101-2021_01_04_425177	102	6	for	for	IN
10_1101-2021_01_04_425177	102	7	this	this	DT
10_1101-2021_01_04_425177	102	8	preprintthis	preprintthis	NN
10_1101-2021_01_04_425177	102	9	version	version	NN
10_1101-2021_01_04_425177	102	10	posted	post	VBD
10_1101-2021_01_04_425177	102	11	January	January	NNP
10_1101-2021_01_04_425177	102	12	4	4	CD
10_1101-2021_01_04_425177	102	13	,	,	,
10_1101-2021_01_04_425177	102	14	2021	2021	CD
10_1101-2021_01_04_425177	102	15	.	.	.
10_1101-2021_01_04_425177	102	16	;	;	:
10_1101-2021_01_04_425177	102	17	https://doi.org/10.1101/2021.01.04.425177doi	https://doi.org/10.1101/2021.01.04.425177doi	ADD
10_1101-2021_01_04_425177	102	18	:	:	:
10_1101-2021_01_04_425177	102	19	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	102	20	preprint	preprint	NN
10_1101-2021_01_04_425177	102	21	https://doi.org/10.1101/2021.01.04.425177	https://doi.org/10.1101/2021.01.04.425177	VBZ
10_1101-2021_01_04_425177	102	22	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2021_01_04_425177	102	23	9	9	CD
10_1101-2021_01_04_425177	102	24	4	4	CD
10_1101-2021_01_04_425177	102	25	.	.	.
10_1101-2021_01_04_425177	103	1	Conclusions	conclusion	NNS
10_1101-2021_01_04_425177	103	2	Our	-PRON-	PRP$
10_1101-2021_01_04_425177	103	3	atomic	atomic	JJ
10_1101-2021_01_04_425177	103	4	force	force	NN
10_1101-2021_01_04_425177	103	5	microscopy	microscopy	JJ
10_1101-2021_01_04_425177	103	6	images	image	NNS
10_1101-2021_01_04_425177	103	7	show	show	VBP
10_1101-2021_01_04_425177	103	8	that	that	IN
10_1101-2021_01_04_425177	103	9	the	the	DT
10_1101-2021_01_04_425177	103	10	in	in	FW
10_1101-2021_01_04_425177	103	11	vitro	vitro	FW
10_1101-2021_01_04_425177	103	12	aggregation	aggregation	NN
10_1101-2021_01_04_425177	103	13	of	of	IN
10_1101-2021_01_04_425177	103	14	the	the	DT
10_1101-2021_01_04_425177	103	15	human	human	JJ
10_1101-2021_01_04_425177	103	16	PrP	PrP	NNP
10_1101-2021_01_04_425177	103	17	protein	protein	NN
10_1101-2021_01_04_425177	103	18	is	be	VBZ
10_1101-2021_01_04_425177	103	19	inhibited	inhibit	VBN
10_1101-2021_01_04_425177	103	20	by	by	IN
10_1101-2021_01_04_425177	103	21	equimolar	equimolar	JJ
10_1101-2021_01_04_425177	103	22	amounts	amount	NNS
10_1101-2021_01_04_425177	103	23	of	of	IN
10_1101-2021_01_04_425177	103	24	the	the	DT
10_1101-2021_01_04_425177	103	25	25	25	CD
10_1101-2021_01_04_425177	103	26	residues	residue	NNS
10_1101-2021_01_04_425177	103	27	long	long	RB
10_1101-2021_01_04_425177	103	28	engineered	engineer	VBN
10_1101-2021_01_04_425177	103	29	peptide	peptide	NN
10_1101-2021_01_04_425177	103	30	NCAM1-Aβ	NCAM1-Aβ	NNP
10_1101-2021_01_04_425177	103	31	.	.	.
10_1101-2021_01_04_425177	104	1	Thus	thus	RB
10_1101-2021_01_04_425177	104	2	,	,	,
10_1101-2021_01_04_425177	104	3	a	a	DT
10_1101-2021_01_04_425177	104	4	very	very	RB
10_1101-2021_01_04_425177	104	5	likely	likely	JJ
10_1101-2021_01_04_425177	104	6	molecular	molecular	JJ
10_1101-2021_01_04_425177	104	7	-	-	HYPH
10_1101-2021_01_04_425177	104	8	level	level	NN
10_1101-2021_01_04_425177	104	9	explanation	explanation	NN
10_1101-2021_01_04_425177	104	10	to	to	IN
10_1101-2021_01_04_425177	104	11	our	-PRON-	PRP$
10_1101-2021_01_04_425177	104	12	previous	previous	JJ
10_1101-2021_01_04_425177	104	13	observation	observation	NN
10_1101-2021_01_04_425177	104	14	that	that	IN
10_1101-2021_01_04_425177	104	15	such	such	JJ
10_1101-2021_01_04_425177	104	16	cell	cell	NN
10_1101-2021_01_04_425177	104	17	-	-	HYPH
10_1101-2021_01_04_425177	104	18	penetrating	penetrate	VBG
10_1101-2021_01_04_425177	104	19	peptide	peptide	NN
10_1101-2021_01_04_425177	104	20	constructs	construct	NNS
10_1101-2021_01_04_425177	104	21	can	can	MD
10_1101-2021_01_04_425177	104	22	reduce	reduce	VB
10_1101-2021_01_04_425177	104	23	the	the	DT
10_1101-2021_01_04_425177	104	24	amount	amount	NN
10_1101-2021_01_04_425177	104	25	of	of	IN
10_1101-2021_01_04_425177	104	26	prion	prion	NN
10_1101-2021_01_04_425177	104	27	aggregates	aggregate	NNS
10_1101-2021_01_04_425177	104	28	in	in	IN
10_1101-2021_01_04_425177	104	29	infected	infected	JJ
10_1101-2021_01_04_425177	104	30	cells	cell	NNS
10_1101-2021_01_04_425177	104	31	,	,	,
10_1101-2021_01_04_425177	104	32	is	be	VBZ
10_1101-2021_01_04_425177	104	33	that	that	IN
10_1101-2021_01_04_425177	104	34	these	these	DT
10_1101-2021_01_04_425177	104	35	peptide	peptide	JJ
10_1101-2021_01_04_425177	104	36	constructs	construct	NNS
10_1101-2021_01_04_425177	104	37	directly	directly	RB
10_1101-2021_01_04_425177	104	38	interact	interact	VBP
10_1101-2021_01_04_425177	104	39	with	with	IN
10_1101-2021_01_04_425177	104	40	the	the	DT
10_1101-2021_01_04_425177	104	41	PrP	PrP	NNP
10_1101-2021_01_04_425177	104	42	protein	protein	NN
10_1101-2021_01_04_425177	104	43	and	and	CC
10_1101-2021_01_04_425177	104	44	prevent	prevent	VB
10_1101-2021_01_04_425177	104	45	its	-PRON-	PRP$
10_1101-2021_01_04_425177	104	46	fibrillation	fibrillation	NN
10_1101-2021_01_04_425177	104	47	.	.	.
10_1101-2021_01_04_425177	105	1	Funding	funding	NN
10_1101-2021_01_04_425177	105	2	:	:	:
10_1101-2021_01_04_425177	105	3	The	the	DT
10_1101-2021_01_04_425177	105	4	research	research	NN
10_1101-2021_01_04_425177	105	5	of	of	IN
10_1101-2021_01_04_425177	105	6	MG	MG	NNP
10_1101-2021_01_04_425177	105	7	,	,	,
10_1101-2021_01_04_425177	105	8	IZ	IZ	NNP
10_1101-2021_01_04_425177	105	9	,	,	,
10_1101-2021_01_04_425177	105	10	LZ	LZ	NNP
10_1101-2021_01_04_425177	105	11	and	and	CC
10_1101-2021_01_04_425177	105	12	MK	MK	NNP
10_1101-2021_01_04_425177	105	13	was	be	VBD
10_1101-2021_01_04_425177	105	14	supported	support	VBN
10_1101-2021_01_04_425177	105	15	by	by	IN
10_1101-2021_01_04_425177	105	16	an	an	DT
10_1101-2021_01_04_425177	105	17	OPUS	OPUS	NNP
10_1101-2021_01_04_425177	105	18	research	research	NN
10_1101-2021_01_04_425177	105	19	grant	grant	NN
10_1101-2021_01_04_425177	105	20	(	(	-LRB-
10_1101-2021_01_04_425177	105	21	2014/15	2014/15	CD
10_1101-2021_01_04_425177	105	22	/	/	SYM
10_1101-2021_01_04_425177	105	23	B	B	NNP
10_1101-2021_01_04_425177	105	24	/	/	SYM
10_1101-2021_01_04_425177	105	25	ST4/04839	st4/04839	NN
10_1101-2021_01_04_425177	105	26	)	)	-RRB-
10_1101-2021_01_04_425177	105	27	from	from	IN
10_1101-2021_01_04_425177	105	28	the	the	DT
10_1101-2021_01_04_425177	105	29	National	National	NNP
10_1101-2021_01_04_425177	105	30	Science	Science	NNP
10_1101-2021_01_04_425177	105	31	Centre	Centre	NNP
10_1101-2021_01_04_425177	105	32	(	(	-LRB-
10_1101-2021_01_04_425177	105	33	Poland	Poland	NNP
10_1101-2021_01_04_425177	105	34	)	)	-RRB-
10_1101-2021_01_04_425177	105	35	.	.	.
10_1101-2021_01_04_425177	106	1	AG	AG	NNP
10_1101-2021_01_04_425177	106	2	was	be	VBD
10_1101-2021_01_04_425177	106	3	supported	support	VBN
10_1101-2021_01_04_425177	106	4	by	by	IN
10_1101-2021_01_04_425177	106	5	grants	grant	NNS
10_1101-2021_01_04_425177	106	6	from	from	IN
10_1101-2021_01_04_425177	106	7	the	the	DT
10_1101-2021_01_04_425177	106	8	Swedish	Swedish	NNP
10_1101-2021_01_04_425177	106	9	Research	Research	NNP
10_1101-2021_01_04_425177	106	10	Council	Council	NNP
10_1101-2021_01_04_425177	106	11	and	and	CC
10_1101-2021_01_04_425177	106	12	from	from	IN
10_1101-2021_01_04_425177	106	13	Byggmästare	Byggmästare	NNP
10_1101-2021_01_04_425177	106	14	Engkvist´s	Engkvist´s	NNP
10_1101-2021_01_04_425177	106	15	Foundation	Foundation	NNP
10_1101-2021_01_04_425177	106	16	.	.	.
10_1101-2021_01_04_425177	107	1	Conflicts	conflict	NNS
10_1101-2021_01_04_425177	107	2	of	of	IN
10_1101-2021_01_04_425177	107	3	Interest	interest	NN
10_1101-2021_01_04_425177	107	4	:	:	:
10_1101-2021_01_04_425177	107	5	The	the	DT
10_1101-2021_01_04_425177	107	6	authors	author	NNS
10_1101-2021_01_04_425177	107	7	declare	declare	VBP
10_1101-2021_01_04_425177	107	8	no	no	DT
10_1101-2021_01_04_425177	107	9	conflict	conflict	NN
10_1101-2021_01_04_425177	107	10	of	of	IN
10_1101-2021_01_04_425177	107	11	interests	interest	NNS
10_1101-2021_01_04_425177	107	12	.	.	.
10_1101-2021_01_04_425177	108	1	.CC	.CC	NFP
10_1101-2021_01_04_425177	108	2	-	-	:
10_1101-2021_01_04_425177	108	3	BY	by	IN
10_1101-2021_01_04_425177	108	4	-	-	HYPH
10_1101-2021_01_04_425177	108	5	NC	NC	NNP
10_1101-2021_01_04_425177	108	6	-	-	HYPH
10_1101-2021_01_04_425177	108	7	ND	ND	NNP
10_1101-2021_01_04_425177	108	8	4.0	4.0	CD
10_1101-2021_01_04_425177	108	9	International	international	JJ
10_1101-2021_01_04_425177	108	10	licensemade	licensemade	NN
10_1101-2021_01_04_425177	108	11	available	available	JJ
10_1101-2021_01_04_425177	108	12	under	under	IN
10_1101-2021_01_04_425177	108	13	a	a	DT
10_1101-2021_01_04_425177	108	14	(	(	-LRB-
10_1101-2021_01_04_425177	108	15	which	which	WDT
10_1101-2021_01_04_425177	108	16	was	be	VBD
10_1101-2021_01_04_425177	108	17	not	not	RB
10_1101-2021_01_04_425177	108	18	certified	certify	VBN
10_1101-2021_01_04_425177	108	19	by	by	IN
10_1101-2021_01_04_425177	108	20	peer	peer	NN
10_1101-2021_01_04_425177	108	21	review	review	NN
10_1101-2021_01_04_425177	108	22	)	)	-RRB-
10_1101-2021_01_04_425177	108	23	is	be	VBZ
10_1101-2021_01_04_425177	108	24	the	the	DT
10_1101-2021_01_04_425177	108	25	author	author	NN
10_1101-2021_01_04_425177	108	26	/	/	SYM
10_1101-2021_01_04_425177	108	27	funder	funder	NN
10_1101-2021_01_04_425177	108	28	,	,	,
10_1101-2021_01_04_425177	108	29	who	who	WP
10_1101-2021_01_04_425177	108	30	has	have	VBZ
10_1101-2021_01_04_425177	108	31	granted	grant	VBN
10_1101-2021_01_04_425177	108	32	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	108	33	a	a	DT
10_1101-2021_01_04_425177	108	34	license	license	NN
10_1101-2021_01_04_425177	108	35	to	to	TO
10_1101-2021_01_04_425177	108	36	display	display	VB
10_1101-2021_01_04_425177	108	37	the	the	DT
10_1101-2021_01_04_425177	108	38	preprint	preprint	NN
10_1101-2021_01_04_425177	108	39	in	in	IN
10_1101-2021_01_04_425177	108	40	perpetuity	perpetuity	NN
10_1101-2021_01_04_425177	108	41	.	.	.
10_1101-2021_01_04_425177	109	1	It	-PRON-	PRP
10_1101-2021_01_04_425177	109	2	is	be	VBZ
10_1101-2021_01_04_425177	109	3	The	the	DT
10_1101-2021_01_04_425177	109	4	copyright	copyright	NN
10_1101-2021_01_04_425177	109	5	holder	holder	NN
10_1101-2021_01_04_425177	109	6	for	for	IN
10_1101-2021_01_04_425177	109	7	this	this	DT
10_1101-2021_01_04_425177	109	8	preprintthis	preprintthis	NN
10_1101-2021_01_04_425177	109	9	version	version	NN
10_1101-2021_01_04_425177	109	10	posted	post	VBD
10_1101-2021_01_04_425177	109	11	January	January	NNP
10_1101-2021_01_04_425177	109	12	4	4	CD
10_1101-2021_01_04_425177	109	13	,	,	,
10_1101-2021_01_04_425177	109	14	2021	2021	CD
10_1101-2021_01_04_425177	109	15	.	.	.
10_1101-2021_01_04_425177	109	16	;	;	:
10_1101-2021_01_04_425177	109	17	https://doi.org/10.1101/2021.01.04.425177doi	https://doi.org/10.1101/2021.01.04.425177doi	ADD
10_1101-2021_01_04_425177	109	18	:	:	:
10_1101-2021_01_04_425177	109	19	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	109	20	preprint	preprint	NN
10_1101-2021_01_04_425177	109	21	https://doi.org/10.1101/2021.01.04.425177	https://doi.org/10.1101/2021.01.04.425177	VBZ
10_1101-2021_01_04_425177	109	22	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2021_01_04_425177	109	23	10	10	CD
10_1101-2021_01_04_425177	109	24	References	reference	NNS
10_1101-2021_01_04_425177	109	25	Ambadi	Ambadi	NNP
10_1101-2021_01_04_425177	109	26	Thody	Thody	NNP
10_1101-2021_01_04_425177	109	27	,	,	,
10_1101-2021_01_04_425177	109	28	S.	S.	NNP
10_1101-2021_01_04_425177	109	29	,	,	,
10_1101-2021_01_04_425177	109	30	Mathew	Mathew	NNP
10_1101-2021_01_04_425177	109	31	,	,	,
10_1101-2021_01_04_425177	109	32	M.K.	M.K.	NNP
10_1101-2021_01_04_425177	109	33	,	,	,
10_1101-2021_01_04_425177	109	34	Udgaonkar	Udgaonkar	NNP
10_1101-2021_01_04_425177	109	35	,	,	,
10_1101-2021_01_04_425177	109	36	J.B.	J.B.	NNP
10_1101-2021_01_04_425177	109	37	,	,	,
10_1101-2021_01_04_425177	109	38	2018	2018	CD
10_1101-2021_01_04_425177	109	39	.	.	.
10_1101-2021_01_04_425177	110	1	Mechanism	mechanism	NN
10_1101-2021_01_04_425177	110	2	of	of	IN
10_1101-2021_01_04_425177	110	3	aggregation	aggregation	NN
10_1101-2021_01_04_425177	110	4	and	and	CC
10_1101-2021_01_04_425177	110	5	membrane	membrane	NN
10_1101-2021_01_04_425177	110	6	interactions	interaction	NNS
10_1101-2021_01_04_425177	110	7	of	of	IN
10_1101-2021_01_04_425177	110	8	mammalian	mammalian	JJ
10_1101-2021_01_04_425177	110	9	prion	prion	NN
10_1101-2021_01_04_425177	110	10	protein	protein	NN
10_1101-2021_01_04_425177	110	11	.	.	.
10_1101-2021_01_04_425177	111	1	Biochim	Biochim	NNP
10_1101-2021_01_04_425177	111	2	Biophys	Biophys	NNP
10_1101-2021_01_04_425177	111	3	Acta	Acta	NNP
10_1101-2021_01_04_425177	111	4	Biomembr	Biomembr	NNP
10_1101-2021_01_04_425177	111	5	.	.	.
10_1101-2021_01_04_425177	112	1	Chemerovski	Chemerovski	NNP
10_1101-2021_01_04_425177	112	2	-	-	HYPH
10_1101-2021_01_04_425177	112	3	Glikman	Glikman	NNP
10_1101-2021_01_04_425177	112	4	,	,	,
10_1101-2021_01_04_425177	112	5	M.	M.	NNP
10_1101-2021_01_04_425177	112	6	,	,	,
10_1101-2021_01_04_425177	112	7	Rozentur	Rozentur	NNP
10_1101-2021_01_04_425177	112	8	-	-	HYPH
10_1101-2021_01_04_425177	112	9	Shkop	Shkop	NNP
10_1101-2021_01_04_425177	112	10	,	,	,
10_1101-2021_01_04_425177	112	11	E.	E.	NNP
10_1101-2021_01_04_425177	112	12	,	,	,
10_1101-2021_01_04_425177	112	13	Richman	Richman	NNP
10_1101-2021_01_04_425177	112	14	,	,	,
10_1101-2021_01_04_425177	112	15	M.	M.	NNP
10_1101-2021_01_04_425177	112	16	,	,	,
10_1101-2021_01_04_425177	112	17	Grupi	Grupi	NNP
10_1101-2021_01_04_425177	112	18	,	,	,
10_1101-2021_01_04_425177	112	19	A.	A.	NNP
10_1101-2021_01_04_425177	112	20	,	,	,
10_1101-2021_01_04_425177	112	21	Getler	Getler	NNP
10_1101-2021_01_04_425177	112	22	,	,	,
10_1101-2021_01_04_425177	112	23	A.	A.	NNP
10_1101-2021_01_04_425177	112	24	,	,	,
10_1101-2021_01_04_425177	112	25	Cohen	Cohen	NNP
10_1101-2021_01_04_425177	112	26	,	,	,
10_1101-2021_01_04_425177	112	27	H.Y.	H.Y.	NNP
10_1101-2021_01_04_425177	112	28	,	,	,
10_1101-2021_01_04_425177	112	29	Shaked	Shaked	NNP
10_1101-2021_01_04_425177	112	30	,	,	,
10_1101-2021_01_04_425177	112	31	H.	H.	NNP
10_1101-2021_01_04_425177	112	32	,	,	,
10_1101-2021_01_04_425177	112	33	Wallin	Wallin	NNP
10_1101-2021_01_04_425177	112	34	,	,	,
10_1101-2021_01_04_425177	112	35	C.	C.	NNP
10_1101-2021_01_04_425177	112	36	,	,	,
10_1101-2021_01_04_425177	112	37	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	112	38	,	,	,
10_1101-2021_01_04_425177	112	39	S.K.	S.K.	NNP
10_1101-2021_01_04_425177	112	40	,	,	,
10_1101-2021_01_04_425177	112	41	Haas	Haas	NNP
10_1101-2021_01_04_425177	112	42	,	,	,
10_1101-2021_01_04_425177	112	43	E.	E.	NNP
10_1101-2021_01_04_425177	112	44	,	,	,
10_1101-2021_01_04_425177	112	45	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	112	46	,	,	,
10_1101-2021_01_04_425177	112	47	A.	A.	NNP
10_1101-2021_01_04_425177	112	48	,	,	,
10_1101-2021_01_04_425177	112	49	Chill	Chill	NNP
10_1101-2021_01_04_425177	112	50	,	,	,
10_1101-2021_01_04_425177	112	51	J.H.	J.H.	NNP
10_1101-2021_01_04_425177	112	52	,	,	,
10_1101-2021_01_04_425177	112	53	Rahimipour	Rahimipour	NNP
10_1101-2021_01_04_425177	112	54	,	,	,
10_1101-2021_01_04_425177	112	55	S.	S.	NNP
10_1101-2021_01_04_425177	112	56	,	,	,
10_1101-2021_01_04_425177	112	57	2016	2016	CD
10_1101-2021_01_04_425177	112	58	.	.	.
10_1101-2021_01_04_425177	113	1	Self	self	NN
10_1101-2021_01_04_425177	113	2	-	-	HYPH
10_1101-2021_01_04_425177	113	3	Assembled	assemble	VBN
10_1101-2021_01_04_425177	113	4	Cyclic	Cyclic	NNP
10_1101-2021_01_04_425177	113	5	d	d	NNP
10_1101-2021_01_04_425177	113	6	,	,	,
10_1101-2021_01_04_425177	113	7	l	l	NN
10_1101-2021_01_04_425177	113	8	-	-	HYPH
10_1101-2021_01_04_425177	113	9	alpha	alpha	NN
10_1101-2021_01_04_425177	113	10	-	-	HYPH
10_1101-2021_01_04_425177	113	11	Peptides	peptide	NNS
10_1101-2021_01_04_425177	113	12	as	as	IN
10_1101-2021_01_04_425177	113	13	Generic	Generic	NNP
10_1101-2021_01_04_425177	113	14	Conformational	Conformational	NNP
10_1101-2021_01_04_425177	113	15	Inhibitors	Inhibitors	NNPS
10_1101-2021_01_04_425177	113	16	of	of	IN
10_1101-2021_01_04_425177	113	17	the	the	DT
10_1101-2021_01_04_425177	113	18	alpha	alpha	NN
10_1101-2021_01_04_425177	113	19	-	-	HYPH
10_1101-2021_01_04_425177	113	20	Synuclein	Synuclein	NNP
10_1101-2021_01_04_425177	113	21	Aggregation	Aggregation	NNP
10_1101-2021_01_04_425177	113	22	and	and	CC
10_1101-2021_01_04_425177	113	23	Toxicity	Toxicity	NNP
10_1101-2021_01_04_425177	113	24	:	:	:
10_1101-2021_01_04_425177	113	25	In	in	IN
10_1101-2021_01_04_425177	113	26	Vitro	Vitro	NNP
10_1101-2021_01_04_425177	113	27	and	and	CC
10_1101-2021_01_04_425177	113	28	Mechanistic	Mechanistic	NNP
10_1101-2021_01_04_425177	113	29	Studies	Studies	NNPS
10_1101-2021_01_04_425177	113	30	.	.	.
10_1101-2021_01_04_425177	114	1	Chemistry	chemistry	NN
10_1101-2021_01_04_425177	114	2	22	22	CD
10_1101-2021_01_04_425177	114	3	,	,	,
10_1101-2021_01_04_425177	114	4	14236	14236	CD
10_1101-2021_01_04_425177	114	5	-	-	SYM
10_1101-2021_01_04_425177	114	6	14246	14246	CD
10_1101-2021_01_04_425177	114	7	.	.	.
10_1101-2021_01_04_425177	115	1	Gasteiger	Gasteiger	NNP
10_1101-2021_01_04_425177	115	2	,	,	,
10_1101-2021_01_04_425177	115	3	E.	E.	NNP
10_1101-2021_01_04_425177	115	4	,	,	,
10_1101-2021_01_04_425177	115	5	Hoogland	Hoogland	NNP
10_1101-2021_01_04_425177	115	6	,	,	,
10_1101-2021_01_04_425177	115	7	C.	C.	NNP
10_1101-2021_01_04_425177	115	8	,	,	,
10_1101-2021_01_04_425177	115	9	Gattiker	Gattiker	NNP
10_1101-2021_01_04_425177	115	10	,	,	,
10_1101-2021_01_04_425177	115	11	A.	a.	NN
10_1101-2021_01_04_425177	115	12	,	,	,
10_1101-2021_01_04_425177	115	13	Duvaud	Duvaud	NNP
10_1101-2021_01_04_425177	115	14	,	,	,
10_1101-2021_01_04_425177	115	15	S.e	S.e	NNP
10_1101-2021_01_04_425177	115	16	.	.	NNP
10_1101-2021_01_04_425177	115	17	,	,	,
10_1101-2021_01_04_425177	115	18	Wilkins	Wilkins	NNP
10_1101-2021_01_04_425177	115	19	,	,	,
10_1101-2021_01_04_425177	115	20	M.R.	M.R.	NNP
10_1101-2021_01_04_425177	115	21	,	,	,
10_1101-2021_01_04_425177	115	22	Appel	Appel	NNP
10_1101-2021_01_04_425177	115	23	,	,	,
10_1101-2021_01_04_425177	115	24	R.D.	R.D.	NNP
10_1101-2021_01_04_425177	115	25	,	,	,
10_1101-2021_01_04_425177	115	26	Amos	Amos	NNP
10_1101-2021_01_04_425177	115	27	,	,	,
10_1101-2021_01_04_425177	115	28	B.	B.	NNP
10_1101-2021_01_04_425177	115	29	,	,	,
10_1101-2021_01_04_425177	115	30	2005	2005	CD
10_1101-2021_01_04_425177	115	31	.	.	.
10_1101-2021_01_04_425177	116	1	Protein	Protein	NNP
10_1101-2021_01_04_425177	116	2	Identification	Identification	NNP
10_1101-2021_01_04_425177	116	3	and	and	CC
10_1101-2021_01_04_425177	116	4	Analysis	Analysis	NNP
10_1101-2021_01_04_425177	116	5	Tools	Tools	NNPS
10_1101-2021_01_04_425177	116	6	on	on	IN
10_1101-2021_01_04_425177	116	7	the	the	DT
10_1101-2021_01_04_425177	116	8	ExPASy	ExPASy	NNP
10_1101-2021_01_04_425177	116	9	Server	Server	NNP
10_1101-2021_01_04_425177	116	10	,	,	,
10_1101-2021_01_04_425177	116	11	in	in	IN
10_1101-2021_01_04_425177	116	12	:	:	:
10_1101-2021_01_04_425177	116	13	Walker	Walker	NNP
10_1101-2021_01_04_425177	116	14	,	,	,
10_1101-2021_01_04_425177	116	15	J.M.	J.M.	NNP
10_1101-2021_01_04_425177	117	1	(	(	-LRB-
10_1101-2021_01_04_425177	117	2	Ed	Ed	NNP
10_1101-2021_01_04_425177	117	3	.	.	.
10_1101-2021_01_04_425177	118	1	)	)	-RRB-
10_1101-2021_01_04_425177	118	2	,	,	,
10_1101-2021_01_04_425177	118	3	The	the	DT
10_1101-2021_01_04_425177	118	4	Proteomics	Proteomics	NNPS
10_1101-2021_01_04_425177	118	5	Protocols	Protocols	NNPS
10_1101-2021_01_04_425177	118	6	Handbook	Handbook	NNP
10_1101-2021_01_04_425177	118	7	.	.	.
10_1101-2021_01_04_425177	119	1	Humana	Humana	NNP
10_1101-2021_01_04_425177	119	2	Press	Press	NNP
10_1101-2021_01_04_425177	119	3	,	,	,
10_1101-2021_01_04_425177	119	4	pp	pp	NNP
10_1101-2021_01_04_425177	119	5	.	.	.
10_1101-2021_01_04_425177	120	1	571	571	CD
10_1101-2021_01_04_425177	120	2	-	-	SYM
10_1101-2021_01_04_425177	120	3	607	607	CD
10_1101-2021_01_04_425177	120	4	.	.	.
10_1101-2021_01_04_425177	121	1	Gielnik	Gielnik	NNP
10_1101-2021_01_04_425177	121	2	,	,	,
10_1101-2021_01_04_425177	121	3	M.	M.	NNP
10_1101-2021_01_04_425177	121	4	,	,	,
10_1101-2021_01_04_425177	121	5	Pietralik	Pietralik	NNP
10_1101-2021_01_04_425177	121	6	,	,	,
10_1101-2021_01_04_425177	121	7	Z.	Z.	NNP
10_1101-2021_01_04_425177	121	8	,	,	,
10_1101-2021_01_04_425177	121	9	Zhukov	Zhukov	NNP
10_1101-2021_01_04_425177	121	10	,	,	,
10_1101-2021_01_04_425177	121	11	I.	I.	NNP
10_1101-2021_01_04_425177	121	12	,	,	,
10_1101-2021_01_04_425177	121	13	Szymańska	Szymańska	NNP
10_1101-2021_01_04_425177	121	14	,	,	,
10_1101-2021_01_04_425177	121	15	A.	A.	NNP
10_1101-2021_01_04_425177	121	16	,	,	,
10_1101-2021_01_04_425177	121	17	Kwiatek	Kwiatek	NNP
10_1101-2021_01_04_425177	121	18	,	,	,
10_1101-2021_01_04_425177	121	19	W.M.	W.M.	NNP
10_1101-2021_01_04_425177	121	20	,	,	,
10_1101-2021_01_04_425177	121	21	Kozak	Kozak	NNP
10_1101-2021_01_04_425177	121	22	,	,	,
10_1101-2021_01_04_425177	121	23	M.	M.	NNP
10_1101-2021_01_04_425177	121	24	,	,	,
10_1101-2021_01_04_425177	121	25	2019	2019	CD
10_1101-2021_01_04_425177	121	26	.	.	.
10_1101-2021_01_04_425177	122	1	PrP	PrP	NNP
10_1101-2021_01_04_425177	122	2	(	(	-LRB-
10_1101-2021_01_04_425177	122	3	58–93	58–93	CD
10_1101-2021_01_04_425177	122	4	)	)	-RRB-
10_1101-2021_01_04_425177	122	5	peptide	peptide	NN
10_1101-2021_01_04_425177	122	6	from	from	IN
10_1101-2021_01_04_425177	122	7	unstructured	unstructured	JJ
10_1101-2021_01_04_425177	122	8	N	N	NNP
10_1101-2021_01_04_425177	122	9	-	-	HYPH
10_1101-2021_01_04_425177	122	10	terminaldomain	terminaldomain	NNP
10_1101-2021_01_04_425177	122	11	of	of	IN
10_1101-2021_01_04_425177	122	12	human	human	JJ
10_1101-2021_01_04_425177	122	13	prion	prion	NN
10_1101-2021_01_04_425177	122	14	protein	protein	NN
10_1101-2021_01_04_425177	122	15	forms	form	NNS
10_1101-2021_01_04_425177	122	16	amyloid-	amyloid-	VBP
10_1101-2021_01_04_425177	122	17	likefibrillar	likefibrillar	JJ
10_1101-2021_01_04_425177	122	18	structures	structure	NNS
10_1101-2021_01_04_425177	122	19	in	in	IN
10_1101-2021_01_04_425177	122	20	the	the	DT
10_1101-2021_01_04_425177	122	21	presence	presence	NN
10_1101-2021_01_04_425177	122	22	of	of	IN
10_1101-2021_01_04_425177	122	23	Zn2+ions	zn2+ion	NNS
10_1101-2021_01_04_425177	122	24	.	.	.
10_1101-2021_01_04_425177	123	1	RSC	RSC	NNP
10_1101-2021_01_04_425177	123	2	Advances	Advances	NNP
10_1101-2021_01_04_425177	123	3	9	9	CD
10_1101-2021_01_04_425177	123	4	,	,	,
10_1101-2021_01_04_425177	123	5	22211–22219	22211–22219	CD
10_1101-2021_01_04_425177	123	6	.	.	.
10_1101-2021_01_04_425177	124	1	Henning	Henning	NNP
10_1101-2021_01_04_425177	124	2	-	-	HYPH
10_1101-2021_01_04_425177	124	3	Knechtel	Knechtel	NNP
10_1101-2021_01_04_425177	124	4	,	,	,
10_1101-2021_01_04_425177	124	5	A.	A.	NNP
10_1101-2021_01_04_425177	124	6	,	,	,
10_1101-2021_01_04_425177	124	7	Kumar	Kumar	NNP
10_1101-2021_01_04_425177	124	8	,	,	,
10_1101-2021_01_04_425177	124	9	S.	S.	NNP
10_1101-2021_01_04_425177	124	10	,	,	,
10_1101-2021_01_04_425177	124	11	Wallin	Wallin	NNP
10_1101-2021_01_04_425177	124	12	,	,	,
10_1101-2021_01_04_425177	124	13	C.	C.	NNP
10_1101-2021_01_04_425177	124	14	,	,	,
10_1101-2021_01_04_425177	124	15	Król	Król	NNP
10_1101-2021_01_04_425177	124	16	,	,	,
10_1101-2021_01_04_425177	124	17	S.	S.	NNP
10_1101-2021_01_04_425177	124	18	,	,	,
10_1101-2021_01_04_425177	124	19	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	124	20	,	,	,
10_1101-2021_01_04_425177	124	21	S.	S.	NNP
10_1101-2021_01_04_425177	124	22	,	,	,
10_1101-2021_01_04_425177	124	23	Jarvet	Jarvet	NNP
10_1101-2021_01_04_425177	124	24	,	,	,
10_1101-2021_01_04_425177	124	25	J.	J.	NNP
10_1101-2021_01_04_425177	124	26	,	,	,
10_1101-2021_01_04_425177	124	27	Esposito	Esposito	NNP
10_1101-2021_01_04_425177	124	28	,	,	,
10_1101-2021_01_04_425177	124	29	G.	G.	NNP
10_1101-2021_01_04_425177	124	30	,	,	,
10_1101-2021_01_04_425177	124	31	Kirmizialtin	Kirmizialtin	NNP
10_1101-2021_01_04_425177	124	32	,	,	,
10_1101-2021_01_04_425177	124	33	S.	S.	NNP
10_1101-2021_01_04_425177	124	34	,	,	,
10_1101-2021_01_04_425177	124	35	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	124	36	,	,	,
10_1101-2021_01_04_425177	124	37	A.	A.	NNP
10_1101-2021_01_04_425177	124	38	,	,	,
10_1101-2021_01_04_425177	124	39	Hamilton	Hamilton	NNP
10_1101-2021_01_04_425177	124	40	,	,	,
10_1101-2021_01_04_425177	124	41	A.D.	A.D.	NNP
10_1101-2021_01_04_425177	124	42	,	,	,
10_1101-2021_01_04_425177	124	43	Magzoub	Magzoub	NNP
10_1101-2021_01_04_425177	124	44	,	,	,
10_1101-2021_01_04_425177	124	45	M.	M.	NNP
10_1101-2021_01_04_425177	124	46	,	,	,
10_1101-2021_01_04_425177	124	47	2020	2020	CD
10_1101-2021_01_04_425177	124	48	.	.	.
10_1101-2021_01_04_425177	125	1	Designed	design	VBN
10_1101-2021_01_04_425177	125	2	cell	cell	NN
10_1101-2021_01_04_425177	125	3	-	-	HYPH
10_1101-2021_01_04_425177	125	4	penetrating	penetrate	VBG
10_1101-2021_01_04_425177	125	5	peptide	peptide	JJ
10_1101-2021_01_04_425177	125	6	inhibitors	inhibitor	NNS
10_1101-2021_01_04_425177	125	7	of	of	IN
10_1101-2021_01_04_425177	125	8	amyloid	amyloid	JJ
10_1101-2021_01_04_425177	125	9	-	-	HYPH
10_1101-2021_01_04_425177	125	10	beta	beta	NN
10_1101-2021_01_04_425177	125	11	aggregation	aggregation	NN
10_1101-2021_01_04_425177	125	12	and	and	CC
10_1101-2021_01_04_425177	125	13	cytotoxicity	cytotoxicity	NN
10_1101-2021_01_04_425177	125	14	.	.	.
10_1101-2021_01_04_425177	126	1	Cell	Cell	NNP
10_1101-2021_01_04_425177	126	2	Reports	report	VBZ
10_1101-2021_01_04_425177	126	3	Physical	Physical	NNP
10_1101-2021_01_04_425177	126	4	Science	Science	NNP
10_1101-2021_01_04_425177	126	5	1	1	CD
10_1101-2021_01_04_425177	126	6	,	,	,
10_1101-2021_01_04_425177	126	7	100014	100014	CD
10_1101-2021_01_04_425177	126	8	.	.	.
10_1101-2021_01_04_425177	127	1	Horvath	Horvath	NNP
10_1101-2021_01_04_425177	127	2	,	,	,
10_1101-2021_01_04_425177	127	3	I.	I.	NNP
10_1101-2021_01_04_425177	127	4	,	,	,
10_1101-2021_01_04_425177	127	5	Iashchishyn	Iashchishyn	NNP
10_1101-2021_01_04_425177	127	6	,	,	,
10_1101-2021_01_04_425177	127	7	I.A.	I.A.	NNP
10_1101-2021_01_04_425177	127	8	,	,	,
10_1101-2021_01_04_425177	127	9	Moskalenko	Moskalenko	NNP
10_1101-2021_01_04_425177	127	10	,	,	,
10_1101-2021_01_04_425177	127	11	R.A.	R.A.	NNP
10_1101-2021_01_04_425177	127	12	,	,	,
10_1101-2021_01_04_425177	127	13	Wang	Wang	NNP
10_1101-2021_01_04_425177	127	14	,	,	,
10_1101-2021_01_04_425177	127	15	C.	C.	NNP
10_1101-2021_01_04_425177	127	16	,	,	,
10_1101-2021_01_04_425177	127	17	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	127	18	,	,	,
10_1101-2021_01_04_425177	127	19	S.K.T.S.	S.K.T.S.	NNP
10_1101-2021_01_04_425177	127	20	,	,	,
10_1101-2021_01_04_425177	127	21	Wallin	Wallin	NNP
10_1101-2021_01_04_425177	127	22	,	,	,
10_1101-2021_01_04_425177	127	23	C.	C.	NNP
10_1101-2021_01_04_425177	127	24	,	,	,
10_1101-2021_01_04_425177	127	25	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	127	26	,	,	,
10_1101-2021_01_04_425177	127	27	A.	A.	NNP
10_1101-2021_01_04_425177	127	28	,	,	,
10_1101-2021_01_04_425177	127	29	Kovacs	Kovacs	NNP
10_1101-2021_01_04_425177	127	30	,	,	,
10_1101-2021_01_04_425177	127	31	G.G.	G.G.	NNP
10_1101-2021_01_04_425177	127	32	,	,	,
10_1101-2021_01_04_425177	127	33	Morozova	Morozova	NNP
10_1101-2021_01_04_425177	127	34	-	-	HYPH
10_1101-2021_01_04_425177	127	35	Roche	Roche	NNP
10_1101-2021_01_04_425177	127	36	,	,	,
10_1101-2021_01_04_425177	127	37	L.A.	L.A.	NNP
10_1101-2021_01_04_425177	127	38	,	,	,
10_1101-2021_01_04_425177	127	39	2018	2018	CD
10_1101-2021_01_04_425177	127	40	.	.	.
10_1101-2021_01_04_425177	128	1	Co	co	NN
10_1101-2021_01_04_425177	128	2	-	-	NN
10_1101-2021_01_04_425177	128	3	aggregation	aggregation	NN
10_1101-2021_01_04_425177	128	4	of	of	IN
10_1101-2021_01_04_425177	128	5	pro	pro	JJ
10_1101-2021_01_04_425177	128	6	-	-	JJ
10_1101-2021_01_04_425177	128	7	inflammatory	inflammatory	JJ
10_1101-2021_01_04_425177	128	8	S100A9	s100a9	NN
10_1101-2021_01_04_425177	128	9	with	with	IN
10_1101-2021_01_04_425177	128	10	alpha	alpha	NN
10_1101-2021_01_04_425177	128	11	-	-	HYPH
10_1101-2021_01_04_425177	128	12	synuclein	synuclein	NNS
10_1101-2021_01_04_425177	128	13	in	in	IN
10_1101-2021_01_04_425177	128	14	Parkinson	Parkinson	NNP
10_1101-2021_01_04_425177	128	15	's	's	POS
10_1101-2021_01_04_425177	128	16	disease	disease	NN
10_1101-2021_01_04_425177	128	17	:	:	:
10_1101-2021_01_04_425177	128	18	ex	ex	NNP
10_1101-2021_01_04_425177	128	19	vivo	vivo	NNP
10_1101-2021_01_04_425177	128	20	and	and	CC
10_1101-2021_01_04_425177	128	21	in	in	FW
10_1101-2021_01_04_425177	128	22	vitro	vitro	FW
10_1101-2021_01_04_425177	128	23	studies	study	NNS
10_1101-2021_01_04_425177	128	24	.	.	.
10_1101-2021_01_04_425177	129	1	J	J	NNP
10_1101-2021_01_04_425177	129	2	Neuroinflammation	Neuroinflammation	NNP
10_1101-2021_01_04_425177	129	3	15	15	CD
10_1101-2021_01_04_425177	129	4	,	,	,
10_1101-2021_01_04_425177	129	5	172	172	CD
10_1101-2021_01_04_425177	129	6	.	.	.
10_1101-2021_01_04_425177	130	1	Hyeon	Hyeon	NNP
10_1101-2021_01_04_425177	130	2	,	,	,
10_1101-2021_01_04_425177	130	3	J.W.	J.W.	NNP
10_1101-2021_01_04_425177	130	4	,	,	,
10_1101-2021_01_04_425177	130	5	Noh	Noh	NNP
10_1101-2021_01_04_425177	130	6	,	,	,
10_1101-2021_01_04_425177	130	7	R.	R.	NNP
10_1101-2021_01_04_425177	130	8	,	,	,
10_1101-2021_01_04_425177	130	9	Choi	Choi	NNP
10_1101-2021_01_04_425177	130	10	,	,	,
10_1101-2021_01_04_425177	130	11	J.	J.	NNP
10_1101-2021_01_04_425177	130	12	,	,	,
10_1101-2021_01_04_425177	130	13	Lee	Lee	NNP
10_1101-2021_01_04_425177	130	14	,	,	,
10_1101-2021_01_04_425177	130	15	S.M.	S.M.	NNP
10_1101-2021_01_04_425177	130	16	,	,	,
10_1101-2021_01_04_425177	130	17	Lee	Lee	NNP
10_1101-2021_01_04_425177	130	18	,	,	,
10_1101-2021_01_04_425177	130	19	Y.S.	Y.S.	NNP
10_1101-2021_01_04_425177	130	20	,	,	,
10_1101-2021_01_04_425177	130	21	An	An	NNP
10_1101-2021_01_04_425177	130	22	,	,	,
10_1101-2021_01_04_425177	130	23	S.S.A.	S.S.A.	NNP
10_1101-2021_01_04_425177	130	24	,	,	,
10_1101-2021_01_04_425177	130	25	No	No	NNP
10_1101-2021_01_04_425177	130	26	,	,	,
10_1101-2021_01_04_425177	130	27	K.T.	K.T.	NNP
10_1101-2021_01_04_425177	130	28	,	,	,
10_1101-2021_01_04_425177	130	29	Lee	Lee	NNP
10_1101-2021_01_04_425177	130	30	,	,	,
10_1101-2021_01_04_425177	130	31	J.	J.	NNP
10_1101-2021_01_04_425177	130	32	,	,	,
10_1101-2021_01_04_425177	130	33	2020	2020	CD
10_1101-2021_01_04_425177	130	34	.	.	.
10_1101-2021_01_04_425177	131	1	BMD42	BMD42	NNP
10_1101-2021_01_04_425177	131	2	-	-	HYPH
10_1101-2021_01_04_425177	131	3	2910	2910	CD
10_1101-2021_01_04_425177	131	4	,	,	,
10_1101-2021_01_04_425177	131	5	a	a	DT
10_1101-2021_01_04_425177	131	6	Novel	Novel	NNP
10_1101-2021_01_04_425177	131	7	Benzoxazole	Benzoxazole	NNP
10_1101-2021_01_04_425177	131	8	Derivative	Derivative	NNP
10_1101-2021_01_04_425177	131	9	,	,	,
10_1101-2021_01_04_425177	131	10	Shows	show	VBZ
10_1101-2021_01_04_425177	131	11	a	a	DT
10_1101-2021_01_04_425177	131	12	Potent	Potent	NNP
10_1101-2021_01_04_425177	131	13	Anti	Anti	NNP
10_1101-2021_01_04_425177	131	14	-	-	NN
10_1101-2021_01_04_425177	131	15	prion	prion	NN
10_1101-2021_01_04_425177	131	16	Activity	Activity	NNP
10_1101-2021_01_04_425177	131	17	and	and	CC
10_1101-2021_01_04_425177	131	18	Prolongs	Prolongs	NNPS
10_1101-2021_01_04_425177	131	19	the	the	DT
10_1101-2021_01_04_425177	131	20	Mean	Mean	NNP
10_1101-2021_01_04_425177	131	21	Survival	Survival	NNP
10_1101-2021_01_04_425177	131	22	in	in	IN
10_1101-2021_01_04_425177	131	23	an	an	DT
10_1101-2021_01_04_425177	131	24	Animal	Animal	NNP
10_1101-2021_01_04_425177	131	25	Model	model	NN
10_1101-2021_01_04_425177	131	26	of	of	IN
10_1101-2021_01_04_425177	131	27	Prion	Prion	NNP
10_1101-2021_01_04_425177	131	28	Disease	Disease	NNP
10_1101-2021_01_04_425177	131	29	.	.	.
10_1101-2021_01_04_425177	132	1	Exp	Exp	NNP
10_1101-2021_01_04_425177	132	2	Neurobiol	Neurobiol	NNP
10_1101-2021_01_04_425177	132	3	29	29	CD
10_1101-2021_01_04_425177	132	4	,	,	,
10_1101-2021_01_04_425177	132	5	93	93	CD
10_1101-2021_01_04_425177	132	6	-	-	SYM
10_1101-2021_01_04_425177	132	7	105	105	CD
10_1101-2021_01_04_425177	132	8	.	.	.
10_1101-2021_01_04_425177	133	1	Jaunmuktane	Jaunmuktane	NNP
10_1101-2021_01_04_425177	133	2	,	,	,
10_1101-2021_01_04_425177	133	3	Z.	Z.	NNP
10_1101-2021_01_04_425177	133	4	,	,	,
10_1101-2021_01_04_425177	133	5	Brandner	Brandner	NNP
10_1101-2021_01_04_425177	133	6	,	,	,
10_1101-2021_01_04_425177	133	7	S.	S.	NNP
10_1101-2021_01_04_425177	133	8	,	,	,
10_1101-2021_01_04_425177	133	9	2019	2019	CD
10_1101-2021_01_04_425177	133	10	.	.	.
10_1101-2021_01_04_425177	134	1	The	the	DT
10_1101-2021_01_04_425177	134	2	role	role	NN
10_1101-2021_01_04_425177	134	3	of	of	IN
10_1101-2021_01_04_425177	134	4	prion	prion	NN
10_1101-2021_01_04_425177	134	5	-	-	HYPH
10_1101-2021_01_04_425177	134	6	like	like	JJ
10_1101-2021_01_04_425177	134	7	mechanisms	mechanism	NNS
10_1101-2021_01_04_425177	134	8	in	in	IN
10_1101-2021_01_04_425177	134	9	neurodegenerative	neurodegenerative	JJ
10_1101-2021_01_04_425177	134	10	diseases	disease	NNS
10_1101-2021_01_04_425177	134	11	.	.	.
10_1101-2021_01_04_425177	135	1	Neuropathol	Neuropathol	NNP
10_1101-2021_01_04_425177	135	2	Appl	Appl	NNP
10_1101-2021_01_04_425177	135	3	Neurobiol	Neurobiol	NNP
10_1101-2021_01_04_425177	135	4	.	.	.
10_1101-2021_01_04_425177	136	1	Jucker	Jucker	NNP
10_1101-2021_01_04_425177	136	2	,	,	,
10_1101-2021_01_04_425177	136	3	M.	M.	NNP
10_1101-2021_01_04_425177	136	4	,	,	,
10_1101-2021_01_04_425177	136	5	Walker	Walker	NNP
10_1101-2021_01_04_425177	136	6	,	,	,
10_1101-2021_01_04_425177	136	7	L.C.	L.C.	NNP
10_1101-2021_01_04_425177	136	8	,	,	,
10_1101-2021_01_04_425177	136	9	2018	2018	CD
10_1101-2021_01_04_425177	136	10	.	.	.
10_1101-2021_01_04_425177	137	1	Propagation	propagation	NN
10_1101-2021_01_04_425177	137	2	and	and	CC
10_1101-2021_01_04_425177	137	3	spread	spread	NN
10_1101-2021_01_04_425177	137	4	of	of	IN
10_1101-2021_01_04_425177	137	5	pathogenic	pathogenic	JJ
10_1101-2021_01_04_425177	137	6	protein	protein	NN
10_1101-2021_01_04_425177	137	7	assemblies	assembly	NNS
10_1101-2021_01_04_425177	137	8	in	in	IN
10_1101-2021_01_04_425177	137	9	neurodegenerative	neurodegenerative	JJ
10_1101-2021_01_04_425177	137	10	diseases	disease	NNS
10_1101-2021_01_04_425177	137	11	.	.	.
10_1101-2021_01_04_425177	138	1	Nat	Nat	NNP
10_1101-2021_01_04_425177	138	2	Neurosci	Neurosci	NNP
10_1101-2021_01_04_425177	138	3	21	21	CD
10_1101-2021_01_04_425177	138	4	,	,	,
10_1101-2021_01_04_425177	138	5	1341	1341	CD
10_1101-2021_01_04_425177	138	6	-	-	SYM
10_1101-2021_01_04_425177	138	7	1349	1349	CD
10_1101-2021_01_04_425177	138	8	.	.	.
10_1101-2021_01_04_425177	139	1	Julien	Julien	NNP
10_1101-2021_01_04_425177	139	2	,	,	,
10_1101-2021_01_04_425177	139	3	O.	O.	NNP
10_1101-2021_01_04_425177	139	4	,	,	,
10_1101-2021_01_04_425177	139	5	Chatterjee	Chatterjee	NNP
10_1101-2021_01_04_425177	139	6	,	,	,
10_1101-2021_01_04_425177	139	7	S.	S.	NNP
10_1101-2021_01_04_425177	139	8	,	,	,
10_1101-2021_01_04_425177	139	9	Thiessen	Thiessen	NNP
10_1101-2021_01_04_425177	139	10	,	,	,
10_1101-2021_01_04_425177	139	11	A.	a.	NN
10_1101-2021_01_04_425177	139	12	,	,	,
10_1101-2021_01_04_425177	139	13	Graether	Graether	NNP
10_1101-2021_01_04_425177	139	14	,	,	,
10_1101-2021_01_04_425177	139	15	S.P.	S.P.	NNP
10_1101-2021_01_04_425177	139	16	,	,	,
10_1101-2021_01_04_425177	139	17	Sykes	Sykes	NNP
10_1101-2021_01_04_425177	139	18	,	,	,
10_1101-2021_01_04_425177	139	19	B.D.	B.D.	NNP
10_1101-2021_01_04_425177	139	20	,	,	,
10_1101-2021_01_04_425177	139	21	2009	2009	CD
10_1101-2021_01_04_425177	139	22	.	.	.
10_1101-2021_01_04_425177	140	1	Differential	differential	JJ
10_1101-2021_01_04_425177	140	2	stability	stability	NN
10_1101-2021_01_04_425177	140	3	of	of	IN
10_1101-2021_01_04_425177	140	4	the	the	DT
10_1101-2021_01_04_425177	140	5	bovine	bovine	JJ
10_1101-2021_01_04_425177	140	6	prion	prion	NN
10_1101-2021_01_04_425177	140	7	protein	protein	NN
10_1101-2021_01_04_425177	140	8	upon	upon	IN
10_1101-2021_01_04_425177	140	9	urea	urea	NNP
10_1101-2021_01_04_425177	140	10	unfolding	unfold	VBG
10_1101-2021_01_04_425177	140	11	.	.	.
10_1101-2021_01_04_425177	141	1	Protein	Protein	NNP
10_1101-2021_01_04_425177	141	2	Sci	Sci	NNP
10_1101-2021_01_04_425177	141	3	18	18	CD
10_1101-2021_01_04_425177	141	4	,	,	,
10_1101-2021_01_04_425177	141	5	2172	2172	CD
10_1101-2021_01_04_425177	141	6	-	-	SYM
10_1101-2021_01_04_425177	141	7	2182	2182	CD
10_1101-2021_01_04_425177	141	8	.	.	.
10_1101-2021_01_04_425177	142	1	Kristensen	Kristensen	NNP
10_1101-2021_01_04_425177	142	2	,	,	,
10_1101-2021_01_04_425177	142	3	M.	M.	NNP
10_1101-2021_01_04_425177	142	4	,	,	,
10_1101-2021_01_04_425177	142	5	Birch	Birch	NNP
10_1101-2021_01_04_425177	142	6	,	,	,
10_1101-2021_01_04_425177	142	7	D.	D.	NNP
10_1101-2021_01_04_425177	142	8	,	,	,
10_1101-2021_01_04_425177	142	9	Morck	Morck	NNP
10_1101-2021_01_04_425177	142	10	Nielsen	Nielsen	NNP
10_1101-2021_01_04_425177	142	11	,	,	,
10_1101-2021_01_04_425177	142	12	H.	H.	NNP
10_1101-2021_01_04_425177	142	13	,	,	,
10_1101-2021_01_04_425177	142	14	2016	2016	CD
10_1101-2021_01_04_425177	142	15	.	.	.
10_1101-2021_01_04_425177	143	1	Applications	application	NNS
10_1101-2021_01_04_425177	143	2	and	and	CC
10_1101-2021_01_04_425177	143	3	Challenges	Challenges	NNPS
10_1101-2021_01_04_425177	143	4	for	for	IN
10_1101-2021_01_04_425177	143	5	Use	Use	NNP
10_1101-2021_01_04_425177	143	6	of	of	IN
10_1101-2021_01_04_425177	143	7	Cell-	Cell-	NNP
10_1101-2021_01_04_425177	143	8	Penetrating	Penetrating	NNP
10_1101-2021_01_04_425177	143	9	Peptides	Peptides	NNPS
10_1101-2021_01_04_425177	143	10	as	as	IN
10_1101-2021_01_04_425177	143	11	Delivery	Delivery	NNP
10_1101-2021_01_04_425177	143	12	Vectors	Vectors	NNPS
10_1101-2021_01_04_425177	143	13	for	for	IN
10_1101-2021_01_04_425177	143	14	Peptide	Peptide	NNP
10_1101-2021_01_04_425177	143	15	and	and	CC
10_1101-2021_01_04_425177	143	16	Protein	Protein	NNP
10_1101-2021_01_04_425177	143	17	Cargos	Cargos	NNP
10_1101-2021_01_04_425177	143	18	.	.	.
10_1101-2021_01_04_425177	144	1	Int	Int	NNP
10_1101-2021_01_04_425177	144	2	J	J	NNP
10_1101-2021_01_04_425177	144	3	Mol	Mol	NNP
10_1101-2021_01_04_425177	144	4	Sci	Sci	NNP
10_1101-2021_01_04_425177	144	5	17	17	CD
10_1101-2021_01_04_425177	144	6	.	.	.
10_1101-2021_01_04_425177	145	1	Lee	Lee	NNP
10_1101-2021_01_04_425177	145	2	,	,	,
10_1101-2021_01_04_425177	145	3	S.M.	S.M.	NNP
10_1101-2021_01_04_425177	145	4	,	,	,
10_1101-2021_01_04_425177	145	5	Kim	Kim	NNP
10_1101-2021_01_04_425177	145	6	,	,	,
10_1101-2021_01_04_425177	145	7	S.S.	S.S.	NNP
10_1101-2021_01_04_425177	145	8	,	,	,
10_1101-2021_01_04_425177	145	9	Kim	Kim	NNP
10_1101-2021_01_04_425177	145	10	,	,	,
10_1101-2021_01_04_425177	145	11	H.	H.	NNP
10_1101-2021_01_04_425177	145	12	,	,	,
10_1101-2021_01_04_425177	145	13	Kim	Kim	NNP
10_1101-2021_01_04_425177	145	14	,	,	,
10_1101-2021_01_04_425177	145	15	S.Y.	S.Y.	NNP
10_1101-2021_01_04_425177	145	16	,	,	,
10_1101-2021_01_04_425177	145	17	2019	2019	CD
10_1101-2021_01_04_425177	145	18	.	.	.
10_1101-2021_01_04_425177	146	1	THERPA	THERPA	NNS
10_1101-2021_01_04_425177	146	2	v2	v2	NN
10_1101-2021_01_04_425177	146	3	:	:	:
10_1101-2021_01_04_425177	146	4	an	an	DT
10_1101-2021_01_04_425177	146	5	update	update	NN
10_1101-2021_01_04_425177	146	6	of	of	IN
10_1101-2021_01_04_425177	146	7	a	a	DT
10_1101-2021_01_04_425177	146	8	small	small	JJ
10_1101-2021_01_04_425177	146	9	molecule	molecule	NN
10_1101-2021_01_04_425177	146	10	database	database	NN
10_1101-2021_01_04_425177	146	11	related	relate	VBN
10_1101-2021_01_04_425177	146	12	to	to	IN
10_1101-2021_01_04_425177	146	13	prion	prion	NN
10_1101-2021_01_04_425177	146	14	protein	protein	NN
10_1101-2021_01_04_425177	146	15	regulation	regulation	NN
10_1101-2021_01_04_425177	146	16	and	and	CC
10_1101-2021_01_04_425177	146	17	prion	prion	NN
10_1101-2021_01_04_425177	146	18	disease	disease	NNP
10_1101-2021_01_04_425177	146	19	progression	progression	NN
10_1101-2021_01_04_425177	146	20	.	.	.
10_1101-2021_01_04_425177	147	1	Prion	prion	NN
10_1101-2021_01_04_425177	147	2	13	13	CD
10_1101-2021_01_04_425177	147	3	,	,	,
10_1101-2021_01_04_425177	147	4	197	197	CD
10_1101-2021_01_04_425177	147	5	-	-	SYM
10_1101-2021_01_04_425177	147	6	198	198	CD
10_1101-2021_01_04_425177	147	7	.	.	.
10_1101-2021_01_04_425177	148	1	Lundberg	Lundberg	NNP
10_1101-2021_01_04_425177	148	2	,	,	,
10_1101-2021_01_04_425177	148	3	P.	P.	NNP
10_1101-2021_01_04_425177	148	4	,	,	,
10_1101-2021_01_04_425177	148	5	Magzoub	Magzoub	NNP
10_1101-2021_01_04_425177	148	6	,	,	,
10_1101-2021_01_04_425177	148	7	M.	M.	NNP
10_1101-2021_01_04_425177	148	8	,	,	,
10_1101-2021_01_04_425177	148	9	Lindberg	Lindberg	NNP
10_1101-2021_01_04_425177	148	10	,	,	,
10_1101-2021_01_04_425177	148	11	M.	M.	NNP
10_1101-2021_01_04_425177	148	12	,	,	,
10_1101-2021_01_04_425177	148	13	Hallbrink	Hallbrink	NNP
10_1101-2021_01_04_425177	148	14	,	,	,
10_1101-2021_01_04_425177	148	15	M.	M.	NNP
10_1101-2021_01_04_425177	148	16	,	,	,
10_1101-2021_01_04_425177	148	17	Jarvet	Jarvet	NNP
10_1101-2021_01_04_425177	148	18	,	,	,
10_1101-2021_01_04_425177	148	19	J.	J.	NNP
10_1101-2021_01_04_425177	148	20	,	,	,
10_1101-2021_01_04_425177	148	21	Eriksson	Eriksson	NNP
10_1101-2021_01_04_425177	148	22	,	,	,
10_1101-2021_01_04_425177	148	23	L.E.	L.E.	NNP
10_1101-2021_01_04_425177	148	24	,	,	,
10_1101-2021_01_04_425177	148	25	Langel	Langel	NNP
10_1101-2021_01_04_425177	148	26	,	,	,
10_1101-2021_01_04_425177	148	27	U.	U.	NNP
10_1101-2021_01_04_425177	148	28	,	,	,
10_1101-2021_01_04_425177	148	29	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	148	30	,	,	,
10_1101-2021_01_04_425177	148	31	A.	a.	NN
10_1101-2021_01_04_425177	148	32	,	,	,
10_1101-2021_01_04_425177	148	33	2002	2002	CD
10_1101-2021_01_04_425177	148	34	.	.	.
10_1101-2021_01_04_425177	149	1	Cell	cell	NN
10_1101-2021_01_04_425177	149	2	membrane	membrane	NN
10_1101-2021_01_04_425177	149	3	translocation	translocation	NN
10_1101-2021_01_04_425177	149	4	of	of	IN
10_1101-2021_01_04_425177	149	5	the	the	DT
10_1101-2021_01_04_425177	149	6	N	n	NN
10_1101-2021_01_04_425177	149	7	-	-	HYPH
10_1101-2021_01_04_425177	149	8	terminal	terminal	NN
10_1101-2021_01_04_425177	149	9	(	(	-LRB-
10_1101-2021_01_04_425177	149	10	1	1	CD
10_1101-2021_01_04_425177	149	11	-	-	SYM
10_1101-2021_01_04_425177	149	12	28	28	CD
10_1101-2021_01_04_425177	149	13	)	)	-RRB-
10_1101-2021_01_04_425177	149	14	part	part	NN
10_1101-2021_01_04_425177	149	15	of	of	IN
10_1101-2021_01_04_425177	149	16	the	the	DT
10_1101-2021_01_04_425177	149	17	prion	prion	NN
10_1101-2021_01_04_425177	149	18	protein	protein	NN
10_1101-2021_01_04_425177	149	19	.	.	.
10_1101-2021_01_04_425177	150	1	Biochem	Biochem	NNP
10_1101-2021_01_04_425177	150	2	Biophys	Biophys	NNP
10_1101-2021_01_04_425177	150	3	Res	Res	NNP
10_1101-2021_01_04_425177	150	4	Commun	Commun	NNP
10_1101-2021_01_04_425177	150	5	299	299	CD
10_1101-2021_01_04_425177	150	6	,	,	,
10_1101-2021_01_04_425177	150	7	85	85	CD
10_1101-2021_01_04_425177	150	8	-	-	SYM
10_1101-2021_01_04_425177	150	9	90	90	CD
10_1101-2021_01_04_425177	150	10	.	.	.
10_1101-2021_01_04_425177	151	1	Luo	Luo	NNP
10_1101-2021_01_04_425177	151	2	,	,	,
10_1101-2021_01_04_425177	151	3	J.	J.	NNP
10_1101-2021_01_04_425177	151	4	,	,	,
10_1101-2021_01_04_425177	151	5	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	151	6	,	,	,
10_1101-2021_01_04_425177	151	7	S.K.	S.K.	NNP
10_1101-2021_01_04_425177	151	8	,	,	,
10_1101-2021_01_04_425177	151	9	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	151	10	,	,	,
10_1101-2021_01_04_425177	151	11	A.	a.	NN
10_1101-2021_01_04_425177	151	12	,	,	,
10_1101-2021_01_04_425177	151	13	Abrahams	Abrahams	NNP
10_1101-2021_01_04_425177	151	14	,	,	,
10_1101-2021_01_04_425177	151	15	J.P.	J.P.	NNP
10_1101-2021_01_04_425177	151	16	,	,	,
10_1101-2021_01_04_425177	151	17	2014	2014	CD
10_1101-2021_01_04_425177	151	18	.	.	.
10_1101-2021_01_04_425177	152	1	Alzheimer	Alzheimer	NNP
10_1101-2021_01_04_425177	152	2	peptides	peptide	NNS
10_1101-2021_01_04_425177	152	3	aggregate	aggregate	VBP
10_1101-2021_01_04_425177	152	4	into	into	IN
10_1101-2021_01_04_425177	152	5	transient	transient	JJ
10_1101-2021_01_04_425177	152	6	nanoglobules	nanoglobule	NNS
10_1101-2021_01_04_425177	152	7	that	that	WDT
10_1101-2021_01_04_425177	152	8	nucleate	nucleate	VBP
10_1101-2021_01_04_425177	152	9	fibrils	fibril	VBZ
10_1101-2021_01_04_425177	152	10	.	.	.
10_1101-2021_01_04_425177	153	1	Biochemistry	Biochemistry	NNP
10_1101-2021_01_04_425177	153	2	53	53	CD
10_1101-2021_01_04_425177	153	3	,	,	,
10_1101-2021_01_04_425177	153	4	6302	6302	CD
10_1101-2021_01_04_425177	153	5	-	-	SYM
10_1101-2021_01_04_425177	153	6	6308	6308	CD
10_1101-2021_01_04_425177	153	7	.	.	.
10_1101-2021_01_04_425177	154	1	Luo	Luo	NNP
10_1101-2021_01_04_425177	154	2	,	,	,
10_1101-2021_01_04_425177	154	3	J.	J.	NNP
10_1101-2021_01_04_425177	154	4	,	,	,
10_1101-2021_01_04_425177	154	5	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	154	6	,	,	,
10_1101-2021_01_04_425177	154	7	S.K.	S.K.	NNP
10_1101-2021_01_04_425177	154	8	,	,	,
10_1101-2021_01_04_425177	154	9	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	154	10	,	,	,
10_1101-2021_01_04_425177	154	11	A.	a.	NN
10_1101-2021_01_04_425177	154	12	,	,	,
10_1101-2021_01_04_425177	154	13	Abrahams	Abrahams	NNP
10_1101-2021_01_04_425177	154	14	,	,	,
10_1101-2021_01_04_425177	154	15	J.P.	J.P.	NNP
10_1101-2021_01_04_425177	154	16	,	,	,
10_1101-2021_01_04_425177	154	17	2016	2016	CD
10_1101-2021_01_04_425177	154	18	.	.	.
10_1101-2021_01_04_425177	155	1	Reciprocal	Reciprocal	NNP
10_1101-2021_01_04_425177	155	2	Molecular	Molecular	NNP
10_1101-2021_01_04_425177	155	3	Interactions	Interactions	NNPS
10_1101-2021_01_04_425177	155	4	between	between	IN
10_1101-2021_01_04_425177	155	5	the	the	DT
10_1101-2021_01_04_425177	155	6	Abeta	Abeta	NNP
10_1101-2021_01_04_425177	155	7	Peptide	Peptide	NNP
10_1101-2021_01_04_425177	155	8	Linked	link	VBN
10_1101-2021_01_04_425177	155	9	to	to	IN
10_1101-2021_01_04_425177	155	10	Alzheimer	Alzheimer	NNP
10_1101-2021_01_04_425177	155	11	's	's	POS
10_1101-2021_01_04_425177	155	12	Disease	Disease	NNP
10_1101-2021_01_04_425177	155	13	and	and	CC
10_1101-2021_01_04_425177	155	14	Insulin	Insulin	NNP
10_1101-2021_01_04_425177	155	15	Linked	link	VBN
10_1101-2021_01_04_425177	155	16	to	to	IN
10_1101-2021_01_04_425177	155	17	Diabetes	Diabetes	NNP
10_1101-2021_01_04_425177	155	18	Mellitus	Mellitus	NNP
10_1101-2021_01_04_425177	155	19	Type	Type	NNP
10_1101-2021_01_04_425177	155	20	II	II	NNP
10_1101-2021_01_04_425177	155	21	.	.	.
10_1101-2021_01_04_425177	156	1	ACS	ACS	NNP
10_1101-2021_01_04_425177	156	2	Chem	Chem	NNP
10_1101-2021_01_04_425177	156	3	Neurosci	Neurosci	NNP
10_1101-2021_01_04_425177	156	4	7	7	CD
10_1101-2021_01_04_425177	156	5	,	,	,
10_1101-2021_01_04_425177	156	6	269	269	CD
10_1101-2021_01_04_425177	156	7	-	-	SYM
10_1101-2021_01_04_425177	156	8	274	274	CD
10_1101-2021_01_04_425177	156	9	.	.	.
10_1101-2021_01_04_425177	157	1	Luo	Luo	NNP
10_1101-2021_01_04_425177	157	2	,	,	,
10_1101-2021_01_04_425177	157	3	J.	J.	NNP
10_1101-2021_01_04_425177	157	4	,	,	,
10_1101-2021_01_04_425177	157	5	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	157	6	,	,	,
10_1101-2021_01_04_425177	157	7	S.K.	S.K.	NNP
10_1101-2021_01_04_425177	157	8	,	,	,
10_1101-2021_01_04_425177	157	9	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	157	10	,	,	,
10_1101-2021_01_04_425177	157	11	A.	a.	NN
10_1101-2021_01_04_425177	157	12	,	,	,
10_1101-2021_01_04_425177	157	13	Abrahams	Abrahams	NNP
10_1101-2021_01_04_425177	157	14	,	,	,
10_1101-2021_01_04_425177	157	15	J.P.	J.P.	NNP
10_1101-2021_01_04_425177	157	16	,	,	,
10_1101-2021_01_04_425177	157	17	2017	2017	CD
10_1101-2021_01_04_425177	157	18	.	.	.
10_1101-2021_01_04_425177	158	1	Cross	cross	NN
10_1101-2021_01_04_425177	158	2	-	-	NNS
10_1101-2021_01_04_425177	158	3	interactions	interaction	NNS
10_1101-2021_01_04_425177	158	4	between	between	IN
10_1101-2021_01_04_425177	158	5	the	the	DT
10_1101-2021_01_04_425177	158	6	Alzheimer	Alzheimer	NNP
10_1101-2021_01_04_425177	158	7	disease	disease	NN
10_1101-2021_01_04_425177	158	8	amyloid	amyloid	NN
10_1101-2021_01_04_425177	158	9	-	-	HYPH
10_1101-2021_01_04_425177	158	10	beta	beta	NN
10_1101-2021_01_04_425177	158	11	peptide	peptide	NN
10_1101-2021_01_04_425177	158	12	and	and	CC
10_1101-2021_01_04_425177	158	13	other	other	JJ
10_1101-2021_01_04_425177	158	14	amyloid	amyloid	NN
10_1101-2021_01_04_425177	158	15	proteins	protein	NNS
10_1101-2021_01_04_425177	158	16	.	.	.
10_1101-2021_01_04_425177	159	1	A	a	DT
10_1101-2021_01_04_425177	159	2	FURTHER	further	JJ
10_1101-2021_01_04_425177	159	3	ASPECT	ASPECT	NNS
10_1101-2021_01_04_425177	159	4	OF	of	IN
10_1101-2021_01_04_425177	159	5	THE	the	DT
10_1101-2021_01_04_425177	159	6	AMYLOID	amyloid	JJ
10_1101-2021_01_04_425177	159	7	CASCADE	cascade	NN
10_1101-2021_01_04_425177	159	8	HYPOTHESIS	hypothesi	NNS
10_1101-2021_01_04_425177	159	9	.	.	.
10_1101-2021_01_04_425177	160	1	J	J	NNP
10_1101-2021_01_04_425177	160	2	Biol	Biol	NNP
10_1101-2021_01_04_425177	160	3	Chem	Chem	NNP
10_1101-2021_01_04_425177	160	4	292	292	CD
10_1101-2021_01_04_425177	160	5	,	,	,
10_1101-2021_01_04_425177	160	6	2046	2046	CD
10_1101-2021_01_04_425177	160	7	.	.	.
10_1101-2021_01_04_425177	161	1	Löfgren	Löfgren	NNP
10_1101-2021_01_04_425177	161	2	,	,	,
10_1101-2021_01_04_425177	161	3	K.	K.	NNP
10_1101-2021_01_04_425177	161	4	,	,	,
10_1101-2021_01_04_425177	161	5	Wahlström	Wahlström	NNP
10_1101-2021_01_04_425177	161	6	,	,	,
10_1101-2021_01_04_425177	161	7	A.	A.	NNP
10_1101-2021_01_04_425177	161	8	,	,	,
10_1101-2021_01_04_425177	161	9	Lundberg	Lundberg	NNP
10_1101-2021_01_04_425177	161	10	,	,	,
10_1101-2021_01_04_425177	161	11	P.	P.	NNP
10_1101-2021_01_04_425177	161	12	,	,	,
10_1101-2021_01_04_425177	161	13	Langel	Langel	NNP
10_1101-2021_01_04_425177	161	14	,	,	,
10_1101-2021_01_04_425177	161	15	U.	U.	NNP
10_1101-2021_01_04_425177	161	16	,	,	,
10_1101-2021_01_04_425177	161	17	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	161	18	,	,	,
10_1101-2021_01_04_425177	161	19	A.	a.	NN
10_1101-2021_01_04_425177	161	20	,	,	,
10_1101-2021_01_04_425177	161	21	Bedecs	Bedecs	NNP
10_1101-2021_01_04_425177	161	22	,	,	,
10_1101-2021_01_04_425177	161	23	K.	K.	NNP
10_1101-2021_01_04_425177	161	24	,	,	,
10_1101-2021_01_04_425177	161	25	2008	2008	CD
10_1101-2021_01_04_425177	161	26	.	.	.
10_1101-2021_01_04_425177	162	1	Antiprion	antiprion	NN
10_1101-2021_01_04_425177	162	2	properties	property	NNS
10_1101-2021_01_04_425177	162	3	of	of	IN
10_1101-2021_01_04_425177	162	4	prion	prion	NN
10_1101-2021_01_04_425177	162	5	protein	protein	NN
10_1101-2021_01_04_425177	162	6	-	-	HYPH
10_1101-2021_01_04_425177	162	7	derived	derive	VBN
10_1101-2021_01_04_425177	162	8	cell	cell	NN
10_1101-2021_01_04_425177	162	9	-	-	HYPH
10_1101-2021_01_04_425177	162	10	penetrating	penetrating	NN
10_1101-2021_01_04_425177	162	11	peptides	peptide	NNS
10_1101-2021_01_04_425177	162	12	.	.	.
10_1101-2021_01_04_425177	163	1	FASEB	FASEB	NNP
10_1101-2021_01_04_425177	163	2	J	J	NNP
10_1101-2021_01_04_425177	163	3	22	22	CD
10_1101-2021_01_04_425177	163	4	,	,	,
10_1101-2021_01_04_425177	163	5	2177	2177	CD
10_1101-2021_01_04_425177	163	6	-	-	SYM
10_1101-2021_01_04_425177	163	7	2184	2184	CD
10_1101-2021_01_04_425177	163	8	.	.	.
10_1101-2021_01_04_425177	164	1	.CC	.CC	NFP
10_1101-2021_01_04_425177	164	2	-	-	:
10_1101-2021_01_04_425177	164	3	BY	by	IN
10_1101-2021_01_04_425177	164	4	-	-	HYPH
10_1101-2021_01_04_425177	164	5	NC	NC	NNP
10_1101-2021_01_04_425177	164	6	-	-	HYPH
10_1101-2021_01_04_425177	164	7	ND	ND	NNP
10_1101-2021_01_04_425177	164	8	4.0	4.0	CD
10_1101-2021_01_04_425177	164	9	International	international	JJ
10_1101-2021_01_04_425177	164	10	licensemade	licensemade	NN
10_1101-2021_01_04_425177	164	11	available	available	JJ
10_1101-2021_01_04_425177	164	12	under	under	IN
10_1101-2021_01_04_425177	164	13	a	a	DT
10_1101-2021_01_04_425177	164	14	(	(	-LRB-
10_1101-2021_01_04_425177	164	15	which	which	WDT
10_1101-2021_01_04_425177	164	16	was	be	VBD
10_1101-2021_01_04_425177	164	17	not	not	RB
10_1101-2021_01_04_425177	164	18	certified	certify	VBN
10_1101-2021_01_04_425177	164	19	by	by	IN
10_1101-2021_01_04_425177	164	20	peer	peer	NN
10_1101-2021_01_04_425177	164	21	review	review	NN
10_1101-2021_01_04_425177	164	22	)	)	-RRB-
10_1101-2021_01_04_425177	164	23	is	be	VBZ
10_1101-2021_01_04_425177	164	24	the	the	DT
10_1101-2021_01_04_425177	164	25	author	author	NN
10_1101-2021_01_04_425177	164	26	/	/	SYM
10_1101-2021_01_04_425177	164	27	funder	funder	NN
10_1101-2021_01_04_425177	164	28	,	,	,
10_1101-2021_01_04_425177	164	29	who	who	WP
10_1101-2021_01_04_425177	164	30	has	have	VBZ
10_1101-2021_01_04_425177	164	31	granted	grant	VBN
10_1101-2021_01_04_425177	164	32	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	164	33	a	a	DT
10_1101-2021_01_04_425177	164	34	license	license	NN
10_1101-2021_01_04_425177	164	35	to	to	TO
10_1101-2021_01_04_425177	164	36	display	display	VB
10_1101-2021_01_04_425177	164	37	the	the	DT
10_1101-2021_01_04_425177	164	38	preprint	preprint	NN
10_1101-2021_01_04_425177	164	39	in	in	IN
10_1101-2021_01_04_425177	164	40	perpetuity	perpetuity	NN
10_1101-2021_01_04_425177	164	41	.	.	.
10_1101-2021_01_04_425177	165	1	It	-PRON-	PRP
10_1101-2021_01_04_425177	165	2	is	be	VBZ
10_1101-2021_01_04_425177	165	3	The	the	DT
10_1101-2021_01_04_425177	165	4	copyright	copyright	NN
10_1101-2021_01_04_425177	165	5	holder	holder	NN
10_1101-2021_01_04_425177	165	6	for	for	IN
10_1101-2021_01_04_425177	165	7	this	this	DT
10_1101-2021_01_04_425177	165	8	preprintthis	preprintthis	NN
10_1101-2021_01_04_425177	165	9	version	version	NN
10_1101-2021_01_04_425177	165	10	posted	post	VBD
10_1101-2021_01_04_425177	165	11	January	January	NNP
10_1101-2021_01_04_425177	165	12	4	4	CD
10_1101-2021_01_04_425177	165	13	,	,	,
10_1101-2021_01_04_425177	165	14	2021	2021	CD
10_1101-2021_01_04_425177	165	15	.	.	.
10_1101-2021_01_04_425177	165	16	;	;	:
10_1101-2021_01_04_425177	165	17	https://doi.org/10.1101/2021.01.04.425177doi	https://doi.org/10.1101/2021.01.04.425177doi	ADD
10_1101-2021_01_04_425177	165	18	:	:	:
10_1101-2021_01_04_425177	165	19	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	165	20	preprint	preprint	NN
10_1101-2021_01_04_425177	165	21	https://doi.org/10.1101/2021.01.04.425177	https://doi.org/10.1101/2021.01.04.425177	VBZ
10_1101-2021_01_04_425177	165	22	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2021_01_04_425177	165	23	11	11	CD
10_1101-2021_01_04_425177	165	24	Magzoub	Magzoub	NNP
10_1101-2021_01_04_425177	165	25	,	,	,
10_1101-2021_01_04_425177	165	26	M.	M.	NNP
10_1101-2021_01_04_425177	165	27	,	,	,
10_1101-2021_01_04_425177	165	28	Oglecka	Oglecka	NNP
10_1101-2021_01_04_425177	165	29	,	,	,
10_1101-2021_01_04_425177	165	30	K.	K.	NNP
10_1101-2021_01_04_425177	165	31	,	,	,
10_1101-2021_01_04_425177	165	32	Pramanik	Pramanik	NNP
10_1101-2021_01_04_425177	165	33	,	,	,
10_1101-2021_01_04_425177	165	34	A.	A.	NNP
10_1101-2021_01_04_425177	165	35	,	,	,
10_1101-2021_01_04_425177	165	36	Eriksson	Eriksson	NNP
10_1101-2021_01_04_425177	165	37	,	,	,
10_1101-2021_01_04_425177	165	38	G.L.E.	G.L.E.	NNP
10_1101-2021_01_04_425177	165	39	,	,	,
10_1101-2021_01_04_425177	165	40	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	165	41	,	,	,
10_1101-2021_01_04_425177	165	42	A.	a.	NN
10_1101-2021_01_04_425177	165	43	,	,	,
10_1101-2021_01_04_425177	165	44	2005	2005	CD
10_1101-2021_01_04_425177	165	45	.	.	.
10_1101-2021_01_04_425177	166	1	Membrane	membrane	NN
10_1101-2021_01_04_425177	166	2	perturbation	perturbation	NN
10_1101-2021_01_04_425177	166	3	effects	effect	NNS
10_1101-2021_01_04_425177	166	4	of	of	IN
10_1101-2021_01_04_425177	166	5	peptides	peptide	NNS
10_1101-2021_01_04_425177	166	6	derived	derive	VBN
10_1101-2021_01_04_425177	166	7	from	from	IN
10_1101-2021_01_04_425177	166	8	the	the	DT
10_1101-2021_01_04_425177	166	9	N	N	NNP
10_1101-2021_01_04_425177	166	10	-	-	HYPH
10_1101-2021_01_04_425177	166	11	termini	termini	NN
10_1101-2021_01_04_425177	166	12	of	of	IN
10_1101-2021_01_04_425177	166	13	unprocessed	unprocessed	JJ
10_1101-2021_01_04_425177	166	14	prion	prion	NN
10_1101-2021_01_04_425177	166	15	proteins	protein	NNS
10_1101-2021_01_04_425177	166	16	.	.	.
10_1101-2021_01_04_425177	167	1	Biochim	Biochim	NNP
10_1101-2021_01_04_425177	167	2	Biophys	Biophys	NNP
10_1101-2021_01_04_425177	167	3	Acta	Acta	NNP
10_1101-2021_01_04_425177	167	4	1716	1716	CD
10_1101-2021_01_04_425177	167	5	,	,	,
10_1101-2021_01_04_425177	167	6	126	126	CD
10_1101-2021_01_04_425177	167	7	-	-	SYM
10_1101-2021_01_04_425177	167	8	136	136	CD
10_1101-2021_01_04_425177	167	9	.	.	.
10_1101-2021_01_04_425177	168	1	Magzoub	Magzoub	NNP
10_1101-2021_01_04_425177	168	2	,	,	,
10_1101-2021_01_04_425177	168	3	M.	M.	NNP
10_1101-2021_01_04_425177	168	4	,	,	,
10_1101-2021_01_04_425177	168	5	Sandgren	Sandgren	NNP
10_1101-2021_01_04_425177	168	6	,	,	,
10_1101-2021_01_04_425177	168	7	S.	S.	NNP
10_1101-2021_01_04_425177	168	8	,	,	,
10_1101-2021_01_04_425177	168	9	Lundberg	Lundberg	NNP
10_1101-2021_01_04_425177	168	10	,	,	,
10_1101-2021_01_04_425177	168	11	P.	P.	NNP
10_1101-2021_01_04_425177	168	12	,	,	,
10_1101-2021_01_04_425177	168	13	Oglecka	Oglecka	NNP
10_1101-2021_01_04_425177	168	14	,	,	,
10_1101-2021_01_04_425177	168	15	K.	K.	NNP
10_1101-2021_01_04_425177	168	16	,	,	,
10_1101-2021_01_04_425177	168	17	Lilja	Lilja	NNP
10_1101-2021_01_04_425177	168	18	,	,	,
10_1101-2021_01_04_425177	168	19	J.	J.	NNP
10_1101-2021_01_04_425177	168	20	,	,	,
10_1101-2021_01_04_425177	168	21	Wittrup	Wittrup	NNP
10_1101-2021_01_04_425177	168	22	,	,	,
10_1101-2021_01_04_425177	168	23	A.	a.	NN
10_1101-2021_01_04_425177	168	24	,	,	,
10_1101-2021_01_04_425177	168	25	Eriksson	Eriksson	NNP
10_1101-2021_01_04_425177	168	26	,	,	,
10_1101-2021_01_04_425177	168	27	G.L.E.	G.L.E.	NNP
10_1101-2021_01_04_425177	168	28	,	,	,
10_1101-2021_01_04_425177	168	29	Langel	Langel	NNP
10_1101-2021_01_04_425177	168	30	,	,	,
10_1101-2021_01_04_425177	168	31	U.	U.	NNP
10_1101-2021_01_04_425177	168	32	,	,	,
10_1101-2021_01_04_425177	168	33	Belting	Belting	NNP
10_1101-2021_01_04_425177	168	34	,	,	,
10_1101-2021_01_04_425177	168	35	M.	M.	NNP
10_1101-2021_01_04_425177	168	36	,	,	,
10_1101-2021_01_04_425177	168	37	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	168	38	,	,	,
10_1101-2021_01_04_425177	168	39	A.	a.	NN
10_1101-2021_01_04_425177	168	40	,	,	,
10_1101-2021_01_04_425177	168	41	2006	2006	CD
10_1101-2021_01_04_425177	168	42	.	.	.
10_1101-2021_01_04_425177	169	1	N	n	CD
10_1101-2021_01_04_425177	169	2	-	-	HYPH
10_1101-2021_01_04_425177	169	3	terminal	terminal	NN
10_1101-2021_01_04_425177	169	4	peptides	peptide	NNS
10_1101-2021_01_04_425177	169	5	from	from	IN
10_1101-2021_01_04_425177	169	6	unprocessed	unprocessed	JJ
10_1101-2021_01_04_425177	169	7	prion	prion	NN
10_1101-2021_01_04_425177	169	8	proteins	protein	NNS
10_1101-2021_01_04_425177	169	9	enter	enter	VBP
10_1101-2021_01_04_425177	169	10	cells	cell	NNS
10_1101-2021_01_04_425177	169	11	by	by	IN
10_1101-2021_01_04_425177	169	12	macropinocytosis	macropinocytosis	NN
10_1101-2021_01_04_425177	169	13	.	.	.
10_1101-2021_01_04_425177	170	1	Biochem	Biochem	NNP
10_1101-2021_01_04_425177	170	2	Biophys	Biophys	NNP
10_1101-2021_01_04_425177	170	3	Res	Res	NNP
10_1101-2021_01_04_425177	170	4	Commun	Commun	NNP
10_1101-2021_01_04_425177	170	5	348	348	CD
10_1101-2021_01_04_425177	170	6	,	,	,
10_1101-2021_01_04_425177	170	7	379	379	CD
10_1101-2021_01_04_425177	170	8	-	-	SYM
10_1101-2021_01_04_425177	170	9	385	385	CD
10_1101-2021_01_04_425177	170	10	.	.	.
10_1101-2021_01_04_425177	171	1	Mashima	Mashima	NNP
10_1101-2021_01_04_425177	171	2	,	,	,
10_1101-2021_01_04_425177	171	3	T.	T.	NNP
10_1101-2021_01_04_425177	171	4	,	,	,
10_1101-2021_01_04_425177	171	5	Lee	Lee	NNP
10_1101-2021_01_04_425177	171	6	,	,	,
10_1101-2021_01_04_425177	171	7	J.H.	J.H.	NNP
10_1101-2021_01_04_425177	171	8	,	,	,
10_1101-2021_01_04_425177	171	9	Kamatari	Kamatari	NNP
10_1101-2021_01_04_425177	171	10	,	,	,
10_1101-2021_01_04_425177	171	11	Y.O.	Y.O.	NNP
10_1101-2021_01_04_425177	171	12	,	,	,
10_1101-2021_01_04_425177	171	13	Hayashi	Hayashi	NNP
10_1101-2021_01_04_425177	171	14	,	,	,
10_1101-2021_01_04_425177	171	15	T.	T.	NNP
10_1101-2021_01_04_425177	171	16	,	,	,
10_1101-2021_01_04_425177	171	17	Nagata	Nagata	NNP
10_1101-2021_01_04_425177	171	18	,	,	,
10_1101-2021_01_04_425177	171	19	T.	T.	NNP
10_1101-2021_01_04_425177	171	20	,	,	,
10_1101-2021_01_04_425177	171	21	Nishikawa	Nishikawa	NNP
10_1101-2021_01_04_425177	171	22	,	,	,
10_1101-2021_01_04_425177	171	23	F.	F.	NNP
10_1101-2021_01_04_425177	171	24	,	,	,
10_1101-2021_01_04_425177	171	25	Nishikawa	Nishikawa	NNP
10_1101-2021_01_04_425177	171	26	,	,	,
10_1101-2021_01_04_425177	171	27	S.	S.	NNP
10_1101-2021_01_04_425177	171	28	,	,	,
10_1101-2021_01_04_425177	171	29	Kinoshita	Kinoshita	NNP
10_1101-2021_01_04_425177	171	30	,	,	,
10_1101-2021_01_04_425177	171	31	M.	M.	NNP
10_1101-2021_01_04_425177	171	32	,	,	,
10_1101-2021_01_04_425177	171	33	Kuwata	Kuwata	NNP
10_1101-2021_01_04_425177	171	34	,	,	,
10_1101-2021_01_04_425177	171	35	K.	K.	NNP
10_1101-2021_01_04_425177	171	36	,	,	,
10_1101-2021_01_04_425177	171	37	Katahira	Katahira	NNP
10_1101-2021_01_04_425177	171	38	,	,	,
10_1101-2021_01_04_425177	171	39	M.	M.	NNP
10_1101-2021_01_04_425177	171	40	,	,	,
10_1101-2021_01_04_425177	171	41	2020	2020	CD
10_1101-2021_01_04_425177	171	42	.	.	.
10_1101-2021_01_04_425177	172	1	Development	development	NN
10_1101-2021_01_04_425177	172	2	and	and	CC
10_1101-2021_01_04_425177	172	3	structural	structural	JJ
10_1101-2021_01_04_425177	172	4	determination	determination	NN
10_1101-2021_01_04_425177	172	5	of	of	IN
10_1101-2021_01_04_425177	172	6	an	an	DT
10_1101-2021_01_04_425177	172	7	anti-	anti-	NN
10_1101-2021_01_04_425177	172	8	PrP(C	PrP(C	NNP
10_1101-2021_01_04_425177	172	9	)	)	-RRB-
10_1101-2021_01_04_425177	172	10	aptamer	aptamer	NN
10_1101-2021_01_04_425177	172	11	that	that	WDT
10_1101-2021_01_04_425177	172	12	blocks	block	VBZ
10_1101-2021_01_04_425177	172	13	pathological	pathological	JJ
10_1101-2021_01_04_425177	172	14	conformational	conformational	JJ
10_1101-2021_01_04_425177	172	15	conversion	conversion	NN
10_1101-2021_01_04_425177	172	16	of	of	IN
10_1101-2021_01_04_425177	172	17	prion	prion	NN
10_1101-2021_01_04_425177	172	18	protein	protein	NN
10_1101-2021_01_04_425177	172	19	.	.	.
10_1101-2021_01_04_425177	173	1	Sci	Sci	NNP
10_1101-2021_01_04_425177	173	2	Rep	Rep	NNP
10_1101-2021_01_04_425177	173	3	10	10	CD
10_1101-2021_01_04_425177	173	4	,	,	,
10_1101-2021_01_04_425177	173	5	4934	4934	CD
10_1101-2021_01_04_425177	173	6	.	.	.
10_1101-2021_01_04_425177	174	1	Miller	Miller	NNP
10_1101-2021_01_04_425177	174	2	,	,	,
10_1101-2021_01_04_425177	174	3	G.	G.	NNP
10_1101-2021_01_04_425177	174	4	,	,	,
10_1101-2021_01_04_425177	174	5	2009	2009	CD
10_1101-2021_01_04_425177	174	6	.	.	.
10_1101-2021_01_04_425177	175	1	Neurodegeneration	neurodegeneration	NN
10_1101-2021_01_04_425177	175	2	.	.	.
10_1101-2021_01_04_425177	176	1	Could	Could	MD
10_1101-2021_01_04_425177	176	2	they	-PRON-	PRP
10_1101-2021_01_04_425177	176	3	all	all	DT
10_1101-2021_01_04_425177	176	4	be	be	VB
10_1101-2021_01_04_425177	176	5	prion	prion	NN
10_1101-2021_01_04_425177	176	6	diseases	disease	NNS
10_1101-2021_01_04_425177	176	7	?	?	.
10_1101-2021_01_04_425177	177	1	Science	science	NN
10_1101-2021_01_04_425177	177	2	326	326	CD
10_1101-2021_01_04_425177	177	3	,	,	,
10_1101-2021_01_04_425177	177	4	1337	1337	CD
10_1101-2021_01_04_425177	177	5	-	-	SYM
10_1101-2021_01_04_425177	177	6	1339	1339	CD
10_1101-2021_01_04_425177	177	7	.	.	.
10_1101-2021_01_04_425177	178	1	Morillas	Morillas	NNP
10_1101-2021_01_04_425177	178	2	,	,	,
10_1101-2021_01_04_425177	178	3	M.	M.	NNP
10_1101-2021_01_04_425177	178	4	,	,	,
10_1101-2021_01_04_425177	178	5	Swietnicki	Swietnicki	NNP
10_1101-2021_01_04_425177	178	6	,	,	,
10_1101-2021_01_04_425177	178	7	W.	W.	NNP
10_1101-2021_01_04_425177	178	8	,	,	,
10_1101-2021_01_04_425177	178	9	Gambetti	Gambetti	NNP
10_1101-2021_01_04_425177	178	10	,	,	,
10_1101-2021_01_04_425177	178	11	P.	P.	NNP
10_1101-2021_01_04_425177	178	12	,	,	,
10_1101-2021_01_04_425177	178	13	Surewicz	Surewicz	NNP
10_1101-2021_01_04_425177	178	14	,	,	,
10_1101-2021_01_04_425177	178	15	W.K.	W.K.	NNP
10_1101-2021_01_04_425177	178	16	,	,	,
10_1101-2021_01_04_425177	178	17	1999	1999	CD
10_1101-2021_01_04_425177	178	18	.	.	.
10_1101-2021_01_04_425177	179	1	Membrane	membrane	NN
10_1101-2021_01_04_425177	179	2	environment	environment	NN
10_1101-2021_01_04_425177	179	3	alters	alter	VBZ
10_1101-2021_01_04_425177	179	4	the	the	DT
10_1101-2021_01_04_425177	179	5	conformational	conformational	JJ
10_1101-2021_01_04_425177	179	6	structure	structure	NN
10_1101-2021_01_04_425177	179	7	of	of	IN
10_1101-2021_01_04_425177	179	8	the	the	DT
10_1101-2021_01_04_425177	179	9	recombinant	recombinant	JJ
10_1101-2021_01_04_425177	179	10	human	human	JJ
10_1101-2021_01_04_425177	179	11	prion	prion	NN
10_1101-2021_01_04_425177	179	12	protein	protein	NN
10_1101-2021_01_04_425177	179	13	.	.	.
10_1101-2021_01_04_425177	180	1	J	J	NNP
10_1101-2021_01_04_425177	180	2	Biol	Biol	NNP
10_1101-2021_01_04_425177	180	3	Chem	Chem	NNP
10_1101-2021_01_04_425177	180	4	274	274	CD
10_1101-2021_01_04_425177	180	5	,	,	,
10_1101-2021_01_04_425177	180	6	36859-	36859-	CD
10_1101-2021_01_04_425177	180	7	36865	36865	CD
10_1101-2021_01_04_425177	180	8	.	.	.
10_1101-2021_01_04_425177	181	1	Mukundan	Mukundan	NNP
10_1101-2021_01_04_425177	181	2	,	,	,
10_1101-2021_01_04_425177	181	3	V.	V.	NNP
10_1101-2021_01_04_425177	181	4	,	,	,
10_1101-2021_01_04_425177	181	5	Maksoudian	Maksoudian	NNP
10_1101-2021_01_04_425177	181	6	,	,	,
10_1101-2021_01_04_425177	181	7	C.	C.	NNP
10_1101-2021_01_04_425177	181	8	,	,	,
10_1101-2021_01_04_425177	181	9	Vogel	Vogel	NNP
10_1101-2021_01_04_425177	181	10	,	,	,
10_1101-2021_01_04_425177	181	11	M.C.	M.C.	NNP
10_1101-2021_01_04_425177	181	12	,	,	,
10_1101-2021_01_04_425177	181	13	Chehade	Chehade	NNP
10_1101-2021_01_04_425177	181	14	,	,	,
10_1101-2021_01_04_425177	181	15	I.	I.	NNP
10_1101-2021_01_04_425177	181	16	,	,	,
10_1101-2021_01_04_425177	181	17	Katsiotis	Katsiotis	NNP
10_1101-2021_01_04_425177	181	18	,	,	,
10_1101-2021_01_04_425177	181	19	M.S.	M.S.	NNP
10_1101-2021_01_04_425177	181	20	,	,	,
10_1101-2021_01_04_425177	181	21	Alhassan	Alhassan	NNP
10_1101-2021_01_04_425177	181	22	,	,	,
10_1101-2021_01_04_425177	181	23	S.M.	S.M.	NNP
10_1101-2021_01_04_425177	181	24	,	,	,
10_1101-2021_01_04_425177	181	25	Magzoub	Magzoub	NNP
10_1101-2021_01_04_425177	181	26	,	,	,
10_1101-2021_01_04_425177	181	27	M.	M.	NNP
10_1101-2021_01_04_425177	181	28	,	,	,
10_1101-2021_01_04_425177	181	29	2017	2017	CD
10_1101-2021_01_04_425177	181	30	.	.	.
10_1101-2021_01_04_425177	182	1	Cytotoxicity	cytotoxicity	NN
10_1101-2021_01_04_425177	182	2	of	of	IN
10_1101-2021_01_04_425177	182	3	prion	prion	NN
10_1101-2021_01_04_425177	182	4	protein	protein	NN
10_1101-2021_01_04_425177	182	5	-	-	HYPH
10_1101-2021_01_04_425177	182	6	derived	derive	VBN
10_1101-2021_01_04_425177	182	7	cell	cell	NN
10_1101-2021_01_04_425177	182	8	-	-	HYPH
10_1101-2021_01_04_425177	182	9	penetrating	penetrating	NN
10_1101-2021_01_04_425177	182	10	peptides	peptide	NNS
10_1101-2021_01_04_425177	182	11	is	be	VBZ
10_1101-2021_01_04_425177	182	12	modulated	modulate	VBN
10_1101-2021_01_04_425177	182	13	by	by	IN
10_1101-2021_01_04_425177	182	14	pH	pH	NNP
10_1101-2021_01_04_425177	182	15	but	but	CC
10_1101-2021_01_04_425177	182	16	independent	independent	JJ
10_1101-2021_01_04_425177	182	17	of	of	IN
10_1101-2021_01_04_425177	182	18	amyloid	amyloid	NN
10_1101-2021_01_04_425177	182	19	formation	formation	NN
10_1101-2021_01_04_425177	182	20	.	.	.
10_1101-2021_01_04_425177	183	1	Arch	Arch	NNP
10_1101-2021_01_04_425177	183	2	Biochem	Biochem	NNP
10_1101-2021_01_04_425177	183	3	Biophys	Biophys	NNP
10_1101-2021_01_04_425177	183	4	613	613	CD
10_1101-2021_01_04_425177	183	5	,	,	,
10_1101-2021_01_04_425177	183	6	31	31	CD
10_1101-2021_01_04_425177	183	7	-	-	SYM
10_1101-2021_01_04_425177	183	8	42	42	CD
10_1101-2021_01_04_425177	183	9	.	.	.
10_1101-2021_01_04_425177	184	1	Necas	Necas	NNP
10_1101-2021_01_04_425177	184	2	,	,	,
10_1101-2021_01_04_425177	184	3	D.	D.	NNP
10_1101-2021_01_04_425177	184	4	,	,	,
10_1101-2021_01_04_425177	184	5	Klapetek	Klapetek	NNP
10_1101-2021_01_04_425177	184	6	,	,	,
10_1101-2021_01_04_425177	184	7	P.	P.	NNP
10_1101-2021_01_04_425177	184	8	,	,	,
10_1101-2021_01_04_425177	184	9	2012	2012	CD
10_1101-2021_01_04_425177	184	10	.	.	.
10_1101-2021_01_04_425177	185	1	Gwyddion	gwyddion	NN
10_1101-2021_01_04_425177	185	2	:	:	:
10_1101-2021_01_04_425177	185	3	an	an	DT
10_1101-2021_01_04_425177	185	4	open	open	JJ
10_1101-2021_01_04_425177	185	5	-	-	HYPH
10_1101-2021_01_04_425177	185	6	source	source	NN
10_1101-2021_01_04_425177	185	7	software	software	NN
10_1101-2021_01_04_425177	185	8	for	for	IN
10_1101-2021_01_04_425177	185	9	SPM	SPM	NNP
10_1101-2021_01_04_425177	185	10	data	data	NN
10_1101-2021_01_04_425177	185	11	analysis	analysis	NN
10_1101-2021_01_04_425177	185	12	.	.	.
10_1101-2021_01_04_425177	186	1	Central	central	JJ
10_1101-2021_01_04_425177	186	2	European	European	NNP
10_1101-2021_01_04_425177	186	3	Journal	Journal	NNP
10_1101-2021_01_04_425177	186	4	of	of	IN
10_1101-2021_01_04_425177	186	5	Physics	Physics	NNP
10_1101-2021_01_04_425177	186	6	10	10	CD
10_1101-2021_01_04_425177	186	7	,	,	,
10_1101-2021_01_04_425177	186	8	181	181	CD
10_1101-2021_01_04_425177	186	9	-	-	SYM
10_1101-2021_01_04_425177	186	10	188	188	CD
10_1101-2021_01_04_425177	186	11	.	.	.
10_1101-2021_01_04_425177	187	1	Oglecka	Oglecka	NNP
10_1101-2021_01_04_425177	187	2	,	,	,
10_1101-2021_01_04_425177	187	3	K.	K.	NNP
10_1101-2021_01_04_425177	187	4	,	,	,
10_1101-2021_01_04_425177	187	5	Lundberg	Lundberg	NNP
10_1101-2021_01_04_425177	187	6	,	,	,
10_1101-2021_01_04_425177	187	7	P.	P.	NNP
10_1101-2021_01_04_425177	187	8	,	,	,
10_1101-2021_01_04_425177	187	9	Magzoub	Magzoub	NNP
10_1101-2021_01_04_425177	187	10	,	,	,
10_1101-2021_01_04_425177	187	11	M.	M.	NNP
10_1101-2021_01_04_425177	187	12	,	,	,
10_1101-2021_01_04_425177	187	13	Eriksson	Eriksson	NNP
10_1101-2021_01_04_425177	187	14	,	,	,
10_1101-2021_01_04_425177	187	15	G.L.E.	G.L.E.	NNP
10_1101-2021_01_04_425177	187	16	,	,	,
10_1101-2021_01_04_425177	187	17	Langel	Langel	NNP
10_1101-2021_01_04_425177	187	18	,	,	,
10_1101-2021_01_04_425177	187	19	U.	U.	NNP
10_1101-2021_01_04_425177	187	20	,	,	,
10_1101-2021_01_04_425177	187	21	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	187	22	,	,	,
10_1101-2021_01_04_425177	187	23	A.	a.	NN
10_1101-2021_01_04_425177	187	24	,	,	,
10_1101-2021_01_04_425177	187	25	2008	2008	CD
10_1101-2021_01_04_425177	187	26	.	.	.
10_1101-2021_01_04_425177	188	1	Relevance	relevance	NN
10_1101-2021_01_04_425177	188	2	of	of	IN
10_1101-2021_01_04_425177	188	3	the	the	DT
10_1101-2021_01_04_425177	188	4	N	n	NN
10_1101-2021_01_04_425177	188	5	-	-	HYPH
10_1101-2021_01_04_425177	188	6	terminal	terminal	JJ
10_1101-2021_01_04_425177	188	7	NLS	NLS	NNP
10_1101-2021_01_04_425177	188	8	-	-	HYPH
10_1101-2021_01_04_425177	188	9	like	like	JJ
10_1101-2021_01_04_425177	188	10	sequence	sequence	NN
10_1101-2021_01_04_425177	188	11	of	of	IN
10_1101-2021_01_04_425177	188	12	the	the	DT
10_1101-2021_01_04_425177	188	13	prion	prion	NN
10_1101-2021_01_04_425177	188	14	protein	protein	NN
10_1101-2021_01_04_425177	188	15	for	for	IN
10_1101-2021_01_04_425177	188	16	membrane	membrane	NN
10_1101-2021_01_04_425177	188	17	perturbation	perturbation	NN
10_1101-2021_01_04_425177	188	18	effects	effect	NNS
10_1101-2021_01_04_425177	188	19	.	.	.
10_1101-2021_01_04_425177	189	1	Biochim	Biochim	NNP
10_1101-2021_01_04_425177	189	2	Biophys	Biophys	NNP
10_1101-2021_01_04_425177	189	3	Acta	Acta	NNP
10_1101-2021_01_04_425177	189	4	1778	1778	CD
10_1101-2021_01_04_425177	189	5	,	,	,
10_1101-2021_01_04_425177	189	6	206	206	CD
10_1101-2021_01_04_425177	189	7	-	-	SYM
10_1101-2021_01_04_425177	189	8	213	213	CD
10_1101-2021_01_04_425177	189	9	.	.	.
10_1101-2021_01_04_425177	190	1	Owen	Owen	NNP
10_1101-2021_01_04_425177	190	2	,	,	,
10_1101-2021_01_04_425177	190	3	M.C.	M.C.	NNP
10_1101-2021_01_04_425177	190	4	,	,	,
10_1101-2021_01_04_425177	190	5	Gnutt	Gnutt	NNP
10_1101-2021_01_04_425177	190	6	,	,	,
10_1101-2021_01_04_425177	190	7	D.	D.	NNP
10_1101-2021_01_04_425177	190	8	,	,	,
10_1101-2021_01_04_425177	190	9	Gao	Gao	NNP
10_1101-2021_01_04_425177	190	10	,	,	,
10_1101-2021_01_04_425177	190	11	M.	M.	NNP
10_1101-2021_01_04_425177	190	12	,	,	,
10_1101-2021_01_04_425177	190	13	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	190	14	,	,	,
10_1101-2021_01_04_425177	190	15	S.K.T.S.	S.K.T.S.	NNP
10_1101-2021_01_04_425177	190	16	,	,	,
10_1101-2021_01_04_425177	190	17	Jarvet	Jarvet	NNP
10_1101-2021_01_04_425177	190	18	,	,	,
10_1101-2021_01_04_425177	190	19	J.	J.	NNP
10_1101-2021_01_04_425177	190	20	,	,	,
10_1101-2021_01_04_425177	190	21	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	190	22	,	,	,
10_1101-2021_01_04_425177	190	23	A.	A.	NNP
10_1101-2021_01_04_425177	190	24	,	,	,
10_1101-2021_01_04_425177	190	25	Winter	Winter	NNP
10_1101-2021_01_04_425177	190	26	,	,	,
10_1101-2021_01_04_425177	190	27	R.	R.	NNP
10_1101-2021_01_04_425177	190	28	,	,	,
10_1101-2021_01_04_425177	190	29	Ebbinghaus	Ebbinghaus	NNP
10_1101-2021_01_04_425177	190	30	,	,	,
10_1101-2021_01_04_425177	190	31	S.	S.	NNP
10_1101-2021_01_04_425177	190	32	,	,	,
10_1101-2021_01_04_425177	190	33	Strodel	Strodel	NNP
10_1101-2021_01_04_425177	190	34	,	,	,
10_1101-2021_01_04_425177	190	35	B.	B.	NNP
10_1101-2021_01_04_425177	190	36	,	,	,
10_1101-2021_01_04_425177	190	37	2019	2019	CD
10_1101-2021_01_04_425177	190	38	.	.	.
10_1101-2021_01_04_425177	191	1	Effects	effect	NNS
10_1101-2021_01_04_425177	191	2	of	of	IN
10_1101-2021_01_04_425177	191	3	in	in	IN
10_1101-2021_01_04_425177	191	4	vivo	vivo	NNP
10_1101-2021_01_04_425177	191	5	conditions	condition	NNS
10_1101-2021_01_04_425177	191	6	on	on	IN
10_1101-2021_01_04_425177	191	7	amyloid	amyloid	NN
10_1101-2021_01_04_425177	191	8	aggregation	aggregation	NN
10_1101-2021_01_04_425177	191	9	.	.	.
10_1101-2021_01_04_425177	192	1	Chem	Chem	NNP
10_1101-2021_01_04_425177	192	2	Soc	Soc	NNP
10_1101-2021_01_04_425177	192	3	Rev	Rev	NNP
10_1101-2021_01_04_425177	192	4	48	48	CD
10_1101-2021_01_04_425177	192	5	,	,	,
10_1101-2021_01_04_425177	192	6	3946	3946	CD
10_1101-2021_01_04_425177	192	7	-	-	SYM
10_1101-2021_01_04_425177	192	8	3996	3996	CD
10_1101-2021_01_04_425177	192	9	.	.	.
10_1101-2021_01_04_425177	193	1	Pansieri	Pansieri	NNP
10_1101-2021_01_04_425177	193	2	,	,	,
10_1101-2021_01_04_425177	193	3	J.	J.	NNP
10_1101-2021_01_04_425177	193	4	,	,	,
10_1101-2021_01_04_425177	193	5	Ostojic	Ostojic	NNP
10_1101-2021_01_04_425177	193	6	,	,	,
10_1101-2021_01_04_425177	193	7	L.	L.	NNP
10_1101-2021_01_04_425177	193	8	,	,	,
10_1101-2021_01_04_425177	193	9	Iashchishyn	Iashchishyn	NNP
10_1101-2021_01_04_425177	193	10	,	,	,
10_1101-2021_01_04_425177	193	11	I.A.	I.A.	NNP
10_1101-2021_01_04_425177	193	12	,	,	,
10_1101-2021_01_04_425177	193	13	Magzoub	Magzoub	NNP
10_1101-2021_01_04_425177	193	14	,	,	,
10_1101-2021_01_04_425177	193	15	M.	M.	NNP
10_1101-2021_01_04_425177	193	16	,	,	,
10_1101-2021_01_04_425177	193	17	Wallin	Wallin	NNP
10_1101-2021_01_04_425177	193	18	,	,	,
10_1101-2021_01_04_425177	193	19	C.	C.	NNP
10_1101-2021_01_04_425177	193	20	,	,	,
10_1101-2021_01_04_425177	193	21	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	193	22	,	,	,
10_1101-2021_01_04_425177	193	23	S.	S.	NNP
10_1101-2021_01_04_425177	193	24	,	,	,
10_1101-2021_01_04_425177	193	25	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	193	26	,	,	,
10_1101-2021_01_04_425177	193	27	A.	A.	NNP
10_1101-2021_01_04_425177	193	28	,	,	,
10_1101-2021_01_04_425177	193	29	Nguyen	Nguyen	NNP
10_1101-2021_01_04_425177	193	30	Ngoc	Ngoc	NNP
10_1101-2021_01_04_425177	193	31	,	,	,
10_1101-2021_01_04_425177	193	32	M.	M.	NNP
10_1101-2021_01_04_425177	193	33	,	,	,
10_1101-2021_01_04_425177	193	34	Smirnovas	Smirnovas	NNP
10_1101-2021_01_04_425177	193	35	,	,	,
10_1101-2021_01_04_425177	193	36	V.	V.	NNP
10_1101-2021_01_04_425177	193	37	,	,	,
10_1101-2021_01_04_425177	193	38	Svedruzic	Svedruzic	NNP
10_1101-2021_01_04_425177	193	39	,	,	,
10_1101-2021_01_04_425177	193	40	Z.	Z.	NNP
10_1101-2021_01_04_425177	193	41	,	,	,
10_1101-2021_01_04_425177	193	42	Morozova	Morozova	NNP
10_1101-2021_01_04_425177	193	43	-	-	HYPH
10_1101-2021_01_04_425177	193	44	Roche	Roche	NNP
10_1101-2021_01_04_425177	193	45	,	,	,
10_1101-2021_01_04_425177	193	46	L.A.	L.A.	NNP
10_1101-2021_01_04_425177	193	47	,	,	,
10_1101-2021_01_04_425177	193	48	2019	2019	CD
10_1101-2021_01_04_425177	193	49	.	.	.
10_1101-2021_01_04_425177	194	1	Pro-	pro-	LS
10_1101-2021_01_04_425177	194	2	Inflammatory	inflammatory	NN
10_1101-2021_01_04_425177	194	3	S100A9	s100a9	VBP
10_1101-2021_01_04_425177	194	4	Protein	Protein	NNP
10_1101-2021_01_04_425177	194	5	Aggregation	Aggregation	NNP
10_1101-2021_01_04_425177	194	6	Promoted	promote	VBN
10_1101-2021_01_04_425177	194	7	by	by	IN
10_1101-2021_01_04_425177	194	8	NCAM1	ncam1	CD
10_1101-2021_01_04_425177	194	9	Peptide	Peptide	NNP
10_1101-2021_01_04_425177	194	10	Constructs	Constructs	NNPS
10_1101-2021_01_04_425177	194	11	.	.	.
10_1101-2021_01_04_425177	195	1	ACS	ACS	NNP
10_1101-2021_01_04_425177	195	2	Chem	Chem	NNP
10_1101-2021_01_04_425177	195	3	Biol	Biol	NNP
10_1101-2021_01_04_425177	195	4	14	14	CD
10_1101-2021_01_04_425177	195	5	,	,	,
10_1101-2021_01_04_425177	195	6	1410	1410	CD
10_1101-2021_01_04_425177	195	7	-	-	SYM
10_1101-2021_01_04_425177	195	8	1417	1417	CD
10_1101-2021_01_04_425177	195	9	.	.	.
10_1101-2021_01_04_425177	196	1	Ren	Ren	NNP
10_1101-2021_01_04_425177	196	2	,	,	,
10_1101-2021_01_04_425177	196	3	B.	B.	NNP
10_1101-2021_01_04_425177	196	4	,	,	,
10_1101-2021_01_04_425177	196	5	Zhang	Zhang	NNP
10_1101-2021_01_04_425177	196	6	,	,	,
10_1101-2021_01_04_425177	196	7	Y.	Y.	NNP
10_1101-2021_01_04_425177	196	8	,	,	,
10_1101-2021_01_04_425177	196	9	Zhang	Zhang	NNP
10_1101-2021_01_04_425177	196	10	,	,	,
10_1101-2021_01_04_425177	196	11	M.	M.	NNP
10_1101-2021_01_04_425177	196	12	,	,	,
10_1101-2021_01_04_425177	196	13	Liu	Liu	NNP
10_1101-2021_01_04_425177	196	14	,	,	,
10_1101-2021_01_04_425177	196	15	Y.	Y.	NNP
10_1101-2021_01_04_425177	196	16	,	,	,
10_1101-2021_01_04_425177	196	17	Zhang	Zhang	NNP
10_1101-2021_01_04_425177	196	18	,	,	,
10_1101-2021_01_04_425177	196	19	D.	D.	NNP
10_1101-2021_01_04_425177	196	20	,	,	,
10_1101-2021_01_04_425177	196	21	Gong	Gong	NNP
10_1101-2021_01_04_425177	196	22	,	,	,
10_1101-2021_01_04_425177	196	23	X.	X.	NNP
10_1101-2021_01_04_425177	196	24	,	,	,
10_1101-2021_01_04_425177	196	25	Feng	Feng	NNP
10_1101-2021_01_04_425177	196	26	,	,	,
10_1101-2021_01_04_425177	196	27	Z.	Z.	NNP
10_1101-2021_01_04_425177	196	28	,	,	,
10_1101-2021_01_04_425177	196	29	Tang	Tang	NNP
10_1101-2021_01_04_425177	196	30	,	,	,
10_1101-2021_01_04_425177	196	31	J.	J.	NNP
10_1101-2021_01_04_425177	196	32	,	,	,
10_1101-2021_01_04_425177	196	33	Chang	Chang	NNP
10_1101-2021_01_04_425177	196	34	,	,	,
10_1101-2021_01_04_425177	196	35	Y.	Y.	NNP
10_1101-2021_01_04_425177	196	36	,	,	,
10_1101-2021_01_04_425177	196	37	Zheng	Zheng	NNP
10_1101-2021_01_04_425177	196	38	,	,	,
10_1101-2021_01_04_425177	196	39	J.	J.	NNP
10_1101-2021_01_04_425177	196	40	,	,	,
10_1101-2021_01_04_425177	196	41	2019	2019	CD
10_1101-2021_01_04_425177	196	42	.	.	.
10_1101-2021_01_04_425177	197	1	Fundamentals	fundamental	NNS
10_1101-2021_01_04_425177	197	2	of	of	IN
10_1101-2021_01_04_425177	197	3	cross	cross	NN
10_1101-2021_01_04_425177	197	4	-	-	JJ
10_1101-2021_01_04_425177	197	5	seeding	seeding	JJ
10_1101-2021_01_04_425177	197	6	of	of	IN
10_1101-2021_01_04_425177	197	7	amyloid	amyloid	NN
10_1101-2021_01_04_425177	197	8	proteins	protein	NNS
10_1101-2021_01_04_425177	197	9	:	:	:
10_1101-2021_01_04_425177	197	10	an	an	DT
10_1101-2021_01_04_425177	197	11	introduction	introduction	NN
10_1101-2021_01_04_425177	197	12	.	.	.
10_1101-2021_01_04_425177	198	1	J	J	NNP
10_1101-2021_01_04_425177	198	2	Mater	Mater	NNP
10_1101-2021_01_04_425177	198	3	Chem	Chem	NNP
10_1101-2021_01_04_425177	198	4	B	B	NNP
10_1101-2021_01_04_425177	198	5	7	7	CD
10_1101-2021_01_04_425177	198	6	,	,	,
10_1101-2021_01_04_425177	198	7	7267	7267	CD
10_1101-2021_01_04_425177	198	8	-	-	SYM
10_1101-2021_01_04_425177	198	9	7282	7282	CD
10_1101-2021_01_04_425177	198	10	.	.	.
10_1101-2021_01_04_425177	199	1	Richman	Richman	NNP
10_1101-2021_01_04_425177	199	2	,	,	,
10_1101-2021_01_04_425177	199	3	M.	M.	NNP
10_1101-2021_01_04_425177	199	4	,	,	,
10_1101-2021_01_04_425177	199	5	Wilk	Wilk	NNP
10_1101-2021_01_04_425177	199	6	,	,	,
10_1101-2021_01_04_425177	199	7	S.	S.	NNP
10_1101-2021_01_04_425177	199	8	,	,	,
10_1101-2021_01_04_425177	199	9	Chemerovski	Chemerovski	NNP
10_1101-2021_01_04_425177	199	10	,	,	,
10_1101-2021_01_04_425177	199	11	M.	M.	NNP
10_1101-2021_01_04_425177	199	12	,	,	,
10_1101-2021_01_04_425177	199	13	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	199	14	,	,	,
10_1101-2021_01_04_425177	199	15	S.K.	S.K.	NNP
10_1101-2021_01_04_425177	199	16	,	,	,
10_1101-2021_01_04_425177	199	17	Wahlström	Wahlström	NNP
10_1101-2021_01_04_425177	199	18	,	,	,
10_1101-2021_01_04_425177	199	19	A.	A.	NNP
10_1101-2021_01_04_425177	199	20	,	,	,
10_1101-2021_01_04_425177	199	21	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	199	22	,	,	,
10_1101-2021_01_04_425177	199	23	A.	a.	NN
10_1101-2021_01_04_425177	199	24	,	,	,
10_1101-2021_01_04_425177	199	25	Rahimipour	Rahimipour	NNP
10_1101-2021_01_04_425177	199	26	,	,	,
10_1101-2021_01_04_425177	199	27	S.	S.	NNP
10_1101-2021_01_04_425177	199	28	,	,	,
10_1101-2021_01_04_425177	199	29	2013	2013	CD
10_1101-2021_01_04_425177	199	30	.	.	.
10_1101-2021_01_04_425177	200	1	In	in	IN
10_1101-2021_01_04_425177	200	2	vitro	vitro	FW
10_1101-2021_01_04_425177	200	3	and	and	CC
10_1101-2021_01_04_425177	200	4	mechanistic	mechanistic	JJ
10_1101-2021_01_04_425177	200	5	studies	study	NNS
10_1101-2021_01_04_425177	200	6	of	of	IN
10_1101-2021_01_04_425177	200	7	an	an	DT
10_1101-2021_01_04_425177	200	8	antiamyloidogenic	antiamyloidogenic	JJ
10_1101-2021_01_04_425177	200	9	self	self	NN
10_1101-2021_01_04_425177	200	10	-	-	HYPH
10_1101-2021_01_04_425177	200	11	assembled	assemble	VBN
10_1101-2021_01_04_425177	200	12	cyclic	cyclic	JJ
10_1101-2021_01_04_425177	200	13	D	d	NN
10_1101-2021_01_04_425177	200	14	,	,	,
10_1101-2021_01_04_425177	200	15	L-	L-	NNP
10_1101-2021_01_04_425177	200	16	alpha	alpha	NN
10_1101-2021_01_04_425177	200	17	-	-	HYPH
10_1101-2021_01_04_425177	200	18	peptide	peptide	NN
10_1101-2021_01_04_425177	200	19	architecture	architecture	NN
10_1101-2021_01_04_425177	200	20	.	.	.
10_1101-2021_01_04_425177	201	1	J	J	NNP
10_1101-2021_01_04_425177	201	2	Am	Am	NNP
10_1101-2021_01_04_425177	201	3	Chem	Chem	NNP
10_1101-2021_01_04_425177	201	4	Soc	Soc	NNP
10_1101-2021_01_04_425177	201	5	135	135	CD
10_1101-2021_01_04_425177	201	6	,	,	,
10_1101-2021_01_04_425177	201	7	3474	3474	CD
10_1101-2021_01_04_425177	201	8	-	-	SYM
10_1101-2021_01_04_425177	201	9	3484	3484	CD
10_1101-2021_01_04_425177	201	10	.	.	.
10_1101-2021_01_04_425177	202	1	Robinson	Robinson	NNP
10_1101-2021_01_04_425177	202	2	,	,	,
10_1101-2021_01_04_425177	202	3	P.J.	P.J.	NNP
10_1101-2021_01_04_425177	202	4	,	,	,
10_1101-2021_01_04_425177	202	5	Pinheiro	Pinheiro	NNP
10_1101-2021_01_04_425177	202	6	,	,	,
10_1101-2021_01_04_425177	202	7	T.J.	T.J.	NNP
10_1101-2021_01_04_425177	202	8	,	,	,
10_1101-2021_01_04_425177	202	9	2010	2010	CD
10_1101-2021_01_04_425177	202	10	.	.	.
10_1101-2021_01_04_425177	203	1	Phospholipid	phospholipid	JJ
10_1101-2021_01_04_425177	203	2	composition	composition	NN
10_1101-2021_01_04_425177	203	3	of	of	IN
10_1101-2021_01_04_425177	203	4	membranes	membrane	NNS
10_1101-2021_01_04_425177	203	5	directs	direct	VBZ
10_1101-2021_01_04_425177	203	6	prions	prion	NNS
10_1101-2021_01_04_425177	203	7	down	down	IN
10_1101-2021_01_04_425177	203	8	alternative	alternative	JJ
10_1101-2021_01_04_425177	203	9	aggregation	aggregation	NN
10_1101-2021_01_04_425177	203	10	pathways	pathway	NNS
10_1101-2021_01_04_425177	203	11	.	.	.
10_1101-2021_01_04_425177	204	1	Biophys	Biophys	NNP
10_1101-2021_01_04_425177	204	2	J	J	NNP
10_1101-2021_01_04_425177	204	3	98	98	CD
10_1101-2021_01_04_425177	204	4	,	,	,
10_1101-2021_01_04_425177	204	5	1520	1520	CD
10_1101-2021_01_04_425177	204	6	-	-	SYM
10_1101-2021_01_04_425177	204	7	1528	1528	CD
10_1101-2021_01_04_425177	204	8	.	.	.
10_1101-2021_01_04_425177	205	1	Santuccione	Santuccione	NNP
10_1101-2021_01_04_425177	205	2	,	,	,
10_1101-2021_01_04_425177	205	3	A.	a.	NN
10_1101-2021_01_04_425177	205	4	,	,	,
10_1101-2021_01_04_425177	205	5	Sytnyk	Sytnyk	NNP
10_1101-2021_01_04_425177	205	6	,	,	,
10_1101-2021_01_04_425177	205	7	V.	V.	NNP
10_1101-2021_01_04_425177	205	8	,	,	,
10_1101-2021_01_04_425177	205	9	Leshchyns'ka	Leshchyns'ka	NNP
10_1101-2021_01_04_425177	205	10	,	,	,
10_1101-2021_01_04_425177	205	11	I.	I.	NNP
10_1101-2021_01_04_425177	205	12	,	,	,
10_1101-2021_01_04_425177	205	13	Schachner	Schachner	NNP
10_1101-2021_01_04_425177	205	14	,	,	,
10_1101-2021_01_04_425177	205	15	M.	M.	NNP
10_1101-2021_01_04_425177	205	16	,	,	,
10_1101-2021_01_04_425177	205	17	2005	2005	CD
10_1101-2021_01_04_425177	205	18	.	.	.
10_1101-2021_01_04_425177	206	1	Prion	prion	NN
10_1101-2021_01_04_425177	206	2	protein	protein	NN
10_1101-2021_01_04_425177	206	3	recruits	recruit	VBZ
10_1101-2021_01_04_425177	206	4	its	-PRON-	PRP$
10_1101-2021_01_04_425177	206	5	neuronal	neuronal	JJ
10_1101-2021_01_04_425177	206	6	receptor	receptor	NN
10_1101-2021_01_04_425177	206	7	NCAM	NCAM	NNP
10_1101-2021_01_04_425177	206	8	to	to	IN
10_1101-2021_01_04_425177	206	9	lipid	lipid	NN
10_1101-2021_01_04_425177	206	10	rafts	raft	NNS
10_1101-2021_01_04_425177	206	11	to	to	TO
10_1101-2021_01_04_425177	206	12	activate	activate	VB
10_1101-2021_01_04_425177	206	13	p59fyn	p59fyn	NN
10_1101-2021_01_04_425177	206	14	and	and	CC
10_1101-2021_01_04_425177	206	15	to	to	TO
10_1101-2021_01_04_425177	206	16	enhance	enhance	VB
10_1101-2021_01_04_425177	206	17	neurite	neurite	NN
10_1101-2021_01_04_425177	206	18	outgrowth	outgrowth	NN
10_1101-2021_01_04_425177	206	19	.	.	.
10_1101-2021_01_04_425177	207	1	J	J	NNP
10_1101-2021_01_04_425177	207	2	Cell	Cell	NNP
10_1101-2021_01_04_425177	207	3	Biol	Biol	NNP
10_1101-2021_01_04_425177	207	4	169	169	CD
10_1101-2021_01_04_425177	207	5	,	,	,
10_1101-2021_01_04_425177	207	6	341	341	CD
10_1101-2021_01_04_425177	207	7	-	-	SYM
10_1101-2021_01_04_425177	207	8	354	354	CD
10_1101-2021_01_04_425177	207	9	.	.	.
10_1101-2021_01_04_425177	208	1	Schmitt	Schmitt	NNP
10_1101-2021_01_04_425177	208	2	-	-	HYPH
10_1101-2021_01_04_425177	208	3	Ulms	Ulms	NNP
10_1101-2021_01_04_425177	208	4	,	,	,
10_1101-2021_01_04_425177	208	5	G.	G.	NNP
10_1101-2021_01_04_425177	208	6	,	,	,
10_1101-2021_01_04_425177	208	7	Legname	Legname	NNP
10_1101-2021_01_04_425177	208	8	,	,	,
10_1101-2021_01_04_425177	208	9	G.	G.	NNP
10_1101-2021_01_04_425177	208	10	,	,	,
10_1101-2021_01_04_425177	208	11	Baldwin	Baldwin	NNP
10_1101-2021_01_04_425177	208	12	,	,	,
10_1101-2021_01_04_425177	208	13	M.A.	M.A.	NNP
10_1101-2021_01_04_425177	208	14	,	,	,
10_1101-2021_01_04_425177	208	15	Ball	Ball	NNP
10_1101-2021_01_04_425177	208	16	,	,	,
10_1101-2021_01_04_425177	208	17	H.L.	H.L.	NNP
10_1101-2021_01_04_425177	208	18	,	,	,
10_1101-2021_01_04_425177	208	19	Bradon	Bradon	NNP
10_1101-2021_01_04_425177	208	20	,	,	,
10_1101-2021_01_04_425177	208	21	N.	N.	NNP
10_1101-2021_01_04_425177	208	22	,	,	,
10_1101-2021_01_04_425177	208	23	Bosque	Bosque	NNP
10_1101-2021_01_04_425177	208	24	,	,	,
10_1101-2021_01_04_425177	208	25	P.J.	P.J.	NNP
10_1101-2021_01_04_425177	208	26	,	,	,
10_1101-2021_01_04_425177	208	27	Crossin	Crossin	NNP
10_1101-2021_01_04_425177	208	28	,	,	,
10_1101-2021_01_04_425177	208	29	K.L.	K.L.	NNP
10_1101-2021_01_04_425177	208	30	,	,	,
10_1101-2021_01_04_425177	208	31	Edelman	Edelman	NNP
10_1101-2021_01_04_425177	208	32	,	,	,
10_1101-2021_01_04_425177	208	33	G.M.	G.M.	NNP
10_1101-2021_01_04_425177	208	34	,	,	,
10_1101-2021_01_04_425177	208	35	DeArmond	DeArmond	NNP
10_1101-2021_01_04_425177	208	36	,	,	,
10_1101-2021_01_04_425177	208	37	S.J.	S.J.	NNP
10_1101-2021_01_04_425177	208	38	,	,	,
10_1101-2021_01_04_425177	208	39	Cohen	Cohen	NNP
10_1101-2021_01_04_425177	208	40	,	,	,
10_1101-2021_01_04_425177	208	41	F.E.	F.E.	NNP
10_1101-2021_01_04_425177	208	42	,	,	,
10_1101-2021_01_04_425177	208	43	Prusiner	Prusiner	NNP
10_1101-2021_01_04_425177	208	44	,	,	,
10_1101-2021_01_04_425177	208	45	S.B.	S.B.	NNP
10_1101-2021_01_04_425177	208	46	,	,	,
10_1101-2021_01_04_425177	208	47	2001	2001	CD
10_1101-2021_01_04_425177	208	48	.	.	.
10_1101-2021_01_04_425177	209	1	Binding	bind	VBG
10_1101-2021_01_04_425177	209	2	of	of	IN
10_1101-2021_01_04_425177	209	3	neural	neural	JJ
10_1101-2021_01_04_425177	209	4	cell	cell	NN
10_1101-2021_01_04_425177	209	5	adhesion	adhesion	NN
10_1101-2021_01_04_425177	209	6	molecules	molecule	NNS
10_1101-2021_01_04_425177	209	7	(	(	-LRB-
10_1101-2021_01_04_425177	209	8	N	n	NN
10_1101-2021_01_04_425177	209	9	-	-	HYPH
10_1101-2021_01_04_425177	209	10	CAMs	CAMs	NNP
10_1101-2021_01_04_425177	209	11	)	)	-RRB-
10_1101-2021_01_04_425177	209	12	to	to	IN
10_1101-2021_01_04_425177	209	13	the	the	DT
10_1101-2021_01_04_425177	209	14	cellular	cellular	JJ
10_1101-2021_01_04_425177	209	15	prion	prion	NN
10_1101-2021_01_04_425177	209	16	protein	protein	NN
10_1101-2021_01_04_425177	209	17	.	.	.
10_1101-2021_01_04_425177	210	1	J	J	NNP
10_1101-2021_01_04_425177	210	2	Mol	Mol	NNP
10_1101-2021_01_04_425177	210	3	Biol	Biol	NNP
10_1101-2021_01_04_425177	210	4	314	314	CD
10_1101-2021_01_04_425177	210	5	,	,	,
10_1101-2021_01_04_425177	210	6	1209	1209	CD
10_1101-2021_01_04_425177	210	7	-	-	SYM
10_1101-2021_01_04_425177	210	8	1225	1225	CD
10_1101-2021_01_04_425177	210	9	.	.	.
10_1101-2021_01_04_425177	211	1	Sengupta	Sengupta	NNP
10_1101-2021_01_04_425177	211	2	,	,	,
10_1101-2021_01_04_425177	211	3	I.	I.	NNP
10_1101-2021_01_04_425177	211	4	,	,	,
10_1101-2021_01_04_425177	211	5	Udgaonkar	Udgaonkar	NNP
10_1101-2021_01_04_425177	211	6	,	,	,
10_1101-2021_01_04_425177	211	7	J.B.	J.B.	NNP
10_1101-2021_01_04_425177	211	8	,	,	,
10_1101-2021_01_04_425177	211	9	2018	2018	CD
10_1101-2021_01_04_425177	211	10	.	.	.
10_1101-2021_01_04_425177	212	1	Structural	structural	JJ
10_1101-2021_01_04_425177	212	2	mechanisms	mechanism	NNS
10_1101-2021_01_04_425177	212	3	of	of	IN
10_1101-2021_01_04_425177	212	4	oligomer	oligomer	NNP
10_1101-2021_01_04_425177	212	5	and	and	CC
10_1101-2021_01_04_425177	212	6	amyloid	amyloid	NNP
10_1101-2021_01_04_425177	212	7	fibril	fibril	NNP
10_1101-2021_01_04_425177	212	8	formation	formation	NN
10_1101-2021_01_04_425177	212	9	by	by	IN
10_1101-2021_01_04_425177	212	10	the	the	DT
10_1101-2021_01_04_425177	212	11	prion	prion	NN
10_1101-2021_01_04_425177	212	12	protein	protein	NN
10_1101-2021_01_04_425177	212	13	.	.	.
10_1101-2021_01_04_425177	213	1	Chem	Chem	NNP
10_1101-2021_01_04_425177	213	2	Commun	Commun	NNP
10_1101-2021_01_04_425177	213	3	(	(	-LRB-
10_1101-2021_01_04_425177	213	4	Camb	camb	NN
10_1101-2021_01_04_425177	213	5	)	)	-RRB-
10_1101-2021_01_04_425177	213	6	54	54	CD
10_1101-2021_01_04_425177	213	7	,	,	,
10_1101-2021_01_04_425177	213	8	6230	6230	CD
10_1101-2021_01_04_425177	213	9	-	-	SYM
10_1101-2021_01_04_425177	213	10	6242	6242	CD
10_1101-2021_01_04_425177	213	11	.	.	.
10_1101-2021_01_04_425177	214	1	Swietnicki	Swietnicki	NNP
10_1101-2021_01_04_425177	214	2	,	,	,
10_1101-2021_01_04_425177	214	3	W.	W.	NNP
10_1101-2021_01_04_425177	214	4	,	,	,
10_1101-2021_01_04_425177	214	5	Morillas	Morillas	NNP
10_1101-2021_01_04_425177	214	6	,	,	,
10_1101-2021_01_04_425177	214	7	M.	M.	NNP
10_1101-2021_01_04_425177	214	8	,	,	,
10_1101-2021_01_04_425177	214	9	Chen	Chen	NNP
10_1101-2021_01_04_425177	214	10	,	,	,
10_1101-2021_01_04_425177	214	11	S.G.	S.G.	NNP
10_1101-2021_01_04_425177	214	12	,	,	,
10_1101-2021_01_04_425177	214	13	Gambetti	Gambetti	NNP
10_1101-2021_01_04_425177	214	14	,	,	,
10_1101-2021_01_04_425177	214	15	P.	P.	NNP
10_1101-2021_01_04_425177	214	16	,	,	,
10_1101-2021_01_04_425177	214	17	Surewicz	Surewicz	NNP
10_1101-2021_01_04_425177	214	18	,	,	,
10_1101-2021_01_04_425177	214	19	W.K.	W.K.	NNP
10_1101-2021_01_04_425177	214	20	,	,	,
10_1101-2021_01_04_425177	214	21	2000	2000	CD
10_1101-2021_01_04_425177	214	22	.	.	.
10_1101-2021_01_04_425177	215	1	Aggregation	aggregation	NN
10_1101-2021_01_04_425177	215	2	and	and	CC
10_1101-2021_01_04_425177	215	3	fibrillization	fibrillization	NN
10_1101-2021_01_04_425177	215	4	of	of	IN
10_1101-2021_01_04_425177	215	5	the	the	DT
10_1101-2021_01_04_425177	215	6	recombinant	recombinant	JJ
10_1101-2021_01_04_425177	215	7	human	human	JJ
10_1101-2021_01_04_425177	215	8	prion	prion	NN
10_1101-2021_01_04_425177	215	9	protein	protein	NN
10_1101-2021_01_04_425177	215	10	huPrP90	huPrP90	NNP
10_1101-2021_01_04_425177	215	11	-	-	HYPH
10_1101-2021_01_04_425177	215	12	231	231	CD
10_1101-2021_01_04_425177	215	13	.	.	.
10_1101-2021_01_04_425177	216	1	Biochemistry	Biochemistry	NNP
10_1101-2021_01_04_425177	216	2	39	39	CD
10_1101-2021_01_04_425177	216	3	,	,	,
10_1101-2021_01_04_425177	216	4	424-	424-	CD
10_1101-2021_01_04_425177	216	5	431	431	CD
10_1101-2021_01_04_425177	216	6	.	.	.
10_1101-2021_01_04_425177	217	1	Söderberg	Söderberg	NNP
10_1101-2021_01_04_425177	217	2	,	,	,
10_1101-2021_01_04_425177	217	3	K.L.	K.L.	NNP
10_1101-2021_01_04_425177	217	4	,	,	,
10_1101-2021_01_04_425177	217	5	Guterstam	Guterstam	NNP
10_1101-2021_01_04_425177	217	6	,	,	,
10_1101-2021_01_04_425177	217	7	P.	P.	NNP
10_1101-2021_01_04_425177	217	8	,	,	,
10_1101-2021_01_04_425177	217	9	Langel	Langel	NNP
10_1101-2021_01_04_425177	217	10	,	,	,
10_1101-2021_01_04_425177	217	11	U.	U.	NNP
10_1101-2021_01_04_425177	217	12	,	,	,
10_1101-2021_01_04_425177	217	13	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	217	14	,	,	,
10_1101-2021_01_04_425177	217	15	A.	a.	NN
10_1101-2021_01_04_425177	217	16	,	,	,
10_1101-2021_01_04_425177	217	17	2014	2014	CD
10_1101-2021_01_04_425177	217	18	.	.	.
10_1101-2021_01_04_425177	218	1	Targeting	target	VBG
10_1101-2021_01_04_425177	218	2	prion	prion	NN
10_1101-2021_01_04_425177	218	3	propagation	propagation	NN
10_1101-2021_01_04_425177	218	4	using	use	VBG
10_1101-2021_01_04_425177	218	5	peptide	peptide	NN
10_1101-2021_01_04_425177	218	6	constructs	construct	NNS
10_1101-2021_01_04_425177	218	7	with	with	IN
10_1101-2021_01_04_425177	218	8	signal	signal	JJ
10_1101-2021_01_04_425177	218	9	sequence	sequence	NN
10_1101-2021_01_04_425177	218	10	motifs	motif	NNS
10_1101-2021_01_04_425177	218	11	.	.	.
10_1101-2021_01_04_425177	219	1	Arch	Arch	NNP
10_1101-2021_01_04_425177	219	2	Biochem	Biochem	NNP
10_1101-2021_01_04_425177	219	3	Biophys	Biophys	NNP
10_1101-2021_01_04_425177	219	4	564	564	CD
10_1101-2021_01_04_425177	219	5	,	,	,
10_1101-2021_01_04_425177	219	6	254	254	CD
10_1101-2021_01_04_425177	219	7	-	-	SYM
10_1101-2021_01_04_425177	219	8	261	261	CD
10_1101-2021_01_04_425177	219	9	.	.	.
10_1101-2021_01_04_425177	220	1	.CC	.CC	NFP
10_1101-2021_01_04_425177	220	2	-	-	:
10_1101-2021_01_04_425177	220	3	BY	by	IN
10_1101-2021_01_04_425177	220	4	-	-	HYPH
10_1101-2021_01_04_425177	220	5	NC	NC	NNP
10_1101-2021_01_04_425177	220	6	-	-	HYPH
10_1101-2021_01_04_425177	220	7	ND	ND	NNP
10_1101-2021_01_04_425177	220	8	4.0	4.0	CD
10_1101-2021_01_04_425177	220	9	International	international	JJ
10_1101-2021_01_04_425177	220	10	licensemade	licensemade	NN
10_1101-2021_01_04_425177	220	11	available	available	JJ
10_1101-2021_01_04_425177	220	12	under	under	IN
10_1101-2021_01_04_425177	220	13	a	a	DT
10_1101-2021_01_04_425177	220	14	(	(	-LRB-
10_1101-2021_01_04_425177	220	15	which	which	WDT
10_1101-2021_01_04_425177	220	16	was	be	VBD
10_1101-2021_01_04_425177	220	17	not	not	RB
10_1101-2021_01_04_425177	220	18	certified	certify	VBN
10_1101-2021_01_04_425177	220	19	by	by	IN
10_1101-2021_01_04_425177	220	20	peer	peer	NN
10_1101-2021_01_04_425177	220	21	review	review	NN
10_1101-2021_01_04_425177	220	22	)	)	-RRB-
10_1101-2021_01_04_425177	220	23	is	be	VBZ
10_1101-2021_01_04_425177	220	24	the	the	DT
10_1101-2021_01_04_425177	220	25	author	author	NN
10_1101-2021_01_04_425177	220	26	/	/	SYM
10_1101-2021_01_04_425177	220	27	funder	funder	NN
10_1101-2021_01_04_425177	220	28	,	,	,
10_1101-2021_01_04_425177	220	29	who	who	WP
10_1101-2021_01_04_425177	220	30	has	have	VBZ
10_1101-2021_01_04_425177	220	31	granted	grant	VBN
10_1101-2021_01_04_425177	220	32	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	220	33	a	a	DT
10_1101-2021_01_04_425177	220	34	license	license	NN
10_1101-2021_01_04_425177	220	35	to	to	TO
10_1101-2021_01_04_425177	220	36	display	display	VB
10_1101-2021_01_04_425177	220	37	the	the	DT
10_1101-2021_01_04_425177	220	38	preprint	preprint	NN
10_1101-2021_01_04_425177	220	39	in	in	IN
10_1101-2021_01_04_425177	220	40	perpetuity	perpetuity	NN
10_1101-2021_01_04_425177	220	41	.	.	.
10_1101-2021_01_04_425177	221	1	It	-PRON-	PRP
10_1101-2021_01_04_425177	221	2	is	be	VBZ
10_1101-2021_01_04_425177	221	3	The	the	DT
10_1101-2021_01_04_425177	221	4	copyright	copyright	NN
10_1101-2021_01_04_425177	221	5	holder	holder	NN
10_1101-2021_01_04_425177	221	6	for	for	IN
10_1101-2021_01_04_425177	221	7	this	this	DT
10_1101-2021_01_04_425177	221	8	preprintthis	preprintthis	NN
10_1101-2021_01_04_425177	221	9	version	version	NN
10_1101-2021_01_04_425177	221	10	posted	post	VBD
10_1101-2021_01_04_425177	221	11	January	January	NNP
10_1101-2021_01_04_425177	221	12	4	4	CD
10_1101-2021_01_04_425177	221	13	,	,	,
10_1101-2021_01_04_425177	221	14	2021	2021	CD
10_1101-2021_01_04_425177	221	15	.	.	.
10_1101-2021_01_04_425177	221	16	;	;	:
10_1101-2021_01_04_425177	221	17	https://doi.org/10.1101/2021.01.04.425177doi	https://doi.org/10.1101/2021.01.04.425177doi	ADD
10_1101-2021_01_04_425177	221	18	:	:	:
10_1101-2021_01_04_425177	221	19	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	221	20	preprint	preprint	NN
10_1101-2021_01_04_425177	221	21	https://doi.org/10.1101/2021.01.04.425177	https://doi.org/10.1101/2021.01.04.425177	NNP
10_1101-2021_01_04_425177	221	22	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	CD
10_1101-2021_01_04_425177	221	23	12	12	CD
10_1101-2021_01_04_425177	221	24	Terry	Terry	NNP
10_1101-2021_01_04_425177	221	25	,	,	,
10_1101-2021_01_04_425177	221	26	C.	C.	NNP
10_1101-2021_01_04_425177	221	27	,	,	,
10_1101-2021_01_04_425177	221	28	Wadsworth	Wadsworth	NNP
10_1101-2021_01_04_425177	221	29	,	,	,
10_1101-2021_01_04_425177	221	30	J.D.F.	J.D.F.	NNP
10_1101-2021_01_04_425177	221	31	,	,	,
10_1101-2021_01_04_425177	221	32	2019	2019	CD
10_1101-2021_01_04_425177	221	33	.	.	.
10_1101-2021_01_04_425177	222	1	Recent	recent	JJ
10_1101-2021_01_04_425177	222	2	Advances	advance	NNS
10_1101-2021_01_04_425177	222	3	in	in	IN
10_1101-2021_01_04_425177	222	4	Understanding	Understanding	NNP
10_1101-2021_01_04_425177	222	5	Mammalian	Mammalian	NNP
10_1101-2021_01_04_425177	222	6	Prion	Prion	NNP
10_1101-2021_01_04_425177	222	7	Structure	Structure	NNP
10_1101-2021_01_04_425177	222	8	:	:	:
10_1101-2021_01_04_425177	222	9	A	a	DT
10_1101-2021_01_04_425177	222	10	Mini	Mini	NNP
10_1101-2021_01_04_425177	222	11	Review	Review	NNP
10_1101-2021_01_04_425177	222	12	.	.	.
10_1101-2021_01_04_425177	223	1	Front	Front	NNP
10_1101-2021_01_04_425177	223	2	Mol	Mol	NNP
10_1101-2021_01_04_425177	223	3	Neurosci	Neurosci	NNP
10_1101-2021_01_04_425177	223	4	12	12	CD
10_1101-2021_01_04_425177	223	5	,	,	,
10_1101-2021_01_04_425177	223	6	169	169	CD
10_1101-2021_01_04_425177	223	7	.	.	.
10_1101-2021_01_04_425177	224	1	Tjernberg	Tjernberg	NNP
10_1101-2021_01_04_425177	224	2	,	,	,
10_1101-2021_01_04_425177	224	3	L.O.	L.O.	NNP
10_1101-2021_01_04_425177	224	4	,	,	,
10_1101-2021_01_04_425177	224	5	Näslund	Näslund	NNP
10_1101-2021_01_04_425177	224	6	,	,	,
10_1101-2021_01_04_425177	224	7	J.	J.	NNP
10_1101-2021_01_04_425177	224	8	,	,	,
10_1101-2021_01_04_425177	224	9	Lindqvist	Lindqvist	NNP
10_1101-2021_01_04_425177	224	10	,	,	,
10_1101-2021_01_04_425177	224	11	F.	F.	NNP
10_1101-2021_01_04_425177	224	12	,	,	,
10_1101-2021_01_04_425177	224	13	Johansson	Johansson	NNP
10_1101-2021_01_04_425177	224	14	,	,	,
10_1101-2021_01_04_425177	224	15	J.	J.	NNP
10_1101-2021_01_04_425177	224	16	,	,	,
10_1101-2021_01_04_425177	224	17	Karlström	Karlström	NNP
10_1101-2021_01_04_425177	224	18	,	,	,
10_1101-2021_01_04_425177	224	19	A.R.	A.R.	NNP
10_1101-2021_01_04_425177	224	20	,	,	,
10_1101-2021_01_04_425177	224	21	Thyberg	Thyberg	NNP
10_1101-2021_01_04_425177	224	22	,	,	,
10_1101-2021_01_04_425177	224	23	J.	J.	NNP
10_1101-2021_01_04_425177	224	24	,	,	,
10_1101-2021_01_04_425177	224	25	Terenius	Terenius	NNP
10_1101-2021_01_04_425177	224	26	,	,	,
10_1101-2021_01_04_425177	224	27	L.	L.	NNP
10_1101-2021_01_04_425177	224	28	,	,	,
10_1101-2021_01_04_425177	224	29	Nordstedt	Nordstedt	NNP
10_1101-2021_01_04_425177	224	30	,	,	,
10_1101-2021_01_04_425177	224	31	C.	C.	NNP
10_1101-2021_01_04_425177	224	32	,	,	,
10_1101-2021_01_04_425177	224	33	1996	1996	CD
10_1101-2021_01_04_425177	224	34	.	.	.
10_1101-2021_01_04_425177	225	1	Arrest	arrest	NN
10_1101-2021_01_04_425177	225	2	of	of	IN
10_1101-2021_01_04_425177	225	3	beta	beta	JJ
10_1101-2021_01_04_425177	225	4	-	-	HYPH
10_1101-2021_01_04_425177	225	5	amyloid	amyloid	NN
10_1101-2021_01_04_425177	225	6	fibril	fibril	NN
10_1101-2021_01_04_425177	225	7	formation	formation	NN
10_1101-2021_01_04_425177	225	8	by	by	IN
10_1101-2021_01_04_425177	225	9	a	a	DT
10_1101-2021_01_04_425177	225	10	pentapeptide	pentapeptide	NN
10_1101-2021_01_04_425177	225	11	ligand	ligand	NN
10_1101-2021_01_04_425177	225	12	.	.	.
10_1101-2021_01_04_425177	226	1	J	J	NNP
10_1101-2021_01_04_425177	226	2	Biol	Biol	NNP
10_1101-2021_01_04_425177	226	3	Chem	Chem	NNP
10_1101-2021_01_04_425177	226	4	271	271	CD
10_1101-2021_01_04_425177	226	5	,	,	,
10_1101-2021_01_04_425177	226	6	8545	8545	CD
10_1101-2021_01_04_425177	226	7	-	-	SYM
10_1101-2021_01_04_425177	226	8	8548	8548	CD
10_1101-2021_01_04_425177	226	9	.	.	.
10_1101-2021_01_04_425177	227	1	Vazquez	Vazquez	NNP
10_1101-2021_01_04_425177	227	2	-	-	HYPH
10_1101-2021_01_04_425177	227	3	Fernandez	Fernandez	NNP
10_1101-2021_01_04_425177	227	4	,	,	,
10_1101-2021_01_04_425177	227	5	E.	E.	NNP
10_1101-2021_01_04_425177	227	6	,	,	,
10_1101-2021_01_04_425177	227	7	Young	Young	NNP
10_1101-2021_01_04_425177	227	8	,	,	,
10_1101-2021_01_04_425177	227	9	H.S.	H.S.	NNP
10_1101-2021_01_04_425177	227	10	,	,	,
10_1101-2021_01_04_425177	227	11	Requena	Requena	NNP
10_1101-2021_01_04_425177	227	12	,	,	,
10_1101-2021_01_04_425177	227	13	J.R.	J.R.	NNP
10_1101-2021_01_04_425177	227	14	,	,	,
10_1101-2021_01_04_425177	227	15	Wille	Wille	NNP
10_1101-2021_01_04_425177	227	16	,	,	,
10_1101-2021_01_04_425177	227	17	H.	H.	NNP
10_1101-2021_01_04_425177	227	18	,	,	,
10_1101-2021_01_04_425177	227	19	2017	2017	CD
10_1101-2021_01_04_425177	227	20	.	.	.
10_1101-2021_01_04_425177	228	1	The	the	DT
10_1101-2021_01_04_425177	228	2	Structure	Structure	NNP
10_1101-2021_01_04_425177	228	3	of	of	IN
10_1101-2021_01_04_425177	228	4	Mammalian	Mammalian	NNP
10_1101-2021_01_04_425177	228	5	Prions	Prions	NNPS
10_1101-2021_01_04_425177	228	6	and	and	CC
10_1101-2021_01_04_425177	228	7	Their	-PRON-	PRP$
10_1101-2021_01_04_425177	228	8	Aggregates	Aggregates	NNPS
10_1101-2021_01_04_425177	228	9	.	.	.
10_1101-2021_01_04_425177	229	1	Int	Int	NNP
10_1101-2021_01_04_425177	229	2	Rev	Rev	NNP
10_1101-2021_01_04_425177	229	3	Cell	Cell	NNP
10_1101-2021_01_04_425177	229	4	Mol	Mol	NNP
10_1101-2021_01_04_425177	229	5	Biol	Biol	NNP
10_1101-2021_01_04_425177	229	6	329	329	CD
10_1101-2021_01_04_425177	229	7	,	,	,
10_1101-2021_01_04_425177	229	8	277	277	CD
10_1101-2021_01_04_425177	229	9	-	-	SYM
10_1101-2021_01_04_425177	229	10	301	301	CD
10_1101-2021_01_04_425177	229	11	.	.	.
10_1101-2021_01_04_425177	230	1	Verma	Verma	NNP
10_1101-2021_01_04_425177	230	2	,	,	,
10_1101-2021_01_04_425177	230	3	M.	M.	NNP
10_1101-2021_01_04_425177	230	4	,	,	,
10_1101-2021_01_04_425177	230	5	Vats	Vats	NNP
10_1101-2021_01_04_425177	230	6	,	,	,
10_1101-2021_01_04_425177	230	7	A.	A.	NNP
10_1101-2021_01_04_425177	230	8	,	,	,
10_1101-2021_01_04_425177	230	9	Taneja	Taneja	NNP
10_1101-2021_01_04_425177	230	10	,	,	,
10_1101-2021_01_04_425177	230	11	V.	V.	NNP
10_1101-2021_01_04_425177	230	12	,	,	,
10_1101-2021_01_04_425177	230	13	2015	2015	CD
10_1101-2021_01_04_425177	230	14	.	.	.
10_1101-2021_01_04_425177	231	1	Toxic	toxic	JJ
10_1101-2021_01_04_425177	231	2	species	specie	NNS
10_1101-2021_01_04_425177	231	3	in	in	IN
10_1101-2021_01_04_425177	231	4	amyloid	amyloid	NN
10_1101-2021_01_04_425177	231	5	disorders	disorder	NNS
10_1101-2021_01_04_425177	231	6	:	:	:
10_1101-2021_01_04_425177	231	7	Oligomers	oligomer	NNS
10_1101-2021_01_04_425177	231	8	or	or	CC
10_1101-2021_01_04_425177	231	9	mature	mature	JJ
10_1101-2021_01_04_425177	231	10	fibrils	fibril	NNS
10_1101-2021_01_04_425177	231	11	.	.	.
10_1101-2021_01_04_425177	232	1	Ann	Ann	NNP
10_1101-2021_01_04_425177	232	2	Indian	Indian	NNP
10_1101-2021_01_04_425177	232	3	Acad	Acad	NNP
10_1101-2021_01_04_425177	232	4	Neurol	Neurol	NNP
10_1101-2021_01_04_425177	232	5	18	18	CD
10_1101-2021_01_04_425177	232	6	,	,	,
10_1101-2021_01_04_425177	232	7	138	138	CD
10_1101-2021_01_04_425177	232	8	-	-	SYM
10_1101-2021_01_04_425177	232	9	145	145	CD
10_1101-2021_01_04_425177	232	10	.	.	.
10_1101-2021_01_04_425177	233	1	Wallin	Wallin	NNP
10_1101-2021_01_04_425177	233	2	,	,	,
10_1101-2021_01_04_425177	233	3	C.	C.	NNP
10_1101-2021_01_04_425177	233	4	,	,	,
10_1101-2021_01_04_425177	233	5	Hiruma	Hiruma	NNP
10_1101-2021_01_04_425177	233	6	,	,	,
10_1101-2021_01_04_425177	233	7	Y.	Y.	NNP
10_1101-2021_01_04_425177	233	8	,	,	,
10_1101-2021_01_04_425177	233	9	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	233	10	,	,	,
10_1101-2021_01_04_425177	233	11	S.	S.	NNP
10_1101-2021_01_04_425177	233	12	,	,	,
10_1101-2021_01_04_425177	233	13	Huvent	Huvent	NNP
10_1101-2021_01_04_425177	233	14	,	,	,
10_1101-2021_01_04_425177	233	15	I.	I.	NNP
10_1101-2021_01_04_425177	233	16	,	,	,
10_1101-2021_01_04_425177	233	17	Jarvet	Jarvet	NNP
10_1101-2021_01_04_425177	233	18	,	,	,
10_1101-2021_01_04_425177	233	19	J.	J.	NNP
10_1101-2021_01_04_425177	233	20	,	,	,
10_1101-2021_01_04_425177	233	21	Abrahams	Abrahams	NNP
10_1101-2021_01_04_425177	233	22	,	,	,
10_1101-2021_01_04_425177	233	23	J.P.	J.P.	NNP
10_1101-2021_01_04_425177	233	24	,	,	,
10_1101-2021_01_04_425177	233	25	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	233	26	,	,	,
10_1101-2021_01_04_425177	233	27	A.	a.	NN
10_1101-2021_01_04_425177	233	28	,	,	,
10_1101-2021_01_04_425177	233	29	Lippens	Lippens	NNP
10_1101-2021_01_04_425177	233	30	,	,	,
10_1101-2021_01_04_425177	233	31	G.	G.	NNP
10_1101-2021_01_04_425177	233	32	,	,	,
10_1101-2021_01_04_425177	233	33	Luo	Luo	NNP
10_1101-2021_01_04_425177	233	34	,	,	,
10_1101-2021_01_04_425177	233	35	J.	J.	NNP
10_1101-2021_01_04_425177	233	36	,	,	,
10_1101-2021_01_04_425177	233	37	2018	2018	CD
10_1101-2021_01_04_425177	233	38	.	.	.
10_1101-2021_01_04_425177	234	1	The	the	DT
10_1101-2021_01_04_425177	234	2	Neuronal	Neuronal	NNP
10_1101-2021_01_04_425177	234	3	Tau	Tau	NNP
10_1101-2021_01_04_425177	234	4	Protein	Protein	NNP
10_1101-2021_01_04_425177	234	5	Blocks	Blocks	NNPS
10_1101-2021_01_04_425177	234	6	in	in	IN
10_1101-2021_01_04_425177	234	7	Vitro	Vitro	NNP
10_1101-2021_01_04_425177	234	8	Fibrillation	Fibrillation	NNP
10_1101-2021_01_04_425177	234	9	of	of	IN
10_1101-2021_01_04_425177	234	10	the	the	DT
10_1101-2021_01_04_425177	234	11	Amyloid	Amyloid	NNP
10_1101-2021_01_04_425177	234	12	-	-	HYPH
10_1101-2021_01_04_425177	234	13	beta	beta	NN
10_1101-2021_01_04_425177	234	14	(	(	-LRB-
10_1101-2021_01_04_425177	234	15	Abeta	Abeta	NNP
10_1101-2021_01_04_425177	234	16	)	)	-RRB-
10_1101-2021_01_04_425177	234	17	Peptide	peptide	VB
10_1101-2021_01_04_425177	234	18	at	at	IN
10_1101-2021_01_04_425177	234	19	the	the	DT
10_1101-2021_01_04_425177	234	20	Oligomeric	Oligomeric	NNP
10_1101-2021_01_04_425177	234	21	Stage	Stage	NNP
10_1101-2021_01_04_425177	234	22	.	.	.
10_1101-2021_01_04_425177	235	1	J	J	NNP
10_1101-2021_01_04_425177	235	2	Am	Am	NNP
10_1101-2021_01_04_425177	235	3	Chem	Chem	NNP
10_1101-2021_01_04_425177	235	4	Soc	Soc	NNP
10_1101-2021_01_04_425177	235	5	140	140	CD
10_1101-2021_01_04_425177	235	6	,	,	,
10_1101-2021_01_04_425177	235	7	8138	8138	CD
10_1101-2021_01_04_425177	235	8	-	-	SYM
10_1101-2021_01_04_425177	235	9	8146	8146	CD
10_1101-2021_01_04_425177	235	10	.	.	.
10_1101-2021_01_04_425177	236	1	Wallin	Wallin	NNP
10_1101-2021_01_04_425177	236	2	,	,	,
10_1101-2021_01_04_425177	236	3	C.	C.	NNP
10_1101-2021_01_04_425177	236	4	,	,	,
10_1101-2021_01_04_425177	236	5	Luo	Luo	NNP
10_1101-2021_01_04_425177	236	6	,	,	,
10_1101-2021_01_04_425177	236	7	J.	J.	NNP
10_1101-2021_01_04_425177	236	8	,	,	,
10_1101-2021_01_04_425177	236	9	Jarvet	Jarvet	NNP
10_1101-2021_01_04_425177	236	10	,	,	,
10_1101-2021_01_04_425177	236	11	J.	J.	NNP
10_1101-2021_01_04_425177	236	12	,	,	,
10_1101-2021_01_04_425177	236	13	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	236	14	,	,	,
10_1101-2021_01_04_425177	236	15	S.K.T.S.	S.K.T.S.	NNP
10_1101-2021_01_04_425177	236	16	,	,	,
10_1101-2021_01_04_425177	236	17	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	236	18	,	,	,
10_1101-2021_01_04_425177	236	19	A.	a.	NN
10_1101-2021_01_04_425177	236	20	,	,	,
10_1101-2021_01_04_425177	236	21	2017	2017	CD
10_1101-2021_01_04_425177	236	22	.	.	.
10_1101-2021_01_04_425177	237	1	The	the	DT
10_1101-2021_01_04_425177	237	2	Amyloid	Amyloid	NNP
10_1101-2021_01_04_425177	237	3	-	-	HYPH
10_1101-2021_01_04_425177	237	4	b	b	NN
10_1101-2021_01_04_425177	237	5	Peptide	peptide	NN
10_1101-2021_01_04_425177	237	6	in	in	IN
10_1101-2021_01_04_425177	237	7	Amyloid	Amyloid	NNP
10_1101-2021_01_04_425177	237	8	Formation	Formation	NNP
10_1101-2021_01_04_425177	237	9	Processes	Processes	NNPS
10_1101-2021_01_04_425177	237	10	:	:	:
10_1101-2021_01_04_425177	237	11	Interactions	interaction	NNS
10_1101-2021_01_04_425177	237	12	with	with	IN
10_1101-2021_01_04_425177	237	13	Blood	Blood	NNP
10_1101-2021_01_04_425177	237	14	Proteins	Proteins	NNPS
10_1101-2021_01_04_425177	237	15	and	and	CC
10_1101-2021_01_04_425177	237	16	Naturally	naturally	RB
10_1101-2021_01_04_425177	237	17	Occurring	Occurring	NNP
10_1101-2021_01_04_425177	237	18	Metal	Metal	NNP
10_1101-2021_01_04_425177	237	19	Ions	ion	NNS
10_1101-2021_01_04_425177	237	20	.	.	.
10_1101-2021_01_04_425177	238	1	Israel	Israel	NNP
10_1101-2021_01_04_425177	238	2	Journal	Journal	NNP
10_1101-2021_01_04_425177	238	3	of	of	IN
10_1101-2021_01_04_425177	238	4	Chemistry	Chemistry	NNP
10_1101-2021_01_04_425177	238	5	57	57	CD
10_1101-2021_01_04_425177	238	6	,	,	,
10_1101-2021_01_04_425177	238	7	674	674	CD
10_1101-2021_01_04_425177	238	8	-	-	SYM
10_1101-2021_01_04_425177	238	9	685	685	CD
10_1101-2021_01_04_425177	238	10	.	.	.
10_1101-2021_01_04_425177	239	1	Wang	Wang	NNP
10_1101-2021_01_04_425177	239	2	,	,	,
10_1101-2021_01_04_425177	239	3	C.	C.	NNP
10_1101-2021_01_04_425177	239	4	,	,	,
10_1101-2021_01_04_425177	239	5	Iashchishyn	Iashchishyn	NNP
10_1101-2021_01_04_425177	239	6	,	,	,
10_1101-2021_01_04_425177	239	7	I.A.	I.A.	NNP
10_1101-2021_01_04_425177	239	8	,	,	,
10_1101-2021_01_04_425177	239	9	Kara	Kara	NNP
10_1101-2021_01_04_425177	239	10	,	,	,
10_1101-2021_01_04_425177	239	11	J.	J.	NNP
10_1101-2021_01_04_425177	239	12	,	,	,
10_1101-2021_01_04_425177	239	13	Fodera	Fodera	NNP
10_1101-2021_01_04_425177	239	14	,	,	,
10_1101-2021_01_04_425177	239	15	V.	V.	NNP
10_1101-2021_01_04_425177	239	16	,	,	,
10_1101-2021_01_04_425177	239	17	Vetri	Vetri	NNP
10_1101-2021_01_04_425177	239	18	,	,	,
10_1101-2021_01_04_425177	239	19	V.	V.	NNP
10_1101-2021_01_04_425177	239	20	,	,	,
10_1101-2021_01_04_425177	239	21	Sancataldo	Sancataldo	NNP
10_1101-2021_01_04_425177	239	22	,	,	,
10_1101-2021_01_04_425177	239	23	G.	G.	NNP
10_1101-2021_01_04_425177	239	24	,	,	,
10_1101-2021_01_04_425177	239	25	Marklund	Marklund	NNP
10_1101-2021_01_04_425177	239	26	,	,	,
10_1101-2021_01_04_425177	239	27	N.	N.	NNP
10_1101-2021_01_04_425177	239	28	,	,	,
10_1101-2021_01_04_425177	239	29	Morozova-	Morozova-	NNP
10_1101-2021_01_04_425177	239	30	Roche	Roche	NNP
10_1101-2021_01_04_425177	239	31	,	,	,
10_1101-2021_01_04_425177	239	32	L.A.	L.A.	NNP
10_1101-2021_01_04_425177	239	33	,	,	,
10_1101-2021_01_04_425177	239	34	2019	2019	CD
10_1101-2021_01_04_425177	239	35	.	.	.
10_1101-2021_01_04_425177	240	1	Proinflammatory	proinflammatory	NN
10_1101-2021_01_04_425177	240	2	and	and	CC
10_1101-2021_01_04_425177	240	3	amyloidogenic	amyloidogenic	JJ
10_1101-2021_01_04_425177	240	4	S100A9	s100a9	NN
10_1101-2021_01_04_425177	240	5	induced	induce	VBN
10_1101-2021_01_04_425177	240	6	by	by	IN
10_1101-2021_01_04_425177	240	7	traumatic	traumatic	JJ
10_1101-2021_01_04_425177	240	8	brain	brain	NN
10_1101-2021_01_04_425177	240	9	injury	injury	NN
10_1101-2021_01_04_425177	240	10	in	in	IN
10_1101-2021_01_04_425177	240	11	mouse	mouse	NN
10_1101-2021_01_04_425177	240	12	model	model	NN
10_1101-2021_01_04_425177	240	13	.	.	.
10_1101-2021_01_04_425177	241	1	Neurosci	Neurosci	NNP
10_1101-2021_01_04_425177	241	2	Lett	Lett	NNP
10_1101-2021_01_04_425177	241	3	699	699	CD
10_1101-2021_01_04_425177	241	4	,	,	,
10_1101-2021_01_04_425177	241	5	199	199	CD
10_1101-2021_01_04_425177	241	6	-	-	SYM
10_1101-2021_01_04_425177	241	7	205	205	CD
10_1101-2021_01_04_425177	241	8	.	.	.
10_1101-2021_01_04_425177	242	1	Wang	Wang	NNP
10_1101-2021_01_04_425177	242	2	,	,	,
10_1101-2021_01_04_425177	242	3	C.	C.	NNP
10_1101-2021_01_04_425177	242	4	,	,	,
10_1101-2021_01_04_425177	242	5	Klechikov	Klechikov	NNP
10_1101-2021_01_04_425177	242	6	,	,	,
10_1101-2021_01_04_425177	242	7	A.G.	A.G.	NNP
10_1101-2021_01_04_425177	242	8	,	,	,
10_1101-2021_01_04_425177	242	9	Gharibyan	Gharibyan	NNP
10_1101-2021_01_04_425177	242	10	,	,	,
10_1101-2021_01_04_425177	242	11	A.L.	A.L.	NNP
10_1101-2021_01_04_425177	242	12	,	,	,
10_1101-2021_01_04_425177	242	13	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	242	14	,	,	,
10_1101-2021_01_04_425177	242	15	S.K.T.S.	S.K.T.S.	NNP
10_1101-2021_01_04_425177	242	16	,	,	,
10_1101-2021_01_04_425177	242	17	Jarvet	Jarvet	NNP
10_1101-2021_01_04_425177	242	18	,	,	,
10_1101-2021_01_04_425177	242	19	J.	J.	NNP
10_1101-2021_01_04_425177	242	20	,	,	,
10_1101-2021_01_04_425177	242	21	Zhao	Zhao	NNP
10_1101-2021_01_04_425177	242	22	,	,	,
10_1101-2021_01_04_425177	242	23	L.	L.	NNP
10_1101-2021_01_04_425177	242	24	,	,	,
10_1101-2021_01_04_425177	242	25	Jia	Jia	NNP
10_1101-2021_01_04_425177	242	26	,	,	,
10_1101-2021_01_04_425177	242	27	X.	X.	NNP
10_1101-2021_01_04_425177	242	28	,	,	,
10_1101-2021_01_04_425177	242	29	Narayana	Narayana	NNP
10_1101-2021_01_04_425177	242	30	,	,	,
10_1101-2021_01_04_425177	242	31	V.K.	V.K.	NNP
10_1101-2021_01_04_425177	242	32	,	,	,
10_1101-2021_01_04_425177	242	33	Shankar	Shankar	NNP
10_1101-2021_01_04_425177	242	34	,	,	,
10_1101-2021_01_04_425177	242	35	S.K.	S.K.	NNP
10_1101-2021_01_04_425177	242	36	,	,	,
10_1101-2021_01_04_425177	242	37	Olofsson	Olofsson	NNP
10_1101-2021_01_04_425177	242	38	,	,	,
10_1101-2021_01_04_425177	242	39	A.	A.	NNP
10_1101-2021_01_04_425177	242	40	,	,	,
10_1101-2021_01_04_425177	242	41	Brännström	Brännström	NNP
10_1101-2021_01_04_425177	242	42	,	,	,
10_1101-2021_01_04_425177	242	43	T.	T.	NNP
10_1101-2021_01_04_425177	242	44	,	,	,
10_1101-2021_01_04_425177	242	45	Mu	Mu	NNP
10_1101-2021_01_04_425177	242	46	,	,	,
10_1101-2021_01_04_425177	242	47	Y.	Y.	NNP
10_1101-2021_01_04_425177	242	48	,	,	,
10_1101-2021_01_04_425177	242	49	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	242	50	,	,	,
10_1101-2021_01_04_425177	242	51	A.	A.	NNP
10_1101-2021_01_04_425177	242	52	,	,	,
10_1101-2021_01_04_425177	242	53	Morozova	Morozova	NNP
10_1101-2021_01_04_425177	242	54	-	-	HYPH
10_1101-2021_01_04_425177	242	55	Roche	Roche	NNP
10_1101-2021_01_04_425177	242	56	,	,	,
10_1101-2021_01_04_425177	242	57	L.A.	L.A.	NNP
10_1101-2021_01_04_425177	242	58	,	,	,
10_1101-2021_01_04_425177	242	59	2014	2014	CD
10_1101-2021_01_04_425177	242	60	.	.	.
10_1101-2021_01_04_425177	243	1	The	the	DT
10_1101-2021_01_04_425177	243	2	role	role	NN
10_1101-2021_01_04_425177	243	3	of	of	IN
10_1101-2021_01_04_425177	243	4	pro	pro	JJ
10_1101-2021_01_04_425177	243	5	-	-	JJ
10_1101-2021_01_04_425177	243	6	inflammatory	inflammatory	JJ
10_1101-2021_01_04_425177	243	7	S100A9	s100a9	NN
10_1101-2021_01_04_425177	243	8	in	in	IN
10_1101-2021_01_04_425177	243	9	Alzheimer	Alzheimer	NNP
10_1101-2021_01_04_425177	243	10	's	's	POS
10_1101-2021_01_04_425177	243	11	disease	disease	NN
10_1101-2021_01_04_425177	243	12	amyloid-	amyloid-	NN
10_1101-2021_01_04_425177	243	13	neuroinflammatory	neuroinflammatory	NN
10_1101-2021_01_04_425177	243	14	cascade	cascade	NN
10_1101-2021_01_04_425177	243	15	.	.	.
10_1101-2021_01_04_425177	244	1	Acta	Acta	NNP
10_1101-2021_01_04_425177	244	2	Neuropathol	Neuropathol	NNP
10_1101-2021_01_04_425177	244	3	127	127	CD
10_1101-2021_01_04_425177	244	4	,	,	,
10_1101-2021_01_04_425177	244	5	507	507	CD
10_1101-2021_01_04_425177	244	6	-	-	HYPH
10_1101-2021_01_04_425177	244	7	522	522	CD
10_1101-2021_01_04_425177	244	8	.	.	.
10_1101-2021_01_04_425177	245	1	Wang	Wang	NNP
10_1101-2021_01_04_425177	245	2	,	,	,
10_1101-2021_01_04_425177	245	3	G.	G.	NNP
10_1101-2021_01_04_425177	245	4	,	,	,
10_1101-2021_01_04_425177	245	5	Li	Li	NNP
10_1101-2021_01_04_425177	245	6	,	,	,
10_1101-2021_01_04_425177	245	7	X.	X.	NNP
10_1101-2021_01_04_425177	245	8	,	,	,
10_1101-2021_01_04_425177	245	9	Wang	Wang	NNP
10_1101-2021_01_04_425177	245	10	,	,	,
10_1101-2021_01_04_425177	245	11	Z.	Z.	NNP
10_1101-2021_01_04_425177	245	12	,	,	,
10_1101-2021_01_04_425177	245	13	2016	2016	CD
10_1101-2021_01_04_425177	245	14	.	.	.
10_1101-2021_01_04_425177	246	1	APD3	APD3	NNP
10_1101-2021_01_04_425177	246	2	:	:	:
10_1101-2021_01_04_425177	246	3	the	the	DT
10_1101-2021_01_04_425177	246	4	antimicrobial	antimicrobial	JJ
10_1101-2021_01_04_425177	246	5	peptide	peptide	NN
10_1101-2021_01_04_425177	246	6	database	database	NN
10_1101-2021_01_04_425177	246	7	as	as	IN
10_1101-2021_01_04_425177	246	8	a	a	DT
10_1101-2021_01_04_425177	246	9	tool	tool	NN
10_1101-2021_01_04_425177	246	10	for	for	IN
10_1101-2021_01_04_425177	246	11	research	research	NN
10_1101-2021_01_04_425177	246	12	and	and	CC
10_1101-2021_01_04_425177	246	13	education	education	NN
10_1101-2021_01_04_425177	246	14	.	.	.
10_1101-2021_01_04_425177	247	1	Nucleic	Nucleic	NNP
10_1101-2021_01_04_425177	247	2	Acids	Acids	NNPS
10_1101-2021_01_04_425177	247	3	Res	Res	NNP
10_1101-2021_01_04_425177	247	4	44	44	CD
10_1101-2021_01_04_425177	247	5	,	,	,
10_1101-2021_01_04_425177	247	6	D1087	d1087	NN
10_1101-2021_01_04_425177	247	7	-	-	HYPH
10_1101-2021_01_04_425177	247	8	1093	1093	CD
10_1101-2021_01_04_425177	247	9	.	.	.
10_1101-2021_01_04_425177	248	1	Wimley	Wimley	NNP
10_1101-2021_01_04_425177	248	2	,	,	,
10_1101-2021_01_04_425177	248	3	W.C.	W.C.	NNP
10_1101-2021_01_04_425177	248	4	,	,	,
10_1101-2021_01_04_425177	248	5	White	White	NNP
10_1101-2021_01_04_425177	248	6	,	,	,
10_1101-2021_01_04_425177	248	7	S.H.	S.H.	NNP
10_1101-2021_01_04_425177	248	8	,	,	,
10_1101-2021_01_04_425177	248	9	1996	1996	CD
10_1101-2021_01_04_425177	248	10	.	.	.
10_1101-2021_01_04_425177	249	1	Experimentally	experimentally	RB
10_1101-2021_01_04_425177	249	2	determined	determine	VBN
10_1101-2021_01_04_425177	249	3	hydrophobicity	hydrophobicity	NN
10_1101-2021_01_04_425177	249	4	scale	scale	NN
10_1101-2021_01_04_425177	249	5	for	for	IN
10_1101-2021_01_04_425177	249	6	proteins	protein	NNS
10_1101-2021_01_04_425177	249	7	at	at	IN
10_1101-2021_01_04_425177	249	8	membrane	membrane	NN
10_1101-2021_01_04_425177	249	9	interfaces	interface	NNS
10_1101-2021_01_04_425177	249	10	.	.	.
10_1101-2021_01_04_425177	250	1	Nat	Nat	NNP
10_1101-2021_01_04_425177	250	2	Struct	Struct	NNP
10_1101-2021_01_04_425177	250	3	Biol	Biol	NNP
10_1101-2021_01_04_425177	250	4	3	3	CD
10_1101-2021_01_04_425177	250	5	,	,	,
10_1101-2021_01_04_425177	250	6	842	842	CD
10_1101-2021_01_04_425177	250	7	-	-	HYPH
10_1101-2021_01_04_425177	250	8	848	848	CD
10_1101-2021_01_04_425177	250	9	.	.	.
10_1101-2021_01_04_425177	251	1	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	251	2	,	,	,
10_1101-2021_01_04_425177	251	3	S.K.T.S.	S.K.T.S.	NNP
10_1101-2021_01_04_425177	251	4	,	,	,
10_1101-2021_01_04_425177	251	5	Tiiman	Tiiman	NNP
10_1101-2021_01_04_425177	251	6	,	,	,
10_1101-2021_01_04_425177	251	7	A.	A.	NNP
10_1101-2021_01_04_425177	251	8	,	,	,
10_1101-2021_01_04_425177	251	9	Abelein	Abelein	NNP
10_1101-2021_01_04_425177	251	10	,	,	,
10_1101-2021_01_04_425177	251	11	A.	a.	NN
10_1101-2021_01_04_425177	251	12	,	,	,
10_1101-2021_01_04_425177	251	13	Luo	Luo	NNP
10_1101-2021_01_04_425177	251	14	,	,	,
10_1101-2021_01_04_425177	251	15	J.	J.	NNP
10_1101-2021_01_04_425177	251	16	,	,	,
10_1101-2021_01_04_425177	251	17	Jarvet	Jarvet	NNP
10_1101-2021_01_04_425177	251	18	,	,	,
10_1101-2021_01_04_425177	251	19	J.	J.	NNP
10_1101-2021_01_04_425177	251	20	,	,	,
10_1101-2021_01_04_425177	251	21	Söderberg	Söderberg	NNP
10_1101-2021_01_04_425177	251	22	,	,	,
10_1101-2021_01_04_425177	251	23	K.L.	K.L.	NNP
10_1101-2021_01_04_425177	251	24	,	,	,
10_1101-2021_01_04_425177	251	25	Danielsson	Danielsson	NNP
10_1101-2021_01_04_425177	251	26	,	,	,
10_1101-2021_01_04_425177	251	27	J.	J.	NNP
10_1101-2021_01_04_425177	251	28	,	,	,
10_1101-2021_01_04_425177	251	29	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	251	30	,	,	,
10_1101-2021_01_04_425177	251	31	A.	a.	NN
10_1101-2021_01_04_425177	251	32	,	,	,
10_1101-2021_01_04_425177	251	33	2013	2013	CD
10_1101-2021_01_04_425177	251	34	.	.	.
10_1101-2021_01_04_425177	252	1	Biophysical	biophysical	JJ
10_1101-2021_01_04_425177	252	2	studies	study	NNS
10_1101-2021_01_04_425177	252	3	of	of	IN
10_1101-2021_01_04_425177	252	4	the	the	DT
10_1101-2021_01_04_425177	252	5	amyloid	amyloid	NN
10_1101-2021_01_04_425177	252	6	beta	beta	NN
10_1101-2021_01_04_425177	252	7	-	-	HYPH
10_1101-2021_01_04_425177	252	8	peptide	peptide	NN
10_1101-2021_01_04_425177	252	9	:	:	:
10_1101-2021_01_04_425177	252	10	interactions	interaction	NNS
10_1101-2021_01_04_425177	252	11	with	with	IN
10_1101-2021_01_04_425177	252	12	metal	metal	NN
10_1101-2021_01_04_425177	252	13	ions	ion	NNS
10_1101-2021_01_04_425177	252	14	and	and	CC
10_1101-2021_01_04_425177	252	15	small	small	JJ
10_1101-2021_01_04_425177	252	16	molecules	molecule	NNS
10_1101-2021_01_04_425177	252	17	.	.	.
10_1101-2021_01_04_425177	253	1	Chembiochem	Chembiochem	NNP
10_1101-2021_01_04_425177	253	2	14	14	CD
10_1101-2021_01_04_425177	253	3	,	,	,
10_1101-2021_01_04_425177	253	4	1692	1692	CD
10_1101-2021_01_04_425177	253	5	-	-	SYM
10_1101-2021_01_04_425177	253	6	1704	1704	CD
10_1101-2021_01_04_425177	253	7	.	.	.
10_1101-2021_01_04_425177	254	1	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	254	2	,	,	,
10_1101-2021_01_04_425177	254	3	S.K.T.S.	S.K.T.S.	NNP
10_1101-2021_01_04_425177	254	4	,	,	,
10_1101-2021_01_04_425177	254	5	Österlund	Österlund	NNP
10_1101-2021_01_04_425177	254	6	,	,	,
10_1101-2021_01_04_425177	254	7	N.	N.	NNP
10_1101-2021_01_04_425177	254	8	,	,	,
10_1101-2021_01_04_425177	254	9	Wallin	Wallin	NNP
10_1101-2021_01_04_425177	254	10	,	,	,
10_1101-2021_01_04_425177	254	11	C.	C.	NNP
10_1101-2021_01_04_425177	254	12	,	,	,
10_1101-2021_01_04_425177	254	13	Wu	Wu	NNP
10_1101-2021_01_04_425177	254	14	,	,	,
10_1101-2021_01_04_425177	254	15	J.	J.	NNP
10_1101-2021_01_04_425177	254	16	,	,	,
10_1101-2021_01_04_425177	254	17	Luo	Luo	NNP
10_1101-2021_01_04_425177	254	18	,	,	,
10_1101-2021_01_04_425177	254	19	J.	J.	NNP
10_1101-2021_01_04_425177	254	20	,	,	,
10_1101-2021_01_04_425177	254	21	Tiiman	Tiiman	NNP
10_1101-2021_01_04_425177	254	22	,	,	,
10_1101-2021_01_04_425177	254	23	A.	A.	NNP
10_1101-2021_01_04_425177	254	24	,	,	,
10_1101-2021_01_04_425177	254	25	Jarvet	Jarvet	NNP
10_1101-2021_01_04_425177	254	26	,	,	,
10_1101-2021_01_04_425177	254	27	J.	J.	NNP
10_1101-2021_01_04_425177	254	28	,	,	,
10_1101-2021_01_04_425177	254	29	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	254	30	,	,	,
10_1101-2021_01_04_425177	254	31	A.	a.	NN
10_1101-2021_01_04_425177	254	32	,	,	,
10_1101-2021_01_04_425177	254	33	2019	2019	CD
10_1101-2021_01_04_425177	254	34	.	.	.
10_1101-2021_01_04_425177	255	1	Metal	metal	NN
10_1101-2021_01_04_425177	255	2	binding	bind	VBG
10_1101-2021_01_04_425177	255	3	to	to	IN
10_1101-2021_01_04_425177	255	4	the	the	DT
10_1101-2021_01_04_425177	255	5	amyloid	amyloid	NN
10_1101-2021_01_04_425177	255	6	-	-	HYPH
10_1101-2021_01_04_425177	255	7	beta	beta	NN
10_1101-2021_01_04_425177	255	8	peptides	peptide	NNS
10_1101-2021_01_04_425177	255	9	in	in	IN
10_1101-2021_01_04_425177	255	10	the	the	DT
10_1101-2021_01_04_425177	255	11	presence	presence	NN
10_1101-2021_01_04_425177	255	12	of	of	IN
10_1101-2021_01_04_425177	255	13	biomembranes	biomembrane	NNS
10_1101-2021_01_04_425177	255	14	:	:	:
10_1101-2021_01_04_425177	255	15	potential	potential	JJ
10_1101-2021_01_04_425177	255	16	mechanisms	mechanism	NNS
10_1101-2021_01_04_425177	255	17	of	of	IN
10_1101-2021_01_04_425177	255	18	cell	cell	NN
10_1101-2021_01_04_425177	255	19	toxicity	toxicity	NN
10_1101-2021_01_04_425177	255	20	.	.	.
10_1101-2021_01_04_425177	256	1	J	J	NNP
10_1101-2021_01_04_425177	256	2	Biol	Biol	NNP
10_1101-2021_01_04_425177	256	3	Inorg	Inorg	NNP
10_1101-2021_01_04_425177	256	4	Chem	Chem	NNP
10_1101-2021_01_04_425177	256	5	24	24	CD
10_1101-2021_01_04_425177	256	6	,	,	,
10_1101-2021_01_04_425177	256	7	1189	1189	CD
10_1101-2021_01_04_425177	256	8	-	-	SYM
10_1101-2021_01_04_425177	256	9	1196	1196	CD
10_1101-2021_01_04_425177	256	10	.	.	.
10_1101-2021_01_04_425177	257	1	Yamaguchi	Yamaguchi	NNP
10_1101-2021_01_04_425177	257	2	,	,	,
10_1101-2021_01_04_425177	257	3	K.I.	K.I.	NNP
10_1101-2021_01_04_425177	257	4	,	,	,
10_1101-2021_01_04_425177	257	5	Kuwata	Kuwata	NNP
10_1101-2021_01_04_425177	257	6	,	,	,
10_1101-2021_01_04_425177	257	7	K.	K.	NNP
10_1101-2021_01_04_425177	257	8	,	,	,
10_1101-2021_01_04_425177	257	9	2018	2018	CD
10_1101-2021_01_04_425177	257	10	.	.	.
10_1101-2021_01_04_425177	258	1	Formation	formation	NN
10_1101-2021_01_04_425177	258	2	and	and	CC
10_1101-2021_01_04_425177	258	3	properties	property	NNS
10_1101-2021_01_04_425177	258	4	of	of	IN
10_1101-2021_01_04_425177	258	5	amyloid	amyloid	NN
10_1101-2021_01_04_425177	258	6	fibrils	fibril	NNS
10_1101-2021_01_04_425177	258	7	of	of	IN
10_1101-2021_01_04_425177	258	8	prion	prion	NN
10_1101-2021_01_04_425177	258	9	protein	protein	NN
10_1101-2021_01_04_425177	258	10	.	.	.
10_1101-2021_01_04_425177	259	1	Biophys	Biophys	NNP
10_1101-2021_01_04_425177	259	2	Rev	Rev	NNP
10_1101-2021_01_04_425177	259	3	10	10	CD
10_1101-2021_01_04_425177	259	4	,	,	,
10_1101-2021_01_04_425177	259	5	517	517	CD
10_1101-2021_01_04_425177	259	6	-	-	SYM
10_1101-2021_01_04_425177	259	7	525	525	CD
10_1101-2021_01_04_425177	259	8	.	.	.
10_1101-2021_01_04_425177	260	1	Zahn	Zahn	NNP
10_1101-2021_01_04_425177	260	2	,	,	,
10_1101-2021_01_04_425177	260	3	R.	R.	NNP
10_1101-2021_01_04_425177	260	4	,	,	,
10_1101-2021_01_04_425177	260	5	von	von	NNP
10_1101-2021_01_04_425177	260	6	Schroetter	Schroetter	NNP
10_1101-2021_01_04_425177	260	7	,	,	,
10_1101-2021_01_04_425177	260	8	C.	C.	NNP
10_1101-2021_01_04_425177	260	9	,	,	,
10_1101-2021_01_04_425177	260	10	Wüthrich	Wüthrich	NNP
10_1101-2021_01_04_425177	260	11	,	,	,
10_1101-2021_01_04_425177	260	12	K.	K.	NNP
10_1101-2021_01_04_425177	260	13	,	,	,
10_1101-2021_01_04_425177	260	14	1997	1997	CD
10_1101-2021_01_04_425177	260	15	.	.	.
10_1101-2021_01_04_425177	261	1	Human	human	JJ
10_1101-2021_01_04_425177	261	2	prion	prion	NN
10_1101-2021_01_04_425177	261	3	proteins	protein	NNS
10_1101-2021_01_04_425177	261	4	expressed	express	VBN
10_1101-2021_01_04_425177	261	5	in	in	IN
10_1101-2021_01_04_425177	261	6	Escherichia	Escherichia	NNP
10_1101-2021_01_04_425177	261	7	coli	coli	NNS
10_1101-2021_01_04_425177	261	8	and	and	CC
10_1101-2021_01_04_425177	261	9	purified	purify	VBN
10_1101-2021_01_04_425177	261	10	by	by	IN
10_1101-2021_01_04_425177	261	11	high	high	JJ
10_1101-2021_01_04_425177	261	12	-	-	HYPH
10_1101-2021_01_04_425177	261	13	affinity	affinity	NN
10_1101-2021_01_04_425177	261	14	column	column	NN
10_1101-2021_01_04_425177	261	15	refolding	refolding	NN
10_1101-2021_01_04_425177	261	16	.	.	.
10_1101-2021_01_04_425177	262	1	FEBS	FEBS	NNP
10_1101-2021_01_04_425177	262	2	Lett	Lett	NNP
10_1101-2021_01_04_425177	262	3	417	417	CD
10_1101-2021_01_04_425177	262	4	,	,	,
10_1101-2021_01_04_425177	262	5	400	400	CD
10_1101-2021_01_04_425177	262	6	-	-	SYM
10_1101-2021_01_04_425177	262	7	404	404	CD
10_1101-2021_01_04_425177	262	8	.	.	.
10_1101-2021_01_04_425177	263	1	Österlund	Österlund	NNP
10_1101-2021_01_04_425177	263	2	,	,	,
10_1101-2021_01_04_425177	263	3	N.	N.	NNP
10_1101-2021_01_04_425177	263	4	,	,	,
10_1101-2021_01_04_425177	263	5	Kulkarni	Kulkarni	NNP
10_1101-2021_01_04_425177	263	6	,	,	,
10_1101-2021_01_04_425177	263	7	Y.S.	Y.S.	NNP
10_1101-2021_01_04_425177	263	8	,	,	,
10_1101-2021_01_04_425177	263	9	Misiaszek	Misiaszek	NNP
10_1101-2021_01_04_425177	263	10	,	,	,
10_1101-2021_01_04_425177	263	11	A.D.	A.D.	NNP
10_1101-2021_01_04_425177	263	12	,	,	,
10_1101-2021_01_04_425177	263	13	Wallin	Wallin	NNP
10_1101-2021_01_04_425177	263	14	,	,	,
10_1101-2021_01_04_425177	263	15	C.	C.	NNP
10_1101-2021_01_04_425177	263	16	,	,	,
10_1101-2021_01_04_425177	263	17	Kruger	Kruger	NNP
10_1101-2021_01_04_425177	263	18	,	,	,
10_1101-2021_01_04_425177	263	19	D.M.	D.M.	NNP
10_1101-2021_01_04_425177	263	20	,	,	,
10_1101-2021_01_04_425177	263	21	Liao	Liao	NNP
10_1101-2021_01_04_425177	263	22	,	,	,
10_1101-2021_01_04_425177	263	23	Q.	Q.	NNP
10_1101-2021_01_04_425177	263	24	,	,	,
10_1101-2021_01_04_425177	263	25	Mashayekhy	Mashayekhy	NNP
10_1101-2021_01_04_425177	263	26	Rad	Rad	NNP
10_1101-2021_01_04_425177	263	27	,	,	,
10_1101-2021_01_04_425177	263	28	F.	F.	NNP
10_1101-2021_01_04_425177	263	29	,	,	,
10_1101-2021_01_04_425177	263	30	Jarvet	Jarvet	NNP
10_1101-2021_01_04_425177	263	31	,	,	,
10_1101-2021_01_04_425177	263	32	J.	J.	NNP
10_1101-2021_01_04_425177	263	33	,	,	,
10_1101-2021_01_04_425177	263	34	Strodel	Strodel	NNP
10_1101-2021_01_04_425177	263	35	,	,	,
10_1101-2021_01_04_425177	263	36	B.	B.	NNP
10_1101-2021_01_04_425177	263	37	,	,	,
10_1101-2021_01_04_425177	263	38	Wärmländer	Wärmländer	NNP
10_1101-2021_01_04_425177	263	39	,	,	,
10_1101-2021_01_04_425177	263	40	S.K.T.S.	S.K.T.S.	NNP
10_1101-2021_01_04_425177	263	41	,	,	,
10_1101-2021_01_04_425177	263	42	Ilag	Ilag	NNP
10_1101-2021_01_04_425177	263	43	,	,	,
10_1101-2021_01_04_425177	263	44	L.L.	L.L.	NNP
10_1101-2021_01_04_425177	263	45	,	,	,
10_1101-2021_01_04_425177	263	46	Kamerlin	Kamerlin	NNP
10_1101-2021_01_04_425177	263	47	,	,	,
10_1101-2021_01_04_425177	263	48	S.C.L.	S.C.L.	NNP
10_1101-2021_01_04_425177	263	49	,	,	,
10_1101-2021_01_04_425177	263	50	Gräslund	Gräslund	NNP
10_1101-2021_01_04_425177	263	51	,	,	,
10_1101-2021_01_04_425177	263	52	A.	a.	NN
10_1101-2021_01_04_425177	263	53	,	,	,
10_1101-2021_01_04_425177	263	54	2018	2018	CD
10_1101-2021_01_04_425177	263	55	.	.	.
10_1101-2021_01_04_425177	264	1	Amyloid	amyloid	JJ
10_1101-2021_01_04_425177	264	2	-	-	HYPH
10_1101-2021_01_04_425177	264	3	beta	beta	NN
10_1101-2021_01_04_425177	264	4	Peptide	Peptide	NNP
10_1101-2021_01_04_425177	264	5	Interactions	Interactions	NNPS
10_1101-2021_01_04_425177	264	6	with	with	IN
10_1101-2021_01_04_425177	264	7	Amphiphilic	amphiphilic	JJ
10_1101-2021_01_04_425177	264	8	Surfactants	surfactant	NNS
10_1101-2021_01_04_425177	264	9	:	:	:
10_1101-2021_01_04_425177	264	10	Electrostatic	electrostatic	JJ
10_1101-2021_01_04_425177	264	11	and	and	CC
10_1101-2021_01_04_425177	264	12	Hydrophobic	Hydrophobic	NNP
10_1101-2021_01_04_425177	264	13	Effects	Effects	NNPS
10_1101-2021_01_04_425177	264	14	.	.	.
10_1101-2021_01_04_425177	265	1	ACS	ACS	NNP
10_1101-2021_01_04_425177	265	2	Chem	Chem	NNP
10_1101-2021_01_04_425177	265	3	Neurosci	Neurosci	NNP
10_1101-2021_01_04_425177	265	4	9	9	CD
10_1101-2021_01_04_425177	265	5	,	,	,
10_1101-2021_01_04_425177	265	6	1680	1680	CD
10_1101-2021_01_04_425177	265	7	-	-	SYM
10_1101-2021_01_04_425177	265	8	1692	1692	CD
10_1101-2021_01_04_425177	265	9	.	.	.
10_1101-2021_01_04_425177	266	1	.CC	.CC	NFP
10_1101-2021_01_04_425177	266	2	-	-	:
10_1101-2021_01_04_425177	266	3	BY	by	IN
10_1101-2021_01_04_425177	266	4	-	-	HYPH
10_1101-2021_01_04_425177	266	5	NC	NC	NNP
10_1101-2021_01_04_425177	266	6	-	-	HYPH
10_1101-2021_01_04_425177	266	7	ND	ND	NNP
10_1101-2021_01_04_425177	266	8	4.0	4.0	CD
10_1101-2021_01_04_425177	266	9	International	international	JJ
10_1101-2021_01_04_425177	266	10	licensemade	licensemade	NN
10_1101-2021_01_04_425177	266	11	available	available	JJ
10_1101-2021_01_04_425177	266	12	under	under	IN
10_1101-2021_01_04_425177	266	13	a	a	DT
10_1101-2021_01_04_425177	266	14	(	(	-LRB-
10_1101-2021_01_04_425177	266	15	which	which	WDT
10_1101-2021_01_04_425177	266	16	was	be	VBD
10_1101-2021_01_04_425177	266	17	not	not	RB
10_1101-2021_01_04_425177	266	18	certified	certify	VBN
10_1101-2021_01_04_425177	266	19	by	by	IN
10_1101-2021_01_04_425177	266	20	peer	peer	NN
10_1101-2021_01_04_425177	266	21	review	review	NN
10_1101-2021_01_04_425177	266	22	)	)	-RRB-
10_1101-2021_01_04_425177	266	23	is	be	VBZ
10_1101-2021_01_04_425177	266	24	the	the	DT
10_1101-2021_01_04_425177	266	25	author	author	NN
10_1101-2021_01_04_425177	266	26	/	/	SYM
10_1101-2021_01_04_425177	266	27	funder	funder	NN
10_1101-2021_01_04_425177	266	28	,	,	,
10_1101-2021_01_04_425177	266	29	who	who	WP
10_1101-2021_01_04_425177	266	30	has	have	VBZ
10_1101-2021_01_04_425177	266	31	granted	grant	VBN
10_1101-2021_01_04_425177	266	32	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	266	33	a	a	DT
10_1101-2021_01_04_425177	266	34	license	license	NN
10_1101-2021_01_04_425177	266	35	to	to	TO
10_1101-2021_01_04_425177	266	36	display	display	VB
10_1101-2021_01_04_425177	266	37	the	the	DT
10_1101-2021_01_04_425177	266	38	preprint	preprint	NN
10_1101-2021_01_04_425177	266	39	in	in	IN
10_1101-2021_01_04_425177	266	40	perpetuity	perpetuity	NN
10_1101-2021_01_04_425177	266	41	.	.	.
10_1101-2021_01_04_425177	267	1	It	-PRON-	PRP
10_1101-2021_01_04_425177	267	2	is	be	VBZ
10_1101-2021_01_04_425177	267	3	The	the	DT
10_1101-2021_01_04_425177	267	4	copyright	copyright	NN
10_1101-2021_01_04_425177	267	5	holder	holder	NN
10_1101-2021_01_04_425177	267	6	for	for	IN
10_1101-2021_01_04_425177	267	7	this	this	DT
10_1101-2021_01_04_425177	267	8	preprintthis	preprintthis	NN
10_1101-2021_01_04_425177	267	9	version	version	NN
10_1101-2021_01_04_425177	267	10	posted	post	VBD
10_1101-2021_01_04_425177	267	11	January	January	NNP
10_1101-2021_01_04_425177	267	12	4	4	CD
10_1101-2021_01_04_425177	267	13	,	,	,
10_1101-2021_01_04_425177	267	14	2021	2021	CD
10_1101-2021_01_04_425177	267	15	.	.	.
10_1101-2021_01_04_425177	267	16	;	;	:
10_1101-2021_01_04_425177	267	17	https://doi.org/10.1101/2021.01.04.425177doi	https://doi.org/10.1101/2021.01.04.425177doi	ADD
10_1101-2021_01_04_425177	267	18	:	:	:
10_1101-2021_01_04_425177	267	19	bioRxiv	biorxiv	IN
10_1101-2021_01_04_425177	267	20	preprint	preprint	NN
10_1101-2021_01_04_425177	267	21	https://doi.org/10.1101/2021.01.04.425177	https://doi.org/10.1101/2021.01.04.425177	UH
10_1101-2021_01_04_425177	267	22	http://creativecommons.org/licenses/by-nc-nd/4.0/	http://creativecommons.org/licenses/by-nc-nd/4.0/	XX